{"acd019c23f9be186f64535f122e04795d6150368": [["The best example of open skies being implemented within a region is in Europe; however, this was not a negotiated move.", [["open skies", "TREATMENT", 20, 30]]], ["Some are populous, others are not; some have high per capita incomes, while others are amongst the poorest in the world; some have well-developed aviation sectors, while others have embryonic aviation industries, at best; and some have efficient, financially strong airlines, while others do not.", [["embryonic", "ANATOMY", 182, 191], ["populous", "OBSERVATION", 9, 17], ["high", "OBSERVATION_MODIFIER", 45, 49]]], ["Current aviation policies amongst the ASEAN countries differ, partly reflecting these differences-some pursue very liberal policies, while others have restrictive policies (some of which are not even clearly articulated at present).", [["restrictive policies", "PROBLEM", 151, 171], ["restrictive", "OBSERVATION", 151, 162]]], ["In this context, achieving the policy goals of open skies will be a considerable challenge.IntroductionAchieving a move to open skies poses a range of issues:IntroductionWill ASEAN countries as a whole gain from liberalisation, and more pointedly, will every individual country gain?IntroductionWill the economic gains from liberalisation persuade the more restrictive countries to be less protective?IntroductionAre there any growing forces, such as tourism development and pressure for access to routes from low-cost airlines, which can counteract pressure for the status quo coming from incumbent airlines?IntroductionWill a staged process facilitate liberalisation, by giving incumbents time to adjust, and by demonstrating the potential benefits of liberalisation?IntroductionAre there some sub-regions that can liberalise faster than the ASEAN region as a whole? and Are there other changes, such as in competition policy and towards state subsidies, which would enable a move to open skies to work more effectively?Introduction2.", [["open skies", "TREATMENT", 47, 57], ["a considerable challenge", "TREATMENT", 66, 90], ["liberalisation", "TREATMENT", 324, 338], ["any growing forces", "PROBLEM", 423, 441], ["pressure for access", "TREATMENT", 475, 494], ["low-cost airlines", "TREATMENT", 510, 527], ["a staged process", "TREATMENT", 626, 642], ["liberalisation", "TREATMENT", 754, 768], ["some sub-regions", "PROBLEM", 791, 807], ["growing", "OBSERVATION_MODIFIER", 427, 434], ["forces", "OBSERVATION", 435, 441], ["sub-", "OBSERVATION_MODIFIER", 796, 800]]], ["ASEAN was formed to accelerate economic growth, social progress and cultural development in the region, and promote regional peace and stability.", [["economic", "OBSERVATION_MODIFIER", 31, 39], ["growth", "OBSERVATION_MODIFIER", 40, 46], ["stability", "OBSERVATION_MODIFIER", 135, 144]]], ["It aimed to promote a more competitive environment for air transport services and operations, by way of liberalisation initiatives and agreements that may be a gradual step towards an Open Sky Policy in ASEAN.", [["air transport services", "TREATMENT", 55, 77], ["operations", "TREATMENT", 82, 92]]], ["Specifically, it called for the following: (a) development of the liberalisation policy for air freight services; and (b) adoption of more liberal and flexible air services arrangements, initially in the ASEAN sub-regional groupings like Brunei-Indonesia-Malaysia-Philippines East ASEAN Growth Area (BIMP-EAGA), and the Cambodia-Laos-Myanmar-Vietnam group (CLMV).", [["CLMV", "SPECIES", 357, 361], ["more liberal and flexible air services", "TREATMENT", 134, 172]]], ["In 2001, the ASEAN Transport Ministers at the 7th Air Transport Meeting (ATM) agreed to launch a regional initiative for the progressive and phased liberalisation of air services in ASEAN, by providing greater market access, flexibility and capability in air services operations.", [["air services operations", "TREATMENT", 255, 278]]], ["Following on from the ASEAN Leaders' directive to accelerate the integration of the air travel and tourism sectors, the Ministers directed their officials to develop a regional action plan for staged and progressive implementation of Open Sky arrangement in ASEAN and to prepare an updated transport co-operation plan for 2005-2010 for the adoption of the 10th ATM.", [["ATM", "GENE_OR_GENE_PRODUCT", 361, 364], ["10th ATM", "PROTEIN", 356, 364]]], ["This outline drew on a Report to the ASEAN Secretariat to which the present authors contributed (Monash International, 2004) .ASEAN moves towards Open SkiesASEAN Open Sky involves internal regional liberalisation.", [["internal regional liberalisation", "TREATMENT", 180, 212], ["internal", "OBSERVATION_MODIFIER", 180, 188], ["regional liberalisation", "OBSERVATION", 189, 212]]], ["Diversity characterises the levels of growth and development of its members (see Table 1 ).", [["growth", "OBSERVATION_MODIFIER", 38, 44]]], ["While Brunei and Singapore have small population bases, their high per capita incomes make their citizens (especially for Singapore) a large source for intra-ASEAN travel.", [["small population bases", "PROBLEM", 32, 54], ["small", "OBSERVATION_MODIFIER", 32, 37], ["population", "OBSERVATION", 38, 48], ["bases", "ANATOMY_MODIFIER", 49, 54], ["high", "OBSERVATION_MODIFIER", 62, 66]]], ["Large domestic aviation markets (actual or potential) characterise middle-income states, namely Indonesia (population of 218 million), Philippines (83 million), Vietnam (82 million) and Malaysia (25 million).", [["Philippines", "TREATMENT", 135, 146], ["domestic", "OBSERVATION_MODIFIER", 6, 14], ["aviation markets", "OBSERVATION", 15, 31], ["middle", "ANATOMY_MODIFIER", 67, 73]]], ["In general, domestic markets in most ASEAN countries remain undeveloped with air routes operating with low traffic densities, low frequencies and small and relatively high cost aircraft.", [["low traffic densities", "PROBLEM", 103, 124], ["low frequencies", "PROBLEM", 126, 141], ["small and relatively high cost aircraft", "PROBLEM", 146, 185], ["low", "OBSERVATION_MODIFIER", 103, 106], ["traffic densities", "OBSERVATION", 107, 124], ["low frequencies", "OBSERVATION_MODIFIER", 126, 141], ["small", "OBSERVATION_MODIFIER", 146, 151], ["relatively", "OBSERVATION_MODIFIER", 156, 166], ["high", "OBSERVATION_MODIFIER", 167, 171], ["cost aircraft", "OBSERVATION", 172, 185]]], ["Thus there is a tendency for overall average cost to be higher than on busier air routes.", [["tendency", "OBSERVATION_MODIFIER", 16, 24], ["higher", "OBSERVATION_MODIFIER", 56, 62]]], ["Some data on travel patterns are given in Table 2 .Aviation in ASEANThe diversities are likewise evident and reflected in the state of airline capabilities, aviation policies, attitudes to liberalisation and airport infrastructure.", [["diversities", "OBSERVATION", 72, 83]]], ["National carriers play significant role in the aviation industries of most ASEAN countries as they operate domestic (except for Singapore and Brunei), intra-ASEAN and extensive networks linking Asian ports to Europe, Middle East, North America and Australasia.", [["significant", "OBSERVATION_MODIFIER", 23, 34], ["Middle", "ANATOMY_MODIFIER", 217, 223]]], ["Hit by a series of crises, 3 ASEAN carriers are struggling to recover huge financial losses and develop more efficient route networks.Aviation in ASEANSingapore's national carrier, Singapore Airlines (SIA) is the largest ASEAN airline and one of the 20 largest in the world.", [["route networks", "MULTI-TISSUE_STRUCTURE", 119, 133], ["crises", "PROBLEM", 19, 25], ["huge financial losses", "PROBLEM", 70, 91], ["largest", "OBSERVATION_MODIFIER", 213, 220], ["largest", "OBSERVATION_MODIFIER", 253, 260]]], ["Other aviation tigers like Malaysia and Thailand also boast of relatively large fleets of aircraft and extensive networks.", [["relatively", "OBSERVATION_MODIFIER", 63, 73], ["large", "OBSERVATION_MODIFIER", 74, 79], ["fleets", "OBSERVATION", 80, 86]]], ["On the other hand, countries like Laos, Myanmar and Cambodia have relatively few bilateral ASAs, undeveloped aviation policies and airlines with limited capabilities in terms of aircraft and choice of aircraft, marketing, supporting network, alliance participation and in achieving reliability of operations.", [["ASAs", "DISEASE", 91, 95], ["network", "MULTI-TISSUE_STRUCTURE", 233, 240]]], ["They also face managerial and skilled labour shortages.Aviation in ASEANThe disparity in capabilities is likewise highlighted by the degree of government support granted to ASEAN airlines.Aviation in ASEANExcept in Philippines and Cambodia, most ASEAN airlines are either wholly owned or majority owned by government.", [["government support", "TREATMENT", 143, 161], ["disparity", "OBSERVATION_MODIFIER", 76, 85]]], ["Thai Airways is also majority (92%) owned by government, although there are longstanding plans to privatise more of the company.", [["Airways", "ANATOMY", 5, 12]]], ["Malaysian ownership rules reserve 51% ownership for Malaysian nationals while the Philippine Constitution provides for 60% ownership by Filipinos and effective Filipino management and control.", [["Filipinos", "CHEMICAL", 136, 145], ["Filipinos", "TREATMENT", 136, 145], ["effective Filipino management", "TREATMENT", 150, 179]]], ["In contrast, Singapore favours more liberal rules, and would like to move to a 'principal place of business' criterion, although the Singapore Government recognises that this would pose problems given that many of its ASAs specify 'substantial ownership and control' (as is the case with the rest of ASEAN).", [["ASAs", "CANCER", 218, 222]]], ["Low-cost carriers (LCCs) have had a major impact on airline competition in the US, Europe, and in other areas, and they have now begun to have a major impact in the ASEAN region.", [["Low-cost carriers", "PROBLEM", 0, 17], ["the US", "TEST", 75, 81]]], ["The deregulation of the domestic markets paved way for the birth of LCCs which have also opened up of new ASEAN routes.", [["LCCs", "CANCER", 68, 72]]], ["The best-known carrier is Air Asia, although Cebu Pacific in the Philippines was established as early as 1997 and operated domestic routes.", [["Air Asia", "OBSERVATION", 26, 34]]], ["Other start-ups include Thai Air Asia, One-Two-Go and Nok Air in Thailand, ValuAir, Jetstar Asia and Tiger Airways in Singapore and Lion Airlines in Indonesia.", [["ValuAir", "TREATMENT", 75, 82], ["Air", "OBSERVATION", 58, 61], ["Airways", "ANATOMY", 107, 114]]], ["At present, the scope for LCCs to operate in ASEAN is limited: they can operate only in deregulated domestic markets and on specific liberalised international routes.", [["the scope", "TEST", 12, 21], ["LCCs", "TEST", 26, 30]]], ["Many LCCs in the region have found that their growth has been stymied by their inability to gain access to regulated international routes.Aviation policiesThe objectives of aviation policy differ across countries but also the sophistication of the policies adopted, and the ability to implement them effectively, differ between ASEAN member countries.", [["LCCs", "ANATOMY", 5, 9], ["LCCs", "CANCER", 5, 9], ["growth", "OBSERVATION_MODIFIER", 46, 52]]], ["To support tourism, Malaysia has poised the Kuala Lumpur International Airport (KLIA) to compete with Singapore, thereby granting liberal traffic rights to carriers of countries offering reciprocal rights, and incentives to new entrants operating in KLIA.", [["reciprocal rights", "TREATMENT", 187, 204]]], ["The attitudes toward liberalisation in ASEAN are also influenced by the relative importance of intra-ASEAN tourism as well.", [["intra-ASEAN tourism", "OBSERVATION", 95, 114]]], ["For the Philippines ASEAN inflows have historically accounted for only 6 percent of the total visitor arrivals.", [["the Philippines ASEAN inflows", "TREATMENT", 4, 33]]], ["Thus, there is greater enthusiasm in opening up the Northeast Asian markets of Japan and China than in ASEAN.Aviation policiesASEAN countries remain heavily reliant on bilateral ASAs, although some have joined regional and multilateral arrangements.", [["Aviation policies", "TREATMENT", 109, 126], ["bilateral ASAs", "TREATMENT", 168, 182], ["greater", "OBSERVATION_MODIFIER", 15, 22], ["enthusiasm", "OBSERVATION", 23, 33]]], ["In the Philippines, Executive Order no. 219 (1995) lays down that at least two international carriers shall be designated official carriers.Aviation policiesIn spite of the liberalisation initiatives of most ASEAN countries, capacity remains restricted on a number of routes because there are no existing ASAs, and/or the agreements are already dated.", [["the liberalisation initiatives", "TREATMENT", 169, 199]]], ["Cases exist where one country (e.g. Malaysia) has high or full utilisation already of its air traffic rights (to the Philippines) by the incumbent carrier but the bilateral partner does not prioritise any renegotiations; this prevents new entrants from developing the market.", [["new", "OBSERVATION_MODIFIER", 235, 238]]], ["In some cases, charter operations are used to circumvent the restrictions imposed by the ASAs, particularly during peak periods.", [["charter operations", "TREATMENT", 15, 33]]], ["Singapore Airlines and Thai Airways are members of the Star Alliance.", [["Airways", "ANATOMY", 28, 35]]], ["Malaysia Airways and Garuda operate 3rd country code sharing services and Myanmar, Philippines and Vietnam also permit code sharing.", [["Vietnam", "TREATMENT", 99, 106], ["Airways", "ANATOMY", 9, 16]]], ["It has been noted that charters are not frequently used at present and the approval process is not necessarily speedy in some countries.", [["not necessarily", "UNCERTAINTY", 95, 110]]], ["In terms of air freight, ASEAN countries have adopted a relatively liberal attitude with member states endorsing the ASEAN MOU on Air Freight Services, the first step towards the full liberalisation of air freight services in the ASEAN region.", [["air freight services", "TREATMENT", 202, 222], ["air freight", "OBSERVATION", 12, 23]]], ["4 However, Singapore, Brunei and Thailand went ahead of the rest of ASEAN by signing an agreement in February 2004.Aviation policiesIn summary, the diversities across ASEAN economies leads to conflicting views about liberalisation, making it difficult to achieve; however, it also means that the scope for gain from a more efficient internal aviation sector is substantial.4The MOU will allow the designated airlines of each member country to operate all-cargo services up to a limit of 100 tons weekly to 20 designated ASEAN airports.Rationales for Open SkiesOpen Skies in ASEAN consists of liberalisation of the aviation routes between ASEAN member countries.", [["liberalisation", "TREATMENT", 216, 230], ["substantial", "OBSERVATION_MODIFIER", 361, 372]]], ["It will involve removal of capacity controls on routes, removal of entry barriers, and freeing up ownership arrangements.", [["removal of capacity controls", "TREATMENT", 16, 44], ["removal", "TREATMENT", 56, 63], ["entry barriers", "TREATMENT", 67, 81]]], ["These can be expected to lead to efficiency gains in the ASEAN air transport industry, leading to net overall gains in economic welfare.Rationales for Open SkiesThe gains from liberalisation will come about from two sources-gains from trade, and gains from more competitive markets.Rationales for Open SkiesGains from trade in airline services come about when liberalisation leads to airlines best suited to particular routes gaining an increased market share on those routes.", [["efficiency gains", "PROBLEM", 33, 49], ["increased", "OBSERVATION", 437, 446]]], ["Under regulation, a high-cost airline will be guaranteed a market share-under liberalisation, a lower cost airline from a partner country will gain market share.Rationales for Open SkiesGains from competition come about when there is stronger competition between incumbents (which are no longer limited by regulation in the market share they can attain) and from new entrants.", [["a high-cost airline", "TREATMENT", 18, 37], ["a lower cost airline", "TREATMENT", 94, 114]]], ["Initially, competition puts pressure on prices, and consumers gain at the expense of airlines and aviation producers.", [["pressure on prices", "TREATMENT", 28, 46]]], ["In practice the competitive process is much less ordered than this suggests, and airline industries experience long periods of poor and good profitability.Rationales for Open SkiesCompetition also stimulates the introduction of new products and the serving of market segments which were not well served before.", [["Open SkiesCompetition", "TREATMENT", 170, 191], ["new products", "TREATMENT", 228, 240], ["new", "OBSERVATION_MODIFIER", 228, 231]]], ["Thus the LCCs have stimulated demand from new market segments which the full service carriers (FSCs) did not serve well before.", [["LCCs", "CANCER", 9, 13], ["LCCs", "CELL_TYPE", 9, 13], ["stimulated demand", "PROBLEM", 19, 36], ["new", "OBSERVATION_MODIFIER", 42, 45]]], ["The European experience suggests that new entrant LCCs play an important part in the competitive process-immediately after liberalisation, competition between the FSCs did not increase sharply, and the benefits from liberalisation were modest (Civil Aviation Authority, 1998).", [["LCCs", "CHEMICAL", 50, 54], ["LCCs", "CANCER", 50, 54], ["new entrant LCCs", "PROBLEM", 38, 54], ["new", "OBSERVATION_MODIFIER", 38, 41]]], ["It was the entry of LCCs which really made a difference to the European market (Doganis, 2001; Lawton, 2002; Williams, 2002) .Rationales for Open SkiesThe main gains and losses will be experienced by the consumers and producers of air transport.", [["LCCs", "PATHOLOGICAL_FORMATION", 20, 24], ["main", "OBSERVATION_MODIFIER", 155, 159]]], ["While overall tourism will gain (especially as tourism in ASEAN becomes more competitive relative to other regions), it is possible that tourism industries in some countries will lose out, if domestic tourists substitute international for domestic tourism.Rationales for Open SkiesThe size of the likely gains from liberalisation is an empirical question.", [["size", "OBSERVATION_MODIFIER", 285, 289], ["likely", "UNCERTAINTY", 297, 303], ["gains", "OBSERVATION_MODIFIER", 304, 309]]], ["Systematic evaluation is difficult, given the lack of data.", [["Systematic evaluation", "TEST", 0, 21]]], ["There appears to be a wide divergence in the productivity and cost efficiency of ASEAN airlines (see Tables 3 and 4 ).", [["a wide divergence", "PROBLEM", 20, 37], ["appears to be", "UNCERTAINTY", 6, 19], ["wide", "OBSERVATION_MODIFIER", 22, 26], ["divergence", "OBSERVATION_MODIFIER", 27, 37], ["productivity", "OBSERVATION_MODIFIER", 45, 57]]], ["There is evidence of wide dispersion of air fares.", [["wide dispersion of air fares", "PROBLEM", 21, 49], ["evidence of", "UNCERTAINTY", 9, 20], ["wide", "OBSERVATION_MODIFIER", 21, 25], ["dispersion", "OBSERVATION_MODIFIER", 26, 36], ["air fares", "OBSERVATION", 40, 49]]], ["Fares on tightly regulated routes are higher than on the more competitive routes.", [["higher", "OBSERVATION_MODIFIER", 38, 44]]], ["There are considerable directional imbalances in fares on some controlled routes-this suggests that not all fares are closely based on costs.", [["considerable directional imbalances in fares", "PROBLEM", 10, 54], ["considerable", "OBSERVATION_MODIFIER", 10, 22], ["directional", "OBSERVATION_MODIFIER", 23, 34], ["imbalances", "OBSERVATION", 35, 45]]], ["A further piece of evidence comes from the fares now being offered on domestic routes by LCCs.", [["LCCs", "CANCER", 89, 93]]], ["These are significantly lower than on international intra-ASEAN routes of similar distance and density.", [["significantly", "OBSERVATION_MODIFIER", 10, 23], ["lower", "OBSERVATION_MODIFIER", 24, 29], ["density", "OBSERVATION", 95, 102]]], ["Overall, while systematic studies of fares and productivity are yet to be done, the evidence which is available strongly suggests the possibility of strong gains from liberalisation.Rationales for Open SkiesOverall, the pattern of gains and losses is likely to be as follows.", [["systematic studies", "TEST", 15, 33], ["strong gains from liberalisation", "PROBLEM", 149, 181], ["Open SkiesOverall", "TREATMENT", 197, 214], ["likely to be", "UNCERTAINTY", 251, 263]]], ["Airline industries will lose, though less than consumers gain, in the short run.", [["Airline industries", "TREATMENT", 0, 18]]], ["Airline industries are not likely to lose out in the long run, when costs have had time to adjust.", [["not likely", "UNCERTAINTY", 23, 33]]], ["However, it is likely that the gains to a country from additional tourism will be of a smaller order of magnitude than the consumer benefits.", [["is likely", "UNCERTAINTY", 12, 21]]], ["However, not all of this gain need accrue to ASEAN countries as a whole, or to individual ASEAN countries.Rationales for Open SkiesIt is very probable that ASEAN countries as a whole will gain in the short and long run.", [["very probable", "UNCERTAINTY", 137, 150]]], ["If they have tourism industries, lower air fares will stimulate these, and provide a source of gain.", [["lower air fares", "PROBLEM", 33, 48]]], ["Countries which do not generate much air travel do not tend to have high cost but highly profitable airlines which would lose out from liberalisation.Impediments to Open SkiesFor countries which have well-established aviation industries, producer interests can be an impediment to change.", [["high cost", "PROBLEM", 68, 77]]], ["Airlines which face more competition may face a loss of market share, and which face pressure on costs, will oppose liberalisation.", [["loss", "OBSERVATION", 48, 52], ["pressure", "OBSERVATION_MODIFIER", 85, 93]]], ["The workforces of these airlines will also oppose change, since they may lose jobs and wages will be put under pressure.", [["these airlines", "TREATMENT", 18, 32]]], ["As in other countries and regions, there are airlines in ASEAN countries which are hostile to liberalisation.Impediments to Open SkiesThe picture is mixed however.", [["Open Skies", "DNA", 124, 134], ["mixed", "OBSERVATION_MODIFIER", 149, 154]]], ["These tend to be the airlines which are successful financially, have high productivity, and which see opportunities if they are permitted to serve new markets, or existing markets on a less restrictive basis.", [["high", "OBSERVATION_MODIFIER", 69, 73], ["productivity", "OBSERVATION_MODIFIER", 74, 86]]], ["In contrast to these, some established airlines oppose liberalisation.", [["airlines", "OBSERVATION", 39, 47]]], ["These tend to be airlines which have been less successful.", [["less", "OBSERVATION_MODIFIER", 42, 46], ["successful", "OBSERVATION_MODIFIER", 47, 57]]], ["The emergence of LCCs in the ASEAN region is making them even more wary-they have observed the difficulties which FSCs in Europe and elsewhere are having competing with LCCs.", [["LCCs", "DISEASE", 17, 21], ["LCCs", "CANCER", 17, 21], ["LCCs", "CANCER", 169, 173], ["the difficulties", "PROBLEM", 91, 107]]], ["Governments, partly reflecting pressure from airlines, but also reflecting their own inclinations, are often protective.", [["pressure", "OBSERVATION_MODIFIER", 31, 39]]], ["There are several countries in ASEAN which do not have large, experienced airlines.", [["several", "OBSERVATION_MODIFIER", 10, 17], ["countries", "OBSERVATION_MODIFIER", 18, 27], ["large", "OBSERVATION_MODIFIER", 55, 60]]], ["Their airlines are small, by regional standards, have few profitable routes, and are financially vulnerable.", [["small", "OBSERVATION_MODIFIER", 19, 24], ["few", "OBSERVATION_MODIFIER", 54, 57]]], ["They are worried about larger incumbent airlines and LCCs alike.", [["LCCs", "CANCER", 53, 57]]], ["Airlines and governments in this situation will oppose rapid liberalisation, though they may be willing to agree to gradual liberalisation if it is accompanied by measures which strengthen their airline industries.Impediments to Open SkiesA natural counterpart to airline or producer interests is the tourism industry.", [["rapid liberalisation", "PROBLEM", 55, 75]]], ["This can be explained by the diverse nature of the industry, and the predominance of small firms.", [["small firms", "PROBLEM", 85, 96], ["diverse", "OBSERVATION_MODIFIER", 29, 36], ["small", "OBSERVATION_MODIFIER", 85, 90], ["firms", "OBSERVATION", 91, 96]]], ["This involved three distinct stages, resulting in a gradual move to extensive liberalisation.", [["extensive liberalisation", "TREATMENT", 68, 92], ["three distinct", "OBSERVATION_MODIFIER", 14, 28], ["extensive", "OBSERVATION_MODIFIER", 68, 77], ["liberalisation", "OBSERVATION", 78, 92]]], ["The phases and their main components are as follows:A timetable for reformPhase 1 Alongside these changes, there would be scope for faster change on a sub-regional basis.", [["faster change", "PROBLEM", 132, 145], ["main", "OBSERVATION_MODIFIER", 21, 25]]], ["One sub-region, involving Cambodia, Laos, Myanmar and Vietnam, (CLMV) has already been formed.", [["sub", "OBSERVATION_MODIFIER", 4, 7], ["region", "ANATOMY_MODIFIER", 8, 14], ["Cambodia", "OBSERVATION", 26, 34]]], ["More extensive liberalisation between like countries with airlines of comparable strength may be relatively easy to achieve.", [["extensive", "OBSERVATION_MODIFIER", 5, 14], ["liberalisation", "OBSERVATION", 15, 29]]], ["It would achieve full Open Skies a couple of years before 1015, the target set for Open Sky.A timetable for reformBenefits from liberalisation would begin in the first phase, though the aviation industries in each of the countries would have time to adjust.", [["reformBenefits", "TREATMENT", 108, 122], ["liberalisation", "TREATMENT", 128, 142]]], ["In the first phase, there would be more competition on major routes, and the removal of capacity controls, along with the opening up of secondary gateways, would enable new airlines (possibly existing domestic airlines) to develop.", [["the removal of capacity controls", "TREATMENT", 73, 105]]], ["Entry of new airlines, such as LCCs, on the secondary gateways would assist tourism destinations to develop, as they have in Europe, and would provide a demonstration of the benefits of opening up markets.", [["new", "OBSERVATION_MODIFIER", 9, 12], ["airlines", "OBSERVATION", 13, 21]]], ["Incumbent carriers would face more competition, though they would have until the second phase before this competition became substantially deregulated.", [["substantially deregulated", "PROBLEM", 125, 150]]], ["Over time, ownership would be liberalised, enabling airlines from the nations with relatively developed aviation to invest in and assist the development of airlines in countries with relatively undeveloped aviation.Sub-regional approaches and parallel liberalisationThere are currently, in ASEAN, a number of subregional approaches to policy change across a variety of sectors.", [["parallel liberalisation", "TREATMENT", 243, 266], ["regional approaches", "OBSERVATION", 219, 238], ["variety", "OBSERVATION_MODIFIER", 358, 365]]], ["The CLMV agreement, on the other hand, is exclusively an aviation agreement between the subscribing parties (CLMV).", [["CLMV", "DNA", 4, 8]]], ["The IMT-GT agreement also allows for airline co-operation between secondary and tertiary points, however again there has been little use of this sub-regional agreement between Indonesia, Malaysia and Thailand.Sub-regional approaches and parallel liberalisationIt is possible, however, within ASEAN, to consider the formation of new sub-regional blocs which involve national level co-operation rather than co-operation associated merely with secondary and tertiary points.", [["airline co-operation", "TREATMENT", 37, 57], ["parallel liberalisation", "TREATMENT", 237, 260], ["new sub-regional blocs", "PROBLEM", 328, 350], ["secondary and tertiary points", "PROBLEM", 441, 470], ["regional approaches", "OBSERVATION", 213, 232], ["new", "OBSERVATION_MODIFIER", 328, 331], ["sub", "OBSERVATION_MODIFIER", 332, 335], ["tertiary points", "OBSERVATION", 455, 470]]], ["Over an agreed time scale, these sub-regional blocs can be integrated, and while this process of sub-regional integration is occurring, there can occur significant policy liberalisation, i.e. there can be simultaneous movement on both a policy and geographic basis.", [["these sub-regional blocs", "PROBLEM", 27, 51], ["sub-regional integration", "PROBLEM", 97, 121]]], ["A particular sub-region may be more advanced in liberalisation than others and as mergers occur, liberalisation will spread.", [["A particular sub-region", "PROBLEM", 0, 23], ["may be", "UNCERTAINTY", 24, 30], ["more", "OBSERVATION_MODIFIER", 31, 35], ["advanced", "OBSERVATION_MODIFIER", 36, 44]]], ["Of course, at the same time, liberalisation should continue on a bilateral basis, as many bilateral agreements will remain in place.Sub-regional approaches and parallel liberalisationThe disparities in the economies, the markets and the aviation capacities mean that progress to an 'Open Sky' cannot be achieved in one step; hence, the proposal for simultaneous policy initiatives and geographically related sub-regions.", [["liberalisation", "TREATMENT", 29, 43], ["a bilateral basis", "TREATMENT", 63, 80], ["parallel liberalisation", "TREATMENT", 160, 183], ["simultaneous policy initiatives", "TREATMENT", 349, 380], ["regional approaches", "OBSERVATION", 136, 155], ["disparities", "OBSERVATION_MODIFIER", 187, 198]]], ["Some countries may participate in more than one sub-region and of course, as the sub-regions merge, there will be multiple participation across the regions, until, eventually the entire sub-regions merge to form the one ASEAN Open Sky.", [["multiple", "OBSERVATION_MODIFIER", 114, 122]]], ["The sub-regions can be based on a similarity of economic and aviation strength, but even within a sub-region there may be disparities.", [["sub", "OBSERVATION_MODIFIER", 4, 7], ["aviation strength", "OBSERVATION", 61, 78], ["may be", "UNCERTAINTY", 115, 121], ["disparities", "OBSERVATION", 122, 133]]], ["In CLMV, Cambodia, Laos and Myanmar are more similar to each other than any of them is to Vietnam in terms of economic and aviation power.", [["CLMV", "SPECIES", 3, 7], ["Cambodia", "OBSERVATION_MODIFIER", 9, 17]]], ["They came together, however, in the CLMV agreement because of perceived benefits and because of perceptions of the economic and aviation strengths of neighbours: there was a perception of a community of interest.Sub-regional approaches and parallel liberalisationThe second sub-region proposed was Vietnam, Indonesia, Philippines plus Brunei (VIP+B).", [["parallel liberalisation", "TREATMENT", 240, 263], ["Philippines plus Brunei (VIP+B)", "TREATMENT", 318, 349], ["regional approaches", "OBSERVATION", 216, 235], ["sub", "OBSERVATION_MODIFIER", 274, 277]]], ["Philippines and Vietnam already have a type of open skies agreement and the three constitute broadly similar aviation economies, though Indonesia because of its archipelago nature and physical size has a larger domestic aviation sector.", [["size", "OBSERVATION_MODIFIER", 193, 197], ["larger", "OBSERVATION_MODIFIER", 204, 210]]], ["The 3rd sub-region is to be SMT & B: Singapore, Malaysia and Thailand, with the addition of Brunei.", [["Brunei", "TREATMENT", 92, 98], ["SMT", "OBSERVATION_MODIFIER", 28, 31]]], ["They each have a large aviation sector with each having major international airlines operating to many countries.", [["large", "OBSERVATION_MODIFIER", 17, 22]]], ["Each of these three have very open 3rd and 4th freedom capacity regimes with each other and thus it would be simple to constitute a third sub-region.Opening secondary marketsWhilst LCCs have an important role to play in the opening of secondary markets in that they have a lower cost of entry than FSCs, they are not the only participants in secondary markets.", [["LCCs", "CANCER", 181, 185], ["participants", "SPECIES", 326, 338], ["open 3rd and 4th freedom capacity regimes", "TREATMENT", 30, 71], ["secondary markets", "OBSERVATION", 157, 174]]], ["Singapore, as an example, has long had two airlines: Singapore Airlines and Silk Air, the former operating wide body equipment on long haul and/ or dense routes, whilst Silk Air (owned by Singapore Airlines) operates exclusively narrow-bodied equipment on short haul and thin routes.", [["body", "ANATOMY", 112, 116], ["body", "ORGANISM_SUBDIVISION", 112, 116], ["Singapore Airlines", "TREATMENT", 53, 71], ["long haul", "TREATMENT", 130, 139], ["short haul and thin routes", "TREATMENT", 256, 282], ["Silk Air", "OBSERVATION", 76, 84], ["narrow", "OBSERVATION_MODIFIER", 229, 235]]], ["Silk Air is a FSC offering, within the confines of its stage lengths and aircraft types, a conventional 2 class (generally) short-haul airline product.Opening secondary marketsSilk Air links secondary markets to the Singapore hub.", [["Air", "OBSERVATION", 5, 8], ["FSC", "OBSERVATION_MODIFIER", 14, 17], ["stage", "OBSERVATION_MODIFIER", 55, 60], ["lengths", "OBSERVATION_MODIFIER", 61, 68], ["aircraft types", "OBSERVATION", 73, 87], ["secondary markets", "OBSERVATION", 159, 176], ["Air", "OBSERVATION", 181, 184], ["secondary markets", "OBSERVATION", 191, 208]]], ["In both Indonesia and Thailand there are secondary airlines serving secondary markets, some are endeavouring to re-invent themselves as ''LCCs''.", [["both", "OBSERVATION_MODIFIER", 3, 7], ["Indonesia", "OBSERVATION", 8, 17], ["secondary airlines", "OBSERVATION", 41, 59], ["secondary markets", "OBSERVATION", 68, 85]]], ["The rise of the secondary carrier, whether LCC or not, has been beneficial to the opening of important tourism destinations such as Mandalay (Myanmar), Siem Reap (Cambodia), Luang Prabang (Laos) and Danang (Vietnam) all of which are served by secondary carriers.Opening secondary marketsUnless countries have an open capacity and route regime under which any designated carrier from one country can fly to any point in the other country without any restriction of capacity, then it can be difficult to develop secondary routes.", [["an open capacity", "TREATMENT", 309, 325], ["route regime", "TREATMENT", 330, 342], ["rise", "OBSERVATION_MODIFIER", 4, 8], ["secondary", "OBSERVATION_MODIFIER", 16, 25], ["secondary markets", "OBSERVATION", 270, 287]]], ["Sometimes there is discrete capacity allocated for secondary routes which can only be used on those routes but there are also situations where dominant carriers control all the capacity and use it exclusively on prime city pairs thus denying or at least restricting growth opportunities for secondary destinations.Role of low-cost carriersOpen Sky will provide fertile conditions within which LCCs can develop in the ASEAN region.", [["LCCs", "CANCER", 393, 397], ["discrete capacity", "PROBLEM", 19, 36], ["fertile conditions", "PROBLEM", 361, 379], ["discrete", "OBSERVATION_MODIFIER", 19, 27], ["capacity", "OBSERVATION_MODIFIER", 28, 36], ["low", "OBSERVATION_MODIFIER", 322, 325]]], ["LCCs have expanded consumer choices and improved the efficiencies of airline industries.", [["LCCs", "ANATOMY", 0, 4], ["LCCs", "CELL_TYPE", 0, 4], ["expanded", "OBSERVATION_MODIFIER", 10, 18], ["consumer choices", "OBSERVATION", 19, 35]]], ["They have also forced regulators to change old rules of the game that tended to protect FSCs and their key markets.", [["FSCs", "CANCER", 88, 92], ["FSCs", "CELL_TYPE", 88, 92]]], ["It is likely that an Open Sky environment in ASEAN that removes restrictions on designation, capacity and fares will support the growth and development of the LCCs.", [["LCCs", "ANATOMY", 159, 163], ["LCCs", "DISEASE", 159, 163], ["LCCs", "CANCER", 159, 163], ["the growth", "PROBLEM", 125, 135], ["the LCCs", "PROBLEM", 155, 163], ["is likely", "UNCERTAINTY", 3, 12]]], ["On the other hand, the rise of more LCCs in the region will exert pressure for the acceleration of the ASEAN Open Sky.Role of low-cost carriersAt present, LCCs are operating to a limited extent in the ASEAN region, often in domestic markets only-because of restrictions imposed by existing bilateral ASAs in terms of designation, capacity and fares.", [["pressure", "TEST", 66, 74], ["rise", "OBSERVATION_MODIFIER", 23, 27], ["pressure", "OBSERVATION", 66, 74], ["low", "OBSERVATION_MODIFIER", 126, 129], ["bilateral", "ANATOMY_MODIFIER", 290, 299]]], ["5 Since these routes are less likely to be served by major carriers, they offer the LCCs the scope to develop during the early stages without encountering head-to-head competition from strong airlines.", [["head", "ANATOMY", 155, 159], ["head", "ORGANISM_SUBDIVISION", 155, 159], ["head", "ANATOMY", 163, 167]]], ["However, even this indirect competition is forcing incumbent FSCs to review their productivity and cost competitiveness to address their low productivity labour arrangements and inability to respond to market changes.", [["their low productivity labour arrangements", "PROBLEM", 131, 173]]], ["Some FSCs have responded to new competition by setting up their own low-cost subsidiaries (e.g. SIA has a 49% stake in Tiger Airways).Role of low-cost carriersThe rapid development of LCCs in Singapore, Indonesia, Malaysia, Thailand is now resulting in pressure on regulators for access to more international routes.", [["FSCs", "ANATOMY", 5, 9], ["FSCs", "CELL_TYPE", 5, 9], ["Some FSCs", "PROBLEM", 0, 9], ["pressure on regulators", "TREATMENT", 253, 275], ["Airways", "ANATOMY", 125, 132], ["low", "OBSERVATION_MODIFIER", 142, 145], ["rapid", "OBSERVATION_MODIFIER", 163, 168], ["pressure", "OBSERVATION_MODIFIER", 253, 261]]], ["ASEAN internal routes, with short to medium hauls and low to moderate density are very suited to the LCCs.", [["LCCs", "ANATOMY", 101, 105], ["LCCs", "CANCER", 101, 105], ["short to medium hauls and low to moderate density", "PROBLEM", 28, 77], ["low to moderate", "OBSERVATION_MODIFIER", 54, 69], ["density", "OBSERVATION", 70, 77]]], ["Many ASEAN routes are blocked to new entrants, and this is constraining the growth of the LCCs.", [["LCCs", "ANATOMY", 90, 94], ["LCCs", "CANCER", 90, 94], ["growth", "OBSERVATION_MODIFIER", 76, 82]]], ["These LCCs are seeking multiple designation, pursuing more liberal traffic rights and greater transparency in the allocation of traffic rights.", [["LCCs", "CELL_TYPE", 6, 10], ["multiple", "OBSERVATION_MODIFIER", 23, 31], ["more", "OBSERVATION_MODIFIER", 54, 58], ["liberal", "OBSERVATION_MODIFIER", 59, 66], ["traffic rights", "OBSERVATION", 67, 81], ["greater", "OBSERVATION_MODIFIER", 86, 93], ["transparency", "OBSERVATION_MODIFIER", 94, 106], ["traffic rights", "OBSERVATION", 128, 142]]], ["These LCCs are likewise forcing regulators to accelerate the development of competition policies that will support their growth and development, provide a framework to address issues like predation by FSCs and more importantly, expand the gains from liberalisation.", [["LCCs", "ANATOMY", 6, 10], ["LCCs", "CELL_TYPE", 6, 10]]], ["These pressures will tend to drive ASEAN to accelerate its liberalisation process.Ownership and investmentBilateral and multilateral air service agreements have traditionally embodied a requirement that an airline be substantially owned and effectively controlled by the state of designation.", [["ASEAN", "PROTEIN", 35, 40], ["These pressures", "TEST", 0, 15], ["its liberalisation process", "PROBLEM", 55, 81], ["multilateral", "OBSERVATION_MODIFIER", 120, 132], ["air service", "OBSERVATION", 133, 144]]], ["Compared to a principal place of business test, this greatly constrains foreign investment and regional co-operation.", [["business test", "TEST", 33, 46], ["foreign investment", "OBSERVATION", 72, 90], ["regional co-operation", "OBSERVATION", 95, 116]]], ["119) argues that regionalism is a first step to the liberalisation of ownership and control in that the traditional concerns about ownership liberalisation (traffic rights and national and economic security) are not as relevant when the (sub)-regional parties are equal.", [["equal", "OBSERVATION", 264, 269]]], ["Cross-border investment between more than two states requires a regional approach, however it is a process, which outside of the EU, has not proceeded well.", [["Cross-border investment", "TREATMENT", 0, 23], ["a regional approach", "TREATMENT", 62, 81]]], ["The CLMV agreement retains very conventional 'ownership and control' clauses which is surprising because of the CLMV sub-regional partners have extensive foreign investment in their airlines, Myanmar from within ASEAN and Cambodia from within ASEAN and importantly, Hong Kong, as well.Ownership and investmentIf more extensive investment in the aviation sectors of the ASEAN countries is to occur, the sub-regional agreements as well as the continuing bilateral agreements should be varied from the traditional 'ownership and control' model, to a 'principal place of business' model.Competition policyAirline liberalisation has normally taken place in countries or regions with extensive competition policies,ARTICLE IN PRESS5 Air Asia's Kuala Lumpur-Senai indirectly competes with Kuala Lumpur-Singapore.", [["the CLMV sub", "PROBLEM", 108, 120], ["business' model", "TREATMENT", 567, 582], ["Airline liberalisation", "TREATMENT", 601, 623], ["extensive", "OBSERVATION_MODIFIER", 144, 153], ["foreign investment", "OBSERVATION", 154, 172], ["extensive", "OBSERVATION_MODIFIER", 317, 326], ["investment", "OBSERVATION_MODIFIER", 327, 337]]], ["The same is true for the Kuala Lumpur-Miri (East Malaysia) which has moved Royal Brunei Airlines to simplify its offerings in short-haul routes (Airline Business, April 2004). such as Europe, North America, Australia and New Zealand.", [["Royal Brunei Airlines", "TREATMENT", 75, 96], ["New", "OBSERVATION_MODIFIER", 221, 224]]], ["In some cases, the pressure for competition policies in ASEAN is coming from external forces, such as trade agreements concluded with other countries.", [["the pressure", "TEST", 15, 27], ["competition policies", "TREATMENT", 32, 52]]], ["These include mergers, collusion and price fixing, and predatory behaviour.ARTICLE IN PRESSControls on mergers exist to prevent the dominance of a market by one or a few firms, and to prevent the elimination of competition.", [["collusion", "TREATMENT", 23, 32]]], ["Merger policy is often applied to airlines.", [["Merger policy", "TREATMENT", 0, 13]]], ["In the US, airline mergers have been permitted after investigation, but it is unlikely that the large carriers, such as United or American, would be permitted to merge with each other.", [["large", "OBSERVATION_MODIFIER", 96, 101]]], ["In Europe, the merger between two large airlines, KLM and Air France, has been permittedcompetition from other airlines was judged sufficient to eliminate the possibility of dominance.", [["dominance", "PROBLEM", 174, 183], ["large", "OBSERVATION_MODIFIER", 34, 39], ["airlines", "OBSERVATION", 40, 48], ["Air France", "OBSERVATION", 58, 68], ["dominance", "OBSERVATION", 174, 183]]], ["If competition from LCCs is strong, the consequences of mergers by major airlines would be less severe.ARTICLE IN PRESSCollusion in pricing has been permitted in airline markets, though it is being increasingly outlawed.", [["competition from LCCs", "TEST", 3, 24], ["less severe", "OBSERVATION_MODIFIER", 91, 102]]], ["The higher profile of airlines may make collusion more difficult to hide.", [["collusion", "PROBLEM", 40, 49], ["higher", "OBSERVATION_MODIFIER", 4, 10]]], ["Price fixing between airlines could be a real problem in a liberalised environment in ASEAN.ARTICLE IN PRESSOf all competition policy issues, predation has been a big one for airlines, especially where small entrants have been challenging large incumbents.", [["large incumbents", "PROBLEM", 239, 255], ["challenging", "OBSERVATION_MODIFIER", 227, 238], ["large", "OBSERVATION_MODIFIER", 239, 244], ["incumbents", "OBSERVATION", 245, 255]]], ["There have been many cases or allegations of predation in the US, Europe, Canada and Australia involving airlines (see Forsyth et al., 2005) .", [["many", "OBSERVATION_MODIFIER", 16, 20], ["cases", "OBSERVATION", 21, 26]]], ["Incumbent airlines have strong advantages, but entrants also have some advantages, such as flexibility and lower costs.", [["lower", "ANATOMY_MODIFIER", 107, 112]]], ["Predation is likely to be an issue in the ASEAN context, where incumbent airlines are being challenged by small new entrants.Guidelines for state assistanceOne concern raised by private carriers in the move to ASEAN Open Sky is the uneven playing field because national carriers do not compete on equal terms.", [["Predation", "DISEASE", 0, 9], ["Predation", "TREATMENT", 0, 9], ["likely to be", "UNCERTAINTY", 13, 25], ["small", "OBSERVATION_MODIFIER", 106, 111], ["new", "OBSERVATION_MODIFIER", 112, 115]]], ["These subsidies take various forms such as direct financial assistance, favoured access to government business, bankruptcy provisions, and monopoly privileges which allow cross-subsidisation of airline operations.", [["airline operations", "TREATMENT", 194, 212]]], ["Subsidies distort the competitive process and based on the experience of ASEAN airlines, can breed inefficiencies, lead to higher costs and fares and make airlines survive competition only through extensive protection.Guidelines for state assistanceHow can ASEAN therefore pursue Open Sky given the various degrees of subsidies granted across airlines?", [["the competitive process", "PROBLEM", 18, 41], ["Open Sky", "TREATMENT", 280, 288], ["competitive", "OBSERVATION_MODIFIER", 22, 33], ["process", "OBSERVATION", 34, 41]]], ["The question therefore, for competitive neutrality, is not necessarily one of whether there are subsidies, but rather how the subsidies are given.", [["subsidies", "OBSERVATION", 96, 105]]], ["It is possible to give subsidies which do not distort the competitive process.", [["competitive", "OBSERVATION", 58, 69]]], ["There is a general policy that any state aid to an airline, for example, for restructuring after a crisis, must be approved by the European Commission, which will only grant approval after a detailed investigation.", [["a detailed investigation", "TEST", 189, 213]]], ["The move takes place in a region of considerable diversity-in real incomes, in the size of aviation and tourism sectors, in airline cost competitiveness, and in air transport policies.", [["considerable", "OBSERVATION_MODIFIER", 36, 48], ["diversity", "OBSERVATION", 49, 58], ["size", "OBSERVATION_MODIFIER", 83, 87]]], ["As against this, there is evidence that open skies within ASEAN would bring considerable benefits to the region as a whole, though these gains might not be equally shared by all countries.ConclusionsThere are no simple ways in which the move to open skies can be achieved.", [["open skies", "PROBLEM", 40, 50], ["simple ways", "PROBLEM", 212, 223], ["no", "UNCERTAINTY", 209, 211], ["simple", "OBSERVATION_MODIFIER", 212, 218]]], ["Pressure from rapidly developing LCCs may assist in breaking down restrictions, and it could lead to liberalisation ahead of the proposed schedule.", [["Pressure from rapidly developing LCCs", "PROBLEM", 0, 37], ["rapidly", "OBSERVATION_MODIFIER", 14, 21]]], ["Opening up secondary markets is giving LCCs scope to expand, and demonstrate the potential gains from more extensive liberalisation.", [["extensive", "OBSERVATION_MODIFIER", 107, 116], ["liberalisation", "OBSERVATION", 117, 131]]]], "040bf050205ece6fd0ccca3a01e5da3f22982e5c": [["During these last weeks we are receiving rather frequent feedback from both polydatin prescribers 43", [["polydatin", "CHEMICAL", 76, 85], ["polydatin", "CHEMICAL", 76, 85], ["polydatin", "SIMPLE_CHEMICAL", 76, 85], ["rather frequent feedback from both polydatin prescribers", "TREATMENT", 41, 97]]]], "6e218868d9a3bf4057ccf0be71cd2ac6828a9c76": [["Since its outbreak by the end of 2019, we have been able to learn some about this new SARS-Cov2 coronavirus.", [["SARS-Cov2 coronavirus", "DISEASE", 86, 107], ["SARS-Cov2 coronavirus", "ORGANISM", 86, 107], ["SARS-Cov2 coronavirus", "SPECIES", 86, 107], ["this new SARS-Cov2 coronavirus", "PROBLEM", 77, 107]]], ["Unfortunately, new facts come with a lag compared to the virus spread and governments are forced to make prompt decisions based on limited evidence which changes at a staggering pace.", [["a lag", "PROBLEM", 35, 40]]], ["The fight against a practically unknown enemy has been and still is the major obstacle.", [["enemy", "OBSERVATION", 40, 45]]], ["Aside from studying the virus's biology, infecting mechanisms, probable treatments and of course vaccine development, epidemic mathematical modelling has stepped forward.IntroductionIn a trade-off between simplicity and detail, compartmental modelling strategies provide a sharp suit that allows exploring a variety of scenarios and provides an intuitive understanding of the most critical factors governing disease dynamics.", [["treatments", "TREATMENT", 72, 82], ["course vaccine", "TREATMENT", 90, 104], ["epidemic mathematical modelling", "PROBLEM", 118, 149], ["IntroductionIn", "TREATMENT", 170, 184], ["compartmental modelling strategies", "TREATMENT", 228, 262], ["a sharp suit", "TREATMENT", 271, 283]]], ["The recent use of S(susceptible)-Exposed(E)-Infected(I)-Recovered(R) models has made a difference for public health care decision making by providing, for example, estimations of the impact of Non-Pharmaceutical Interventions (NPI) [1] .", [["Non-Pharmaceutical Interventions", "TREATMENT", 193, 225]]], ["The main challenge is to create a model that predicts plausible scenarios for a disease we have known for only four months.IntroductionOne of the most important barriers for the provision of solid epidemiological parameters has been the different management strategies that each country has taken in response to this outbreak.", [["a disease", "PROBLEM", 78, 87], ["IntroductionOne", "TREATMENT", 123, 138], ["the different management strategies", "TREATMENT", 233, 268], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Most importantly, uneven and time-varying testing criteria in different countries make the CFR an inadequate severity parameter.", [["the CFR", "TEST", 87, 94]]], ["South Korea and especially and more recently, Iceland's approach to testing massively for COVID-19 has brought us closer to the real Infection Fatality Rate (IFR) which describes more precisely the magnitude of the threat [2] .", [["testing", "TEST", 68, 75], ["COVID", "TEST", 90, 95], ["Infection", "OBSERVATION", 133, 142]]], ["Firstly, the asymptomatic or very mildly symptomatic group of individuals is more significant than previously thought [3] [4] [5] since they represent the vast majority of the infected individuals.", [["individuals", "ORGANISM", 185, 196], ["very mildly symptomatic group of individuals", "PROBLEM", 29, 73], ["mildly", "OBSERVATION_MODIFIER", 34, 40], ["symptomatic", "OBSERVATION", 41, 52], ["infected", "OBSERVATION", 176, 184]]], ["Secondly, these individuals, in most cases, are not detected nor isolated, and therefore appear to be the leading cause of the epidemic's spread.IntroductionWe proposed ourselves to model the strike of the virus locally (Mendoza-Argentina).", [["the epidemic's spread", "PROBLEM", 123, 144], ["IntroductionWe", "TREATMENT", 145, 159], ["epidemic", "OBSERVATION_MODIFIER", 127, 135]]], ["Argentina, as a developing country, was not going to be able to bear this pandemic without a health care collapse.", [["a health care collapse", "PROBLEM", 91, 113], ["collapse", "OBSERVATION", 105, 113]]], ["Based on the epidemic behaviour in Europe, the government determined a complete lock-down as the primary measure of control for the country as from March 20th, when Argentina's confirmed positive cases were only 128, mainly located in the capital city Buenos Aires and mostly imported.", [["Argentina's", "TEST", 165, 176], ["capital", "ANATOMY_MODIFIER", 239, 246]]], ["Prompt lock-down measures significantly flattened the curve at an early stage.", [["Prompt lock-down measures", "TREATMENT", 0, 25], ["curve", "OBSERVATION_MODIFIER", 54, 59], ["early stage", "OBSERVATION_MODIFIER", 66, 77]]], ["Arguably this was an anticipated measure, and it gave time to prepare (at least to some extent) for what was/is coming.IntroductionAs mentioned by Ferguson et al. [1] , the efficiency of mitigation and suppression measures depends on the size of the country or region in which these actions are implemented.", [["mitigation and suppression measures", "TREATMENT", 187, 222]]], ["Different population densities, uneven access to intensive health care, distinguishing age-related communities, all make the epidemic spread distinctively.", [["Different population densities", "PROBLEM", 0, 30], ["intensive health care", "TREATMENT", 49, 70], ["population", "OBSERVATION_MODIFIER", 10, 20], ["densities", "OBSERVATION", 21, 30], ["uneven", "OBSERVATION_MODIFIER", 32, 38]]], ["Therefore, a model should be able to take these variables into account.IntroductionWe propose here an SEIR model for COVID-19 epidemics that incorporates specific compartments that classify infected individuals in several clinical categories.", [["an SEIR model", "TEST", 99, 112], ["COVID", "TEST", 117, 122], ["epidemics", "PROBLEM", 126, 135], ["infected", "OBSERVATION", 190, 198]]], ["These compartments provide figures that can inform the strategic planning of health care requirements.", [["health care requirements", "TREATMENT", 77, 101]]], ["On the other hand, different regions exchange infectious and exposed individuals through communication routes.", [["different regions exchange infectious", "PROBLEM", 19, 56], ["infectious", "OBSERVATION", 46, 56]]], ["Consequently, the model can provide the possibility to trigger measures independently for each city and block intercommunications selectively.", [["block intercommunications", "TREATMENT", 104, 129]]], ["Most importantly, we model asymptomatic individuals as a subset of the infectious compartment.", [["infectious", "OBSERVATION", 71, 81]]], ["We demonstrate here the significant impact that detecting and isolating these individuals can have on the disease outcome.MethodsWe augmented the basic SEIR scheme by modelling symptomatic and asymptomatic individuals separately.", [["the disease outcome", "PROBLEM", 102, 121], ["significant", "OBSERVATION_MODIFIER", 24, 35]]], ["Symptomatic individuals can move into mild and severe cases which can recover or further evolve into critical care and recover or die.", [["individuals", "ORGANISM", 12, 23], ["Symptomatic individuals", "PROBLEM", 0, 23], ["mild and severe cases", "PROBLEM", 38, 59]]], ["Asymptomatic individuals may move into an isolated compartment after a detection lag of variable efficiency.", [["individuals", "ORGANISM", 13, 24], ["Asymptomatic individuals", "PROBLEM", 0, 24], ["variable efficiency", "PROBLEM", 88, 107], ["variable efficiency", "OBSERVATION", 88, 107]]], ["Figure 2 shows the possible timelines of the evolution of an initially susceptible individual together with the relevant parameters that determine the flow between compartments.", [["flow", "OBSERVATION", 151, 155]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)MethodsThe copyright holder for this preprint this version posted April 29, 2020.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["Table 2 .MethodsBased on recent calculations on the IFR, of 0.39-1.33% [2] , and most recently of 0.01-0.19% inferred from Iceland's statistics [3] , we adapted the parameters for our model to our country.", [["recent calculations", "TEST", 25, 44], ["the IFR", "TEST", 48, 55]]], ["Taking in consideration an IFR of ~0.3% and the current CFR in Argentina of ~3% we concluded that 90% of the infected cases were asymptomatic or with very mild symptoms not fulfilling the current Argentine criteria for COVID-19 testing (fever & sore throat or cough or respiratory distress).", [["respiratory", "ANATOMY", 269, 280], ["COVID-19", "CHEMICAL", 219, 227], ["fever", "DISEASE", 237, 242], ["sore throat", "DISEASE", 245, 256], ["cough", "DISEASE", 260, 265], ["respiratory distress", "DISEASE", 269, 289], ["an IFR", "TEST", 24, 30], ["the infected cases", "PROBLEM", 105, 123], ["asymptomatic", "PROBLEM", 129, 141], ["very mild symptoms", "PROBLEM", 150, 168], ["COVID", "TEST", 219, 224], ["fever", "PROBLEM", 237, 242], ["sore throat", "PROBLEM", 245, 256], ["cough", "PROBLEM", 260, 265], ["respiratory distress", "PROBLEM", 269, 289]]], ["The asymptomatic case percentage is in line with the published data by Li et al. [7] who estimated the undocumented cases in 86%.MethodsArgentina's principle to test only highly suspicious cases is leaving out asymptomatic and paucisymptomatic individuals.", [["asymptomatic and paucisymptomatic individuals", "PROBLEM", 210, 255], ["asymptomatic", "OBSERVATION_MODIFIER", 4, 16]]], ["For our model, we used the complete epidemiological data we found [1, 2] that referred to a subset of patients from China for which a similar criterion for COVID-19 testing and hospitalization than Argentina was used [1, 2] .", [["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["COVID", "TEST", 156, 161]]], ["We adapted it to maintain the CFR of ~3% and IFR~0.3%.", [["the CFR", "TEST", 26, 33], ["IFR", "TEST", 45, 48]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.23.20077255 doi: medRxiv preprint \"symptomatic cases\" in Argentina today, around 10% will require hospital care, of those, 36% will need intensive care unit facilities, and of the latter, 50% will die.(which was not certified by peer review)Based on European case growth rates, and in agreement with the parameters we set for our model, we presumed a basic reproduction number of 4 [8] .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["We assumed that mitigation measures (case-isolation, general social distancing, banning of public gatherings, school closures) lower R0 to 2 and suppression measures (complete lockdown or quarantine of the whole population except for essential activities) could make R0\u22641 [4] .", [["mitigation measures", "TREATMENT", 16, 35], ["suppression measures", "TREATMENT", 145, 165], ["the whole population", "TREATMENT", 202, 222]]], ["We supposed, as published, that asymptomatic individuals are half as infective as symptomatic patients [7] .", [["individuals", "ORGANISM", 45, 56], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["asymptomatic individuals", "PROBLEM", 32, 56]]], ["We inferred for these an attenuation factor of 0.5 in the basic reproduction number and \u2153-\u00bd the infective time of symptomatic cases [9].", [["symptomatic cases", "PROBLEM", 114, 131], ["attenuation", "OBSERVATION_MODIFIER", 25, 36]]], ["Time for which asymptomatic individual is infectious (days) 4 Li et al. 2020 [5] Time to recover for and cases that do not require ICU (days) 14 Fang et al. 2020 [6] Time to recover for an (days) 7 Zhang et al. 2020 [7, 8] Time for to require ICU (days) 7(which was not certified by peer review)[9](which was not certified by peer review)Time for to recover in ICU (days) 14 Fang et al. 2020 [6] Probability of an infected patient to be asymptomatic 0.9 Li et al. 2020 [5] Probability of an infected individual to require hospitalization 0. .", [["patient", "ORGANISM", 423, 430], ["patient", "SPECIES", 423, 430], ["asymptomatic", "PROBLEM", 437, 449], ["infectious", "OBSERVATION", 42, 52], ["infected", "OBSERVATION", 414, 422], ["infected", "OBSERVATION", 491, 499]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Attenuation factor for asymptomatic patients 0.", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44]]], ["Probabilistic parameters are adjusted to provide a CFR and IFR of 3 and 0.3% respectively in equilibrium.", [["a CFR", "TEST", 49, 54], ["IFR", "TEST", 59, 62]]], ["The quantity represents the probability that .", [["quantity", "OBSERVATION_MODIFIER", 4, 12]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.23.20077255 doi: medRxiv preprint an asymptomatic individual is detected and isolated.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv", "TREATMENT", 327, 334], ["an asymptomatic individual", "PROBLEM", 344, 370], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["asymptomatic", "OBSERVATION", 347, 359]]], ["The mean residence time parameters govern the dynamical evolution of the compartment populations.", [["compartment populations", "OBSERVATION", 73, 96]]], ["The model is scaled up to describe different interconnected areas or cities by integrating the ordinary differential equation set for periods of a day and exchanging exposed and infectious individuals at the end of each day according to the following equation:(which was not certified by peer review)Where and stand for the fraction of exposed and infectious individuals in regions and respectively, is the population of area and is the number of people exchanged daily between areas and .", [["people", "ORGANISM", 447, 453], ["people", "SPECIES", 447, 453], ["exchanging exposed and infectious individuals", "PROBLEM", 155, 200], ["scaled", "OBSERVATION_MODIFIER", 13, 19], ["interconnected", "OBSERVATION_MODIFIER", 45, 59], ["areas", "OBSERVATION", 60, 65], ["infectious", "OBSERVATION", 178, 188], ["infectious", "OBSERVATION", 348, 358], ["population", "OBSERVATION_MODIFIER", 407, 417], ["area", "OBSERVATION_MODIFIER", 421, 425], ["number", "OBSERVATION_MODIFIER", 437, 443]]], ["Infectious individuals include both asymptomatic and symptomatic ones.(which was not certified by peer review)We divided the Mendoza province into 4 regions: North (mostly urban), West (vineyard and mountain zone), East (primarily rural) and South (urban and rural).", [["Infectious individuals", "PROBLEM", 0, 22], ["both asymptomatic and symptomatic ones", "PROBLEM", 31, 69], ["asymptomatic", "OBSERVATION_MODIFIER", 36, 48], ["symptomatic", "OBSERVATION_MODIFIER", 53, 64]]], ["Hospital beds and ICU units for each area were added to the model.", [["Hospital beds", "TREATMENT", 0, 13], ["ICU units", "TREATMENT", 18, 27], ["each area", "TREATMENT", 32, 41]]], ["Additionally, an estimate of how many people travel daily between the regions was considered (Figure 3 ).ResultsUse of the regional compartmentalization of the model .", [["people", "ORGANISM", 38, 44], ["people", "SPECIES", 38, 44], ["regional compartmentalization", "OBSERVATION", 123, 152]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["We set our model to run in 4 zones of the Mendoza province considering their respective population, daily mobilization of people between the regions, and health care facilities for each area ( Figure 3) .", [["people", "ORGANISM", 122, 128], ["people", "SPECIES", 122, 128]]], ["As an example of the application of this tool, we simulated an outbreak in the North zone, starting with one infected person and monitored its arrival to the West area.", [["person", "SPECIES", 118, 124], ["outbreak", "OBSERVATION_MODIFIER", 63, 71], ["North", "ANATOMY_MODIFIER", 79, 84], ["zone", "ANATOMY_MODIFIER", 85, 89]]], ["Around 10400 people travel every day between these districts.", [["people", "ORGANISM", 13, 19], ["people", "SPECIES", 13, 19]]], ["Without interfering in the communication routes between zones, it took 29 days (R0=4) and 88 days ( 0 = 2) for the virus to spread to the West zone.", [["the virus", "PROBLEM", 111, 120], ["interfering", "OBSERVATION_MODIFIER", 8, 19]]], ["As expected, this shows that blocking communication routes between districts is an excellent strategy to delay the entrance of the epidemic.", [["excellent", "OBSERVATION_MODIFIER", 83, 92], ["epidemic", "OBSERVATION_MODIFIER", 131, 139]]], ["Furthermore, in this restricted communication situation, the exponential curves eventually catch up if no other interventions are instated (data not shown in graph).", [["the exponential curves", "TEST", 57, 79]]], ["The importance of the asymptomatic group in the model.(which was not certified by peer review)Considering that the asymptomatic or very mildly affected individuals are the majority, as can be expected, to detect and isolate them diminishes the total infectious population and changes the epidemic evolution dynamics.", [["the asymptomatic or very mildly affected individuals", "PROBLEM", 111, 163], ["the total infectious population", "PROBLEM", 240, 271], ["asymptomatic", "OBSERVATION_MODIFIER", 115, 127], ["very", "OBSERVATION_MODIFIER", 131, 135], ["mildly", "OBSERVATION_MODIFIER", 136, 142], ["affected", "OBSERVATION", 143, 151], ["total", "OBSERVATION_MODIFIER", 244, 249], ["infectious", "OBSERVATION", 250, 260]]], ["As Li et al. have shown [3] the introduction of an asymptomatic reservoir with a different reproduction number modifies the epidemic evolution in a non-trivial manner.", [["Li", "CHEMICAL", 3, 5], ["an asymptomatic reservoir", "TREATMENT", 48, 73]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.23.20077255 doi: medRxiv preprint modification of the effective reproduction number when asymptomatic individuals are considered.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint modification", "TREATMENT", 327, 356], ["asymptomatic individuals", "PROBLEM", 399, 423], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Elaborating on this result, we can add that fast and efficient detection plus the isolation of asymptomatic individuals can indeed control the epidemic.", [["asymptomatic individuals", "PROBLEM", 95, 119]]], ["The effective reproduction number of the model shown in Figure 1 is significantly altered by fast and efficient detection plus the isolation of asymptomatic individuals, as shown in Figure 5 .", [["asymptomatic individuals", "PROBLEM", 144, 168], ["effective", "OBSERVATION_MODIFIER", 4, 13]]], ["If the efficiency of detection is 50% within three days of becoming infectious, the effective reproduction number can be reduced by a half.", [["detection", "TEST", 21, 30], ["infectious", "PROBLEM", 68, 78], ["infectious", "OBSERVATION", 68, 78]]], ["If this policy is accompanied by other non-pharmaceutical interventions that lower the basic reproduction number such as mitigation and suppression measures then the effective reproduction number can be brought to values lower than one, effectively controlling the epidemic.", [["non-pharmaceutical interventions", "TREATMENT", 39, 71], ["mitigation and suppression measures", "TREATMENT", 121, 156]]], ["On the opposite extreme, the effective reproduction number is larger than the 0 parameter when asymptomatics are not isolated and therefore remain infectious until recovery.", [["effective", "OBSERVATION_MODIFIER", 29, 38], ["larger", "OBSERVATION_MODIFIER", 62, 68], ["infectious", "OBSERVATION", 147, 157]]], ["For details on the calculation of the effective reproduction number please refer to the supplementary information.(which was not certified by peer review)As can be expected from its influence on the effective reproduction number, the isolation of asymptomatic individuals has a dramatic effect on the duplication time of the epidemic in the exponential growth phase.", [["asymptomatic individuals", "PROBLEM", 247, 271], ["dramatic", "OBSERVATION_MODIFIER", 278, 286], ["growth", "OBSERVATION_MODIFIER", 353, 359], ["phase", "OBSERVATION_MODIFIER", 360, 365]]], ["In a basic reproduction number scenario of 2, isolating half of the asymptomatic individuals within four days of becoming infectious can effectively double the time it takes for clinical cases to duplicate in the exponential growth phase.", [["infectious", "PROBLEM", 122, 132], ["infectious", "OBSERVATION", 122, 132]]], ["This effect is smaller for more significant reproduction numbers reinforcing the statement that other interventions must accompany this policy in order to control the epidemic.", [["smaller", "OBSERVATION_MODIFIER", 15, 22]]], ["The consequence on the effective reproduction number of the removal of asymptomatic individuals from the infectious pool affects both epidemic dynamics and equilibrium values.", [["the removal", "TREATMENT", 56, 67], ["asymptomatic individuals", "PROBLEM", 71, 95], ["the infectious pool", "PROBLEM", 101, 120], ["infectious", "OBSERVATION_MODIFIER", 105, 115]]], ["The result is robust over a wide range of parameters.", [["robust", "OBSERVATION_MODIFIER", 14, 20]]], ["Figure 6 shows the effect of efficient asymptomatic isolation on health capacity burden and overall mortality for the whole population.", [["efficient asymptomatic isolation on health capacity burden", "PROBLEM", 29, 87], ["asymptomatic", "OBSERVATION_MODIFIER", 39, 51], ["isolation", "OBSERVATION", 52, 61]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.23.20077255 doi: medRxiv preprint 100000 sets of parameters.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv", "TREATMENT", 327, 334], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["We assumed the detection and isolation of 50% of asymptomatic individuals in day 3.(which was not certified by peer review)Efficient removal of asymptomatic infectious individuals from circulation has dramatic effects on healthcare burden and fatality over the total population, mainly when R remains at the lower end.", [["the detection", "TEST", 11, 24], ["isolation", "TREATMENT", 29, 38], ["Efficient removal", "TREATMENT", 123, 140], ["asymptomatic infectious individuals", "PROBLEM", 144, 179], ["removal", "OBSERVATION_MODIFIER", 133, 140], ["asymptomatic", "OBSERVATION_MODIFIER", 144, 156], ["infectious", "OBSERVATION", 157, 167], ["dramatic", "OBSERVATION_MODIFIER", 201, 209], ["effects", "OBSERVATION_MODIFIER", 210, 217], ["lower", "ANATOMY_MODIFIER", 308, 313]]], ["Once more, this supports the importance to maintain other mitigation actions in combination with asymptomatic detection and isolation.", [["other mitigation actions", "TREATMENT", 52, 76], ["asymptomatic detection", "TEST", 97, 119], ["isolation", "TREATMENT", 124, 133]]], ["Figure 6 : Healthcare burden effect of detection and isolation of 50% of asymptomatic individuals within three days of becoming infectious.", [["detection", "TEST", 39, 48], ["isolation", "TREATMENT", 53, 62], ["asymptomatic individuals", "PROBLEM", 73, 97], ["infectious", "PROBLEM", 128, 138], ["infectious", "OBSERVATION", 128, 138]]], ["The plots show medians and interquartile ranges over a sample of 100000 sets of parameters of important healthcare parameters: maximum usage of hospital beds (ICU and non-ICU), and accumulated fatalities when system reaches equilibrium.Suppression TriggersConsidering the hospital beds and ICU facilities for each zone, we ventured to see if a zone-specific on-off suppression measure policy was feasible, as suggested by Ferguson et al. [1] .", [["a zone", "PROBLEM", 342, 348]]], ["Considering the results shown in Figure 4 , the communication between all the districts was diminished to a tenth as well.", [["diminished", "OBSERVATION", 92, 102]]], ["We set a trigger of 50% ICU occupancy (of beds destined to be used for COVID-19, assuming ~70% of total ICU beds were going to be intended to the pandemic) to turn on suppression measures and a stopper of 30% of ICU occupancy to relax these actions.", [["COVID", "TEST", 71, 76], ["total ICU beds", "TREATMENT", 98, 112], ["suppression measures", "TREATMENT", 167, 187], ["ICU occupancy", "TREATMENT", 212, 225]]], ["Considering 0 = 4 as normal activities before this pandemic and 0 = 2 with necessary containment measures .", [["pandemic", "DISEASE", 51, 59], ["necessary containment measures", "TREATMENT", 75, 105]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.23.20077255 doi: medRxiv preprint but not complete lock-down.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv", "TREATMENT", 327, 334], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["An = 1 was considered when complete lock-down or quarantine was ordered.(which was not certified by peer review)In the first scenario, the exponentiality of an 0 = 4 curve is impossible to stop, even when a complete lock-down is set, and inevitably the sanitary system collapses in all areas, making this undoubtedly a lousy strategy.", [["quarantine", "TREATMENT", 49, 59], ["collapses", "OBSERVATION", 269, 278]]], ["This evidence supports once more what we said in the previous scheme; life cannot return to normal when suppression measures are relaxed.", [["normal", "OBSERVATION", 92, 98]]], ["In Figure 8 we show that the Northern area can stand this situation without a sanitary collapse, needing two quarantines to surpass the epidemic.", [["a sanitary collapse", "PROBLEM", 76, 95], ["collapse", "OBSERVATION", 87, 95]]], ["The other, more rural areas still have an overwhelmed health care system and need much more time in maximum isolation.(which was not certified by peer review).", [["maximum isolation", "TREATMENT", 100, 117]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.23.20077255 doi: medRxiv preprint Since intensive health care facilities are mainly located in the North, we set our model with the ICU beds as a single pool for the whole province.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["the ICU beds", "TREATMENT", 438, 450], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["We still maintained the areas separated regarding the rest of the parameters.", [["areas", "OBSERVATION_MODIFIER", 24, 29]]], ["Also, movement between cities remained restricted to a tenth.", [["movement", "OBSERVATION_MODIFIER", 6, 14]]], ["This strategy kept the health system below saturation and the quarantine periods were more acceptable for the whole territory.", [["the quarantine periods", "TREATMENT", 58, 80]]], ["Still, in this scenario, 4.5 months of lock-down are needed to endure the pandemic and the inconvenience of having to transfer patients throughout the territory yet needs to be taken into account.", [["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 127, 135]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.23.20077255 doi: medRxiv preprint Figure 9 : The effect of triggered on-off suppression measures in the whole territory (trigger=50% ICU occupancy, stopper=30% ICU occupancy) in a 0 = 2 scenario.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["suppression measures", "TREATMENT", 386, 406], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["ICU beds were considered as a single pool for the entire province.", [["ICU beds", "TREATMENT", 0, 8]]], ["Dotted lines represent reproduction number fluctuance between 0 = 2 (moderate containment measures installed) and 0 = 1 (lock-down).", [["Dotted lines", "CELL", 0, 12], ["Dotted lines", "TREATMENT", 0, 12], ["reproduction", "OBSERVATION_MODIFIER", 23, 35], ["number", "OBSERVATION_MODIFIER", 36, 42], ["fluctuance", "OBSERVATION_MODIFIER", 43, 53]]], ["Full lines represent % of ICU occupied beds throughout the timeline for which these on-off measures were simulated.(which was not certified by peer review)Since the asymptomatic group is such an essential part of the system, we ventured to see what would happen if one could detect and isolate at least a proportion of them.", [["Full lines", "TREATMENT", 0, 10], ["lines", "OBSERVATION", 5, 10]]], ["Thus, using the same triggers as before (ICU beds 50%-30%), in a synchronized system, we added the detection and isolation of different proportions of asymptomatic individuals.", [["ICU beds", "TREATMENT", 41, 49], ["the detection", "TEST", 95, 108], ["asymptomatic individuals", "PROBLEM", 151, 175]]], ["In Figure 10 we see that screening for asymptomatic cases diminishes significantly the time needed with complete lock-down.", [["screening", "TEST", 25, 34], ["asymptomatic cases diminishes", "PROBLEM", 39, 68]]], ["In the ideal assumption that 45% of the asymptomatics could be detected and isolated, there would be no need for quarantine, and the health care system would not collapse.(which was not certified by peer review).", [["asymptomatics", "CANCER", 40, 53], ["quarantine", "TREATMENT", 113, 123], ["collapse", "PROBLEM", 162, 170], ["collapse", "OBSERVATION", 162, 170]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.23.20077255 doi: medRxiv preprint Figure 10 : The effect of detecting and isolating different percentages of asymptomatic individuals on a model triggering on-off suppression measures in the whole territory (trigger=50% ICU occupancy, stopper=30% ICU occupancy) in a 0 = 2 scenario.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["asymptomatic individuals", "PROBLEM", 419, 443], ["suppression measures", "TREATMENT", 473, 493], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["asymptomatic", "OBSERVATION_MODIFIER", 419, 431]]], ["ICU beds were considered as a single pool for the entire province.", [["ICU beds", "TREATMENT", 0, 8]]], ["Dotted lines represent reproduction number fluctuance between 0 = 2 (moderate containment measures installed) and 0 = 1 (lock-down).", [["Dotted lines", "CELL", 0, 12], ["Dotted lines", "TREATMENT", 0, 12], ["reproduction", "OBSERVATION_MODIFIER", 23, 35], ["number", "OBSERVATION_MODIFIER", 36, 42], ["fluctuance", "OBSERVATION_MODIFIER", 43, 53]]], ["Full lines represent % of ICU occupied beds throughout the timeline for which these on-off measures were simulated.Discussion and conclusionsArgentina was one of the countries that acted fastest and most rigorously very early in the arrival of the pandemic, setting a complete lock-down when only 128 cases had been reported.", [["Full lines", "TREATMENT", 0, 10], ["lines", "OBSERVATION", 5, 10]]], ["This policy has indeed \"flattened the curve\" as it has in many countries around the world for which the growth of clinical cases has changed from exponential to linear in time.", [["flattened", "OBSERVATION_MODIFIER", 24, 33], ["growth", "OBSERVATION_MODIFIER", 104, 110]]], ["The sustainment of drastic suppression measures over months, albeit possibly successful, is not sustainable and alternatives must be considered.Discussion and conclusionsTo establish a reliable mathematical model for a practically unknown disease was a challenge, but we had the advantage to count with previous epidemiological studies [2, 6, 11, 12] and modelling proposals [5, 10, 13] .", [["drastic suppression measures", "TREATMENT", 19, 47], ["a practically unknown disease", "PROBLEM", 217, 246], ["previous epidemiological studies", "TEST", 303, 335], ["drastic suppression", "OBSERVATION", 19, 38]]], ["We established a locally inspired mathematical model of the disease, in the ~1,900,000 population province of Mendoza-Argentina, which can apply to any other city or country.Discussion and conclusionsThe model we propose provides explicit variables such as the number of patients under intensive care, hospital admissions, mild cases, and asymptomatic individuals.", [["patients", "ORGANISM", 271, 279], ["patients", "SPECIES", 271, 279], ["the disease", "PROBLEM", 56, 67], ["mild cases", "PROBLEM", 323, 333], ["asymptomatic individuals", "PROBLEM", 339, 363], ["locally", "OBSERVATION_MODIFIER", 17, 24], ["disease", "OBSERVATION", 60, 67], ["mild", "OBSERVATION_MODIFIER", 323, 327]]], ["These variables are described dynamically according to the different residence times in each compartment and branching probabilities.", [["branching probabilities", "OBSERVATION", 109, 132]]], ["We consider this to be a superior alternative to evaluating health burden parameters from a purely probabilistic point of view that does not consider the dynamical nature of the epidemic evolution.", [["epidemic", "OBSERVATION", 178, 186]]], ["Furthermore, our model is adapted to the regional realities of small districts, which can be used as a strategy tool for any place in the world.Discussion and conclusionsWe confirmed that if an outbreak were to burst in one city, blocking circulating routes can as expected, have an essential impact.", [["small districts", "PROBLEM", 63, 78], ["an outbreak", "PROBLEM", 191, 202], ["small", "OBSERVATION_MODIFIER", 63, 68], ["districts", "OBSERVATION", 69, 78], ["essential", "OBSERVATION_MODIFIER", 283, 292], ["impact", "OBSERVATION", 293, 299]]], ["On the other hand, the health care distribution of Mendoza made a regionalized trigger for suppression impractical because of the uneven assignment of intensive care units.", [["intensive care units", "TREATMENT", 151, 171]]], ["Still, in other countries or regions, this strategy might be useful.Discussion and conclusionsThe significant contribution we can make is to suggest that asymptomatic or very mildly ill patients provide a primordial hinge to manage the epidemic.", [["patients", "ORGANISM", 186, 194], ["patients", "SPECIES", 186, 194], ["very mildly ill", "PROBLEM", 170, 185], ["a primordial hinge", "TREATMENT", 203, 221], ["the epidemic", "PROBLEM", 232, 244], ["significant", "OBSERVATION_MODIFIER", 98, 109]]], ["Any control upon them exerts a substantial impact on the disease outcome.", [["the disease outcome", "PROBLEM", 53, 72]]], ["Previously described on-off suppression strategies [10] become much more effective when combined with the detection and isolation of asymptomatic cases.", [["suppression strategies", "TREATMENT", 28, 50], ["the detection", "TEST", 102, 115], ["asymptomatic cases", "PROBLEM", 133, 151]]], ["The association of mitigation measures with detection and isolation of around half of the asymptomatic and paucisymptomatic individuals would not need strict suppressive actions.", [["mitigation measures", "TREATMENT", 19, 38], ["detection", "TEST", 44, 53], ["isolation", "TREATMENT", 58, 67], ["the asymptomatic and paucisymptomatic individuals", "PROBLEM", 86, 135], ["strict suppressive actions", "TREATMENT", 151, 177]]], ["Therefore, massive COVID-19 screening would be an alternative to the province's complete lock-down.Discussion and conclusions.", [["massive COVID-19 screening", "TEST", 11, 37]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Discussion and conclusionsThe copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.23.20077255 doi: medRxiv preprint For low-income countries, like ours, screening by pool-testing could be a helpful strategy if started early in the epidemic.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 228, 248], ["medRxiv", "TREATMENT", 354, 361], ["pool-testing", "TEST", 421, 433], ["med", "ANATOMY", 105, 108]]], ["Yelin et al. [14] showed that samples could be examined adequately in pools of 32, reducing dramatically the costs needed for extensive screening.", [["samples", "ANATOMY", 30, 37], ["extensive screening", "TEST", 126, 145]]], ["Argentina could use this strategy to detect and isolate as many asymptomatic or very mildly affected individuals as possible to be able to reduce the time span over which strict suppression measures are in effect.Discussion and conclusionsOur model and its analysis inform that the detection and isolation of all infected individuals, without leaving aside the asymptomatic group is the key to surpass this pandemic.FundingThis work was supported by funding from: CONICET and Universidad Nacional de Cuyo.", [["this strategy", "TREATMENT", 20, 33], ["very mildly affected individuals", "PROBLEM", 80, 112], ["strict suppression measures", "TREATMENT", 171, 198], ["its analysis", "TEST", 253, 265], ["the detection", "TEST", 278, 291], ["all infected individuals", "PROBLEM", 309, 333]]]], "af61bbcf5bf8870b8f20b0262cc60b05ca108f51": [["Introduction to RNA-Based and Gene Therapeutic StrategiesIn this chapter we will discuss the current status and challenges of using RNA interference (RNAi) and microRNA modulation strategies for the treatment of myocardial disorders and relate them to the classical gene therapeutic approaches of the past decade.", [["myocardial", "ANATOMY", 212, 222], ["myocardial disorders", "DISEASE", 212, 232], ["myocardial", "MULTI-TISSUE_STRUCTURE", 212, 222], ["RNA", "TREATMENT", 16, 19], ["Gene Therapeutic Strategies", "TREATMENT", 30, 57], ["RNA interference (RNAi)", "TREATMENT", 132, 155], ["microRNA modulation strategies", "TREATMENT", 160, 190], ["myocardial disorders", "PROBLEM", 212, 232], ["myocardial", "ANATOMY", 212, 222]]], ["2 summarizes the key issues of current vector technologies which critically determine if they may be suitable for clinical translation of experimental RNAi or microRNA therapeutic protocols.", [["current vector technologies", "TREATMENT", 31, 58], ["experimental RNAi", "TREATMENT", 138, 155], ["microRNA therapeutic protocols", "TREATMENT", 159, 189]]], ["We will then present and discuss two examples dealing with the potential of cardiac RNAi therapy.", [["cardiac", "ANATOMY", 76, 83], ["cardiac", "ORGAN", 76, 83], ["cardiac RNAi therapy", "TREATMENT", 76, 96], ["cardiac", "ANATOMY", 76, 83], ["RNAi therapy", "OBSERVATION", 84, 96]]], ["The first example deals with an attempt to block a very early step in the pathogenesis of a virus-induced cardiomyopathy and the resulting heart failure by RNAi targeting of a cellular receptor for cardiopathogenic viruses (Sect.", [["heart", "ANATOMY", 139, 144], ["cellular", "ANATOMY", 176, 184], ["cardiomyopathy", "DISEASE", 106, 120], ["heart failure", "DISEASE", 139, 152], ["heart", "ORGAN", 139, 144], ["cellular", "CELL", 176, 184], ["cellular receptor", "PROTEIN", 176, 193], ["a virus", "PROBLEM", 90, 97], ["cardiomyopathy", "PROBLEM", 106, 120], ["the resulting heart failure", "PROBLEM", 125, 152], ["a cellular receptor", "TREATMENT", 174, 193], ["cardiopathogenic viruses", "PROBLEM", 198, 222], ["cardiomyopathy", "OBSERVATION", 106, 120], ["heart", "ANATOMY", 139, 144], ["failure", "OBSERVATION", 145, 152]]], ["The second examples deals with an approach to improve cardiac function by RNAi targeting a late, common pathway of heart failure pathogenesis which is common to myocardial disorders of multiple etiologies.", [["cardiac", "ANATOMY", 54, 61], ["heart", "ANATOMY", 115, 120], ["myocardial", "ANATOMY", 161, 171], ["heart failure", "DISEASE", 115, 128], ["myocardial disorders", "DISEASE", 161, 181], ["cardiac", "ORGAN", 54, 61], ["heart", "ORGAN", 115, 120], ["myocardial", "MULTI-TISSUE_STRUCTURE", 161, 171], ["an approach", "TREATMENT", 31, 42], ["heart failure pathogenesis", "PROBLEM", 115, 141], ["myocardial disorders", "PROBLEM", 161, 181], ["multiple etiologies", "PROBLEM", 185, 204], ["heart", "ANATOMY", 115, 120], ["failure", "OBSERVATION", 121, 128], ["multiple", "OBSERVATION_MODIFIER", 185, 193], ["etiologies", "OBSERVATION", 194, 204]]], ["This strategy is directed at myocardiac Ca 2+ homeostasis which is a major component of heart failure due to coronary heart disease (ischemic cardiomyopathy), heart valve dysfunction (valvular cardio moypathy), cardiac inflammation (inflammatory cardiomyopathy), or genetic defects (dilated cardiomyopathy) (Sect.", [["myocardiac", "ANATOMY", 29, 39], ["heart", "ANATOMY", 88, 93], ["coronary", "ANATOMY", 109, 117], ["heart", "ANATOMY", 118, 123], ["heart valve", "ANATOMY", 159, 170], ["valvular", "ANATOMY", 184, 192], ["cardiac", "ANATOMY", 211, 218], ["Ca", "CHEMICAL", 40, 42], ["heart failure", "DISEASE", 88, 101], ["coronary heart disease", "DISEASE", 109, 131], ["ischemic cardiomyopathy", "DISEASE", 133, 156], ["heart valve dysfunction", "DISEASE", 159, 182], ["valvular cardio moypathy", "DISEASE", 184, 208], ["cardiac inflammation", "DISEASE", 211, 231], ["inflammatory cardiomyopathy", "DISEASE", 233, 260], ["genetic defects", "DISEASE", 266, 281], ["dilated cardiomyopathy", "DISEASE", 283, 305], ["Ca 2+", "CHEMICAL", 40, 45], ["heart", "ORGAN", 88, 93], ["heart", "ORGAN", 118, 123], ["heart valve", "MULTI-TISSUE_STRUCTURE", 159, 170], ["cardiac", "ORGAN", 211, 218], ["heart failure", "PROBLEM", 88, 101], ["coronary heart disease", "PROBLEM", 109, 131], ["ischemic cardiomyopathy", "PROBLEM", 133, 156], ["heart valve dysfunction", "PROBLEM", 159, 182], ["valvular cardio moypathy)", "PROBLEM", 184, 209], ["cardiac inflammation", "PROBLEM", 211, 231], ["inflammatory cardiomyopathy)", "PROBLEM", 233, 261], ["genetic defects", "PROBLEM", 266, 281], ["dilated cardiomyopathy", "PROBLEM", 283, 305], ["heart", "ANATOMY", 88, 93], ["failure", "OBSERVATION", 94, 101], ["coronary heart", "ANATOMY", 109, 123], ["disease", "OBSERVATION", 124, 131], ["ischemic", "OBSERVATION_MODIFIER", 133, 141], ["cardiomyopathy", "OBSERVATION", 142, 156], ["heart valve", "ANATOMY", 159, 170], ["dysfunction", "OBSERVATION", 171, 182], ["valvular cardio", "ANATOMY", 184, 199], ["cardiac", "ANATOMY", 211, 218], ["inflammation", "OBSERVATION", 219, 231], ["inflammatory", "OBSERVATION_MODIFIER", 233, 245], ["genetic defects", "OBSERVATION", 266, 281], ["dilated", "OBSERVATION_MODIFIER", 283, 290], ["cardiomyopathy", "OBSERVATION", 291, 305]]], ["Whereas the first type of strategies (directed at early pathogenic steps) needs to be tailor-made for each different type of pathogenesis, the second type (which target late common pathways) has a much broader range of application.", [["pathogenesis", "PROBLEM", 125, 137]]], ["This advantage of the second type of approach is of major importance since enormous efforts need to be undertaken before an RNAi or micro RNA-based therapeutic protocol enters the stage of possible clinical translation.", [["an RNAi", "TREATMENT", 121, 128], ["micro RNA", "TREATMENT", 132, 141], ["therapeutic protocol", "TREATMENT", 148, 168]]], ["If, then, the number of patients eligible for this protocol is large, the actual transformation of the experimental therapy into a new therapeutic option of major clinical importance is far more likely to occur.Key Issues of Current Vector TechnologiesThe classical first concept of gene therapy which has been developed for monogenic disorders caused by deficiency of a single gene is gene substitution therapy.Key Issues of Current Vector TechnologiesIn the field of cardiology, several monogenic disorders primarily manifested in the myocardium could theoretically be cured by this approach.", [["myocardium", "ANATOMY", 537, 547], ["monogenic disorders", "DISEASE", 325, 344], ["monogenic disorders", "DISEASE", 489, 508], ["patients", "ORGANISM", 24, 32], ["myocardium", "ORGAN", 537, 547], ["patients", "SPECIES", 24, 32], ["this protocol", "TREATMENT", 46, 59], ["the experimental therapy", "TREATMENT", 99, 123], ["Current Vector Technologies", "TREATMENT", 225, 252], ["gene therapy", "TREATMENT", 283, 295], ["monogenic disorders", "PROBLEM", 325, 344], ["deficiency", "PROBLEM", 355, 365], ["a single gene", "TREATMENT", 369, 382], ["gene substitution therapy", "TREATMENT", 386, 411], ["Current Vector Technologies", "TREATMENT", 426, 453], ["several monogenic disorders", "PROBLEM", 481, 508], ["large", "OBSERVATION_MODIFIER", 63, 68], ["substitution therapy", "OBSERVATION", 391, 411], ["monogenic", "OBSERVATION_MODIFIER", 489, 498], ["disorders", "OBSERVATION", 499, 508], ["myocardium", "ANATOMY", 537, 547]]], ["Among them are the various long-QT syndromes, the arrhythmogenic right ventricular dysplasia, the Brugada syndrome, the hypertrophic cardiomyopathies caused by a host of mutations in various sarcomeric proteins, and the dilated cardiomyopathies.", [["right ventricular dysplasia", "ANATOMY", 65, 92], ["arrhythmogenic right ventricular dysplasia", "DISEASE", 50, 92], ["Brugada syndrome", "DISEASE", 98, 114], ["hypertrophic cardiomyopathies", "DISEASE", 120, 149], ["dilated cardiomyopathies", "DISEASE", 220, 244], ["ventricular dysplasia", "PATHOLOGICAL_FORMATION", 71, 92], ["sarcomeric proteins", "PROTEIN", 191, 210], ["the various long-QT syndromes", "PROBLEM", 15, 44], ["the arrhythmogenic right ventricular dysplasia", "PROBLEM", 46, 92], ["the Brugada syndrome", "PROBLEM", 94, 114], ["the hypertrophic cardiomyopathies", "PROBLEM", 116, 149], ["mutations in various sarcomeric proteins", "PROBLEM", 170, 210], ["the dilated cardiomyopathies", "PROBLEM", 216, 244], ["arrhythmogenic", "OBSERVATION_MODIFIER", 50, 64], ["right ventricular", "ANATOMY", 65, 82], ["dysplasia", "OBSERVATION", 83, 92], ["Brugada syndrome", "OBSERVATION", 98, 114], ["hypertrophic", "OBSERVATION_MODIFIER", 120, 132], ["cardiomyopathies", "OBSERVATION", 133, 149], ["sarcomeric proteins", "OBSERVATION", 191, 210], ["dilated", "OBSERVATION_MODIFIER", 220, 227], ["cardiomyopathies", "OBSERVATION", 228, 244]]], ["A second concept of gene therapy is the enhancement of gene functions to cells, tissues, and organs by overexpression of primarily endogenous genes using gene transfer vectors.", [["cells", "ANATOMY", 73, 78], ["tissues", "ANATOMY", 80, 87], ["organs", "ANATOMY", 93, 99], ["cells", "CELL", 73, 78], ["tissues", "TISSUE", 80, 87], ["organs", "ORGAN", 93, 99], ["endogenous genes", "DNA", 131, 147], ["gene therapy", "TREATMENT", 20, 32], ["gene transfer vectors", "TREATMENT", 154, 175], ["gene therapy", "OBSERVATION", 20, 32]]], ["Under appropriate conditions, a therapeutic effect may be achieved not only in genetically determined but also in acquired diseases.", [["acquired diseases", "PROBLEM", 114, 131]]], ["A third concept is the addition of truly novel gene functions to the target organ by vectorbased expression of foreign genes.", [["organ", "ANATOMY", 76, 81], ["organ", "ORGAN", 76, 81], ["foreign genes", "DNA", 111, 124], ["truly novel gene functions", "PROBLEM", 35, 61], ["foreign genes", "PROBLEM", 111, 124], ["foreign genes", "OBSERVATION", 111, 124]]], ["Novel concepts of far more recent origin involve the use of non-protein-coding, small regulatory RNA molecules for therapeutic purposes.", [["non-protein-coding, small regulatory RNA molecules", "PROTEIN", 60, 110], ["small regulatory RNA molecules", "PROBLEM", 80, 110], ["therapeutic purposes", "TREATMENT", 115, 135]]], ["They include the fourth concept of short hairpin RNA transcription from vectors for the suppression of gene functions in the diseased target organ or organism via the mechanism of RNA interference, and the fifth concept of using microRNA generation from vectors to achieve therapeutic modulation of cell and organ functions on the level of the cellular microRNA system (see Part I of this book).", [["organ", "ANATOMY", 141, 146], ["cell", "ANATOMY", 299, 303], ["organ", "ANATOMY", 308, 313], ["cellular", "ANATOMY", 344, 352], ["organ", "ORGAN", 141, 146], ["cell", "CELL", 299, 303], ["organ", "ORGAN", 308, 313], ["cellular", "CELL", 344, 352], ["short hairpin RNA", "RNA", 35, 52], ["short hairpin RNA transcription", "TREATMENT", 35, 66], ["gene functions", "PROBLEM", 103, 117], ["RNA interference", "PROBLEM", 180, 196], ["microRNA generation from vectors", "TREATMENT", 229, 261], ["therapeutic modulation of cell", "TREATMENT", 273, 303], ["organ functions", "TEST", 308, 323], ["diseased", "OBSERVATION", 125, 133], ["cellular microRNA", "OBSERVATION", 344, 361]]], ["Naturally, all of the following key issues of classical gene therapy (concepts 1-3) also apply similarly to the RNA-based therapies (concepts 4 and 5).", [["classical gene therapy", "TREATMENT", 46, 68], ["the RNA-based therapies", "TREATMENT", 108, 131]]], ["Figure 1 illustrates the fundamental difference in action between classical gene therapy vs. RNA therapy, but at the same time points to an important partial overlap between the two otherwise distinct strategies.", [["classical gene therapy", "TREATMENT", 66, 88], ["RNA therapy", "TREATMENT", 93, 104], ["therapy", "OBSERVATION", 97, 104], ["partial overlap", "OBSERVATION", 150, 165], ["distinct", "OBSERVATION_MODIFIER", 192, 200], ["strategies", "OBSERVATION", 201, 211]]], ["Common to both is the need to deliver the therapeutic structure (cDNA-encoded protein vs. regulatory RNA) to the right place, at an appropriate concentration for a sufficient period of time, and with adequate safety features.", [["cDNA", "DNA", 65, 69], ["encoded protein", "PROTEIN", 70, 85], ["regulatory RNA", "RNA", 90, 104], ["RNA", "OBSERVATION", 101, 104], ["right", "ANATOMY_MODIFIER", 113, 118]]], ["This partial overlap allows to exploit advanced vector technologies, initially developed in the gene therapy field, for most types of RNA therapy, too.Targeting of Vectors for Regulatory RNAs or GenesThe first key issue of vector technology is the mere physical steering (targeting) of the vector (irrespective of expressing a protein-encoding cDNA, a short hairpin RNA or a pre-microRNA) to the target tissue, e.g., the myocardium, which proved to be a difficult task.", [["tissue", "ANATOMY", 403, 409], ["myocardium", "ANATOMY", 421, 431], ["tissue", "TISSUE", 403, 409], ["myocardium", "MULTI-TISSUE_STRUCTURE", 421, 431], ["Vectors", "DNA", 164, 171], ["Regulatory RNAs", "RNA", 176, 191], ["cDNA", "DNA", 344, 348], ["short hairpin RNA", "RNA", 352, 369], ["advanced vector technologies", "TREATMENT", 39, 67], ["the gene therapy field", "TREATMENT", 92, 114], ["RNA therapy", "TREATMENT", 134, 145], ["Vectors", "TREATMENT", 164, 171], ["Regulatory RNAs", "TREATMENT", 176, 191], ["vector technology", "TREATMENT", 223, 240], ["a protein", "TEST", 325, 334], ["encoding cDNA", "PROBLEM", 335, 348], ["a short hairpin RNA", "PROBLEM", 350, 369], ["RNA therapy", "OBSERVATION", 134, 145], ["myocardium", "ANATOMY", 421, 431]]], ["Various approaches (Hoshijima et al. 2002; Rockman et al. 1998; White et al. 2000; Kypson et al. 1999; Koch et al. 2000; Ikeda et al. 2002) including intracoronary application (Giordano et al. 1996; Maurice et al. 1999) have been employed to achieve this goal, including already in clinical trials (Yl\u00e4-Herttuala and Alitalo 2003; Simons et al. 2000; Grines et al. 2002; Hedman et al. 2003) .", [["intracoronary application", "TREATMENT", 150, 175]]], ["A better understanding of the molecular and cellular determinants of vector targeting in the cardiovascular system has evolved during the past few years based on studies of the expression patterns of vector receptors (i.e. the receptors primarily mediating the cellular uptake of the virus from which the vector is derived) in animals (Fechner et al. 1999 (Fechner et al. , 2003a and humans (Noutsias et al. 2001; Poller et al. 2002a,b) , and on the discovery of anatomical barriers such as the vascular endothelium or intracellular matrix (Fechner et al. 1999) inhibiting or preventing vector transfer to particular parts of the heart and other organs and tumors.", [["cellular", "ANATOMY", 44, 52], ["cardiovascular system", "ANATOMY", 93, 114], ["cellular", "ANATOMY", 261, 269], ["vascular endothelium", "ANATOMY", 495, 515], ["intracellular matrix", "ANATOMY", 519, 539], ["heart", "ANATOMY", 630, 635], ["organs", "ANATOMY", 646, 652], ["tumors", "ANATOMY", 657, 663], ["tumors", "DISEASE", 657, 663], ["cellular", "CELL", 44, 52], ["cardiovascular", "ANATOMICAL_SYSTEM", 93, 107], ["system", "ANATOMICAL_SYSTEM", 108, 114], ["cellular", "CELL", 261, 269], ["humans", "ORGANISM", 384, 390], ["vascular endothelium", "TISSUE", 495, 515], ["intracellular matrix", "CELLULAR_COMPONENT", 519, 539], ["heart", "ORGAN", 630, 635], ["organs", "ORGAN", 646, 652], ["tumors", "CANCER", 657, 663], ["vector receptors", "PROTEIN", 200, 216], ["humans", "SPECIES", 384, 390], ["humans", "SPECIES", 384, 390], ["the virus", "PROBLEM", 280, 289], ["anatomical barriers", "PROBLEM", 463, 482], ["tumors", "PROBLEM", 657, 663], ["cardiovascular system", "ANATOMY", 93, 114], ["vascular endothelium", "ANATOMY", 495, 515], ["heart", "ANATOMY", 630, 635], ["organs", "ANATOMY", 646, 652], ["tumors", "OBSERVATION", 657, 663]]], ["Interestingly, the expression of a particularly important vector receptor, the Coxsackievirus- Adenovirus-Receptor (CAR), was found to be highly variable in human hearts (generalized induction in dilated cardiomyopathy) (Noutsias et al. 2001; Communal et al. 2003) and in animals (local induction after myocardial infarction) (Fechner et al. 2003a ).", [["hearts", "ANATOMY", 163, 169], ["myocardial", "ANATOMY", 303, 313], ["dilated cardiomyopathy", "DISEASE", 196, 218], ["myocardial infarction", "DISEASE", 303, 324], ["Coxsackievirus- Adenovirus", "ORGANISM", 79, 105], ["-Receptor", "GENE_OR_GENE_PRODUCT", 105, 114], ["CAR", "GENE_OR_GENE_PRODUCT", 116, 119], ["human", "ORGANISM", 157, 162], ["hearts", "ORGAN", 163, 169], ["myocardial", "MULTI-TISSUE_STRUCTURE", 303, 313], ["Coxsackievirus- Adenovirus-Receptor", "PROTEIN", 79, 114], ["CAR", "PROTEIN", 116, 119], ["Coxsackievirus- Adenovirus", "SPECIES", 79, 105], ["human", "SPECIES", 157, 162], ["Coxsackievirus- Adenovirus", "SPECIES", 79, 105], ["human", "SPECIES", 157, 162], ["dilated cardiomyopathy", "PROBLEM", 196, 218], ["myocardial infarction", "PROBLEM", 303, 324], ["human hearts", "ANATOMY", 157, 169], ["dilated", "OBSERVATION", 196, 203], ["myocardial", "ANATOMY", 303, 313], ["infarction", "OBSERVATION", 314, 324]]], ["Receptor-directed strategies (Curiel 1999) for the improvement of myocardial vector targeting have been evaluated but without significant success in vivo.", [["myocardial", "ANATOMY", 66, 76], ["myocardial", "MULTI-TISSUE_STRUCTURE", 66, 76], ["myocardial vector targeting", "TREATMENT", 66, 93], ["myocardial", "ANATOMY", 66, 76]]], ["If perfect physical vector targeting to the diseased tissue cannot be achieved, additional transcriptional confinement of the transgene may be achieved by using cardiac-specific promotors (Franz et al. 1997; Henderson et al. 1989; Reynolds et al. 2001) .", [["tissue", "ANATOMY", 53, 59], ["cardiac", "ANATOMY", 161, 168], ["tissue", "TISSUE", 53, 59], ["the diseased tissue", "PROBLEM", 40, 59], ["diseased", "OBSERVATION", 44, 52]]], ["Recognition of the strong receptor-dependency of vector targeting has prompted investigation dealing with the possible therapeutic potential of tropism modifications by altering the receptor-interaction domains of the viruses used as vectors.", [["receptor-interaction domains", "PROTEIN", 182, 210], ["tropism modifications", "TREATMENT", 144, 165], ["tropism", "OBSERVATION", 144, 151], ["viruses", "OBSERVATION", 218, 225]]], ["A number of studies on the vector-susceptibility of different primary cell types for tropism modification have been conducted both for adenoviral (Wickham 2000; Wickham et al. 1997) and AAV vectors (Nicklin and Baker 2002; Rabinowitz et al. 2002; Ponnazhagan et al. 2002; Ponnazhagan and Hoover 2004; Shi and Bartlett 2003; Perabo et al. 2003; B\u00fcning et al. 2003) .", [["cell", "ANATOMY", 70, 74], ["cell", "CELL", 70, 74], ["adenoviral", "ORGANISM", 135, 145], ["AAV", "ORGANISM", 186, 189], ["tropism modification", "TREATMENT", 85, 105], ["AAV vectors", "TREATMENT", 186, 197], ["Ponnazhagan", "TREATMENT", 272, 283], ["primary cell types", "OBSERVATION", 62, 80]]], ["Basically, these approaches employ alterations of viral surface structures mediating cellular receptor binding and internalization of the vector.", [["surface structures", "ANATOMY", 56, 74], ["cellular", "ANATOMY", 85, 93], ["cellular", "CELL", 85, 93], ["viral surface structures", "TREATMENT", 50, 74], ["cellular receptor binding", "TREATMENT", 85, 110], ["internalization of the vector", "TREATMENT", 115, 144], ["viral surface", "OBSERVATION", 50, 63], ["cellular receptor binding", "OBSERVATION", 85, 110]]], ["This has been achieved by genetic engineering of vector genes encoding vector surface components (Ogorelkova et al. 2006; Poller et al. 2002b) , by bi-functional antibodies binding both to a vector surface epitope and a cellular structure specific for the desired target cells (Noutsias et al. 2001) , or by bi-specific targeting proteins conjugated to the vector surface via avidin-biotin complexes (Perabo t al. 2003) .", [["surface", "ANATOMY", 78, 85], ["surface", "ANATOMY", 198, 205], ["cellular", "ANATOMY", 220, 228], ["cells", "ANATOMY", 271, 276], ["surface", "ANATOMY", 364, 371], ["biotin", "CHEMICAL", 383, 389], ["cellular", "CELL", 220, 228], ["cells", "CELL", 271, 276], ["avidin", "GENE_OR_GENE_PRODUCT", 376, 382], ["biotin", "SIMPLE_CHEMICAL", 383, 389], ["vector genes", "DNA", 49, 61], ["bi-functional antibodies", "PROTEIN", 148, 172], ["vector surface epitope", "PROTEIN", 191, 213], ["target cells", "CELL_TYPE", 264, 276], ["bi-specific targeting proteins", "PROTEIN", 308, 338], ["avidin", "PROTEIN", 376, 382], ["biotin complexes", "PROTEIN", 383, 399], ["bi-functional antibodies binding", "PROBLEM", 148, 180], ["a vector surface epitope", "TREATMENT", 189, 213], ["bi-specific targeting proteins", "TREATMENT", 308, 338], ["avidin-biotin complexes", "TREATMENT", 376, 399]]], ["However, none of these approaches has achieved similar success in vivo as the most recent generation of pseudotyped AAV vectors (in particular AAV8 and AAV9 for cardiac targeting), although use of these vectors may be combined with further tropism optimization by introducing additional alterations in the pseudotyped AAV capsids, and with tissue-specific promoters.", [["cardiac", "ANATOMY", 161, 168], ["tissue", "ANATOMY", 340, 346], ["pseudotyped", "ORGANISM", 104, 115], ["AAV", "ORGANISM", 116, 119], ["AAV8", "GENE_OR_GENE_PRODUCT", 143, 147], ["AAV9", "GENE_OR_GENE_PRODUCT", 152, 156], ["cardiac", "ORGAN", 161, 168], ["AAV", "ORGANISM", 318, 321], ["tissue", "TISSUE", 340, 346], ["tissue-specific promoters", "DNA", 340, 365], ["AAV", "SPECIES", 116, 119], ["pseudotyped AAV vectors", "TREATMENT", 104, 127], ["AAV8 and AAV9", "TREATMENT", 143, 156], ["cardiac targeting", "TREATMENT", 161, 178], ["these vectors", "TREATMENT", 197, 210], ["further tropism optimization", "TREATMENT", 232, 260], ["the pseudotyped AAV capsids", "TREATMENT", 302, 329], ["pseudotyped AAV", "OBSERVATION", 104, 119]]], ["It should be emphasized that in order for the above tropism modifications to become useful in vivo the vectors first need to get direct access to the desired target cells, which may be prevented, however, by anatomical barriers (vascular endothelium, basal membrane, extracellular matrix).", [["cells", "ANATOMY", 165, 170], ["vascular endothelium", "ANATOMY", 229, 249], ["basal membrane", "ANATOMY", 251, 265], ["extracellular matrix", "ANATOMY", 267, 287], ["cells", "CELL", 165, 170], ["vascular endothelium", "TISSUE", 229, 249], ["basal membrane", "CELLULAR_COMPONENT", 251, 265], ["extracellular matrix", "CELLULAR_COMPONENT", 267, 287], ["target cells", "CELL_TYPE", 158, 170], ["the above tropism modifications", "TREATMENT", 42, 73], ["vascular endothelium", "ANATOMY", 229, 249], ["basal", "ANATOMY_MODIFIER", 251, 256]]], ["In addition to studies addressing the receptor issue, a number of approaches to overcome the anatomical barriers have been evaluated (Vale et al. 1999; Boekstegers et al. 2000; Beeri et al. 2002; Davidson et al. 2001; Price et al. 1998; Donahue et al. 1997; Hajjar et al. 1998 ), but none of these methods is simple or as yet appropriate for application in the clinical setting.", [["studies", "TEST", 15, 22]]], ["In myocardial gene therapy, the final target cells -beyond the anatomical barriers -are particularly difficult targets as compared to other cell types and, at the current state of the art, viral vectors are the only option to achieve transfer rates sufficient for therapeutic efficacy.", [["myocardial", "ANATOMY", 3, 13], ["cells", "ANATOMY", 45, 50], ["cell", "ANATOMY", 140, 144], ["myocardial", "MULTI-TISSUE_STRUCTURE", 3, 13], ["cells", "CELL", 45, 50], ["cell", "CELL", 140, 144], ["target cells", "CELL_TYPE", 38, 50], ["myocardial gene therapy", "TREATMENT", 3, 26], ["viral vectors", "TREATMENT", 189, 202], ["myocardial", "ANATOMY", 3, 13], ["gene therapy", "OBSERVATION", 14, 26]]], ["So far, no report on successful in vivo treatment of cardiac diseases using non-viral systems (including nanoparticles) has been published.", [["cardiac", "ANATOMY", 53, 60], ["cardiac diseases", "DISEASE", 53, 69], ["cardiac", "ORGAN", 53, 60], ["cardiac diseases", "PROBLEM", 53, 69], ["non-viral systems", "TREATMENT", 76, 93], ["nanoparticles", "TREATMENT", 105, 118], ["cardiac", "ANATOMY", 53, 60], ["diseases", "OBSERVATION", 61, 69]]], ["Given the obstacles against efficient and targeted vector delivery, the recent development of imaging techniques for the in vivo detection of transgene expression may greatly facilitate the further development, monitoring, and assessment of cardiac gene therapeutic procedures (Wu et al. 2002; Inubushi et al. 2003; Auricchio et al. 2003 ).Stability of Regulatory RNA or Transgene ExpressionThe second key issue of vector technology is the stability of transgene function (be it transgenic protein expression or short hairpin or pre-microRNA transcription).", [["cardiac", "ANATOMY", 241, 248], ["cardiac", "ORGAN", 241, 248], ["Transgene", "GENE_OR_GENE_PRODUCT", 371, 380], ["pre-microRNA", "GENE_OR_GENE_PRODUCT", 529, 541], ["Regulatory RNA", "RNA", 353, 367], ["targeted vector delivery", "TREATMENT", 42, 66], ["imaging techniques", "TEST", 94, 112], ["monitoring", "TEST", 211, 221], ["assessment", "TEST", 227, 237], ["cardiac gene therapeutic procedures", "TREATMENT", 241, 276], ["Regulatory RNA", "TREATMENT", 353, 367], ["vector technology", "TREATMENT", 415, 432], ["transgene function", "PROBLEM", 453, 471], ["transgenic protein expression", "TREATMENT", 479, 508], ["short hairpin", "TREATMENT", 512, 525], ["pre-microRNA transcription", "TREATMENT", 529, 555], ["cardiac", "ANATOMY", 241, 248], ["Regulatory RNA", "OBSERVATION", 353, 367]]], ["If genetic therapy for heart failure is not only meant to serve as a bridge-totransplant or bridge-to-recovery, then long-term stability of the therapeutic vector plus transgene is required.", [["heart", "ANATOMY", 23, 28], ["heart failure", "DISEASE", 23, 36], ["heart", "ORGAN", 23, 28], ["genetic therapy", "TREATMENT", 3, 18], ["heart failure", "PROBLEM", 23, 36], ["the therapeutic vector plus transgene", "TREATMENT", 140, 177], ["heart", "ANATOMY", 23, 28], ["failure", "OBSERVATION", 29, 36]]], ["Among the virus-based vector systems used for myocardial gene transfer, the currently most promising systems to achieve long-term stability are derived from adeno-associated viruses (AAVs).", [["myocardial", "ANATOMY", 46, 56], ["myocardial", "MULTI-TISSUE_STRUCTURE", 46, 56], ["adeno-associated viruses", "ORGANISM", 157, 181], ["AAVs", "CANCER", 183, 187], ["myocardial gene transfer", "TREATMENT", 46, 70], ["long-term stability", "PROBLEM", 120, 139], ["virus", "OBSERVATION", 10, 15]]], ["AAV vectors -although still difficult to produce at the high titers needed for in vivo applications -have shown stability for than a year in fully immunocompetent hemophilic dogs treated intramuscularly with a coagulation factor IX-producing AAV vector (Monahan et al. 1998; Herzog et al. 2002) .", [["AAV", "ORGANISM", 0, 3], ["dogs", "ORGANISM", 174, 178], ["IX", "GENE_OR_GENE_PRODUCT", 229, 231], ["AAV", "ORGANISM", 242, 245], ["coagulation factor IX", "PROTEIN", 210, 231], ["dogs", "SPECIES", 174, 178], ["AAV vectors", "TREATMENT", 0, 11], ["vivo applications", "TREATMENT", 82, 99], ["fully immunocompetent hemophilic dogs", "TREATMENT", 141, 178], ["a coagulation factor IX", "TREATMENT", 208, 231]]], ["Based on the experimental data a factor IX AAV vector has been evaluated in a clinical phase I trial (Kay et al. 2000) .", [["IX", "GENE_OR_GENE_PRODUCT", 40, 42], ["factor IX AAV vector", "DNA", 33, 53], ["a factor IX AAV vector", "TREATMENT", 31, 53]]], ["The high stability appears to be a consequence of inherent fundamental biological properties of the AAV genome (Afione et al. 1996) .", [["AAV", "ORGANISM", 100, 103], ["AAV genome", "DNA", 100, 110], ["high stability", "OBSERVATION_MODIFIER", 4, 18], ["appears to be", "UNCERTAINTY", 19, 32], ["AAV genome", "OBSERVATION", 100, 110]]], ["Although it is not always clear whether transgene expression occurs from integrated or episomal vector genomes, sequencing of vector-genome junctions has demonstrated the presence of integrated AAV genomes in cultured human cells and in mice after treatment with AAV vectors (Miller et al. 2002; Rutledge and Russell 1997; Nakai et al. 1999 Nakai et al. , 2001 Nakai et al. , 2003 .", [["cells", "ANATOMY", 224, 229], ["AAV", "ORGANISM", 194, 197], ["human", "ORGANISM", 218, 223], ["cells", "CELL", 224, 229], ["mice", "ORGANISM", 237, 241], ["AAV", "ORGANISM", 263, 266], ["episomal vector genomes", "DNA", 87, 110], ["AAV genomes", "DNA", 194, 205], ["cultured human cells", "CELL_LINE", 209, 229], ["human", "SPECIES", 218, 223], ["mice", "SPECIES", 237, 241], ["human", "SPECIES", 218, 223], ["mice", "SPECIES", 237, 241], ["AAV", "SPECIES", 263, 266], ["transgene expression", "PROBLEM", 40, 60], ["episomal vector genomes", "TREATMENT", 87, 110], ["vector-genome junctions", "TREATMENT", 126, 149], ["integrated AAV genomes", "PROBLEM", 183, 205], ["AAV vectors", "TREATMENT", 263, 274], ["AAV genomes", "OBSERVATION", 194, 205]]], ["AAV vectors have only recently been employed for the cardiac genetic treatment of heart failure (Hoshijima et al. 2002) , for the systemic treatment of Fabry disease (Takahashi et al. 2002) , and for substitution gene therapy of an inherited cardiomyopathy due to a \u03b4-sarcoglycan gene defect (Kawada et al. 2002) , with transgene expression over several months in all cases.Safety of RNA-Based and Gene Therapeutic ApproachesThe third key of vector technology -of paramount importance before any clinical application may be considered -is the safety of the gene transfer protocols.", [["cardiac", "ANATOMY", 53, 60], ["heart", "ANATOMY", 82, 87], ["heart failure", "DISEASE", 82, 95], ["Fabry disease", "DISEASE", 152, 165], ["inherited cardiomyopathy", "DISEASE", 232, 256], ["AAV", "ORGANISM", 0, 3], ["heart", "ORGAN", 82, 87], ["\u03b4-sarcoglycan", "GENE_OR_GENE_PRODUCT", 266, 279], ["\u03b4-sarcoglycan gene defect", "DNA", 266, 291], ["AAV", "SPECIES", 0, 3], ["AAV vectors", "TREATMENT", 0, 11], ["the cardiac genetic treatment", "TREATMENT", 49, 78], ["heart failure", "PROBLEM", 82, 95], ["the systemic treatment", "TREATMENT", 126, 148], ["Fabry disease", "PROBLEM", 152, 165], ["substitution gene therapy", "TREATMENT", 200, 225], ["an inherited cardiomyopathy", "PROBLEM", 229, 256], ["a \u03b4-sarcoglycan gene defect", "PROBLEM", 264, 291], ["Safety of RNA", "TREATMENT", 374, 387], ["the gene transfer protocols", "TREATMENT", 553, 580], ["heart", "ANATOMY", 82, 87], ["failure", "OBSERVATION", 88, 95], ["cardiomyopathy", "OBSERVATION", 242, 256]]], ["This may not be required for any application but is necessary in situations when adaptation of transgene activity to the physiologically required level is desired.", [["any application", "TREATMENT", 29, 44]]], ["An option to shut down the transgene completely at any time in the case of serious adverse effects is highly desirable under safety considerations (Bliznakov 2002) .", [["serious adverse effects", "PROBLEM", 75, 98]]], ["Vectors systems that can be shut off by withdrawal of an inducer drug have been described, most of them using doxycycline as inducer (Fechner et al. 2003b; Srour et al. 2003; Chtarto et al. 2003) .Safety of RNA-Based and Gene Therapeutic ApproachesSafety issues inherent to specific vector types are, e.g., the inflammatory responses against adenoviral vectors which were transient, however, and appeared to be of no clinical significance in two recent cardiological clinical trials in 2002 and 2003 employing intracoronary injection of adenoviral vectors expressing VEGF (Grines et al. 2002; Hedman et al. 2003) .", [["doxycycline", "CHEMICAL", 110, 121], ["doxycycline", "CHEMICAL", 110, 121], ["doxycycline", "SIMPLE_CHEMICAL", 110, 121], ["adenoviral", "ORGANISM", 342, 352], ["intracoronary", "IMMATERIAL_ANATOMICAL_ENTITY", 510, 523], ["adenoviral", "ORGANISM", 537, 547], ["VEGF", "GENE_OR_GENE_PRODUCT", 567, 571], ["VEGF", "PROTEIN", 567, 571], ["adenoviral", "SPECIES", 342, 352], ["adenoviral", "SPECIES", 537, 547], ["Vectors systems", "TREATMENT", 0, 15], ["an inducer drug", "TREATMENT", 54, 69], ["doxycycline", "TREATMENT", 110, 121], ["Safety of RNA", "TREATMENT", 197, 210], ["Gene Therapeutic ApproachesSafety issues", "TREATMENT", 221, 261], ["the inflammatory responses", "PROBLEM", 307, 333], ["adenoviral vectors", "TREATMENT", 342, 360], ["intracoronary injection of adenoviral vectors", "TREATMENT", 510, 555], ["inflammatory", "OBSERVATION", 311, 323]]], ["In a previous trial in the year 1999 (Raper et al. 2002) ; a liver-targeted gene therapy protocol aiming at the treatment of ornithin transcarboxylase deficiency had used vector doses three orders of magnitude higher than those in the recent cardiological trials.", [["liver", "ANATOMY", 61, 66], ["ornithin", "CHEMICAL", 125, 133], ["liver", "ORGAN", 61, 66], ["ornithin transcarboxylase", "SIMPLE_CHEMICAL", 125, 150], ["a liver-targeted gene therapy protocol", "TREATMENT", 59, 97], ["ornithin transcarboxylase deficiency", "PROBLEM", 125, 161], ["vector doses", "TREATMENT", 171, 183], ["liver", "ANATOMY", 61, 66]]], ["The highest dose used therein was 3.3 \u00d7 1,010 vector particles (Grines et al. 2002) , whereas in the former liver-directed study the multiorgan failure and death occurred in one patient who had received the highest dose of 3.8 \u00d7 1,013 particles (Raper et al. 2002) .", [["liver", "ANATOMY", 108, 113], ["multiorgan", "ANATOMY", 133, 143], ["multiorgan failure", "DISEASE", 133, 151], ["death", "DISEASE", 156, 161], ["liver", "ORGAN", 108, 113], ["multiorgan", "ORGAN", 133, 143], ["patient", "ORGANISM", 178, 185], ["patient", "SPECIES", 178, 185], ["the multiorgan failure", "PROBLEM", 129, 151], ["death", "PROBLEM", 156, 161], ["liver", "ANATOMY", 108, 113], ["multiorgan failure", "OBSERVATION", 133, 151]]], ["That tragic event prompted thorough additional investigations (Lehrman 1999; Marshall 2000) into the risks of adenovector-mediated gene therapy including serious adverse events even if they may occur only very rarely, in predisposed individuals, or at very high vector doses.", [["adenovector", "TREATMENT", 110, 121], ["mediated gene therapy", "TREATMENT", 122, 143], ["serious adverse events", "PROBLEM", 154, 176]]], ["A survey of clinical trials in 100 cancer patients employing intravascular adenoviral vectors reports that doses up to 2.5 \u00d7 1,013 had an acceptable safety profile (Reid et al. 2002) .", [["cancer", "ANATOMY", 35, 41], ["intravascular", "ANATOMY", 61, 74], ["cancer", "DISEASE", 35, 41], ["cancer", "CANCER", 35, 41], ["patients", "ORGANISM", 42, 50], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 61, 74], ["adenoviral", "ORGANISM", 75, 85], ["patients", "SPECIES", 42, 50], ["clinical trials", "TREATMENT", 12, 27], ["intravascular adenoviral vectors", "TREATMENT", 61, 93]]], ["Even very rare serious side effects will be considered unacceptable, however, for non-malignant diseases.Safety of RNA-Based and Gene Therapeutic ApproachesThe safety of AAV vector-based cardiac gene therapy is currently under investigation in a Phase I safety trial at the Mount Sinai Hospital in New York (unpublished data).", [["non-malignant", "ANATOMY", 82, 95], ["cardiac", "ANATOMY", 187, 194], ["AAV", "ORGANISM", 170, 173], ["cardiac", "ORGAN", 187, 194], ["AAV", "SPECIES", 170, 173], ["non-malignant diseases", "PROBLEM", 82, 104], ["Safety of RNA", "TREATMENT", 105, 118], ["Gene Therapeutic Approaches", "TREATMENT", 129, 156], ["AAV vector", "TREATMENT", 170, 180], ["based cardiac gene therapy", "TREATMENT", 181, 207]]], ["With respect to possible risks specific to the AAV vectors their immunogenicity is low as compared to adenovectors (Sun et al. 2002 (Sun et al. , 2003 .", [["AAV", "ORGANISM", 47, 50], ["the AAV vectors", "TREATMENT", 43, 58]]], ["Another possible risk has been deduced from the capacity of wild-type AAV for chromosomal integration which appears to be lost, however, in recombinant AAV vectors such as used for gene therapy (Rutledge and Russell 1997; Rutledge et al. 1998; Miller et al. 2002 Miller et al. , 2004 .", [["chromosomal", "ANATOMY", 78, 89], ["AAV", "ORGANISM", 70, 73], ["chromosomal", "CELLULAR_COMPONENT", 78, 89], ["AAV", "ORGANISM", 152, 155], ["AAV", "SPECIES", 152, 155], ["chromosomal integration", "PROBLEM", 78, 101], ["recombinant AAV vectors", "TREATMENT", 140, 163], ["gene therapy", "TREATMENT", 181, 193], ["possible", "UNCERTAINTY", 8, 16]]], ["A recent study has searched for possible chromosomal effects of AAV vector integration (Miller et al. 2002) which deserve particular attention after a recent report on the late and unexpected occurrence of leukemia in children treated with retroviral vectors for severe combined immmunodeficiency (SCID), after successful correction of the primary genetic defect (Kohn et al. 2003) .", [["chromosomal", "ANATOMY", 41, 52], ["leukemia", "ANATOMY", 206, 214], ["leukemia", "DISEASE", 206, 214], ["SCID", "DISEASE", 298, 302], ["chromosomal", "CELLULAR_COMPONENT", 41, 52], ["AAV", "ORGANISM", 64, 67], ["leukemia", "CANCER", 206, 214], ["children", "ORGANISM", 218, 226], ["retroviral", "ORGANISM", 240, 250], ["children", "SPECIES", 218, 226], ["A recent study", "TEST", 0, 14], ["AAV vector integration", "TREATMENT", 64, 86], ["leukemia", "PROBLEM", 206, 214], ["retroviral vectors", "TREATMENT", 240, 258], ["severe combined immmunodeficiency (SCID", "PROBLEM", 263, 302], ["the primary genetic defect", "PROBLEM", 336, 362], ["leukemia", "OBSERVATION", 206, 214], ["defect", "OBSERVATION", 356, 362]]], ["Whereas retroviral vectors such as used in the SCID study are integrating into the human genome at random sites, wild-type AAV shows a preference for chromosome 19 (Miller et al. 2002; Nakai et al. 1999) .", [["retroviral", "ORGANISM", 8, 18], ["human", "ORGANISM", 83, 88], ["AAV", "ORGANISM", 123, 126], ["human genome", "DNA", 83, 95], ["chromosome 19", "DNA", 150, 163], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 83, 88], ["retroviral vectors", "TREATMENT", 8, 26], ["the SCID study", "TEST", 43, 57], ["retroviral vectors", "OBSERVATION", 8, 26], ["human genome", "OBSERVATION", 83, 95]]], ["The possible consequences of genomic integration of AAV vectors deserves close attention over years, since the retrovector-associated leukemia occurred only years after successful ex vivo gene therapy for SCID by retrovirally mediated transfer of the \u03b3c gene into CD34+ cells (Kohn et al. 2003; Check 2003; Hacein-Bey-Abina et al. 2002 , 2003 .RNA Interference Targeting Early PathogenicSteps in CardiomyopathiesOverviewSince coxsackievirus B3 (CoxB3) and adenoviruses may cause acute myocarditis and inflammatory cardiomyopathy, isolation of the common Coxsackievirus-Adenovirus-Receptor (CAR) has provided an interesting new target for molecular antiviral therapy.", [["leukemia", "ANATOMY", 134, 142], ["CD34+ cells", "ANATOMY", 264, 275], ["leukemia", "DISEASE", 134, 142], ["SCID", "DISEASE", 205, 209], ["myocarditis", "DISEASE", 485, 496], ["inflammatory cardiomyopathy", "DISEASE", 501, 528], ["AAV", "ORGANISM", 52, 55], ["leukemia", "CANCER", 134, 142], ["\u03b3c", "GENE_OR_GENE_PRODUCT", 251, 253], ["CD34", "GENE_OR_GENE_PRODUCT", 264, 268], ["coxsackievirus B3", "ORGANISM", 426, 443], ["CoxB3", "GENE_OR_GENE_PRODUCT", 445, 450], ["adenoviruses", "ORGANISM", 456, 468], ["Coxsackievirus-Adenovirus", "ORGANISM", 554, 579], ["CAR", "GENE_OR_GENE_PRODUCT", 590, 593], ["\u03b3c gene", "DNA", 251, 258], ["CD34+ cells", "CELL_TYPE", 264, 275], ["common Coxsackievirus-Adenovirus-Receptor", "PROTEIN", 547, 588], ["CAR", "PROTEIN", 590, 593], ["Coxsackievirus-Adenovirus", "SPECIES", 554, 579], ["coxsackievirus B3", "SPECIES", 426, 443], ["Coxsackievirus-Adenovirus", "SPECIES", 554, 579], ["AAV vectors", "TREATMENT", 52, 63], ["the retrovector-associated leukemia", "PROBLEM", 107, 142], ["successful ex vivo gene therapy", "TREATMENT", 169, 200], ["SCID", "PROBLEM", 205, 209], ["Hacein", "TEST", 307, 313], ["Early PathogenicSteps", "PROBLEM", 371, 392], ["Cardiomyopathies", "PROBLEM", 396, 412], ["coxsackievirus B3 (CoxB3)", "TREATMENT", 426, 451], ["adenoviruses", "TREATMENT", 456, 468], ["acute myocarditis", "PROBLEM", 479, 496], ["inflammatory cardiomyopathy", "PROBLEM", 501, 528], ["the common Coxsackievirus", "PROBLEM", 543, 568], ["molecular antiviral therapy", "TREATMENT", 638, 665], ["leukemia", "OBSERVATION", 134, 142], ["may cause", "UNCERTAINTY", 469, 478], ["acute", "OBSERVATION_MODIFIER", 479, 484], ["myocarditis", "OBSERVATION", 485, 496], ["inflammatory", "OBSERVATION_MODIFIER", 501, 513], ["common Coxsackievirus", "ANATOMY", 547, 568], ["antiviral therapy", "OBSERVATION", 648, 665]]], ["Whereas many viruses show high mutation rates enabling them to develop escape mutants, mutations of their cellular virus receptors are far less likely.", [["cellular", "ANATOMY", 106, 114], ["cellular", "CELL", 106, 114], ["cellular virus receptors", "PROTEIN", 106, 130], ["many viruses", "PROBLEM", 8, 20], ["high mutation rates", "PROBLEM", 26, 45], ["escape mutants", "PROBLEM", 71, 85], ["mutations of their cellular virus receptors", "PROBLEM", 87, 130], ["viruses", "OBSERVATION", 13, 20], ["high mutation", "OBSERVATION", 26, 39], ["cellular virus", "OBSERVATION", 106, 120]]], ["We report on antiviral efficacies of CAR gene silencing by short hairpin (sh)RNAs in the cardiac-derived HL-1 cell line and in primary neonatal rat cardiomyocytes (PNCMs).", [["cardiac", "ANATOMY", 89, 96], ["HL-1 cell line", "ANATOMY", 105, 119], ["cardiomyocytes", "ANATOMY", 148, 162], ["PNCMs", "ANATOMY", 164, 169], ["CAR", "GENE_OR_GENE_PRODUCT", 37, 40], ["cardiac-derived HL-1 cell line", "CELL", 89, 119], ["rat", "ORGANISM", 144, 147], ["cardiomyocytes", "CELL", 148, 162], ["PNCMs", "CELL", 164, 169], ["CAR gene", "DNA", 37, 45], ["short hairpin (sh)RNAs", "RNA", 59, 81], ["cardiac-derived HL-1 cell line", "CELL_LINE", 89, 119], ["primary neonatal rat cardiomyocytes", "CELL_TYPE", 127, 162], ["PNCMs", "CELL_TYPE", 164, 169], ["rat", "SPECIES", 144, 147], ["rat", "SPECIES", 144, 147], ["antiviral efficacies", "TREATMENT", 13, 33], ["CAR gene silencing", "TREATMENT", 37, 55], ["short hairpin (sh)RNAs", "PROBLEM", 59, 81], ["1 cell line", "TREATMENT", 108, 119], ["primary neonatal rat cardiomyocytes", "PROBLEM", 127, 162], ["cardiac", "ANATOMY", 89, 96], ["cell line", "OBSERVATION", 110, 119], ["rat cardiomyocytes", "ANATOMY", 144, 162]]], ["Treatment with CAR-shRNA-generating vectors resulted in almost complete silencing of CAR expression both in HL-1 cells and PNCMs.", [["HL-1 cells", "ANATOMY", 108, 118], ["PNCMs", "ANATOMY", 123, 128], ["CAR", "GENE_OR_GENE_PRODUCT", 15, 18], ["CAR", "GENE_OR_GENE_PRODUCT", 85, 88], ["HL-1 cells", "CELL", 108, 118], ["PNCMs", "CELL", 123, 128], ["CAR-shRNA-generating vectors", "DNA", 15, 43], ["CAR", "PROTEIN", 85, 88], ["HL-1 cells", "CELL_LINE", 108, 118], ["PNCMs", "CELL_TYPE", 123, 128], ["CAR-shRNA-generating vectors", "TREATMENT", 15, 43], ["PNCMs", "TREATMENT", 123, 128]]], ["While in HL-1 cells, CAR was already silenced 24 h after transduction of CAR-shRNA expressing vector in PNCMs CAR downregulation becomes visible only at day 6 and thereafter.", [["HL-1 cells", "ANATOMY", 9, 19], ["PNCMs", "ANATOMY", 104, 109], ["HL-1 cells", "CELL", 9, 19], ["CAR", "GENE_OR_GENE_PRODUCT", 21, 24], ["CAR", "GENE_OR_GENE_PRODUCT", 73, 76], ["PNCMs CAR", "GENE_OR_GENE_PRODUCT", 104, 113], ["HL-1 cells", "CELL_LINE", 9, 19], ["CAR", "PROTEIN", 21, 24], ["CAR-shRNA expressing vector", "DNA", 73, 100], ["CAR", "PROTEIN", 110, 113], ["CAR-shRNA expressing vector", "TREATMENT", 73, 100]]], ["CAR knockout resulted in strong inhibition of CoxB3 infections by up to 97% in HL-1 cells and by up to 90% in PNCMs, while adenovirus infections were inhibited by only 75% in HL-1 cells but up to 92% in PNCMs.", [["HL-1 cells", "ANATOMY", 79, 89], ["PNCMs", "ANATOMY", 110, 115], ["HL-1 cells", "ANATOMY", 175, 185], ["PNCMs", "ANATOMY", 203, 208], ["infections", "DISEASE", 52, 62], ["adenovirus infections", "DISEASE", 123, 144], ["CAR", "GENE_OR_GENE_PRODUCT", 0, 3], ["CoxB3", "GENE_OR_GENE_PRODUCT", 46, 51], ["HL-1 cells", "CELL", 79, 89], ["PNCMs", "PATHOLOGICAL_FORMATION", 110, 115], ["adenovirus", "ORGANISM", 123, 133], ["HL-1 cells", "CELL", 175, 185], ["PNCMs", "PATHOLOGICAL_FORMATION", 203, 208], ["CAR", "PROTEIN", 0, 3], ["HL-1 cells", "CELL_LINE", 79, 89], ["PNCMs", "CELL_TYPE", 110, 115], ["HL-1 cells", "CELL_LINE", 175, 185], ["PNCMs", "CELL_TYPE", 203, 208], ["HL-1", "SPECIES", 79, 83], ["adenovirus", "SPECIES", 123, 133], ["HL-1", "SPECIES", 175, 179], ["CoxB3 infections", "PROBLEM", 46, 62], ["PNCMs", "TEST", 110, 115], ["adenovirus infections", "PROBLEM", 123, 144], ["strong", "OBSERVATION_MODIFIER", 25, 31], ["inhibition", "OBSERVATION_MODIFIER", 32, 42], ["infections", "OBSERVATION", 52, 62]]], ["We conclude that CAR knockout by shRNA vectors is promising against CoxB3 and adenovirus infections, but cell type specific CAR silencing by vector expressed shRNAs needs to be considered for the antiviral approaches.Introduction to Viral CardiomyopathiesInitially, cardiac viral infections were documented in the clinical context of acute myocarditis.", [["cell", "ANATOMY", 105, 109], ["cardiac", "ANATOMY", 266, 273], ["adenovirus infections", "DISEASE", 78, 99], ["Viral Cardiomyopathies", "DISEASE", 233, 255], ["cardiac viral infections", "DISEASE", 266, 290], ["myocarditis", "DISEASE", 340, 351], ["CAR", "GENE_OR_GENE_PRODUCT", 17, 20], ["CoxB3", "GENE_OR_GENE_PRODUCT", 68, 73], ["adenovirus", "ORGANISM", 78, 88], ["cell", "CELL", 105, 109], ["CAR", "GENE_OR_GENE_PRODUCT", 124, 127], ["CAR", "PROTEIN", 17, 20], ["CAR", "PROTEIN", 124, 127], ["shRNAs", "DNA", 158, 164], ["adenovirus", "SPECIES", 78, 88], ["CAR knockout by shRNA vectors", "TREATMENT", 17, 46], ["CoxB3", "PROBLEM", 68, 73], ["adenovirus infections", "PROBLEM", 78, 99], ["the antiviral approaches", "TREATMENT", 192, 216], ["Viral Cardiomyopathies", "PROBLEM", 233, 255], ["cardiac viral infections", "PROBLEM", 266, 290], ["acute myocarditis", "PROBLEM", 334, 351], ["Viral Cardiomyopathies", "OBSERVATION", 233, 255], ["cardiac", "ANATOMY", 266, 273], ["viral infections", "OBSERVATION", 274, 290], ["acute", "OBSERVATION_MODIFIER", 334, 339], ["myocarditis", "OBSERVATION", 340, 351]]], ["Coxsackievirus B3 (CoxB3) was the first virus detected in this condition in humans (Bowles et al. 1986) , and adenoviruses of serotypes 2 and 5 were later described as common agents of myocarditis in children (Bowles et al. 2003) .", [["myocarditis", "DISEASE", 185, 196], ["Coxsackievirus B3", "ORGANISM", 0, 17], ["CoxB3", "GENE_OR_GENE_PRODUCT", 19, 24], ["humans", "ORGANISM", 76, 82], ["adenoviruses", "ORGANISM", 110, 122], ["serotypes 2", "ORGANISM", 126, 137], ["5", "ORGANISM", 142, 143], ["children", "ORGANISM", 200, 208], ["Coxsackievirus B3", "SPECIES", 0, 17], ["humans", "SPECIES", 76, 82], ["children", "SPECIES", 200, 208], ["Coxsackievirus B3", "SPECIES", 0, 17], ["humans", "SPECIES", 76, 82], ["Coxsackievirus B3 (CoxB3)", "PROBLEM", 0, 25], ["the first virus", "PROBLEM", 30, 45], ["adenoviruses of serotypes", "TREATMENT", 110, 135], ["myocarditis", "PROBLEM", 185, 196], ["myocarditis", "OBSERVATION", 185, 196]]], ["Systematic screening of patients with dilated cardiomyopathy (DCM) has recently revealed that a rather broad spectrum of viruses may also chronically persist in human myocardium (K\u00fchl et al. 2005a) .", [["myocardium", "ANATOMY", 167, 177], ["dilated cardiomyopathy", "DISEASE", 38, 60], ["DCM", "DISEASE", 62, 65], ["patients", "ORGANISM", 24, 32], ["human", "ORGANISM", 161, 166], ["myocardium", "MULTI-TISSUE_STRUCTURE", 167, 177], ["patients", "SPECIES", 24, 32], ["human", "SPECIES", 161, 166], ["human", "SPECIES", 161, 166], ["Systematic screening", "TEST", 0, 20], ["dilated cardiomyopathy", "PROBLEM", 38, 60], ["DCM", "PROBLEM", 62, 65], ["a rather broad spectrum of viruses", "PROBLEM", 94, 128], ["dilated", "OBSERVATION_MODIFIER", 38, 45], ["cardiomyopathy", "OBSERVATION", 46, 60], ["viruses", "OBSERVATION", 121, 128]]], ["It is therefore assumed that acute cardiac viral infections may not only cause acute illness, but also chronic heart disease if not definitely eliminated from the heart (K\u00fchl et al. 2005b ).", [["cardiac", "ANATOMY", 35, 42], ["heart", "ANATOMY", 111, 116], ["heart", "ANATOMY", 163, 168], ["cardiac viral infections", "DISEASE", 35, 59], ["heart disease", "DISEASE", 111, 124], ["heart", "ORGAN", 111, 116], ["heart", "ORGAN", 163, 168], ["acute cardiac viral infections", "PROBLEM", 29, 59], ["acute illness", "PROBLEM", 79, 92], ["chronic heart disease", "PROBLEM", 103, 124], ["acute", "OBSERVATION_MODIFIER", 29, 34], ["cardiac", "ANATOMY", 35, 42], ["viral infections", "OBSERVATION", 43, 59], ["may not only cause", "UNCERTAINTY", 60, 78], ["acute", "OBSERVATION_MODIFIER", 79, 84], ["illness", "OBSERVATION", 85, 92], ["chronic", "OBSERVATION_MODIFIER", 103, 110], ["heart", "ANATOMY", 111, 116], ["disease", "OBSERVATION", 117, 124], ["heart", "ANATOMY", 163, 168]]], ["The disease may progress to terminal heart failure and then require heart transplantation as a last therapeutic option.", [["heart", "ANATOMY", 37, 42], ["heart", "ANATOMY", 68, 73], ["heart failure", "DISEASE", 37, 50], ["heart", "ORGAN", 37, 42], ["heart", "ORGAN", 68, 73], ["The disease", "PROBLEM", 0, 11], ["terminal heart failure", "PROBLEM", 28, 50], ["heart transplantation", "TREATMENT", 68, 89], ["a last therapeutic option", "TREATMENT", 93, 118], ["disease", "OBSERVATION", 4, 11], ["heart", "ANATOMY", 37, 42], ["failure", "OBSERVATION", 43, 50], ["heart", "ANATOMY", 68, 73], ["transplantation", "OBSERVATION", 74, 89]]], ["RNA interference (RNAi) is a process of posttranscriptional gene silencing mediated by double-stranded RNA (dsRNA).", [["double-stranded RNA", "RNA", 87, 106], ["posttranscriptional gene silencing", "TREATMENT", 40, 74], ["double-stranded RNA (dsRNA", "TREATMENT", 87, 113], ["posttranscriptional gene silencing", "OBSERVATION", 40, 74], ["stranded RNA", "OBSERVATION_MODIFIER", 94, 106]]], ["The introduction of double-stranded small interfering RNAs (siRNA) or vectors expressing short hairpin RNA (shRNA) have already been successfully used to inhibit the replication of multiple viruses in vitro and in vivo including respiratory viruses (Bitko et al. 2005) , hepatitis B (Carmona et al. 2006; Weinberg et al. 2007; Chen et al. 2007 ) and C viruses (Takigawa et al. 2004 ), human herpes virus-6 ( Yoon et al. 2004) , cytomegalovirus (Wiebusch et al. 2004 ), SARS coronarvirus (Lu et al. 2004 ), HIV-1 (Hayafune et al. 2006a,b) and CoxB3 (Merl et al. 2005; Werk et al. 2005) .", [["respiratory viruses", "DISEASE", 229, 248], ["hepatitis B", "DISEASE", 271, 282], ["herpes virus", "DISEASE", 391, 403], ["SARS coronarvirus", "DISEASE", 469, 486], ["short hairpin RNA", "GENE_OR_GENE_PRODUCT", 89, 106], ["hepatitis B", "ORGANISM", 271, 282], ["C viruses", "ORGANISM", 350, 359], ["human", "ORGANISM", 385, 390], ["herpes virus-6", "ORGANISM", 391, 405], ["cytomegalovirus", "ORGANISM", 428, 443], ["HIV-1", "ORGANISM", 506, 511], ["double-stranded small interfering RNAs", "RNA", 20, 58], ["siRNA", "DNA", 60, 65], ["short hairpin RNA", "RNA", 89, 106], ["shRNA", "DNA", 108, 113], ["human", "SPECIES", 385, 390], ["herpes virus-", "SPECIES", 391, 404], ["HIV", "SPECIES", 506, 509], ["C viruses", "SPECIES", 350, 359], ["human herpes virus-6", "SPECIES", 385, 405], ["SARS coronarvirus", "SPECIES", 469, 486], ["HIV-1", "SPECIES", 506, 511], ["double-stranded small interfering RNAs (siRNA)", "TREATMENT", 20, 66], ["short hairpin RNA (shRNA", "PROBLEM", 89, 113], ["multiple viruses", "PROBLEM", 181, 197], ["vitro", "TREATMENT", 201, 206], ["respiratory viruses", "PROBLEM", 229, 248], ["hepatitis B", "PROBLEM", 271, 282], ["C viruses", "PROBLEM", 350, 359], ["human herpes virus", "PROBLEM", 385, 403], ["cytomegalovirus", "PROBLEM", 428, 443], ["small", "OBSERVATION_MODIFIER", 36, 41], ["interfering RNAs", "OBSERVATION", 42, 58], ["multiple", "OBSERVATION_MODIFIER", 181, 189], ["viruses", "OBSERVATION", 190, 197], ["respiratory viruses", "OBSERVATION", 229, 248]]], ["However, the efficiency of RNAi depends on exact homology of the siRNA to the target sequence.", [["target sequence", "DNA", 78, 93], ["RNAi", "PROBLEM", 27, 31], ["RNAi", "OBSERVATION", 27, 31]]], ["A single mismatch can be sufficient to abrogate silencing by RNAi (Sabariegos et al. 2006) .Introduction to Viral CardiomyopathiesMany RNA viruses encode polymerase enzymes that lack proof reading abilities and as a result have a high mutations rate.", [["Viral Cardiomyopathies", "DISEASE", 108, 130], ["polymerase enzymes", "PROTEIN", 154, 172], ["A single mismatch", "TREATMENT", 0, 17], ["Viral Cardiomyopathies", "PROBLEM", 108, 130], ["polymerase enzymes", "TEST", 154, 172], ["a high mutations rate", "PROBLEM", 228, 249]]], ["Thus, there is a high probability that viruses will rapidly develop resistance to a particular siRNA during virus replication by incorporation of nucleotide mutations within the target sequence of the siRNA.", [["nucleotide", "CHEMICAL", 146, 156], ["nucleotide", "CHEMICAL", 146, 156], ["a high probability that viruses", "PROBLEM", 15, 46], ["a particular siRNA", "PROBLEM", 82, 100], ["virus replication", "TREATMENT", 108, 125], ["nucleotide mutations", "PROBLEM", 146, 166], ["viruses", "OBSERVATION", 39, 46], ["nucleotide mutations", "OBSERVATION", 146, 166], ["siRNA", "ANATOMY", 201, 206]]], ["Furthermore, it has been shown that hepatitis C virus becomes resistant against a particular siRNA after several cycles of replication by the incorporation of point mutations within the siRNA target sequence (Wilson and Richardson 2005) .", [["hepatitis C", "DISEASE", 36, 47], ["hepatitis C virus", "ORGANISM", 36, 53], ["siRNA target sequence", "DNA", 186, 207], ["hepatitis C virus", "SPECIES", 36, 53], ["hepatitis C virus", "SPECIES", 36, 53], ["hepatitis C virus", "PROBLEM", 36, 53], ["a particular siRNA", "PROBLEM", 80, 98], ["replication", "TREATMENT", 123, 134], ["point mutations", "PROBLEM", 159, 174], ["hepatitis", "OBSERVATION", 36, 45]]], ["Similar data have been reported for HIV-1 (Boden et al. 2003 (Boden et al. , 2007 and poliovirus infections (Gitlin et al. 2005) .", [["poliovirus infections", "DISEASE", 86, 107], ["HIV-1", "ORGANISM", 36, 41], ["poliovirus", "ORGANISM", 86, 96], ["HIV", "SPECIES", 36, 39], ["HIV-1", "SPECIES", 36, 41], ["HIV", "PROBLEM", 36, 39], ["poliovirus infections", "PROBLEM", 86, 107], ["poliovirus infections", "OBSERVATION", 86, 107]]], ["Therefore, therapeutic targeting of nonvariable virus-binding receptors on susceptible cells or other host cell molecules directly or indirectly involved in virus infections is an interesting alternative to targeting of the virus itself (Werk et al. 2005; Murray et al. 2005; Anderson and Akkina 2005; Arrighi et al. 2004; Gao et al. 2004; Ping et al. 2004; Kameoka et al. 2004) .", [["cells", "ANATOMY", 87, 92], ["cell", "ANATOMY", 107, 111], ["infections", "DISEASE", 163, 173], ["nonvariable virus", "ORGANISM", 36, 53], ["cells", "CELL", 87, 92], ["host cell", "CELL", 102, 111], ["nonvariable virus-binding receptors", "PROTEIN", 36, 71], ["susceptible cells", "CELL_TYPE", 75, 92], ["nonvariable virus", "PROBLEM", 36, 53], ["binding receptors", "PROBLEM", 54, 71], ["susceptible cells", "PROBLEM", 75, 92], ["other host cell molecules", "PROBLEM", 96, 121], ["virus infections", "PROBLEM", 157, 173], ["the virus itself", "PROBLEM", 220, 236], ["host cell molecules", "OBSERVATION", 102, 121]]], ["One approach of this type showed that downregulation of the CD4-independent attachment receptor (DC-SIGN) significantly inhibited HIV infection of dendritic cells (DC) and prevented the transfer of infectious HIV-1 particles from DC to T cells (Arrighi et al. 2004) .Introduction to Viral CardiomyopathiesAdenoviruses of types 2 and 5 and CoxB3 use the Coxsackievirus-Adenovirus-Receptor (CAR) to infect their target cells, either for virus attachment (adenoviruses) or virus internalization (CoxB3) (Bergelson et al. 1998 ).", [["dendritic cells", "ANATOMY", 147, 162], ["DC", "ANATOMY", 164, 166], ["DC", "ANATOMY", 230, 232], ["T cells", "ANATOMY", 236, 243], ["cells", "ANATOMY", 417, 422], ["HIV infection", "DISEASE", 130, 143], ["CD4-independent attachment receptor", "GENE_OR_GENE_PRODUCT", 60, 95], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 97, 104], ["HIV", "ORGANISM", 130, 133], ["dendritic cells", "CELL", 147, 162], ["DC", "CELL", 164, 166], ["HIV-1", "ORGANISM", 209, 214], ["DC", "CELL", 230, 232], ["T cells", "CELL", 236, 243], ["5", "ORGANISM", 333, 334], ["CoxB3", "GENE_OR_GENE_PRODUCT", 339, 344], ["Coxsackievirus-Adenovirus-Receptor", "ORGANISM", 353, 387], ["CAR", "GENE_OR_GENE_PRODUCT", 389, 392], ["cells", "CELL", 417, 422], ["adenoviruses", "ORGANISM", 453, 465], ["CD4-independent attachment receptor", "PROTEIN", 60, 95], ["DC", "PROTEIN", 97, 99], ["SIGN", "PROTEIN", 100, 104], ["dendritic cells", "CELL_TYPE", 147, 162], ["DC", "CELL_TYPE", 164, 166], ["DC", "CELL_TYPE", 230, 232], ["T cells", "CELL_TYPE", 236, 243], ["CoxB3", "PROTEIN", 339, 344], ["Coxsackievirus-Adenovirus-Receptor", "PROTEIN", 353, 387], ["CAR", "PROTEIN", 389, 392], ["target cells", "CELL_TYPE", 410, 422], ["HIV", "SPECIES", 130, 133], ["HIV-1", "SPECIES", 209, 214], ["Coxsackievirus-Adenovirus", "SPECIES", 353, 378], ["HIV", "SPECIES", 130, 133], ["HIV-1", "SPECIES", 209, 214], ["Coxsackievirus-Adenovirus", "SPECIES", 353, 378], ["HIV infection of dendritic cells", "PROBLEM", 130, 162], ["infectious HIV", "PROBLEM", 198, 212], ["Viral CardiomyopathiesAdenoviruses of types 2", "PROBLEM", 283, 328], ["CoxB3", "TREATMENT", 339, 344], ["the Coxsackievirus", "PROBLEM", 349, 367], ["Adenovirus", "PROBLEM", 368, 378], ["Receptor (CAR)", "TREATMENT", 379, 393], ["virus attachment (adenoviruses", "PROBLEM", 435, 465], ["virus internalization", "PROBLEM", 470, 491], ["dendritic cells", "OBSERVATION", 147, 162], ["infectious", "OBSERVATION", 198, 208], ["Viral Cardiomyopathies", "OBSERVATION", 283, 305]]], ["Therefore, CAR represents an attractive target for the inhibition of cardiac CoxB3 and adenovirus infections.", [["cardiac", "ANATOMY", 69, 76], ["adenovirus infections", "DISEASE", 87, 108], ["CAR", "GENE_OR_GENE_PRODUCT", 11, 14], ["cardiac", "ORGAN", 69, 76], ["CoxB3", "GENE_OR_GENE_PRODUCT", 77, 82], ["adenovirus", "ORGANISM", 87, 97], ["CAR", "PROTEIN", 11, 14], ["cardiac CoxB3", "PROBLEM", 69, 82], ["adenovirus infections", "PROBLEM", 87, 108], ["cardiac", "ANATOMY", 69, 76]]], ["It has been shown recently that suppression of CAR by RNAi results in inhibition of CoxB3 infections (Werk et al. 2005; Coyne and Bergelson 2006) .", [["infections", "DISEASE", 90, 100], ["CAR", "GENE_OR_GENE_PRODUCT", 47, 50], ["CoxB3", "GENE_OR_GENE_PRODUCT", 84, 89], ["CAR", "PROTEIN", 47, 50], ["CoxB3 infections", "PROBLEM", 84, 100]]], ["These studies were carried out with cells of non-cardiac origin and chemically synthesized siRNAs were used to inhibit CAR expression.", [["cells", "ANATOMY", 36, 41], ["non-cardiac", "ANATOMY", 45, 56], ["cells", "CELL", 36, 41], ["CAR", "GENE_OR_GENE_PRODUCT", 119, 122], ["CAR", "PROTEIN", 119, 122], ["These studies", "TEST", 0, 13], ["non-cardiac origin", "PROBLEM", 45, 63], ["chemically synthesized siRNAs", "TREATMENT", 68, 97]]], ["However, the therapeutic use of synthetic siRNAs is significantly limited by their rapid degradation in target cells resulting in only transient gene silencing (Watanabe et al. 2004 ).", [["cells", "ANATOMY", 111, 116], ["cells", "CELL", 111, 116], ["target cells", "CELL_TYPE", 104, 116], ["synthetic siRNAs", "TREATMENT", 32, 48], ["their rapid degradation in target cells", "PROBLEM", 77, 116], ["transient gene silencing", "PROBLEM", 135, 159], ["target cells", "OBSERVATION", 104, 116], ["transient", "OBSERVATION_MODIFIER", 135, 144], ["gene silencing", "OBSERVATION", 145, 159]]], ["Moreover, most cells of cardiac origin are very difficult to transfect with chemically synthesized siRNAs even in vitro.", [["cells", "ANATOMY", 15, 20], ["cardiac", "ANATOMY", 24, 31], ["cells", "CELL", 15, 20], ["cardiac", "ORGAN", 24, 31], ["chemically synthesized siRNAs", "PROBLEM", 76, 105], ["most cells", "OBSERVATION_MODIFIER", 10, 20], ["cardiac", "ANATOMY", 24, 31], ["origin", "ANATOMY_MODIFIER", 32, 38], ["siRNAs", "OBSERVATION", 99, 105]]], ["These problems are significantly aggravated in vivo.", [["significantly", "OBSERVATION_MODIFIER", 19, 32], ["aggravated", "OBSERVATION", 33, 43]]], ["Despite intense efforts during recent years systemic and target organ-specific delivery of siRNAs remains a major hurdle for in vivo applications of RNAi.Introduction to Viral CardiomyopathiesTherefore, we investigated the antiviral potential of CAR gene silencing in cells of cardiac origin by use of newly developed AdVs generating shRNA against murine or rat CAR (shCAR). shCAR treatment of HL-1 cells and primary neonatal rat cardiomyocytes (PNCMs) led to almost complete silencing of CAR gene expression and efficient inhibition of CoxB3 infection, while efficient inhibition of adenovirus infections was only seen in PNCMs.", [["organ", "ANATOMY", 64, 69], ["cells", "ANATOMY", 268, 273], ["cardiac", "ANATOMY", 277, 284], ["HL-1 cells", "ANATOMY", 394, 404], ["cardiomyocytes", "ANATOMY", 430, 444], ["PNCMs", "ANATOMY", 446, 451], ["PNCMs", "ANATOMY", 623, 628], ["Viral Cardiomyopathies", "DISEASE", 170, 192], ["shCAR", "CHEMICAL", 375, 380], ["infection", "DISEASE", 543, 552], ["adenovirus infections", "DISEASE", 584, 605], ["organ", "ORGAN", 64, 69], ["CAR", "GENE_OR_GENE_PRODUCT", 246, 249], ["cells", "CELL", 268, 273], ["cardiac", "ORGAN", 277, 284], ["AdVs", "SIMPLE_CHEMICAL", 318, 322], ["murine", "ORGANISM", 348, 354], ["rat", "ORGANISM", 358, 361], ["CAR", "GENE_OR_GENE_PRODUCT", 362, 365], ["shCAR", "GENE_OR_GENE_PRODUCT", 367, 372], ["shCAR", "SIMPLE_CHEMICAL", 375, 380], ["HL-1 cells", "CELL", 394, 404], ["rat", "ORGANISM", 426, 429], ["cardiomyocytes", "CELL", 430, 444], ["PNCMs", "CELL", 446, 451], ["CAR", "GENE_OR_GENE_PRODUCT", 489, 492], ["CoxB3", "GENE_OR_GENE_PRODUCT", 537, 542], ["adenovirus", "ORGANISM", 584, 594], ["PNCMs", "PATHOLOGICAL_FORMATION", 623, 628], ["CAR gene", "DNA", 246, 254], ["AdVs", "PROTEIN", 318, 322], ["murine or rat CAR", "PROTEIN", 348, 365], ["shCAR", "PROTEIN", 367, 372], ["HL-1 cells", "CELL_LINE", 394, 404], ["primary neonatal rat cardiomyocytes", "CELL_TYPE", 409, 444], ["PNCMs", "CELL_TYPE", 446, 451], ["CAR gene", "DNA", 489, 497], ["PNCMs", "CELL_TYPE", 623, 628], ["murine", "SPECIES", 348, 354], ["rat", "SPECIES", 358, 361], ["rat", "SPECIES", 426, 429], ["rat", "SPECIES", 358, 361], ["rat", "SPECIES", 426, 429], ["adenovirus", "SPECIES", 584, 594], ["specific delivery of siRNAs", "TREATMENT", 70, 97], ["Viral Cardiomyopathies", "PROBLEM", 170, 192], ["CAR gene silencing", "TREATMENT", 246, 264], ["shCAR treatment", "TREATMENT", 375, 390], ["HL-1 cells", "PROBLEM", 394, 404], ["primary neonatal rat cardiomyocytes", "PROBLEM", 409, 444], ["CAR gene expression", "PROBLEM", 489, 508], ["CoxB3 infection", "PROBLEM", 537, 552], ["adenovirus infections", "PROBLEM", 584, 605], ["organ", "ANATOMY", 64, 69], ["siRNAs", "OBSERVATION", 91, 97], ["Viral Cardiomyopathies", "OBSERVATION", 170, 192], ["cardiac", "ANATOMY", 277, 284], ["origin", "ANATOMY_MODIFIER", 285, 291], ["infection", "OBSERVATION", 543, 552]]], ["The studies also revealed cell type-specific responses of cellular CAR protein to shCAR treatment which need to be considered as important determinants of this new antiviral approach in vivo.Selection and Specificity of Mouse CAR shRNAsTo investigate the efficacy of CAR silencing for the inhibition of adenovirus and CoxB3 infection in cardiac HL-1 cells, we generated a total of three shRNAs (shCAR2m, shCAR3m, shCAR4m) directed against extracellular domains of the mCAR splice variants mCAR-1 (Bergelson et al. 1998 ) and mCAR-2 (Tomko et al. 1997) (Fig. 2) following published siRNA selection criteria (Reynolds et al. 2004) .", [["cell", "ANATOMY", 26, 30], ["cellular", "ANATOMY", 58, 66], ["cardiac HL-1 cells", "ANATOMY", 337, 355], ["extracellular", "ANATOMY", 439, 452], ["shCAR", "CHEMICAL", 82, 87], ["infection", "DISEASE", 324, 333], ["cell", "CELL", 26, 30], ["cellular CAR", "GENE_OR_GENE_PRODUCT", 58, 70], ["shCAR", "GENE_OR_GENE_PRODUCT", 82, 87], ["Mouse", "ORGANISM", 220, 225], ["CAR shRNAsTo", "GENE_OR_GENE_PRODUCT", 226, 238], ["CAR", "GENE_OR_GENE_PRODUCT", 267, 270], ["adenovirus", "ORGANISM", 303, 313], ["CoxB3", "GENE_OR_GENE_PRODUCT", 318, 323], ["cardiac HL-1 cells", "CELL", 337, 355], ["shCAR2m", "GENE_OR_GENE_PRODUCT", 395, 402], ["shCAR3m", "GENE_OR_GENE_PRODUCT", 404, 411], ["shCAR4m", "GENE_OR_GENE_PRODUCT", 413, 420], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 439, 452], ["mCAR", "GENE_OR_GENE_PRODUCT", 468, 472], ["mCAR-1", "GENE_OR_GENE_PRODUCT", 489, 495], ["mCAR-2", "GENE_OR_GENE_PRODUCT", 525, 531], ["CAR protein", "PROTEIN", 67, 78], ["Mouse CAR shRNAsTo", "PROTEIN", 220, 238], ["CAR", "PROTEIN", 267, 270], ["cardiac HL-1 cells", "CELL_TYPE", 337, 355], ["shRNAs", "DNA", 387, 393], ["shCAR2m", "PROTEIN", 395, 402], ["shCAR3m", "PROTEIN", 404, 411], ["shCAR4m", "PROTEIN", 413, 420], ["extracellular domains", "PROTEIN", 439, 460], ["Mouse", "SPECIES", 220, 225], ["Mouse", "SPECIES", 220, 225], ["adenovirus", "SPECIES", 303, 313], ["The studies", "TEST", 0, 11], ["cell type-specific responses", "PROBLEM", 26, 54], ["cellular CAR protein", "TREATMENT", 58, 78], ["shCAR treatment", "TREATMENT", 82, 97], ["this new antiviral approach", "TREATMENT", 155, 182], ["Selection", "TEST", 191, 200], ["Mouse CAR shRNAsTo", "TREATMENT", 220, 238], ["CAR silencing", "TREATMENT", 267, 280], ["adenovirus", "PROBLEM", 303, 313], ["CoxB3 infection", "PROBLEM", 318, 333], ["three shRNAs (shCAR2m, shCAR3m, shCAR4m)", "TREATMENT", 381, 421], ["mCAR", "TEST", 489, 493], ["mCAR", "TEST", 525, 529], ["cell type-specific", "OBSERVATION", 26, 44], ["cardiac", "ANATOMY", 337, 344], ["mCAR splice", "OBSERVATION", 468, 479]]], ["DNA oligonucleotides encoding these shRNAs were then cloned into expression plasmids under the control of a murine RNA polymerase III U6 promotor.", [["plasmids", "ANATOMY", 76, 84], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["murine", "ORGANISM", 108, 114], ["RNA polymerase III U6", "GENE_OR_GENE_PRODUCT", 115, 136], ["shRNAs", "DNA", 36, 42], ["expression plasmids", "DNA", 65, 84], ["murine RNA polymerase III U6 promotor", "DNA", 108, 145], ["murine", "SPECIES", 108, 114], ["DNA oligonucleotides", "TREATMENT", 0, 20], ["these shRNAs", "TREATMENT", 30, 42], ["expression plasmids", "TREATMENT", 65, 84], ["a murine RNA polymerase III U6 promotor", "TREATMENT", 106, 145]]], ["To test their efficacies, we co-transfected 293T cells with shCAR2m, shCAR3m, or shCAR4m-expressing plasmid, together with plasmids expressing recombinant mCAR1 and mCAR2.", [["293T cells", "ANATOMY", 44, 54], ["plasmid", "ANATOMY", 100, 107], ["plasmids", "ANATOMY", 123, 131], ["293T cells", "CELL", 44, 54], ["shCAR2m", "GENE_OR_GENE_PRODUCT", 60, 67], ["shCAR3m", "GENE_OR_GENE_PRODUCT", 69, 76], ["shCAR4m", "GENE_OR_GENE_PRODUCT", 81, 88], ["mCAR1", "GENE_OR_GENE_PRODUCT", 155, 160], ["mCAR2", "GENE_OR_GENE_PRODUCT", 165, 170], ["293T cells", "CELL_LINE", 44, 54], ["shCAR2m, shCAR3m, or shCAR4m-expressing plasmid", "DNA", 60, 107], ["plasmids", "DNA", 123, 131], ["mCAR1", "PROTEIN", 155, 160], ["mCAR2", "PROTEIN", 165, 170], ["shCAR2m", "TEST", 60, 67], ["shCAR3m", "TEST", 69, 76], ["plasmids", "TREATMENT", 123, 131]]], ["As a transfection control a plasmid expressing an irrelevant shRNA was used.", [["plasmid", "ANATOMY", 28, 35], ["plasmid", "DNA", 28, 35], ["a transfection control", "TREATMENT", 3, 25], ["a plasmid", "TREATMENT", 26, 35], ["an irrelevant shRNA", "TREATMENT", 47, 66], ["irrelevant shRNA", "OBSERVATION", 50, 66]]], ["To determine the extent of recombinant mCAR1-and mCAR2-mRNA downregulation, total cellular RNA was isolated 48 h after transfection and Northern blot hybridization was carried out.", [["cellular", "ANATOMY", 82, 90], ["mCAR1", "GENE_OR_GENE_PRODUCT", 39, 44], ["mCAR2", "GENE_OR_GENE_PRODUCT", 49, 54], ["cellular", "CELL", 82, 90], ["mCAR1", "PROTEIN", 39, 44], ["mCAR2", "PROTEIN", 49, 54], ["cellular RNA", "RNA", 82, 94], ["recombinant mCAR1", "TEST", 27, 44], ["mRNA downregulation", "PROBLEM", 55, 74], ["total cellular RNA", "PROBLEM", 76, 94], ["transfection", "TREATMENT", 119, 131], ["Northern blot hybridization", "TEST", 136, 163], ["recombinant", "OBSERVATION_MODIFIER", 27, 38], ["mCAR1", "OBSERVATION", 39, 44], ["mRNA downregulation", "OBSERVATION", 55, 74], ["total", "OBSERVATION_MODIFIER", 76, 81], ["cellular RNA", "OBSERVATION", 82, 94]]], ["These experiments showed that two shRNAs were highly efficient: shCAR2m with 93% silencing, and shCAR4m with 97% silencing of mCAR1-and mCAR2-mRNA.", [["shCAR2m", "GENE_OR_GENE_PRODUCT", 64, 71], ["shCAR4m", "GENE_OR_GENE_PRODUCT", 96, 103], ["mCAR1", "GENE_OR_GENE_PRODUCT", 126, 131], ["mCAR2-mRNA", "GENE_OR_GENE_PRODUCT", 136, 146], ["shRNAs", "DNA", 34, 40], ["shCAR2m", "PROTEIN", 64, 71], ["shCAR4m", "DNA", 96, 103], ["mCAR1", "PROTEIN", 126, 131], ["mCAR2", "PROTEIN", 136, 141], ["These experiments", "TEST", 0, 17], ["shCAR4m", "TEST", 96, 103], ["mCAR1", "TEST", 126, 131], ["mCAR2-mRNA", "ANATOMY", 136, 146]]], ["The control shRNA affected neither mCAR1-nor mCAR2-mRNA expression (Fig. 3a) .", [["mCAR1", "GENE_OR_GENE_PRODUCT", 35, 40], ["mCAR2", "GENE_OR_GENE_PRODUCT", 45, 50], ["mCAR1", "PROTEIN", 35, 40], ["mCAR2", "PROTEIN", 45, 50]]], ["To analyze the specificities of shCAR2m and shCAR4m, both were also tested for downregulation of human CAR (hCAR) by co-transfection with a plasmid expressing recombinant soluble hCAR.", [["plasmid", "ANATOMY", 140, 147], ["shCAR2m", "GENE_OR_GENE_PRODUCT", 32, 39], ["shCAR4m", "GENE_OR_GENE_PRODUCT", 44, 51], ["human", "ORGANISM", 97, 102], ["CAR", "GENE_OR_GENE_PRODUCT", 103, 106], ["hCAR", "GENE_OR_GENE_PRODUCT", 108, 112], ["hCAR", "GENE_OR_GENE_PRODUCT", 179, 183], ["shCAR2m", "PROTEIN", 32, 39], ["shCAR4m", "PROTEIN", 44, 51], ["human CAR", "PROTEIN", 97, 106], ["hCAR", "PROTEIN", 108, 112], ["plasmid", "DNA", 140, 147], ["recombinant soluble hCAR", "PROTEIN", 159, 183], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 97, 102], ["a plasmid expressing recombinant soluble hCAR", "TREATMENT", 138, 183]]], ["None of the mouse CAR-specific shRNAs influenced human CAR-mRNA expression.", [["mouse", "ORGANISM", 12, 17], ["CAR", "GENE_OR_GENE_PRODUCT", 18, 21], ["shRNAs", "GENE_OR_GENE_PRODUCT", 31, 37], ["human", "ORGANISM", 49, 54], ["CAR", "GENE_OR_GENE_PRODUCT", 55, 58], ["mouse CAR-specific shRNAs", "DNA", 12, 37], ["CAR", "PROTEIN", 55, 58], ["mouse", "SPECIES", 12, 17], ["human", "SPECIES", 49, 54], ["mouse", "SPECIES", 12, 17], ["human", "SPECIES", 49, 54], ["the mouse CAR", "TEST", 8, 21]]], ["In contrast, a human-specific shRNA efficiently silenced hCAR-mRNA expression (Fig. 3b ).", [["hCAR-mRNA", "GENE_OR_GENE_PRODUCT", 57, 66], ["hCAR", "PROTEIN", 57, 61], ["a human-specific shRNA", "TREATMENT", 13, 35]]], ["Considering that shCAR2m has only one mismatch and shCAR4m three mismatches as compared to hCAR-mRNA, these experiments indicate very high species-specificity of the selected mCAR-shRNAs.Silencing of mCAR in Mouse Cardiac HL-1 CellsTo determine the optimal AdV dose for transduction of mouse cardiac HL-1 cells, we first transduced HL-1 cells with a GFP-expressing marker AdV at an MOI from 5 to 1,000.", [["Cardiac HL-1 CellsTo", "ANATOMY", 214, 234], ["cardiac HL-1 cells", "ANATOMY", 292, 310], ["HL-1 cells", "ANATOMY", 332, 342], ["shCAR2m", "GENE_OR_GENE_PRODUCT", 17, 24], ["shCAR4m", "GENE_OR_GENE_PRODUCT", 51, 58], ["hCAR", "GENE_OR_GENE_PRODUCT", 91, 95], ["mCAR", "GENE_OR_GENE_PRODUCT", 175, 179], ["mCAR", "GENE_OR_GENE_PRODUCT", 200, 204], ["Mouse", "ORGANISM", 208, 213], ["Cardiac HL-1 CellsTo", "CELL", 214, 234], ["AdV", "ORGANISM", 257, 260], ["mouse", "ORGANISM", 286, 291], ["cardiac HL-1 cells", "CELL", 292, 310], ["HL-1 cells", "CELL", 332, 342], ["GFP", "GENE_OR_GENE_PRODUCT", 350, 353], ["AdV", "ORGANISM", 372, 375], ["shCAR2m", "DNA", 17, 24], ["shCAR4m", "DNA", 51, 58], ["hCAR-mRNA", "RNA", 91, 100], ["mCAR", "DNA", 175, 179], ["shRNAs", "DNA", 180, 186], ["mCAR", "PROTEIN", 200, 204], ["mouse cardiac HL-1 cells", "CELL_LINE", 286, 310], ["HL-1 cells", "CELL_LINE", 332, 342], ["GFP", "PROTEIN", 350, 353], ["Mouse", "SPECIES", 208, 213], ["mouse", "SPECIES", 286, 291], ["mouse", "SPECIES", 286, 291], ["shCAR4m three mismatches", "PROBLEM", 51, 75], ["very high species", "PROBLEM", 129, 146], ["Cardiac HL", "TEST", 214, 224], ["transduction of mouse cardiac HL", "TREATMENT", 270, 302], ["a GFP", "TEST", 348, 353], ["mismatch", "OBSERVATION", 38, 46], ["very", "OBSERVATION_MODIFIER", 129, 133], ["high species", "OBSERVATION", 134, 146], ["cardiac", "ANATOMY", 292, 299]]], ["At an MOI from 60 to 100 GFP expression was seen in 76-80% of the cells, whereas no cytotoxic effects were observed.", [["cells", "ANATOMY", 66, 71], ["GFP", "GENE_OR_GENE_PRODUCT", 25, 28], ["cells", "CELL", 66, 71], ["cytotoxic effects", "PROBLEM", 84, 101], ["no", "UNCERTAINTY", 81, 83], ["cytotoxic effects", "OBSERVATION", 84, 101]]], ["Further dose escalation resulted in an only slight further increase of transduction rate (Fig. 4a) , and at an MOI of 500 or higher cytotoxic effects became evident (increase of apoptotic cells, reduction of cell growth).", [["cells", "ANATOMY", 188, 193], ["cell", "ANATOMY", 208, 212], ["cells", "CELL", 188, 193], ["cell", "CELL", 208, 212], ["apoptotic cells", "CELL_TYPE", 178, 193], ["Further dose escalation", "TREATMENT", 0, 23], ["transduction rate", "TEST", 71, 88], ["an MOI", "TEST", 108, 114], ["higher cytotoxic effects", "PROBLEM", 125, 149], ["apoptotic cells", "PROBLEM", 178, 193], ["cell growth", "PROBLEM", 208, 219], ["slight", "OBSERVATION_MODIFIER", 44, 50], ["increase", "OBSERVATION_MODIFIER", 59, 67], ["increase", "OBSERVATION_MODIFIER", 166, 174], ["apoptotic cells", "OBSERVATION", 178, 193], ["cell growth", "OBSERVATION", 208, 219]]], ["HL-1 cells express mCAR1 but no mCAR2 on their cell surface (not shown).", [["HL-1 cells", "ANATOMY", 0, 10], ["cell surface", "ANATOMY", 47, 59], ["HL-1 cells", "CELL", 0, 10], ["mCAR1", "GENE_OR_GENE_PRODUCT", 19, 24], ["mCAR2", "GENE_OR_GENE_PRODUCT", 32, 37], ["cell surface", "CELLULAR_COMPONENT", 47, 59], ["HL-1 cells", "CELL_LINE", 0, 10], ["mCAR1", "PROTEIN", 19, 24], ["mCAR2", "PROTEIN", 32, 37], ["HL", "TEST", 0, 2], ["no", "UNCERTAINTY", 29, 31]]], ["Therefore, the silencing capacity of the new AdshCAR4m (Fig. 2 ) which expresses the above evaluated most efficient shCAR4m was investigated with respect to mCAR1 expression in HL-1 cells only.", [["HL-1 cells", "ANATOMY", 177, 187], ["AdshCAR4m", "GENE_OR_GENE_PRODUCT", 45, 54], ["shCAR4m", "GENE_OR_GENE_PRODUCT", 116, 123], ["mCAR1", "GENE_OR_GENE_PRODUCT", 157, 162], ["HL-1 cells", "CELL", 177, 187], ["AdshCAR4m", "PROTEIN", 45, 54], ["shCAR4m", "PROTEIN", 116, 123], ["mCAR1", "PROTEIN", 157, 162], ["HL-1 cells", "CELL_LINE", 177, 187], ["the silencing capacity", "PROBLEM", 11, 33], ["capacity", "OBSERVATION_MODIFIER", 25, 33]]], ["To assess the amount of AdV-generated shCAR4m, HL-1 cells were transduced with AdshCAR4m at an MOI from 5 to 1,000.", [["HL-1 cells", "ANATOMY", 47, 57], ["AdV", "ORGANISM", 24, 27], ["shCAR4m", "CELL", 38, 45], ["HL-1 cells", "CELL", 47, 57], ["AdshCAR4m", "GENE_OR_GENE_PRODUCT", 79, 88], ["shCAR4m", "PROTEIN", 38, 45], ["HL-1 cells", "CELL_LINE", 47, 57], ["AdshCAR4m", "PROTEIN", 79, 88], ["AdV", "TEST", 24, 27], ["AdshCAR4m", "TREATMENT", 79, 88]]], ["Twenty-four, 48, and 72 h (c) Downregulation of mCAR-mRNA expression by AdshCAR4m.", [["mCAR", "GENE_OR_GENE_PRODUCT", 48, 52], ["AdshCAR4m", "GENE_OR_GENE_PRODUCT", 72, 81], ["mCAR", "PROTEIN", 48, 52], ["AdshCAR4m", "PROTEIN", 72, 81]]], ["HL-1 cells were transduced with AdshCAR4m or AdshPLBr (MOI from 5 to 1,000) and mCAR-mRNA expression was measured by real-time RT-PCR at the indicated time points later the expression of shCAR4m was analyzed.", [["HL-1 cells", "ANATOMY", 0, 10], ["HL-1 cells", "CELL", 0, 10], ["AdshCAR4m", "GENE_OR_GENE_PRODUCT", 32, 41], ["AdshPLBr", "GENE_OR_GENE_PRODUCT", 45, 53], ["mCAR", "GENE_OR_GENE_PRODUCT", 80, 84], ["shCAR4m", "GENE_OR_GENE_PRODUCT", 187, 194], ["HL-1 cells", "CELL_LINE", 0, 10], ["AdshCAR4m", "PROTEIN", 32, 41], ["mCAR", "PROTEIN", 80, 84], ["shCAR4m", "PROTEIN", 187, 194], ["AdshCAR4m", "TEST", 32, 41], ["PCR", "TEST", 130, 133]]], ["A time-and dose-dependent transcription of shCAR4m was detected (Fig. 4b) .", [["shCAR4m", "GENE_OR_GENE_PRODUCT", 43, 50], ["shCAR4m", "PROTEIN", 43, 50], ["dose-dependent transcription of shCAR4m", "TREATMENT", 11, 50]]], ["As a consequence of shRNA expression, strong downregulation of mCAR1-mRNA was observed 48 and 72 h after transduction.", [["mCAR1", "GENE_OR_GENE_PRODUCT", 63, 68], ["mCAR1-mRNA", "RNA", 63, 73], ["shRNA expression", "PROBLEM", 20, 36]]], ["Near maximal reduction of 85-90% was observed at an MOI of 100.", [["Near maximal reduction", "TEST", 0, 22], ["an MOI", "TEST", 49, 55], ["maximal", "OBSERVATION_MODIFIER", 5, 12], ["reduction", "OBSERVATION_MODIFIER", 13, 22]]], ["Higher doses did not result in significant further downregulation of mCAR1-mRNA (Fig. 4c) .", [["mCAR1", "GENE_OR_GENE_PRODUCT", 69, 74], ["Fig. 4c", "GENE_OR_GENE_PRODUCT", 81, 88], ["mCAR1", "PROTEIN", 69, 74], ["mRNA", "RNA", 75, 79]]], ["These results indicate that an MOI of 100 was optimal for HL-1 transduction, since this dose allowed strong downregulation of mCAR1-mRNA in HL-1 cells, while cytotoxicity of the viral vector was still very low.", [["HL-1 cells", "ANATOMY", 140, 150], ["HL-1", "GENE_OR_GENE_PRODUCT", 58, 62], ["mCAR1", "GENE_OR_GENE_PRODUCT", 126, 131], ["HL-1 cells", "CELL", 140, 150], ["mCAR1-mRNA", "RNA", 126, 136], ["HL-1 cells", "CELL_LINE", 140, 150], ["an MOI", "TEST", 28, 34], ["cytotoxicity", "TEST", 158, 170], ["the viral vector", "TEST", 174, 190], ["viral vector", "OBSERVATION", 178, 190]]], ["We next investigated mCAR1 protein expression after transduction of HL-1 cells with AdshCAR4m at an MOI of 100.", [["HL-1 cells", "ANATOMY", 68, 78], ["mCAR1", "GENE_OR_GENE_PRODUCT", 21, 26], ["HL-1 cells", "CELL", 68, 78], ["AdshCAR4m", "CELL", 84, 93], ["mCAR1", "PROTEIN", 21, 26], ["HL-1 cells", "CELL_LINE", 68, 78], ["AdshCAR4m", "PROTEIN", 84, 93], ["transduction of HL", "TREATMENT", 52, 70], ["AdshCAR4m", "TREATMENT", 84, 93]]], ["To disrupt pre-existing membrane-associated mCAR1, HL-1 cells were trypsinized 24 h after AdshCAR4m transduction and then re-seeded.", [["membrane", "ANATOMY", 24, 32], ["HL-1 cells", "ANATOMY", 51, 61], ["membrane", "CELLULAR_COMPONENT", 24, 32], ["mCAR1", "GENE_OR_GENE_PRODUCT", 44, 49], ["HL-1 cells", "CELL", 51, 61], ["mCAR1", "PROTEIN", 44, 49], ["HL-1 cells", "CELL_LINE", 51, 61], ["AdshCAR4m", "PROTEIN", 90, 99], ["AdshCAR4m transduction", "TREATMENT", 90, 112]]], ["This procedure led to ablation of mCAR1 protein at the cell surface 2 days after transduction ( Fig. 5a/b ).", [["cell surface", "ANATOMY", 55, 67], ["mCAR1", "GENE_OR_GENE_PRODUCT", 34, 39], ["cell surface", "CELLULAR_COMPONENT", 55, 67], ["mCAR1 protein", "PROTEIN", 34, 47], ["This procedure", "TREATMENT", 0, 14], ["ablation of mCAR1 protein", "TREATMENT", 22, 47]]], ["In contrast, control cells rapidly re-expressed mCAR1 (Fig. 5b) .", [["cells", "ANATOMY", 21, 26], ["cells", "CELL", 21, 26], ["mCAR1", "GENE_OR_GENE_PRODUCT", 48, 53], ["control cells", "CELL_TYPE", 13, 26], ["mCAR1", "PROTEIN", 48, 53]]], ["Two days after AdshCAR4m treatment, a few cells still displayed some membrane-associated mCAR1 immunoreactivity (Fig. 5b) , probably reflecting residual mCAR1 domains still anchored in the cell membrane after trypsinization.", [["cells", "ANATOMY", 42, 47], ["membrane", "ANATOMY", 69, 77], ["cell membrane", "ANATOMY", 189, 202], ["AdshCAR4m", "CHEMICAL", 15, 24], ["AdshCAR4m", "CHEMICAL", 15, 24], ["AdshCAR4m", "SIMPLE_CHEMICAL", 15, 24], ["cells", "CELL", 42, 47], ["membrane", "CELLULAR_COMPONENT", 69, 77], ["mCAR1", "GENE_OR_GENE_PRODUCT", 89, 94], ["mCAR1", "GENE_OR_GENE_PRODUCT", 153, 158], ["cell membrane", "CELLULAR_COMPONENT", 189, 202], ["AdshCAR4m", "PROTEIN", 15, 24], ["mCAR1", "PROTEIN", 89, 94], ["mCAR1 domains", "PROTEIN", 153, 166], ["AdshCAR4m treatment", "TREATMENT", 15, 34], ["a few cells", "PROBLEM", 36, 47], ["some membrane-associated mCAR1 immunoreactivity", "PROBLEM", 64, 111], ["residual mCAR1 domains", "PROBLEM", 144, 166], ["mCAR1 immunoreactivity", "OBSERVATION", 89, 111], ["probably reflecting", "UNCERTAINTY", 124, 143], ["residual mCAR1", "OBSERVATION", 144, 158], ["cell membrane", "OBSERVATION", 189, 202]]], ["At days 3 and 4 after AdshCAR4m transduction mCAR1 immunoreactivity disappeared from HL-1 cells, whereas it remained permanently detectable in the control cells (Fig. 5b) .", [["HL-1 cells", "ANATOMY", 85, 95], ["cells", "ANATOMY", 155, 160], ["AdshCAR4m", "GENE_OR_GENE_PRODUCT", 22, 31], ["mCAR1", "GENE_OR_GENE_PRODUCT", 45, 50], ["HL-1 cells", "CELL", 85, 95], ["cells", "CELL", 155, 160], ["AdshCAR4m", "PROTEIN", 22, 31], ["mCAR1", "PROTEIN", 45, 50], ["HL-1 cells", "CELL_LINE", 85, 95], ["control cells", "CELL_TYPE", 147, 160], ["AdshCAR4m transduction mCAR1 immunoreactivity", "TEST", 22, 67]]], ["Interestingly, CAR was only expressed at cell-to-cell contact sites in HL-1 cells suggesting that the observed stability of CAR in intact monolayers is determined by homophilic or heterophilic CAR interaction at cell-tocell contact sites.", [["cell", "ANATOMY", 41, 45], ["cell", "ANATOMY", 49, 53], ["sites", "ANATOMY", 62, 67], ["HL-1 cells", "ANATOMY", 71, 81], ["monolayers", "ANATOMY", 138, 148], ["cell", "ANATOMY", 212, 216], ["CAR", "GENE_OR_GENE_PRODUCT", 15, 18], ["cell", "CELL", 41, 45], ["cell", "CELL", 49, 53], ["HL-1 cells", "CELL", 71, 81], ["CAR", "GENE_OR_GENE_PRODUCT", 124, 127], ["monolayers", "CELL", 138, 148], ["CAR", "GENE_OR_GENE_PRODUCT", 193, 196], ["cell-tocell contact sites", "CELLULAR_COMPONENT", 212, 237], ["CAR", "PROTEIN", 15, 18], ["HL-1 cells", "CELL_LINE", 71, 81], ["CAR", "PROTEIN", 124, 127], ["CAR", "PROTEIN", 193, 196], ["heterophilic CAR interaction", "PROBLEM", 180, 208], ["heterophilic CAR", "OBSERVATION", 180, 196]]], ["Together, the results indicate that AdshCAR4m treatment efficiently inhibits de novo synthesis of mCAR1.Inhibition of CoxB3 Replication in HL-1 Cells by AdshCAR4mThe antiviral effect of mCAR1 silencing was now investigated with respect to CoxB3 for which cellular CAR constitutes the internalization receptor.", [["HL-1 Cells", "ANATOMY", 139, 149], ["cellular", "ANATOMY", 255, 263], ["AdshCAR4m", "CHEMICAL", 36, 45], ["AdshCAR4m", "CHEMICAL", 153, 162], ["AdshCAR4m", "CHEMICAL", 36, 45], ["AdshCAR4m", "CHEMICAL", 153, 162], ["AdshCAR4m", "SIMPLE_CHEMICAL", 36, 45], ["mCAR1", "GENE_OR_GENE_PRODUCT", 98, 103], ["CoxB3", "GENE_OR_GENE_PRODUCT", 118, 123], ["HL-1 Cells", "CELL", 139, 149], ["AdshCAR4m", "CELL", 153, 162], ["mCAR1", "GENE_OR_GENE_PRODUCT", 186, 191], ["CoxB3", "GENE_OR_GENE_PRODUCT", 239, 244], ["cellular", "CELL", 255, 263], ["CAR", "GENE_OR_GENE_PRODUCT", 264, 267], ["mCAR1", "PROTEIN", 98, 103], ["CoxB3", "PROTEIN", 118, 123], ["HL-1 Cells", "CELL_LINE", 139, 149], ["AdshCAR4m", "PROTEIN", 153, 162], ["mCAR1", "PROTEIN", 186, 191], ["CoxB3", "PROTEIN", 239, 244], ["CAR", "PROTEIN", 264, 267], ["internalization receptor", "PROTEIN", 284, 308], ["AdshCAR4m treatment", "TREATMENT", 36, 55], ["de novo synthesis of mCAR1", "PROBLEM", 77, 103], ["CoxB3 Replication in HL", "TREATMENT", 118, 141], ["The antiviral effect of mCAR1 silencing", "TREATMENT", 162, 201], ["CoxB3", "TREATMENT", 239, 244], ["antiviral effect", "OBSERVATION", 166, 182], ["mCAR1 silencing", "OBSERVATION", 186, 201]]], ["For this purpose, we first investigated the CoxB3 protective efficacy of AdshCAR4m as a function of dose, at an MOI of AdshCAR4m ranging from 10 to 100, using the same trypsin-involved experimental procedure as described above.", [["AdshCAR4m", "CHEMICAL", 73, 82], ["AdshCAR4m", "CHEMICAL", 73, 82], ["CoxB3", "GENE_OR_GENE_PRODUCT", 44, 49], ["AdshCAR4m", "SIMPLE_CHEMICAL", 73, 82], ["trypsin", "GENE_OR_GENE_PRODUCT", 168, 175], ["AdshCAR4m", "PROTEIN", 73, 82], ["trypsin", "PROTEIN", 168, 175], ["AdshCAR4m", "TREATMENT", 73, 82], ["AdshCAR4m", "TEST", 119, 128], ["experimental procedure", "TREATMENT", 185, 207]]], ["HL-1 cells were infected with CoxB3 48 h after transduction with AdshCAR4m and the amount of new generated progeny virus determined six days later.", [["HL-1 cells", "ANATOMY", 0, 10], ["HL-1 cells", "CELL", 0, 10], ["AdshCAR4m", "GENE_OR_GENE_PRODUCT", 65, 74], ["HL-1 cells", "CELL_LINE", 0, 10], ["AdshCAR4m", "PROTEIN", 65, 74], ["CoxB3", "TREATMENT", 30, 35], ["AdshCAR4m", "TREATMENT", 65, 74], ["new generated progeny virus", "PROBLEM", 93, 120], ["progeny virus", "OBSERVATION", 107, 120]]], ["Virus plaque assays clearly demonstrated that CoxB3 replicates in HL-1 cells, but at a rather low frequency, since no cytopathogenic effect was visible during the 6-day investigation period.", [["plaque", "ANATOMY", 6, 12], ["HL-1 cells", "ANATOMY", 66, 76], ["Virus", "ORGANISM", 0, 5], ["CoxB3", "GENE_OR_GENE_PRODUCT", 46, 51], ["HL-1 cells", "CELL", 66, 76], ["CoxB3", "PROTEIN", 46, 51], ["HL-1 cells", "CELL_LINE", 66, 76], ["Virus plaque assays", "TEST", 0, 19], ["cytopathogenic effect", "PROBLEM", 118, 139], ["plaque", "OBSERVATION", 6, 12], ["low frequency", "OBSERVATION_MODIFIER", 94, 107], ["no", "UNCERTAINTY", 115, 117], ["cytopathogenic", "OBSERVATION_MODIFIER", 118, 132]]], ["As expected, the strongest reduction of CoxB3 progeny virus production by 97% was observed at the highest AdshCAR4m dose with an MOI of 100.", [["CoxB3", "GENE_OR_GENE_PRODUCT", 40, 45], ["CoxB3 progeny virus production", "PROBLEM", 40, 70], ["an MOI", "TEST", 126, 132]]], ["Nevertheless, MOIs of 50 and 25 still led to significant inhibition of CoxB3 replication by 85 and 75%, respectively, whereas a MOI of 10 showed no significant effect (Fig. 6a) .", [["CoxB3", "GENE_OR_GENE_PRODUCT", 71, 76], ["CoxB3", "PROTEIN", 71, 76], ["MOIs", "TEST", 14, 18], ["CoxB3 replication", "TREATMENT", 71, 88], ["a MOI", "TEST", 126, 131]]], ["To investigate whether disruption of pre-existing CAR affects CoxB3 infection we treated HL-1 cells with the trypsin-involved experimental procedure as described above or omitted the trypsin step after AdshCAR4m transduction.", [["HL-1 cells", "ANATOMY", 89, 99], ["infection", "DISEASE", 68, 77], ["CAR", "GENE_OR_GENE_PRODUCT", 50, 53], ["CoxB3", "GENE_OR_GENE_PRODUCT", 62, 67], ["HL-1 cells", "CELL", 89, 99], ["trypsin", "GENE_OR_GENE_PRODUCT", 109, 116], ["trypsin", "GENE_OR_GENE_PRODUCT", 183, 190], ["AdshCAR4m", "SIMPLE_CHEMICAL", 202, 211], ["CAR", "PROTEIN", 50, 53], ["HL-1 cells", "CELL_LINE", 89, 99], ["trypsin", "PROTEIN", 109, 116], ["trypsin", "PROTEIN", 183, 190], ["AdshCAR4m", "PROTEIN", 202, 211], ["pre-existing CAR affects", "PROBLEM", 37, 61], ["CoxB3 infection", "PROBLEM", 62, 77], ["the trypsin", "TREATMENT", 105, 116], ["experimental procedure", "TREATMENT", 126, 148], ["AdshCAR4m transduction", "TREATMENT", 202, 224]]], ["Titers of CoxB3 progeny virus generated 5 and 6 days after CoxB3 infection were strongly reduced by about 97% in AdshCAR4m-transduced cells, irrespective of whether membrane-associated CAR was disrupted by trypsinization or not (Fig. 6b) .", [["cells", "ANATOMY", 134, 139], ["membrane", "ANATOMY", 165, 173], ["infection", "DISEASE", 65, 74], ["CoxB3 progeny virus", "ORGANISM", 10, 29], ["CoxB3", "GENE_OR_GENE_PRODUCT", 59, 64], ["AdshCAR4m", "GENE_OR_GENE_PRODUCT", 113, 122], ["cells", "CELL", 134, 139], ["membrane", "CELLULAR_COMPONENT", 165, 173], ["CAR", "GENE_OR_GENE_PRODUCT", 185, 188], ["AdshCAR4m-transduced cells", "CELL_LINE", 113, 139], ["CAR", "PROTEIN", 185, 188], ["CoxB3 progeny virus", "PROBLEM", 10, 29], ["CoxB3 infection", "PROBLEM", 59, 74], ["infection", "OBSERVATION", 65, 74]]], ["These experiments indicate that AdshCAR4m inhibits CoxB3 replication in HL-1 cells with high efficacy.", [["HL-1 cells", "ANATOMY", 72, 82], ["AdshCAR4m", "CHEMICAL", 32, 41], ["AdshCAR4m", "SIMPLE_CHEMICAL", 32, 41], ["CoxB3", "GENE_OR_GENE_PRODUCT", 51, 56], ["HL-1 cells", "CELL", 72, 82], ["AdshCAR4m", "PROTEIN", 32, 41], ["CoxB3", "DNA", 51, 56], ["HL-1 cells", "CELL_LINE", 72, 82], ["high efficacy", "PROBLEM", 88, 101]]], ["Moreover, proteolysis of membrane-associated CAR seems to be not affect CoxB3 infection.Inhibition of Adenovirus Infection of HL-1 Cells by AdshCAR4mCAR is also involved in adenovirus infection as attachment receptor.", [["membrane", "ANATOMY", 25, 33], ["HL-1 Cells", "ANATOMY", 126, 136], ["infection", "DISEASE", 78, 87], ["adenovirus infection", "DISEASE", 173, 193], ["membrane", "CELLULAR_COMPONENT", 25, 33], ["CAR", "GENE_OR_GENE_PRODUCT", 45, 48], ["CoxB3", "GENE_OR_GENE_PRODUCT", 72, 77], ["Adenovirus", "ORGANISM", 102, 112], ["HL-1 Cells", "CELL", 126, 136], ["AdshCAR4mCAR", "GENE_OR_GENE_PRODUCT", 140, 152], ["adenovirus", "ORGANISM", 173, 183], ["CAR", "PROTEIN", 45, 48], ["AdshCAR4mCAR", "PROTEIN", 140, 152], ["attachment receptor", "PROTEIN", 197, 216], ["Adenovirus", "SPECIES", 102, 112], ["adenovirus", "SPECIES", 173, 183], ["proteolysis of membrane", "PROBLEM", 10, 33], ["CoxB3 infection", "PROBLEM", 72, 87], ["Adenovirus Infection of HL", "PROBLEM", 102, 128], ["adenovirus infection", "PROBLEM", 173, 193], ["infection", "OBSERVATION", 78, 87], ["Adenovirus", "OBSERVATION_MODIFIER", 102, 112], ["Infection", "OBSERVATION", 113, 122], ["adenovirus", "ANATOMY", 173, 183], ["infection", "OBSERVATION", 184, 193]]], ["To investigate the long-term efficacy of AdshCAR4m with respect to the inhibition of Cells were then trypsinized, re-seeded, and investigated using the polyclonal rabbit-anti-CAR antibody H-300 directed against the extracellular domain of CAR. mCAR1 protein became undetectable as early as 2 days after transduction with AdshCAR4m, whereas in the controls mCAR1 protein was abundantly expressed. (b) Detection of mCAR1 knockdown by indirect immunofluorescence.", [["Cells", "ANATOMY", 85, 90], ["extracellular", "ANATOMY", 215, 228], ["AdshCAR4m", "CHEMICAL", 41, 50], ["H-300", "CHEMICAL", 188, 193], ["AdshCAR4m", "SIMPLE_CHEMICAL", 41, 50], ["Cells", "CELL", 85, 90], ["rabbit", "ORGANISM", 163, 169], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 215, 228], ["CAR", "GENE_OR_GENE_PRODUCT", 239, 242], ["mCAR1", "GENE_OR_GENE_PRODUCT", 244, 249], ["AdshCAR4m", "GENE_OR_GENE_PRODUCT", 321, 330], ["mCAR1", "GENE_OR_GENE_PRODUCT", 356, 361], ["mCAR1", "GENE_OR_GENE_PRODUCT", 413, 418], ["AdshCAR4m", "PROTEIN", 41, 50], ["CAR antibody H-300", "PROTEIN", 175, 193], ["extracellular domain", "PROTEIN", 215, 235], ["CAR", "PROTEIN", 239, 242], ["mCAR1 protein", "PROTEIN", 244, 257], ["AdshCAR4m", "PROTEIN", 321, 330], ["mCAR1 protein", "PROTEIN", 356, 369], ["mCAR1", "PROTEIN", 413, 418], ["rabbit", "SPECIES", 163, 169], ["rabbit", "SPECIES", 163, 169], ["H-300", "SPECIES", 188, 193], ["AdshCAR4m", "TREATMENT", 41, 50], ["the inhibition of Cells", "TREATMENT", 67, 90], ["the polyclonal rabbit", "TREATMENT", 148, 169], ["mCAR1 protein", "TEST", 244, 257], ["AdshCAR4m", "TREATMENT", 321, 330], ["mCAR1 knockdown", "TREATMENT", 413, 428], ["indirect immunofluorescence", "TEST", 432, 459], ["long-term", "OBSERVATION_MODIFIER", 19, 28], ["undetectable", "OBSERVATION_MODIFIER", 265, 277]]], ["HL-1 cells were treated as in (a). mCAR1 expression was detected by indirect immunofluorescence using the polyclonal rabbitantibody RP-291 (Sollerbrant et al. 2003 ) directed against the CAR variant with intracellular SIV tail (mCAR variant 1, accession no. NM_001025192). mCAR1 was abundantly expressed over the whole investigation period (4 days after transduction) in HL-1 cells transduced with control vector (left-hand panels).", [["HL-1 cells", "ANATOMY", 0, 10], ["intracellular", "ANATOMY", 204, 217], ["HL-1 cells", "ANATOMY", 371, 381], ["left-hand", "ANATOMY", 414, 423], ["RP-291", "CHEMICAL", 132, 138], ["NM_001025192", "CHEMICAL", 258, 270], ["NM_001025192", "CHEMICAL", 258, 270], ["HL-1 cells", "CELL", 0, 10], ["mCAR1", "GENE_OR_GENE_PRODUCT", 35, 40], ["CAR", "GENE_OR_GENE_PRODUCT", 187, 190], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 204, 217], ["mCAR1", "GENE_OR_GENE_PRODUCT", 273, 278], ["HL-1 cells", "CELL", 371, 381], ["HL-1 cells", "CELL_LINE", 0, 10], ["mCAR1", "PROTEIN", 35, 40], ["CAR variant", "PROTEIN", 187, 198], ["intracellular SIV tail", "PROTEIN", 204, 226], ["mCAR variant 1", "PROTEIN", 228, 242], ["mCAR1", "PROTEIN", 273, 278], ["HL-1 cells", "CELL_LINE", 371, 381], ["indirect immunofluorescence", "TEST", 68, 95], ["the polyclonal rabbitantibody RP", "TEST", 102, 134], ["transduction) in HL", "TREATMENT", 354, 373], ["control vector", "TREATMENT", 398, 412], ["intracellular", "ANATOMY_MODIFIER", 204, 217], ["SIV tail", "ANATOMY", 218, 226], ["left", "ANATOMY_MODIFIER", 414, 418]]], ["In contrast, mCAR1 was visible at low levels 2 days after transduction but became undetectable at later time points (right-hand panels).", [["right-hand", "ANATOMY", 117, 127], ["mCAR1", "GENE_OR_GENE_PRODUCT", 13, 18], ["mCAR1", "PROTEIN", 13, 18], ["right", "ANATOMY_MODIFIER", 117, 122]]], ["Cell nuclei are stained with DAPI and overlayed images are shown.", [["Cell nuclei", "ANATOMY", 0, 11], ["DAPI", "CHEMICAL", 29, 33], ["Cell nuclei", "CELL", 0, 11], ["DAPI", "SIMPLE_CHEMICAL", 29, 33], ["DAPI and overlayed images", "TEST", 29, 54]]], ["Notably mCAR1 was localized only at cell-cell contact sites (white arrows), whereas cell membrane regions not in contact with other cells displayed no mCAR1 protein (yellow arrows). mCAR2 expression was not detectable in HL-1 cells by using polyclonal rabbit-antibody directed against the CAR variant with intracellular TVV tail (mCAR variant 2, accession no. NM_009988) (not shown) Fig. 5 .", [["cell-cell contact sites", "ANATOMY", 36, 59], ["cell membrane regions", "ANATOMY", 84, 105], ["cells", "ANATOMY", 132, 137], ["HL-1 cells", "ANATOMY", 221, 231], ["intracellular", "ANATOMY", 306, 319], ["mCAR1", "GENE_OR_GENE_PRODUCT", 8, 13], ["cell-cell contact sites", "CELLULAR_COMPONENT", 36, 59], ["white arrows", "CELLULAR_COMPONENT", 61, 73], ["cell membrane", "CELLULAR_COMPONENT", 84, 97], ["cells", "CELL", 132, 137], ["mCAR1", "GENE_OR_GENE_PRODUCT", 151, 156], ["mCAR2", "GENE_OR_GENE_PRODUCT", 182, 187], ["HL-1 cells", "CELL", 221, 231], ["rabbit", "ORGANISM", 252, 258], ["CAR", "GENE_OR_GENE_PRODUCT", 289, 292], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 306, 319], ["mCAR1", "PROTEIN", 8, 13], ["mCAR1 protein", "PROTEIN", 151, 164], ["mCAR2", "PROTEIN", 182, 187], ["HL-1 cells", "CELL_LINE", 221, 231], ["CAR variant", "PROTEIN", 289, 300], ["intracellular TVV tail", "PROTEIN", 306, 328], ["mCAR variant 2", "PROTEIN", 330, 344], ["rabbit", "SPECIES", 252, 258], ["HL-1", "SPECIES", 221, 225], ["rabbit", "SPECIES", 252, 258], ["white arrows", "PROBLEM", 61, 73], ["cell membrane regions", "TEST", 84, 105], ["mCAR1 protein (yellow arrows", "PROBLEM", 151, 179], ["mCAR2 expression", "TEST", 182, 198], ["polyclonal rabbit-antibody", "TREATMENT", 241, 267], ["cell-cell", "OBSERVATION", 36, 45], ["contact sites", "OBSERVATION", 46, 59], ["cell membrane", "OBSERVATION", 84, 97], ["not detectable", "UNCERTAINTY", 203, 217], ["TVV tail", "ANATOMY", 320, 328]]], ["24 h later cells were trypsinated and re-seeded (with trypsinization) or medium was changed (without trypsinization).", [["cells", "ANATOMY", 11, 16], ["cells", "CELL", 11, 16]]], ["48 h after transduction the cells were infected with CoxB3 at an MOI of 1.", [["cells", "ANATOMY", 28, 33], ["cells", "CELL", 28, 33], ["CoxB3", "GENE_OR_GENE_PRODUCT", 53, 58], ["CoxB3", "PROTEIN", 53, 58], ["transduction the cells", "TREATMENT", 11, 33]]], ["Five and six days later cells were lysed by three freeze/thaw cycles and virus titers were determined by plaque assay on HeLa cells (left-hand diagram).", [["cells", "ANATOMY", 24, 29], ["plaque", "ANATOMY", 105, 111], ["HeLa cells", "ANATOMY", 121, 131], ["left-hand", "ANATOMY", 133, 142], ["cells", "CELL", 24, 29], ["HeLa cells", "CELL", 121, 131], ["HeLa cells", "CELL_LINE", 121, 131], ["three freeze/thaw cycles", "TREATMENT", 44, 68], ["virus titers", "TEST", 73, 85], ["HeLa cells", "TEST", 121, 131], ["left", "ANATOMY_MODIFIER", 133, 137]]], ["Right side Example for plaque assay on HeLa cells using a dilution of 1:500 of HL-1 cell lysate from AdshCAR4m and control vector transduced cells adenovirus infection and to investigate whether proteolysis of pre-existing CAR affects adenovirus infection, HL-1 cells were transduced with AdshCAR4m versus the control vector at an MOI of 100.", [["plaque", "ANATOMY", 23, 29], ["HeLa cells", "ANATOMY", 39, 49], ["HL-1 cell lysate", "ANATOMY", 79, 95], ["AdshCAR4m", "ANATOMY", 101, 110], ["cells", "ANATOMY", 141, 146], ["HL-1 cells", "ANATOMY", 257, 267], ["adenovirus infection", "DISEASE", 147, 167], ["adenovirus infection", "DISEASE", 235, 255], ["HeLa cells", "CELL", 39, 49], ["HL-1 cell lysate", "CELL", 79, 95], ["AdshCAR4m", "CELL", 101, 110], ["cells", "CELL", 141, 146], ["adenovirus", "ORGANISM", 147, 157], ["CAR", "GENE_OR_GENE_PRODUCT", 223, 226], ["adenovirus", "ORGANISM", 235, 245], ["HL-1 cells", "CELL", 257, 267], ["AdshCAR4m", "GENE_OR_GENE_PRODUCT", 289, 298], ["HeLa cells", "CELL_LINE", 39, 49], ["AdshCAR4m", "CELL_LINE", 101, 110], ["CAR", "PROTEIN", 223, 226], ["HL-1 cells", "CELL_LINE", 257, 267], ["AdshCAR4m", "PROTEIN", 289, 298], ["adenovirus", "SPECIES", 235, 245], ["plaque assay", "PROBLEM", 23, 35], ["HeLa cells", "TREATMENT", 39, 49], ["a dilution", "TREATMENT", 56, 66], ["HL", "TREATMENT", 79, 81], ["1 cell lysate", "TREATMENT", 82, 95], ["AdshCAR4m", "TREATMENT", 101, 110], ["control vector transduced cells adenovirus infection", "PROBLEM", 115, 167], ["pre-existing CAR affects adenovirus infection", "PROBLEM", 210, 255], ["AdshCAR4m", "TREATMENT", 289, 298], ["plaque", "OBSERVATION", 23, 29]]], ["Twenty-four hours later, cells were either trypsinized and re-seeded, or the medium was changed (treatment without trypsinization).", [["cells", "ANATOMY", 25, 30], ["cells", "CELL", 25, 30], ["trypsinization", "TREATMENT", 115, 129]]], ["At 2, 3, 4 and 5 days after transduction, the cells were infected with a luciferase marker adenovirus (MOI of 5).", [["cells", "ANATOMY", 46, 51], ["cells", "CELL", 46, 51], ["luciferase", "GENE_OR_GENE_PRODUCT", 73, 83], ["adenovirus", "ORGANISM", 91, 101], ["luciferase", "PROTEIN", 73, 83], ["the cells", "PROBLEM", 42, 51], ["a luciferase marker adenovirus", "TREATMENT", 71, 101]]], ["The measurement of luciferase activity 24 h later revealed persistent reduction of marker gene expression of about \u224875% in AdshCAR4m-treated HL-1 cells during the 5-day investigation period.", [["HL-1 cells", "ANATOMY", 141, 151], ["luciferase", "GENE_OR_GENE_PRODUCT", 19, 29], ["AdshCAR4m", "SIMPLE_CHEMICAL", 123, 132], ["HL-1 cells", "CELL", 141, 151], ["luciferase", "PROTEIN", 19, 29], ["AdshCAR4m-treated HL-1 cells", "CELL_LINE", 123, 151], ["The measurement of luciferase activity", "TEST", 0, 38], ["persistent reduction of marker gene expression", "PROBLEM", 59, 105], ["AdshCAR4m", "TEST", 123, 132], ["persistent", "OBSERVATION_MODIFIER", 59, 69], ["reduction", "OBSERVATION_MODIFIER", 70, 79]]], ["This clearly demonstrates that CAR-shRNA treatment inhibits adenovirus uptake into HL-1 cells, but markedly less efficient than for CoxB3.", [["HL-1 cells", "ANATOMY", 83, 93], ["CAR", "GENE_OR_GENE_PRODUCT", 31, 34], ["adenovirus", "ORGANISM", 60, 70], ["HL-1 cells", "CELL", 83, 93], ["CoxB3", "GENE_OR_GENE_PRODUCT", 132, 137], ["CAR", "PROTEIN", 31, 34], ["HL-1 cells", "CELL_LINE", 83, 93], ["CoxB3", "PROTEIN", 132, 137], ["CAR-shRNA treatment", "TREATMENT", 31, 50], ["adenovirus uptake into HL-1 cells", "PROBLEM", 60, 93], ["CoxB3", "PROBLEM", 132, 137], ["markedly", "OBSERVATION_MODIFIER", 99, 107], ["less efficient", "OBSERVATION_MODIFIER", 108, 122]]], ["Inhibition of adenovirus infections was closely similar between trypsinized and non-trypsinized cells (Fig. 7) indicating that proteolysis of CAR does not affect the function of CAR in adenovirus infections.", [["cells", "ANATOMY", 96, 101], ["adenovirus infections", "DISEASE", 14, 35], ["adenovirus infections", "DISEASE", 185, 206], ["adenovirus", "ORGANISM", 14, 24], ["cells", "CELL", 96, 101], ["CAR", "GENE_OR_GENE_PRODUCT", 142, 145], ["CAR", "GENE_OR_GENE_PRODUCT", 178, 181], ["adenovirus", "ORGANISM", 185, 195], ["non-trypsinized cells", "CELL_LINE", 80, 101], ["CAR", "PROTEIN", 142, 145], ["CAR", "PROTEIN", 178, 181], ["adenovirus", "SPECIES", 14, 24], ["adenovirus", "SPECIES", 185, 195], ["adenovirus infections", "PROBLEM", 14, 35], ["proteolysis of CAR", "PROBLEM", 127, 145], ["adenovirus infections", "PROBLEM", 185, 206], ["adenovirus infections", "OBSERVATION", 14, 35]]], ["Two, three, four, and five days after transduction the cells were infected with a luciferase marker adenovirus (MOI of 5) and luciferase expression was measured after 24 h. (b) Inhibition of adenovirus infection by AdshCAR4m (without trypsiinization).", [["cells", "ANATOMY", 55, 60], ["adenovirus infection", "DISEASE", 191, 211], ["cells", "CELL", 55, 60], ["luciferase", "GENE_OR_GENE_PRODUCT", 82, 92], ["adenovirus", "ORGANISM", 100, 110], ["luciferase", "GENE_OR_GENE_PRODUCT", 126, 136], ["adenovirus", "ORGANISM", 191, 201], ["AdshCAR4m", "GENE_OR_GENE_PRODUCT", 215, 224], ["luciferase", "PROTEIN", 126, 136], ["AdshCAR4m", "PROTEIN", 215, 224], ["adenovirus", "SPECIES", 191, 201], ["transduction the cells", "TREATMENT", 38, 60], ["a luciferase marker adenovirus", "TREATMENT", 80, 110], ["luciferase expression", "TEST", 126, 147], ["adenovirus infection", "PROBLEM", 191, 211], ["infection", "OBSERVATION", 202, 211]]], ["HL-1 cells were transduced with AdshCAR4m or the control vector AdshPLBr (each MOI of 100).", [["HL-1 cells", "ANATOMY", 0, 10], ["HL-1 cells", "CELL", 0, 10], ["AdshCAR4m", "GENE_OR_GENE_PRODUCT", 32, 41], ["AdshPLBr", "GENE_OR_GENE_PRODUCT", 64, 72], ["HL-1 cells", "CELL_LINE", 0, 10], ["AdshCAR4m", "PROTEIN", 32, 41], ["AdshPLBr", "DNA", 64, 72], ["AdshCAR4m", "TREATMENT", 32, 41]]], ["The medium was changed after 24 h.", [["medium", "OBSERVATION_MODIFIER", 4, 10]]], ["Two, three, four, and five days after transduction the cells were infected with a luciferase marker adenovirus (MOI of 5) and luciferase expression was measured 24 h laterThe Anti-Adenovirus and Anti-CoxB3 Effect of CAR Silencing in PNCMsAs HL-1 cells represent a permanent tumor cell line from heart, we were also interested in investigation of the effect of CAR silencing onto viral infection in primary cardiac cells.", [["cells", "ANATOMY", 55, 60], ["HL-1 cells", "ANATOMY", 241, 251], ["tumor cell line", "ANATOMY", 274, 289], ["heart", "ANATOMY", 295, 300], ["primary cardiac cells", "ANATOMY", 398, 419], ["tumor", "DISEASE", 274, 279], ["viral infection", "DISEASE", 379, 394], ["cells", "CELL", 55, 60], ["luciferase", "GENE_OR_GENE_PRODUCT", 82, 92], ["adenovirus", "ORGANISM", 100, 110], ["luciferase", "GENE_OR_GENE_PRODUCT", 126, 136], ["CAR", "GENE_OR_GENE_PRODUCT", 216, 219], ["PNCMs", "PATHOLOGICAL_FORMATION", 233, 238], ["HL-1 cells", "CELL", 241, 251], ["tumor cell line", "CELL", 274, 289], ["heart", "ORGAN", 295, 300], ["CAR", "GENE_OR_GENE_PRODUCT", 360, 363], ["cardiac cells", "CELL", 406, 419], ["luciferase", "PROTEIN", 126, 136], ["Anti-CoxB3", "PROTEIN", 195, 205], ["CAR", "PROTEIN", 216, 219], ["PNCMs", "CELL_TYPE", 233, 238], ["HL-1 cells", "CELL_LINE", 241, 251], ["permanent tumor cell line", "CELL_LINE", 264, 289], ["CAR", "PROTEIN", 360, 363], ["primary cardiac cells", "CELL_TYPE", 398, 419], ["transduction the cells", "TREATMENT", 38, 60], ["a luciferase marker adenovirus", "TREATMENT", 80, 110], ["luciferase expression", "TEST", 126, 147], ["The Anti-Adenovirus", "TREATMENT", 171, 190], ["Anti-CoxB3 Effect", "TREATMENT", 195, 212], ["CAR Silencing", "TREATMENT", 216, 229], ["a permanent tumor cell line", "PROBLEM", 262, 289], ["CAR silencing", "TREATMENT", 360, 373], ["viral infection in primary cardiac cells", "PROBLEM", 379, 419], ["permanent", "OBSERVATION_MODIFIER", 264, 273], ["tumor", "OBSERVATION", 274, 279], ["cell line", "OBSERVATION", 280, 289], ["heart", "ANATOMY", 295, 300], ["infection", "OBSERVATION", 385, 394], ["cardiac cells", "ANATOMY", 406, 419]]], ["For this reason, PNCMs were transduced with AdshCAR2m, which shRNA sequence complete matches with mouse and rat CAR sequences or the control vector AdshGFP, both at an MOI of 100.", [["PNCMs", "ANATOMY", 17, 22], ["PNCMs", "CANCER", 17, 22], ["AdshCAR2m", "GENE_OR_GENE_PRODUCT", 44, 53], ["mouse", "ORGANISM", 98, 103], ["rat", "ORGANISM", 108, 111], ["CAR", "GENE_OR_GENE_PRODUCT", 112, 115], ["AdshGFP", "GENE_OR_GENE_PRODUCT", 148, 155], ["PNCMs", "CELL_TYPE", 17, 22], ["AdshCAR2m", "PROTEIN", 44, 53], ["shRNA sequence", "DNA", 61, 75], ["mouse and rat CAR sequences", "DNA", 98, 125], ["control vector AdshGFP", "DNA", 133, 155], ["mouse", "SPECIES", 98, 103], ["rat", "SPECIES", 108, 111], ["mouse", "SPECIES", 98, 103], ["rat", "SPECIES", 108, 111], ["AdshCAR2m", "TREATMENT", 44, 53]]], ["At this dose nearly 80% of PNCMs are transduce with AdV (results not shown), which is closely similar to the HL-1 cells.", [["PNCMs", "ANATOMY", 27, 32], ["HL-1 cells", "ANATOMY", 109, 119], ["PNCMs", "CANCER", 27, 32], ["AdV", "ORGANISM", 52, 55], ["HL-1 cells", "CELL", 109, 119], ["HL-1 cells", "CELL_LINE", 109, 119], ["AdV", "SPECIES", 52, 55], ["AdV", "TEST", 52, 55]]], ["Following treatment of PNCMs with AdshCAR2m CAR expression was unaffected up to day 3 after transduction, but it becomes strongly downregulated 6 days and 8 days after transduction (Fig. 8a) .", [["PNCMs", "ANATOMY", 23, 28], ["PNCMs", "PATHOLOGICAL_FORMATION", 23, 28], ["AdshCAR2m CAR", "GENE_OR_GENE_PRODUCT", 34, 47], ["CAR", "PROTEIN", 44, 47], ["treatment", "TREATMENT", 10, 19]]], ["As a consequence of delayed CAR downregulation challenge of AdshCAR2m-treated PNCMs with CoxB3 (MOI of 1) resulted in delayed inhibition of CoxB3 replication.", [["PNCMs", "ANATOMY", 78, 83], ["AdshCAR2m", "CHEMICAL", 60, 69], ["CoxB3", "CHEMICAL", 89, 94], ["CAR", "GENE_OR_GENE_PRODUCT", 28, 31], ["AdshCAR2m", "SIMPLE_CHEMICAL", 60, 69], ["PNCMs", "PATHOLOGICAL_FORMATION", 78, 83], ["CoxB3", "GENE_OR_GENE_PRODUCT", 89, 94], ["CoxB3", "GENE_OR_GENE_PRODUCT", 140, 145], ["CAR", "PROTEIN", 28, 31], ["AdshCAR2m", "PROTEIN", 60, 69], ["CoxB3", "PROTEIN", 89, 94], ["CoxB3", "PROTEIN", 140, 145], ["delayed CAR downregulation challenge", "TREATMENT", 20, 56], ["AdshCAR2m", "TEST", 60, 69], ["CoxB3 replication", "TREATMENT", 140, 157], ["CoxB3 replication", "OBSERVATION", 140, 157]]], ["In fact, significant reduction of CoxB3 replication was seen if PNCMs were infected with CoxB3 at day 6 and 8 but not at day 3 after AdshCAR2m transduction.", [["PNCMs", "ANATOMY", 64, 69], ["CoxB3", "GENE_OR_GENE_PRODUCT", 34, 39], ["PNCMs", "PATHOLOGICAL_FORMATION", 64, 69], ["CoxB3", "GENE_OR_GENE_PRODUCT", 89, 94], ["AdshCAR2m", "GENE_OR_GENE_PRODUCT", 133, 142], ["CoxB3", "PROTEIN", 34, 39], ["PNCMs", "CELL_TYPE", 64, 69], ["CoxB3", "PROTEIN", 89, 94], ["AdshCAR2m", "PROTEIN", 133, 142], ["CoxB3 replication", "TREATMENT", 34, 51], ["CoxB3", "TREATMENT", 89, 94], ["significant", "OBSERVATION_MODIFIER", 9, 20], ["reduction", "OBSERVATION_MODIFIER", 21, 30], ["CoxB3 replication", "OBSERVATION", 34, 51]]], ["Moreover, inhibition of CoxB3 replication strongly depended on the initially used AdshCAR2m dose.", [["AdshCAR2m", "CHEMICAL", 82, 91], ["AdshCAR2m", "CHEMICAL", 82, 91], ["CoxB3", "GENE_OR_GENE_PRODUCT", 24, 29], ["AdshCAR2m", "SIMPLE_CHEMICAL", 82, 91], ["CoxB3", "PROTEIN", 24, 29], ["AdshCAR2m", "PROTEIN", 82, 91], ["CoxB3 replication", "TREATMENT", 24, 41]]], ["An MOI of 100 of AdshCAR2m resulted in reduction of CoxB3 titers of about 66 and 90%, while an MOI of 25 resulted in reduction of CoxB3 titers of only 16 and 34% at day 6 and 8, respectively (Fig. 8b) .", [["AdshCAR2m", "CHEMICAL", 17, 26], ["CoxB3", "GENE_OR_GENE_PRODUCT", 52, 57], ["CoxB3", "GENE_OR_GENE_PRODUCT", 130, 135], ["AdshCAR2m", "PROTEIN", 17, 26], ["CoxB3", "PROTEIN", 52, 57], ["CoxB3", "PROTEIN", 130, 135], ["AdshCAR2m", "TREATMENT", 17, 26], ["CoxB3 titers", "TEST", 52, 64], ["an MOI", "TEST", 92, 98], ["CoxB3 titers", "TEST", 130, 142], ["reduction", "OBSERVATION_MODIFIER", 39, 48], ["reduction", "OBSERVATION_MODIFIER", 117, 126]]], ["Very similar results were obtained if AdshCAR2m (MOI 100) transduced PNCMs were infected with AdVs.", [["PNCMs", "ANATOMY", 69, 74], ["PNCMs", "CANCER", 69, 74], ["infected", "OBSERVATION", 80, 88]]], ["Adenovirus uptake was reduced of about 85% at day 6 and about 92% at day 8 after AdshCAR2m transduction, while no effect was seen at day 3 (Fig. 8c ).Discussion of Anti-Viral StrategiesCoxB3 and adenoviruses are common agents of acute myocarditis and inflammatory cardiomyopathy (Bowles et al. 1986; K\u00fchl et al. 2005a) .", [["myocarditis", "DISEASE", 235, 246], ["inflammatory cardiomyopathy", "DISEASE", 251, 278], ["Adenovirus", "ORGANISM", 0, 10], ["AdshCAR2m", "GENE_OR_GENE_PRODUCT", 81, 90], ["Anti-Viral StrategiesCoxB3", "ORGANISM", 164, 190], ["adenoviruses", "ORGANISM", 195, 207], ["Adenovirus", "SPECIES", 0, 10], ["Adenovirus uptake", "TEST", 0, 17], ["Anti-Viral StrategiesCoxB3", "TREATMENT", 164, 190], ["adenoviruses", "TREATMENT", 195, 207], ["acute myocarditis", "PROBLEM", 229, 246], ["inflammatory cardiomyopathy", "PROBLEM", 251, 278], ["reduced", "OBSERVATION_MODIFIER", 22, 29], ["acute", "OBSERVATION_MODIFIER", 229, 234], ["myocarditis", "OBSERVATION", 235, 246], ["inflammatory", "OBSERVATION_MODIFIER", 251, 263]]], ["Although interferon-\u03b2 treatment has the potential to eliminate cardiotropic viruses and to improve heart function in patients with myocardial persistence of viral genomes (K\u00fchl et al. 2003) , no specific treatment against CoxB3 and adenovirus infections is available to date.", [["heart", "ANATOMY", 99, 104], ["myocardial", "ANATOMY", 131, 141], ["interferon-\u03b2", "CHEMICAL", 9, 21], ["adenovirus infections", "DISEASE", 232, 253], ["interferon-\u03b2", "GENE_OR_GENE_PRODUCT", 9, 21], ["heart", "ORGAN", 99, 104], ["patients", "ORGANISM", 117, 125], ["myocardial", "MULTI-TISSUE_STRUCTURE", 131, 141], ["CoxB3", "GENE_OR_GENE_PRODUCT", 222, 227], ["adenovirus", "ORGANISM", 232, 242], ["interferon", "PROTEIN", 9, 19], ["patients", "SPECIES", 117, 125], ["adenovirus", "SPECIES", 232, 242], ["interferon-\u03b2 treatment", "TREATMENT", 9, 31], ["cardiotropic viruses", "PROBLEM", 63, 83], ["viral genomes", "PROBLEM", 157, 170], ["specific treatment", "TREATMENT", 195, 213], ["CoxB3", "PROBLEM", 222, 227], ["adenovirus infections", "PROBLEM", 232, 253], ["viruses", "OBSERVATION", 76, 83], ["heart", "ANATOMY", 99, 104], ["viral genomes", "OBSERVATION", 157, 170]]], ["With respect to antiviral therapy, RNAi is a promising new technology.", [["antiviral therapy", "TREATMENT", 16, 33], ["antiviral therapy", "OBSERVATION", 16, 33]]], ["Its therapeutic potential against viral infections has been demonstrated in multiple in vitro and in vivo studies (Bitko et al. 2005; McCaffrey et al. 2003; Carmona et al. 2006; Park et al. 2003; Merl et al. 2005; Werk et al. 2005) .", [["viral infections", "DISEASE", 34, 50], ["viral infections", "PROBLEM", 34, 50], ["infections", "OBSERVATION", 40, 50], ["multiple", "OBSERVATION_MODIFIER", 76, 84]]], ["Despite encouraging results, however, several reports have revealed a fundamental general problem of siRNA-based antiviral therapy.", [["siRNA", "TREATMENT", 101, 106], ["antiviral therapy", "TREATMENT", 113, 130], ["antiviral therapy", "OBSERVATION", 113, 130]]], ["Due to the requirement for strict sequence-specificity between therapeutic siRNA and target mRNA, even single point mutations in the viral target sequence may result in the rapid selection of escape mutants during persistent viral infections (Wilson and Richardson 2005; Boden et al. 2007; Gitlin et al. 2005) .Discussion of Anti-Viral StrategiesIn this study, we show that inhibition of CoxB3 and adenovirus infections is possible via silencing of the CAR receptor by means of vector-generated CAR-shRNA.", [["viral infections", "DISEASE", 225, 241], ["adenovirus infections", "DISEASE", 398, 419], ["CoxB3", "GENE_OR_GENE_PRODUCT", 388, 393], ["adenovirus", "ORGANISM", 398, 408], ["CAR receptor", "GENE_OR_GENE_PRODUCT", 453, 465], ["CAR", "GENE_OR_GENE_PRODUCT", 495, 498], ["therapeutic siRNA and target mRNA", "RNA", 63, 96], ["viral target sequence", "DNA", 133, 154], ["CAR receptor", "PROTEIN", 453, 465], ["CAR", "PROTEIN", 495, 498], ["strict sequence", "TEST", 27, 42], ["therapeutic siRNA", "TREATMENT", 63, 80], ["target mRNA", "TREATMENT", 85, 96], ["single point mutations", "PROBLEM", 103, 125], ["the viral target sequence", "TEST", 129, 154], ["escape mutants", "PROBLEM", 192, 206], ["persistent viral infections", "PROBLEM", 214, 241], ["Anti-Viral Strategies", "TREATMENT", 325, 346], ["this study", "TEST", 349, 359], ["CoxB3", "PROBLEM", 388, 393], ["adenovirus infections", "PROBLEM", 398, 419], ["persistent", "OBSERVATION_MODIFIER", 214, 224], ["viral", "OBSERVATION_MODIFIER", 225, 230], ["infections", "OBSERVATION", 231, 241]]], ["This strategy is an attractive alternative to siRNA-based silencing of virus-encoded gene, since it drastically reduces the probability of escape mutant development (Arrighi et al. 2004 ).", [["virus-encoded gene", "DNA", 71, 89], ["virus", "PROBLEM", 71, 76], ["escape mutant development", "PROBLEM", 139, 164]]], ["In contrast to previous work (Werk et al. 2005) , our investigations were carried out in myocardial cells representing the actual targets for CoxB3 and adenovirus infections in acute myocarditis and inflammatory cardiomyopathy (Kandolf 2004 (Bergelson et al. 1997) , while its internalization occurs through \u03b1v\u03b21, \u03b1v\u03b23, and \u03b1v\u03b25 integrin (Tomko et al. 1997 ; (Wickham et al. 1993; Li et al. 2001) .", [["myocardial cells", "ANATOMY", 89, 105], ["adenovirus infections", "DISEASE", 152, 173], ["myocarditis", "DISEASE", 183, 194], ["inflammatory cardiomyopathy", "DISEASE", 199, 226], ["myocardial cells", "CELL", 89, 105], ["CoxB3", "GENE_OR_GENE_PRODUCT", 142, 147], ["adenovirus", "ORGANISM", 152, 162], ["\u03b1v\u03b21", "GENE_OR_GENE_PRODUCT", 308, 312], ["\u03b1v\u03b23", "GENE_OR_GENE_PRODUCT", 314, 318], ["\u03b1v\u03b25 integrin", "GENE_OR_GENE_PRODUCT", 324, 337], ["myocardial cells", "CELL_TYPE", 89, 105], ["\u03b1v\u03b21", "PROTEIN", 308, 312], ["\u03b1v\u03b23", "PROTEIN", 314, 318], ["\u03b1v\u03b25 integrin", "PROTEIN", 324, 337], ["our investigations", "TEST", 50, 68], ["myocardial cells", "PROBLEM", 89, 105], ["CoxB3", "PROBLEM", 142, 147], ["adenovirus infections", "PROBLEM", 152, 173], ["acute myocarditis", "PROBLEM", 177, 194], ["inflammatory cardiomyopathy", "PROBLEM", 199, 226], ["myocardial", "ANATOMY", 89, 99], ["acute", "OBSERVATION_MODIFIER", 177, 182], ["myocarditis", "OBSERVATION", 183, 194], ["inflammatory", "OBSERVATION_MODIFIER", 199, 211]]], ["Others have shown that heparan sulfate glycosamino-glycans and MHC class I molecules may also be involved in the binding of adenovirus 2 and 5 (Hong et al. 1997; (Dechecchi et al. 2001) .", [["heparan sulfate", "CHEMICAL", 23, 38], ["sulfate", "CHEMICAL", 31, 38], ["heparan sulfate glycosamino-glycans", "GENE_OR_GENE_PRODUCT", 23, 58], ["MHC class I", "GENE_OR_GENE_PRODUCT", 63, 74], ["adenovirus 2", "ORGANISM", 124, 136], ["5", "ORGANISM", 141, 142], ["MHC class I molecules", "PROTEIN", 63, 84], ["heparan sulfate glycosamino", "TREATMENT", 23, 50], ["glycans and MHC class I molecules", "TREATMENT", 51, 84]]], ["Moreover, expression of receptors involved in adenovirus infection is highly variable between different cell types and tissues (Fechner et al. 1999) .", [["cell", "ANATOMY", 104, 108], ["tissues", "ANATOMY", 119, 126], ["adenovirus infection", "DISEASE", 46, 66], ["adenovirus", "ORGANISM", 46, 56], ["cell", "CELL", 104, 108], ["tissues", "TISSUE", 119, 126], ["adenovirus", "SPECIES", 46, 56], ["adenovirus infection", "PROBLEM", 46, 66], ["adenovirus", "ANATOMY", 46, 56], ["infection", "OBSERVATION", 57, 66], ["different cell types", "OBSERVATION", 94, 114], ["tissues", "ANATOMY", 119, 126]]], ["Thus, variable receptor expression levels and interaction of adenoviruses with cell type specific expressed alternative receptors is the most likely explanation for the failure of complete CAR silencing to achieve efficient blockade of adenovirus infection in HL-1 cells.", [["cell", "ANATOMY", 79, 83], ["HL-1 cells", "ANATOMY", 260, 270], ["adenovirus infection", "DISEASE", 236, 256], ["adenoviruses", "ORGANISM", 61, 73], ["cell", "CELL", 79, 83], ["CAR", "GENE_OR_GENE_PRODUCT", 189, 192], ["adenovirus", "ORGANISM", 236, 246], ["HL-1 cells", "CELL", 260, 270], ["alternative receptors", "PROTEIN", 108, 129], ["CAR", "PROTEIN", 189, 192], ["HL-1 cells", "CELL_LINE", 260, 270], ["adenovirus", "SPECIES", 236, 246], ["HL-1", "SPECIES", 260, 264], ["variable receptor expression levels", "PROBLEM", 6, 41], ["adenoviruses", "PROBLEM", 61, 73], ["the failure", "PROBLEM", 165, 176], ["complete CAR silencing", "TREATMENT", 180, 202], ["adenovirus infection in HL", "PROBLEM", 236, 262], ["most likely explanation", "UNCERTAINTY", 137, 160]]], ["To enhance efficacy in inhibition of adenovirus infection via the anti-receptor approach, therefore, it seems to be necessary to simultaneously inhibit CAR and its co-receptors.Discussion of Anti-Viral StrategiesIn contrast to the anti-adenovirus experiments, the anti-CAR approach was efficient with respect to CoxB3 in both HL-1 cells and PNCMs.", [["HL-1 cells", "ANATOMY", 326, 336], ["PNCMs", "ANATOMY", 341, 346], ["adenovirus infection", "DISEASE", 37, 57], ["adenovirus", "ORGANISM", 37, 47], ["CAR", "GENE_OR_GENE_PRODUCT", 152, 155], ["CoxB3", "GENE_OR_GENE_PRODUCT", 312, 317], ["HL-1 cells", "CELL", 326, 336], ["PNCMs", "CELL", 341, 346], ["CAR", "PROTEIN", 152, 155], ["co-receptors", "PROTEIN", 164, 176], ["CoxB3", "PROTEIN", 312, 317], ["HL-1 cells", "CELL_LINE", 326, 336], ["PNCMs", "CELL_TYPE", 341, 346], ["adenovirus", "SPECIES", 37, 47], ["adenovirus infection", "PROBLEM", 37, 57], ["the anti-receptor approach", "TREATMENT", 62, 88], ["Anti-Viral Strategies", "TREATMENT", 191, 212], ["the anti-CAR approach", "TREATMENT", 260, 281], ["CoxB3", "TEST", 312, 317], ["PNCMs", "TREATMENT", 341, 346], ["adenovirus infection", "OBSERVATION", 37, 57]]], ["The magnitude of inhibition of CoxB3 infection correlated well with the vector-induced ablation of mCAR from the cell surface and emphasizes the key role of CAR for CoxB3 infections of cardiac cells.", [["cell surface", "ANATOMY", 113, 125], ["cardiac cells", "ANATOMY", 185, 198], ["infection", "DISEASE", 37, 46], ["infections", "DISEASE", 171, 181], ["CoxB3", "GENE_OR_GENE_PRODUCT", 31, 36], ["mCAR", "GENE_OR_GENE_PRODUCT", 99, 103], ["cell surface", "CELLULAR_COMPONENT", 113, 125], ["CAR", "GENE_OR_GENE_PRODUCT", 157, 160], ["CoxB3", "GENE_OR_GENE_PRODUCT", 165, 170], ["cardiac cells", "CELL", 185, 198], ["mCAR", "PROTEIN", 99, 103], ["CAR", "PROTEIN", 157, 160], ["cardiac cells", "CELL_TYPE", 185, 198], ["CoxB3 infection", "PROBLEM", 31, 46], ["the vector", "TREATMENT", 68, 78], ["the cell surface", "TREATMENT", 109, 125], ["CoxB3 infections of cardiac cells", "PROBLEM", 165, 198], ["magnitude", "OBSERVATION_MODIFIER", 4, 13], ["infection", "OBSERVATION", 37, 46], ["cell surface", "OBSERVATION", 113, 125], ["cardiac cells", "ANATOMY", 185, 198]]], ["The molecular reason for the differences of anti-CAR treatment in adenovirus versus CoxB3 infections may be due to the unique role playing CAR during CoxB3 infection as it induces conformational changes in the virus capsid that are essential for CoxB3 entry into the target cell (Coyne and Bergelson 2006) .", [["cell", "ANATOMY", 274, 278], ["anti-CAR", "CHEMICAL", 44, 52], ["infections", "DISEASE", 90, 100], ["infection", "DISEASE", 156, 165], ["anti-CAR", "GENE_OR_GENE_PRODUCT", 44, 52], ["adenovirus", "ORGANISM", 66, 76], ["CoxB3", "GENE_OR_GENE_PRODUCT", 84, 89], ["CAR", "GENE_OR_GENE_PRODUCT", 139, 142], ["CoxB3", "GENE_OR_GENE_PRODUCT", 150, 155], ["CoxB3", "GENE_OR_GENE_PRODUCT", 246, 251], ["cell", "CELL", 274, 278], ["anti-CAR", "PROTEIN", 44, 52], ["CAR", "PROTEIN", 139, 142], ["CoxB3", "PROTEIN", 246, 251], ["target cell", "CELL_TYPE", 267, 278], ["adenovirus", "SPECIES", 66, 76], ["anti-CAR treatment", "TREATMENT", 44, 62], ["adenovirus", "PROBLEM", 66, 76], ["CoxB3 infections", "PROBLEM", 84, 100], ["CoxB3 infection", "PROBLEM", 150, 165], ["conformational changes in the virus capsid", "PROBLEM", 180, 222]]], ["The high efficacy of the shCAR vector against this virus indicates, that CAR silencing is a promising therapeutic approach against CoxB3 infections of the myocardium.", [["myocardium", "ANATOMY", 155, 165], ["infections", "DISEASE", 137, 147], ["shCAR", "GENE_OR_GENE_PRODUCT", 25, 30], ["CAR", "GENE_OR_GENE_PRODUCT", 73, 76], ["CoxB3", "GENE_OR_GENE_PRODUCT", 131, 136], ["myocardium", "ORGAN", 155, 165], ["shCAR vector", "DNA", 25, 37], ["CAR", "PROTEIN", 73, 76], ["CoxB3", "SPECIES", 131, 136], ["the shCAR vector", "TREATMENT", 21, 37], ["this virus", "PROBLEM", 46, 56], ["CoxB3 infections of the myocardium", "PROBLEM", 131, 165], ["high", "OBSERVATION_MODIFIER", 4, 8], ["efficacy", "OBSERVATION_MODIFIER", 9, 17], ["myocardium", "ANATOMY", 155, 165]]], ["Previous studies have shown a similar degree of inhibition when using siRNAs directed against CoxB3 viral genomic RNA or its RNA intermediate (Merl et al. 2005; Werk et al. 2005; Yuan et al. 2005) .", [["CoxB3", "GENE_OR_GENE_PRODUCT", 94, 99], ["CoxB3 viral genomic RNA", "RNA", 94, 117], ["Previous studies", "TEST", 0, 16], ["siRNAs", "TREATMENT", 70, 76], ["CoxB3 viral genomic RNA", "PROBLEM", 94, 117]]], ["Combination of direct anti-viral approaches which are prone to escape mutant development with the current anti-receptor strategy are likely to further increase the efficacy of RNAi-based antiviral therapy.Discussion of Anti-Viral StrategiesRecently, it has been shown that silencing of CAR by chemically synthetisized siRNA inhibited CoxB3 infection in human cells of non-cardiac origin (Werk et al. 2005) .", [["cells", "ANATOMY", 359, 364], ["non-cardiac", "ANATOMY", 368, 379], ["CoxB3", "CHEMICAL", 334, 339], ["infection", "DISEASE", 340, 349], ["CAR", "GENE_OR_GENE_PRODUCT", 286, 289], ["CoxB3", "GENE_OR_GENE_PRODUCT", 334, 339], ["human", "ORGANISM", 353, 358], ["cells", "CELL", 359, 364], ["CAR", "PROTEIN", 286, 289], ["human cells", "CELL_TYPE", 353, 364], ["human", "SPECIES", 353, 358], ["human", "SPECIES", 353, 358], ["direct anti-viral approaches", "TREATMENT", 15, 43], ["the current anti-receptor strategy", "TREATMENT", 94, 128], ["RNAi-based antiviral therapy", "TREATMENT", 176, 204], ["Anti-Viral Strategies", "TREATMENT", 219, 240], ["chemically synthetisized siRNA", "PROBLEM", 293, 323], ["CoxB3 infection in human cells", "PROBLEM", 334, 364], ["antiviral therapy", "OBSERVATION", 187, 204], ["infection", "OBSERVATION", 340, 349], ["non-cardiac origin", "ANATOMY", 368, 386]]], ["However, this approach decreased virus titers by only \u224860% which is markedly less than in the present study employing AdV-generating shCAR.", [["AdV", "ORGANISM", 118, 121], ["shCAR", "GENE_OR_GENE_PRODUCT", 133, 138], ["shCAR", "PROTEIN", 133, 138], ["AdV", "SPECIES", 118, 121], ["this approach decreased virus titers", "PROBLEM", 9, 45], ["decreased", "OBSERVATION_MODIFIER", 23, 32], ["virus", "OBSERVATION", 33, 38], ["markedly", "OBSERVATION_MODIFIER", 68, 76], ["less", "OBSERVATION_MODIFIER", 77, 81]]], ["This difference should be the result of high transduction efficacy of AdVs and the prolonged high-level expression of the shCAR.", [["AdVs", "GENE_OR_GENE_PRODUCT", 70, 74], ["shCAR", "GENE_OR_GENE_PRODUCT", 122, 127], ["AdVs", "PROTEIN", 70, 74], ["shCAR", "PROTEIN", 122, 127], ["high transduction efficacy of AdVs", "PROBLEM", 40, 74], ["the shCAR", "TREATMENT", 118, 127]]], ["A bottleneck of chemically synthesized siRNAs is its transient silencing activity of \u22483 days in cardiac cells (Watanabe et al. 2004 ).", [["cardiac cells", "ANATOMY", 96, 109], ["cardiac cells", "CELL", 96, 109], ["cardiac cells", "CELL_TYPE", 96, 109], ["A bottleneck of chemically synthesized siRNAs", "TREATMENT", 0, 45], ["synthesized siRNAs", "OBSERVATION", 27, 45], ["transient", "OBSERVATION_MODIFIER", 53, 62], ["silencing", "OBSERVATION_MODIFIER", 63, 72], ["activity", "OBSERVATION_MODIFIER", 73, 81], ["cardiac cells", "ANATOMY", 96, 109]]], ["Viral vectors expressing shRNAs, however, enable long term silencing of target genes in cells of cardiac origin (Fechner et al. 2007 ) and allow efficient delivery of transgenic sequences to the heart Wang et al. 2005) .", [["cells", "ANATOMY", 88, 93], ["cardiac", "ANATOMY", 97, 104], ["heart", "ANATOMY", 195, 200], ["Viral", "ORGANISM", 0, 5], ["shRNAs", "GENE_OR_GENE_PRODUCT", 25, 31], ["cells", "CELL", 88, 93], ["cardiac", "ORGAN", 97, 104], ["heart", "ORGAN", 195, 200], ["shRNAs", "DNA", 25, 31], ["target genes", "DNA", 72, 84], ["transgenic sequences", "DNA", 167, 187], ["Viral vectors expressing shRNAs", "PROBLEM", 0, 31], ["efficient delivery of transgenic sequences", "TREATMENT", 145, 187], ["cardiac", "ANATOMY", 97, 104], ["origin", "ANATOMY_MODIFIER", 105, 111], ["heart", "ANATOMY", 195, 200]]], ["Between them, pseudotyped AAV2/9 vectors seems to be most promising vectors for cardiac gene transfer as they enable highly efficient transduction of the heart by use of the simple intravenous application route (Pacak et al. 2006; Inagaki et al. 2006) .Discussion of Anti-Viral StrategiesCAR is a cell adhesion protein mediating homotypic (Cohen et al. 2001; Honda et al. 2000) and heterotypic (Zen et al. 2005 ) intercellular interactions.", [["cardiac", "ANATOMY", 80, 87], ["heart", "ANATOMY", 154, 159], ["intravenous", "ANATOMY", 181, 192], ["cell", "ANATOMY", 297, 301], ["intercellular", "ANATOMY", 413, 426], ["pseudotyped", "ORGANISM", 14, 25], ["AAV2/9", "ORGANISM", 26, 32], ["cardiac", "ORGAN", 80, 87], ["heart", "ORGAN", 154, 159], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 181, 192], ["cell", "CELL", 297, 301], ["pseudotyped AAV2/9 vectors", "DNA", 14, 40], ["Anti-Viral StrategiesCAR", "PROTEIN", 267, 291], ["cell adhesion protein", "PROTEIN", 297, 318], ["pseudotyped AAV2/9 vectors", "TREATMENT", 14, 40], ["cardiac gene transfer", "TREATMENT", 80, 101], ["the simple intravenous application route", "TREATMENT", 170, 210], ["Anti-Viral StrategiesCAR", "TREATMENT", 267, 291], ["a cell adhesion protein", "TREATMENT", 295, 318], ["pseudotyped AAV2", "OBSERVATION", 14, 30], ["heart", "ANATOMY", 154, 159]]], ["It is a component of specialized intercellular junctions including epithelial tight junctions (Cohen et al. 2001) , neuro-muscular junctions (Shaw et al. 2004) , and myocardial intercalated discs (Noutsias et al. 2001) .", [["intercellular junctions", "ANATOMY", 33, 56], ["epithelial tight junctions", "ANATOMY", 67, 93], ["neuro-muscular junctions", "ANATOMY", 116, 140], ["myocardial", "ANATOMY", 166, 176], ["myocardial intercalated discs", "DISEASE", 166, 195], ["intercellular junctions", "CELLULAR_COMPONENT", 33, 56], ["epithelial tight junctions", "CELLULAR_COMPONENT", 67, 93], ["neuro-muscular junctions", "CELLULAR_COMPONENT", 116, 140], ["myocardial intercalated discs", "TISSUE", 166, 195], ["epithelial tight junctions", "PROBLEM", 67, 93], ["myocardial intercalated discs", "PROBLEM", 166, 195], ["component", "OBSERVATION_MODIFIER", 8, 17], ["intercellular junctions", "OBSERVATION", 33, 56], ["epithelial", "ANATOMY_MODIFIER", 67, 77], ["tight junctions", "OBSERVATION", 78, 93], ["neuro-muscular junctions", "ANATOMY", 116, 140], ["myocardial", "ANATOMY", 166, 176], ["intercalated", "ANATOMY_MODIFIER", 177, 189], ["discs", "ANATOMY", 190, 195]]], ["We found it to be localized exclusively at cell-to-cell contact sites between HL-1 cells, possibly as a consequence of cell membrane-associated CAR stabilization through homotypic (CAR-CAR) or heterotypic (CAR-protein) intercellular protein interactions.", [["cell", "ANATOMY", 43, 47], ["cell", "ANATOMY", 51, 55], ["sites", "ANATOMY", 64, 69], ["HL-1 cells", "ANATOMY", 78, 88], ["cell membrane", "ANATOMY", 119, 132], ["intercellular", "ANATOMY", 219, 232], ["cell", "CELL", 43, 47], ["cell", "CELL", 51, 55], ["contact sites", "CELLULAR_COMPONENT", 56, 69], ["HL-1 cells", "CELL", 78, 88], ["cell membrane", "CELLULAR_COMPONENT", 119, 132], ["CAR", "GENE_OR_GENE_PRODUCT", 144, 147], ["CAR-CAR", "GENE_OR_GENE_PRODUCT", 181, 188], ["CAR-protein) intercellular protein", "GENE_OR_GENE_PRODUCT", 206, 240], ["HL-1 cells", "CELL_LINE", 78, 88], ["CAR", "PROTEIN", 144, 147], ["CAR", "PROTEIN", 181, 184], ["CAR", "PROTEIN", 185, 188], ["CAR", "PROTEIN", 206, 209], ["cell membrane", "PROBLEM", 119, 132], ["CAR stabilization", "TREATMENT", 144, 161], ["intercellular protein interactions", "PROBLEM", 219, 253], ["cell", "OBSERVATION", 51, 55], ["contact sites", "OBSERVATION", 56, 69], ["1 cells", "OBSERVATION_MODIFIER", 81, 88], ["cell membrane", "OBSERVATION", 119, 132], ["CAR stabilization", "OBSERVATION", 144, 161]]], ["In contrast to previous CAR silencing attempts using synthetic siRNAs, the newly developed viral vectors AdshCAR4m and AdshCAR2m achieved near complete and stable knockout of CAR.", [["CAR", "GENE_OR_GENE_PRODUCT", 24, 27], ["AdshCAR4m", "GENE_OR_GENE_PRODUCT", 105, 114], ["AdshCAR2m", "GENE_OR_GENE_PRODUCT", 119, 128], ["CAR", "GENE_OR_GENE_PRODUCT", 175, 178], ["CAR", "PROTEIN", 24, 27], ["viral vectors", "DNA", 91, 104], ["AdshCAR4m", "DNA", 105, 114], ["AdshCAR2m", "DNA", 119, 128], ["CAR", "PROTEIN", 175, 178], ["previous CAR silencing attempts", "TREATMENT", 15, 46], ["synthetic siRNAs", "TREATMENT", 53, 69], ["viral vectors AdshCAR4m", "TREATMENT", 91, 114], ["AdshCAR2m", "TREATMENT", 119, 128], ["viral vectors", "OBSERVATION", 91, 104], ["stable", "OBSERVATION_MODIFIER", 156, 162], ["knockout", "OBSERVATION", 163, 171]]], ["This was an essential prerequisite to reveal significantly different kinetics of CAR protein ablation in different cell types, in particular an unexpectedly high stability of CAR in primary cells versus a stable cell line.", [["cell", "ANATOMY", 115, 119], ["primary cells", "ANATOMY", 182, 195], ["cell line", "ANATOMY", 212, 221], ["CAR", "GENE_OR_GENE_PRODUCT", 81, 84], ["cell", "CELL", 115, 119], ["CAR", "GENE_OR_GENE_PRODUCT", 175, 178], ["cells", "CELL", 190, 195], ["cell line", "CELL", 212, 221], ["CAR protein", "PROTEIN", 81, 92], ["CAR", "PROTEIN", 175, 178], ["primary cells", "CELL_TYPE", 182, 195], ["stable cell line", "CELL_LINE", 205, 221], ["CAR protein ablation", "TREATMENT", 81, 101], ["CAR in primary cells", "PROBLEM", 175, 195], ["a stable cell line", "TREATMENT", 203, 221], ["different cell types", "OBSERVATION", 105, 125], ["high", "OBSERVATION_MODIFIER", 157, 161], ["stability", "OBSERVATION_MODIFIER", 162, 171], ["primary cells", "OBSERVATION", 182, 195], ["stable", "OBSERVATION_MODIFIER", 205, 211], ["cell line", "OBSERVATION", 212, 221]]], ["These data may be explained by cell type-specific CAR protein kinetics.", [["cell", "ANATOMY", 31, 35], ["cell", "CELL", 31, 35], ["CAR", "GENE_OR_GENE_PRODUCT", 50, 53], ["CAR protein", "PROTEIN", 50, 61], ["cell type-specific CAR protein kinetics", "PROBLEM", 31, 70], ["may be explained", "UNCERTAINTY", 11, 27]]], ["But, differences in CAR mRNA stability or processing of the CAR-shRNA through the RNA interference machinery also have to be taken into account.", [["CAR", "GENE_OR_GENE_PRODUCT", 20, 23], ["CAR", "GENE_OR_GENE_PRODUCT", 60, 63], ["CAR mRNA", "RNA", 20, 28], ["CAR", "PROTEIN", 60, 63], ["shRNA", "DNA", 64, 69], ["CAR mRNA stability", "PROBLEM", 20, 38], ["the CAR-shRNA", "TREATMENT", 56, 69]]], ["The delayed downregulation of CAR following vector-mediated CAR-shRNA delivery into primary cardiomyocytes is relevant for in vivo investigations, since the time lag between vector application and CAR silencing needs to be taken into consideration in antiviral therapy studies.Discussion of Anti-Viral StrategiesOne important concern associated with downregulation of a cellular receptor molecule for antiviral therapy is possible side effects resulting from ablation of the normal cellular functions of the receptor.", [["primary cardiomyocytes", "ANATOMY", 84, 106], ["cellular", "ANATOMY", 370, 378], ["cellular", "ANATOMY", 482, 490], ["CAR", "GENE_OR_GENE_PRODUCT", 30, 33], ["CAR", "GENE_OR_GENE_PRODUCT", 60, 63], ["cardiomyocytes", "CELL", 92, 106], ["CAR", "GENE_OR_GENE_PRODUCT", 197, 200], ["cellular", "CELL", 370, 378], ["cellular", "CELL", 482, 490], ["CAR", "PROTEIN", 30, 33], ["CAR", "PROTEIN", 60, 63], ["primary cardiomyocytes", "CELL_TYPE", 84, 106], ["CAR", "PROTEIN", 197, 200], ["cellular receptor molecule", "PROTEIN", 370, 396], ["vector-mediated CAR-shRNA delivery", "TREATMENT", 44, 78], ["primary cardiomyocytes", "PROBLEM", 84, 106], ["vivo investigations", "TEST", 126, 145], ["vector application", "TREATMENT", 174, 192], ["CAR silencing", "TREATMENT", 197, 210], ["antiviral therapy studies", "TREATMENT", 251, 276], ["Anti-Viral Strategies", "TREATMENT", 291, 312], ["a cellular receptor molecule", "TREATMENT", 368, 396], ["antiviral therapy", "TREATMENT", 401, 418], ["side effects", "PROBLEM", 431, 443], ["ablation", "TREATMENT", 459, 467], ["cellular receptor molecule", "OBSERVATION", 370, 396], ["antiviral therapy", "OBSERVATION", 401, 418], ["ablation", "OBSERVATION", 459, 467], ["normal cellular functions", "OBSERVATION", 475, 500]]], ["During organogenesis, CAR is highly expressed in the heart, but rapidly downregulated post partum (Fechner et al. 2003a) .", [["heart", "ANATOMY", 53, 58], ["CAR", "GENE_OR_GENE_PRODUCT", 22, 25], ["heart", "ORGAN", 53, 58], ["CAR", "PROTEIN", 22, 25], ["heart", "ANATOMY", 53, 58]]], ["In a recently published genomic mouse knockout model, cardiomyocyte-specific CAR deletion resulted in severe cardiac anomalies and death between day 11.5 and 13.5 of embryonal development (Chen et al. 2006; Dorner et al. 2005) .", [["cardiomyocyte", "ANATOMY", 54, 67], ["cardiac", "ANATOMY", 109, 116], ["embryonal", "ANATOMY", 166, 175], ["cardiac anomalies", "DISEASE", 109, 126], ["death", "DISEASE", 131, 136], ["mouse", "ORGANISM", 32, 37], ["cardiomyocyte", "CELL", 54, 67], ["CAR", "GENE_OR_GENE_PRODUCT", 77, 80], ["cardiac", "ORGAN", 109, 116], ["embryonal", "ORGAN", 166, 175], ["CAR", "PROTEIN", 77, 80], ["mouse", "SPECIES", 32, 37], ["mouse", "SPECIES", 32, 37], ["cardiomyocyte", "TEST", 54, 67], ["specific CAR deletion", "PROBLEM", 68, 89], ["severe cardiac anomalies", "PROBLEM", 102, 126], ["death", "PROBLEM", 131, 136], ["embryonal development", "PROBLEM", 166, 187], ["cardiomyocyte", "ANATOMY", 54, 67], ["severe", "OBSERVATION_MODIFIER", 102, 108], ["cardiac", "ANATOMY", 109, 116], ["anomalies", "OBSERVATION", 117, 126]]], ["If the CAR gene became ablated late in embryonic development, however, the CAR-deficient animals survived into adulthood and had no evident cardiac anomalies (Chen et al. 2006) .", [["embryonic", "ANATOMY", 39, 48], ["cardiac", "ANATOMY", 140, 147], ["cardiac anomalies", "DISEASE", 140, 157], ["CAR", "GENE_OR_GENE_PRODUCT", 7, 10], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 39, 48], ["CAR", "GENE_OR_GENE_PRODUCT", 75, 78], ["cardiac", "ORGAN", 140, 147], ["CAR gene", "DNA", 7, 15], ["CAR", "PROTEIN", 75, 78], ["evident cardiac anomalies", "PROBLEM", 132, 157], ["no evident", "UNCERTAINTY", 129, 139], ["cardiac", "ANATOMY", 140, 147], ["anomalies", "OBSERVATION", 148, 157]]], ["This finding suggests that CAR silencing by RNAi as employed in our study should be well tolerable over considerable periods of time, during which virus migration and spreading were efficiently inhibited.", [["CAR", "GENE_OR_GENE_PRODUCT", 27, 30], ["CAR", "PROTEIN", 27, 30], ["our study", "TEST", 64, 73], ["virus migration", "PROBLEM", 147, 162]]], ["Furthermore, treatment of HL-1 cells with AdVgenerating shCAR revealed no side effects since we found no changes in cell growth, cell morphology, or F-actin cytoskeleton protein expression (not shown).", [["HL-1 cells", "ANATOMY", 26, 36], ["cell", "ANATOMY", 116, 120], ["cell", "ANATOMY", 129, 133], ["cytoskeleton", "ANATOMY", 157, 169], ["HL-1 cells", "CELL", 26, 36], ["shCAR", "SIMPLE_CHEMICAL", 56, 61], ["cell", "CELL", 116, 120], ["cell", "CELL", 129, 133], ["F-actin", "GENE_OR_GENE_PRODUCT", 149, 156], ["cytoskeleton", "CELLULAR_COMPONENT", 157, 169], ["HL-1 cells", "CELL_LINE", 26, 36], ["AdVgenerating shCAR", "PROTEIN", 42, 61], ["F-actin", "PROTEIN", 149, 156], ["treatment of HL-1 cells", "TEST", 13, 36], ["AdVgenerating shCAR", "TEST", 42, 61], ["side effects", "PROBLEM", 74, 86], ["changes in cell growth", "PROBLEM", 105, 127], ["cell morphology", "TEST", 129, 144], ["F-actin cytoskeleton protein expression", "PROBLEM", 149, 188], ["no", "UNCERTAINTY", 71, 73], ["cell growth", "OBSERVATION", 116, 127], ["F-actin cytoskeleton", "OBSERVATION", 149, 169], ["protein expression", "OBSERVATION", 170, 188]]], ["However, as CAR is an integral component of the tight junctions and may play an important role in cell methabolism in several tissues and organs, experiments have to confirm that shRNA-mediated CAR knockdown does not have undesirable side effects in vivo.Discussion of Anti-Viral StrategiesIn summary, high efficacy of CAR gene silencing by shRNAs in cardiac-derived cells was observed against CoxB3, while variable results were obtained for adenoviruses.", [["tight junctions", "ANATOMY", 48, 63], ["cell", "ANATOMY", 98, 102], ["tissues", "ANATOMY", 126, 133], ["organs", "ANATOMY", 138, 144], ["cardiac-derived cells", "ANATOMY", 351, 372], ["CAR", "GENE_OR_GENE_PRODUCT", 12, 15], ["tight junctions", "CELLULAR_COMPONENT", 48, 63], ["cell", "CELL", 98, 102], ["tissues", "TISSUE", 126, 133], ["organs", "ORGAN", 138, 144], ["CAR", "GENE_OR_GENE_PRODUCT", 194, 197], ["CAR", "GENE_OR_GENE_PRODUCT", 319, 322], ["cardiac-derived cells", "CELL", 351, 372], ["CoxB3", "GENE_OR_GENE_PRODUCT", 394, 399], ["adenoviruses", "ORGANISM", 442, 454], ["CAR", "PROTEIN", 12, 15], ["CAR", "PROTEIN", 194, 197], ["CAR gene", "DNA", 319, 327], ["shRNAs", "DNA", 341, 347], ["cardiac-derived cells", "CELL_TYPE", 351, 372], ["CoxB3", "PROTEIN", 394, 399], ["Anti-Viral Strategies", "TREATMENT", 269, 290], ["CAR gene silencing", "TREATMENT", 319, 337], ["shRNAs in cardiac-derived cells", "PROBLEM", 341, 372], ["adenoviruses", "PROBLEM", 442, 454], ["tight junctions", "OBSERVATION", 48, 63], ["cell methabolism", "OBSERVATION", 98, 114], ["cardiac", "ANATOMY", 351, 358]]], ["In contrast to previous silencing attempts using siRNAs or shRNA-plasmid the newly developed shRNA-vectors were able to achieve near complete and stable knockout of CAR transcription.", [["CAR", "GENE_OR_GENE_PRODUCT", 165, 168], ["shRNA-plasmid", "DNA", 59, 72], ["shRNA-vectors", "DNA", 93, 106], ["CAR", "PROTEIN", 165, 168], ["previous silencing attempts", "TREATMENT", 15, 42], ["siRNAs or shRNA", "TREATMENT", 49, 64], ["plasmid", "TREATMENT", 65, 72], ["shRNA-vectors", "TREATMENT", 93, 106], ["stable", "OBSERVATION_MODIFIER", 146, 152], ["knockout", "OBSERVATION", 153, 161]]], ["This in turn revealed significantly different responses of cellular CAR protein to CAR-shRNA treatment which need to be considered as important determinants of this new antiviral approach in vivo.RNA Interference to Improve Cardiac Function in AdvancedHeart FailureOverviewImpaired function of the phospholamban (PLB)-regulated sarcoplasmic reticulum (SR) Ca 2+ pump (SERCA2a) contributes to cardiac dysfunction in heart failure (HF).", [["cellular", "ANATOMY", 59, 67], ["Cardiac", "ANATOMY", 224, 231], ["Heart", "ANATOMY", 252, 257], ["sarcoplasmic reticulum", "ANATOMY", 328, 350], ["cardiac", "ANATOMY", 392, 399], ["heart", "ANATOMY", 415, 420], ["Ca", "CHEMICAL", 356, 358], ["cardiac dysfunction", "DISEASE", 392, 411], ["heart failure", "DISEASE", 415, 428], ["HF", "DISEASE", 430, 432], ["Ca 2+", "CHEMICAL", 356, 361], ["cellular", "CELL", 59, 67], ["CAR", "GENE_OR_GENE_PRODUCT", 68, 71], ["CAR", "GENE_OR_GENE_PRODUCT", 83, 86], ["phospholamban", "GENE_OR_GENE_PRODUCT", 298, 311], ["PLB", "GENE_OR_GENE_PRODUCT", 313, 316], ["sarcoplasmic reticulum (SR) Ca 2+ pump", "GENE_OR_GENE_PRODUCT", 328, 366], ["SERCA2a", "GENE_OR_GENE_PRODUCT", 368, 375], ["cardiac", "ORGAN", 392, 399], ["heart", "ORGAN", 415, 420], ["CAR protein", "PROTEIN", 68, 79], ["CAR", "PROTEIN", 83, 86], ["phospholamban (PLB)-regulated sarcoplasmic reticulum (SR) Ca 2+ pump", "PROTEIN", 298, 366], ["SERCA2a", "PROTEIN", 368, 375], ["cellular CAR protein", "TREATMENT", 59, 79], ["CAR-shRNA treatment", "TREATMENT", 83, 102], ["this new antiviral approach", "TREATMENT", 160, 187], ["Cardiac Function", "TEST", 224, 240], ["AdvancedHeart FailureOverview", "PROBLEM", 244, 273], ["sarcoplasmic reticulum", "PROBLEM", 328, 350], ["Ca", "TEST", 356, 358], ["pump (SERCA2a", "TREATMENT", 362, 375], ["cardiac dysfunction", "PROBLEM", 392, 411], ["heart failure", "PROBLEM", 415, 428], ["HF", "PROBLEM", 430, 432], ["significantly different", "OBSERVATION_MODIFIER", 22, 45], ["cellular CAR protein", "OBSERVATION", 59, 79], ["Heart", "ANATOMY", 252, 257], ["sarcoplasmic reticulum", "OBSERVATION", 328, 350], ["cardiac", "ANATOMY", 392, 399], ["dysfunction", "OBSERVATION", 400, 411], ["heart", "ANATOMY", 415, 420], ["failure", "OBSERVATION", 421, 428]]], ["PLB downregulation may increase SERCA2a activity and improve cardiac function.", [["cardiac", "ANATOMY", 61, 68], ["PLB", "GENE_OR_GENE_PRODUCT", 0, 3], ["SERCA2a", "GENE_OR_GENE_PRODUCT", 32, 39], ["cardiac", "ORGAN", 61, 68], ["PLB", "PROTEIN", 0, 3], ["SERCA2a", "PROTEIN", 32, 39], ["PLB downregulation", "TREATMENT", 0, 18], ["SERCA2a activity", "TREATMENT", 32, 48], ["downregulation", "OBSERVATION", 4, 18], ["SERCA2a activity", "OBSERVATION", 32, 48]]], ["Small interfering (si)RNAs mediate efficient gene silencing by RNA interference (RNAi).", [["Small interfering (si)", "GENE_OR_GENE_PRODUCT", 0, 22], ["Small interfering (si)RNAs", "RNA", 0, 26], ["Small interfering (si)RNAs mediate efficient gene silencing", "PROBLEM", 0, 59], ["interfering", "OBSERVATION", 6, 17]]], ["However, their use for in vivo gene therapy is limited by siRNA instability in plasma and tissues, and by low siRNA transfer rates into target cells.", [["plasma", "ANATOMY", 79, 85], ["tissues", "ANATOMY", 90, 97], ["cells", "ANATOMY", 143, 148], ["plasma", "ORGANISM_SUBSTANCE", 79, 85], ["tissues", "TISSUE", 90, 97], ["cells", "CELL", 143, 148], ["target cells", "CELL_TYPE", 136, 148], ["vivo gene therapy", "TREATMENT", 26, 43], ["siRNA instability in plasma and tissues", "PROBLEM", 58, 97], ["siRNA instability", "OBSERVATION", 58, 75], ["tissues", "ANATOMY", 90, 97]]], ["To address these problems we developed an adenoviral vector (AdV) transcribing short hairpin (sh)RNAs against rat PLB and evaluated its potential to silence the PLB gene and to modulate SERCA2a-mediated Ca 2+ sequestration in primary neonatal rat cardiomyocytes (PNCMs).", [["cardiomyocytes", "ANATOMY", 247, 261], ["PNCMs", "ANATOMY", 263, 268], ["Ca", "CHEMICAL", 203, 205], ["Ca 2+", "CHEMICAL", 203, 208], ["adenoviral", "ORGANISM", 42, 52], ["AdV", "ORGANISM", 61, 64], ["rat", "ORGANISM", 110, 113], ["PLB", "GENE_OR_GENE_PRODUCT", 114, 117], ["PLB", "GENE_OR_GENE_PRODUCT", 161, 164], ["SERCA2a", "GENE_OR_GENE_PRODUCT", 186, 193], ["Ca 2+", "SIMPLE_CHEMICAL", 203, 208], ["rat", "ORGANISM", 243, 246], ["cardiomyocytes", "CELL", 247, 261], ["PNCMs", "CELL", 263, 268], ["short hairpin (sh)RNAs", "RNA", 79, 101], ["rat PLB", "PROTEIN", 110, 117], ["PLB gene", "DNA", 161, 169], ["SERCA2a", "PROTEIN", 186, 193], ["primary neonatal rat cardiomyocytes", "CELL_TYPE", 226, 261], ["PNCMs", "CELL_TYPE", 263, 268], ["rat", "SPECIES", 110, 113], ["rat", "SPECIES", 243, 246], ["AdV", "SPECIES", 61, 64], ["rat", "SPECIES", 110, 113], ["rat", "SPECIES", 243, 246], ["these problems", "PROBLEM", 11, 25], ["an adenoviral vector", "TREATMENT", 39, 59], ["short hairpin (sh)RNAs against rat PLB", "PROBLEM", 79, 117], ["SERCA2a", "TEST", 186, 193], ["sequestration in primary neonatal rat cardiomyocytes", "PROBLEM", 209, 261], ["PLB", "ANATOMY", 161, 164], ["SERCA2a", "ANATOMY", 186, 193]]], ["Over a period of 13 days, vector transduction resulted in stable >99.9% ablation of PLB-mRNA at an MOI of 100.", [["PLB", "GENE_OR_GENE_PRODUCT", 84, 87], ["PLB-mRNA", "RNA", 84, 92], ["vector transduction", "TREATMENT", 26, 45], ["stable", "OBSERVATION_MODIFIER", 58, 64], ["PLB", "ANATOMY", 84, 87]]], ["PLB protein gradually decreased until day 7 (7 \u00b1 2% left), whereas SERCA, Na + / Ca 2+ exchanger (NCX1), calsequestrin (CSQ2), and troponin I (TnI) protein remained unchanged.", [["left", "ANATOMY", 52, 56], ["Na", "CHEMICAL", 74, 76], ["Ca", "CHEMICAL", 81, 83], ["Na +", "CHEMICAL", 74, 78], ["Ca 2+", "CHEMICAL", 81, 86], ["PLB", "GENE_OR_GENE_PRODUCT", 0, 3], ["SERCA", "GENE_OR_GENE_PRODUCT", 67, 72], ["Na + / Ca 2+ exchanger", "GENE_OR_GENE_PRODUCT", 74, 96], ["NCX1", "GENE_OR_GENE_PRODUCT", 98, 102], ["calsequestrin", "GENE_OR_GENE_PRODUCT", 105, 118], ["CSQ2", "GENE_OR_GENE_PRODUCT", 120, 124], ["troponin I", "GENE_OR_GENE_PRODUCT", 131, 141], ["TnI", "GENE_OR_GENE_PRODUCT", 143, 146], ["PLB protein", "PROTEIN", 0, 11], ["SERCA", "PROTEIN", 67, 72], ["Na + / Ca 2+ exchanger", "PROTEIN", 74, 96], ["NCX1", "PROTEIN", 98, 102], ["calsequestrin", "PROTEIN", 105, 118], ["CSQ2", "PROTEIN", 120, 124], ["troponin I (TnI) protein", "PROTEIN", 131, 155], ["PLB protein", "TEST", 0, 11], ["SERCA", "TEST", 67, 72], ["Na", "TEST", 74, 76], ["Ca", "TEST", 81, 83], ["NCX1", "TEST", 98, 102], ["calsequestrin (CSQ2", "TEST", 105, 124], ["troponin I (TnI) protein", "TEST", 131, 155], ["gradually", "OBSERVATION_MODIFIER", 12, 21], ["decreased", "OBSERVATION_MODIFIER", 22, 31], ["unchanged", "OBSERVATION_MODIFIER", 165, 174]]], ["PLB silencing was associated with a marked increase in ATPdependent oxalate-supported Ca 2+ uptake at 0.34 \u00b5M of free Ca 2+ , and rapid loss of responsiveness to PKA-dependent stimulation of Ca 2+ uptake was maintained until day 7.", [["oxalate", "CHEMICAL", 68, 75], ["Ca", "CHEMICAL", 86, 88], ["Ca", "CHEMICAL", 118, 120], ["Ca", "CHEMICAL", 191, 193], ["oxalate", "CHEMICAL", 68, 75], ["Ca 2+", "CHEMICAL", 86, 91], ["Ca 2+", "CHEMICAL", 118, 123], ["Ca 2+", "CHEMICAL", 191, 196], ["PLB", "GENE_OR_GENE_PRODUCT", 0, 3], ["ATPdependent", "SIMPLE_CHEMICAL", 55, 67], ["oxalate", "SIMPLE_CHEMICAL", 68, 75], ["Ca 2+", "SIMPLE_CHEMICAL", 86, 91], ["Ca 2+", "SIMPLE_CHEMICAL", 118, 123], ["PKA", "GENE_OR_GENE_PRODUCT", 162, 165], ["Ca 2+", "SIMPLE_CHEMICAL", 191, 196], ["PLB", "PROTEIN", 0, 3], ["PKA", "PROTEIN", 162, 165], ["PLB silencing", "PROBLEM", 0, 13], ["a marked increase in ATPdependent oxalate", "PROBLEM", 34, 75], ["Ca", "TEST", 86, 88], ["free Ca", "TEST", 113, 120], ["rapid loss of responsiveness", "PROBLEM", 130, 158], ["PKA", "TEST", 162, 165], ["Ca", "TEST", 191, 193], ["marked", "OBSERVATION_MODIFIER", 36, 42], ["increase", "OBSERVATION_MODIFIER", 43, 51], ["rapid", "OBSERVATION_MODIFIER", 130, 135], ["loss", "OBSERVATION", 136, 140]]], ["In summary, these results indicate that AdV-derived PLB-shRNA mediates highly efficient, specific, and stable PLB gene silencing and modulation of active Ca 2+ sequestration in PNCMs.", [["PNCMs", "ANATOMY", 177, 182], ["Ca", "CHEMICAL", 154, 156], ["Ca 2+", "CHEMICAL", 154, 159], ["AdV", "ORGANISM", 40, 43], ["PLB", "GENE_OR_GENE_PRODUCT", 52, 55], ["PLB", "GENE_OR_GENE_PRODUCT", 110, 113], ["Ca 2+", "SIMPLE_CHEMICAL", 154, 159], ["PNCMs", "PATHOLOGICAL_FORMATION", 177, 182], ["PLB", "PROTEIN", 52, 55], ["PLB gene", "DNA", 110, 118], ["PNCMs", "CELL_TYPE", 177, 182], ["AdV", "TEST", 40, 43], ["active Ca", "PROBLEM", 147, 156], ["sequestration in PNCMs", "PROBLEM", 160, 182], ["stable", "OBSERVATION_MODIFIER", 103, 109], ["active", "OBSERVATION_MODIFIER", 147, 153], ["Ca", "OBSERVATION", 154, 156]]], ["The availability of the new vector now enables employment of RNAi for the treatment of HF in vivo.Regulatory RNA-and Gene-Based Therapies of Heart FailureHeart failure (HF) remains a leading cause of mortality in the developed world.", [["Heart", "ANATOMY", 141, 146], ["HF", "DISEASE", 87, 89], ["Heart FailureHeart failure", "DISEASE", 141, 167], ["HF", "DISEASE", 169, 171], ["RNAi", "TREATMENT", 61, 65], ["HF", "PROBLEM", 87, 89], ["Regulatory RNA", "TEST", 98, 112], ["Heart FailureHeart failure", "PROBLEM", 141, 167], ["HF", "PROBLEM", 169, 171], ["RNA", "OBSERVATION_MODIFIER", 109, 112], ["Heart", "ANATOMY", 141, 146], ["FailureHeart failure", "OBSERVATION", 147, 167]]], ["Deteriorated function of the failing heart has been partially attributed to dysfunction of the PLB-controlled SERCA2a (Piacentino et al. 2003) .", [["heart", "ANATOMY", 37, 42], ["heart", "ORGAN", 37, 42], ["PLB", "GENE_OR_GENE_PRODUCT", 95, 98], ["SERCA2a", "GENE_OR_GENE_PRODUCT", 110, 117], ["PLB", "PROTEIN", 95, 98], ["SERCA2a", "PROTEIN", 110, 117], ["dysfunction", "PROBLEM", 76, 87], ["the PLB", "PROBLEM", 91, 98], ["heart", "ANATOMY", 37, 42], ["dysfunction", "OBSERVATION", 76, 87], ["PLB", "ANATOMY", 95, 98], ["SERCA2a", "ANATOMY", 110, 117]]], ["Reduction of both SERCA2a expression and PLB phosphorylation (Wolska et al. 2002; Schmidt et al. 1999 ) may contribute to this dysfunction.", [["SERCA2a", "GENE_OR_GENE_PRODUCT", 18, 25], ["PLB", "GENE_OR_GENE_PRODUCT", 41, 44], ["SERCA2a", "PROTEIN", 18, 25], ["PLB", "PROTEIN", 41, 44], ["both SERCA2a expression", "TREATMENT", 13, 36], ["PLB phosphorylation", "TREATMENT", 41, 60], ["this dysfunction", "PROBLEM", 122, 138], ["both", "ANATOMY_MODIFIER", 13, 17], ["SERCA2a", "ANATOMY", 18, 25], ["PLB", "ANATOMY", 41, 44]]], ["Nonphosphorylated PLB keeps the Ca 2+ affinity of SERCA2a low resulting in decreased SR Ca 2+ uptake, slowed relaxation and decreased SR Ca 2+ load, while PLB phosphorylation in response to \u03b2-adrenergic stimulation relieves this inhibition.", [["Ca", "CHEMICAL", 32, 34], ["Ca", "CHEMICAL", 88, 90], ["Ca", "CHEMICAL", 137, 139], ["Ca 2+", "CHEMICAL", 32, 37], ["Ca 2+", "CHEMICAL", 88, 93], ["Ca 2+", "CHEMICAL", 137, 142], ["PLB", "GENE_OR_GENE_PRODUCT", 18, 21], ["SERCA2a", "GENE_OR_GENE_PRODUCT", 50, 57], ["Ca 2+", "SIMPLE_CHEMICAL", 88, 93], ["PLB", "GENE_OR_GENE_PRODUCT", 155, 158], ["PLB", "PROTEIN", 18, 21], ["SERCA2a", "PROTEIN", 50, 57], ["PLB", "PROTEIN", 155, 158], ["the Ca", "TEST", 28, 34], ["SERCA2a low", "PROBLEM", 50, 61], ["decreased SR Ca", "PROBLEM", 75, 90], ["slowed relaxation", "PROBLEM", 102, 119], ["decreased SR Ca", "PROBLEM", 124, 139], ["PLB phosphorylation", "TREATMENT", 155, 174], ["\u03b2-adrenergic stimulation", "TREATMENT", 190, 214], ["this inhibition", "TREATMENT", 224, 239], ["SERCA2a", "ANATOMY", 50, 57]]], ["Germline transgenic approaches for ablation of PLB expression and function in mice (Luo et al. 1994) , and somatic gene transfer for dominant negative PLB mutants (Iwanaga et al. 2004; Hoshijima et al. 2002) , PLB-antisense-RNAs (Eizema et al. 2000; Li et al. 2005; He et al. 1999; delMonte et al. 2002) , or intracellular inhibitory PLB antibodies (Dieterle et al. 2005; Meyer et al. 2004 ) were employed to increase cardiac SR Ca 2+ transport activity and hence the contractile function of cardiomyocytes under physiological and diseased conditions.", [["intracellular", "ANATOMY", 309, 322], ["cardiac", "ANATOMY", 418, 425], ["cardiomyocytes", "ANATOMY", 492, 506], ["Ca", "CHEMICAL", 429, 431], ["Ca 2+", "CHEMICAL", 429, 434], ["PLB", "GENE_OR_GENE_PRODUCT", 47, 50], ["mice", "ORGANISM", 78, 82], ["PLB", "GENE_OR_GENE_PRODUCT", 151, 154], ["PLB", "GENE_OR_GENE_PRODUCT", 210, 213], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 309, 322], ["PLB", "GENE_OR_GENE_PRODUCT", 334, 337], ["cardiomyocytes", "CELL", 492, 506], ["PLB", "PROTEIN", 47, 50], ["dominant negative PLB mutants", "PROTEIN", 133, 162], ["PLB", "PROTEIN", 210, 213], ["intracellular inhibitory PLB antibodies", "PROTEIN", 309, 348], ["cardiomyocytes", "CELL_TYPE", 492, 506], ["mice", "SPECIES", 78, 82], ["mice", "SPECIES", 78, 82], ["Germline transgenic approaches", "TREATMENT", 0, 30], ["ablation of PLB expression", "TREATMENT", 35, 61], ["dominant negative PLB mutants", "PROBLEM", 133, 162], ["cardiac SR Ca", "TREATMENT", 418, 431], ["cardiomyocytes under physiological and diseased conditions", "PROBLEM", 492, 550], ["PLB", "ANATOMY", 47, 50], ["PLB", "ANATOMY", 210, 213], ["cardiac", "ANATOMY", 418, 425], ["cardiomyocytes", "ANATOMY", 492, 506]]], ["RNA interference (RNAi) mediated by chemically synthesized siRNAs was recently employed to silence PLB expression in cardiomyocytes (Watanabe et al. 2004) .", [["cardiomyocytes", "ANATOMY", 117, 131], ["PLB", "GENE_OR_GENE_PRODUCT", 99, 102], ["cardiomyocytes", "CELL", 117, 131], ["PLB", "PROTEIN", 99, 102], ["cardiomyocytes", "CELL_TYPE", 117, 131], ["RNA interference (RNAi)", "PROBLEM", 0, 23], ["chemically synthesized siRNAs", "PROBLEM", 36, 65], ["siRNAs", "OBSERVATION", 59, 65], ["cardiomyocytes", "ANATOMY", 117, 131]]], ["RNAi relies on post-trancriptional, sequence-specific gene silencing via small homologous double-stranded RNAs (Leung and Whittaker 2005) .", [["small homologous double-stranded RNAs", "DNA", 73, 110], ["sequence", "TEST", 36, 44], ["small homologous double-stranded RNAs", "TREATMENT", 73, 110], ["small", "OBSERVATION_MODIFIER", 73, 78]]], ["Its silencing efficacy is higher than that of antisense RNAs (Ogorelkova et al. 2006 ).", [["antisense RNAs", "RNA", 46, 60], ["Its silencing efficacy", "PROBLEM", 0, 22], ["antisense RNAs", "TREATMENT", 46, 60], ["silencing", "OBSERVATION_MODIFIER", 4, 13], ["efficacy", "OBSERVATION_MODIFIER", 14, 22], ["higher", "OBSERVATION_MODIFIER", 26, 32]]], ["Nevertheless, therapeutic use of synthetic siRNAs is significantly limited by their rapid degradation in target cells, resulting in only transient gene silencing (Watanabe et al. 2004) , and by the difficulties in achieving sufficient transfer rates into multiple cells of therapeutic interest including cardiomyocytes.", [["cells", "ANATOMY", 112, 117], ["cells", "ANATOMY", 264, 269], ["cardiomyocytes", "ANATOMY", 304, 318], ["cells", "CELL", 112, 117], ["cells", "CELL", 264, 269], ["cardiomyocytes", "CELL", 304, 318], ["target cells", "CELL_TYPE", 105, 117], ["cardiomyocytes", "CELL_TYPE", 304, 318], ["synthetic siRNAs", "TREATMENT", 33, 49], ["their rapid degradation in target cells", "PROBLEM", 78, 117], ["transient gene silencing", "PROBLEM", 137, 161], ["cardiomyocytes", "PROBLEM", 304, 318], ["target cells", "OBSERVATION", 105, 117]]], ["These limitations are significantly aggravated in vivo and despite intense efforts in recent years systemic delivery of siRNAs remains a major hurdle for in vivo applications of RNAi (Lewis et al. 2002) .", [["systemic delivery of siRNAs", "TREATMENT", 99, 126]]], ["Since viral vector systems have been shown to be suitable to overcome these limitations in vitro and in vivo, we have developed a novel adenoviral vector (AdV) suitable for transcription of shRNA targeting PLB.", [["adenoviral", "ORGANISM", 136, 146], ["AdV", "ORGANISM", 155, 158], ["PLB", "GENE_OR_GENE_PRODUCT", 206, 209], ["PLB", "PROTEIN", 206, 209], ["AdV", "SPECIES", 155, 158], ["viral vector systems", "TREATMENT", 6, 26], ["a novel adenoviral vector", "TREATMENT", 128, 153], ["transcription of shRNA targeting PLB", "TREATMENT", 173, 209]]], ["Treatment with this vector resulted in highly efficient and specific PLB gene silencing in primary neonatal rat cardiac myocytes (PNCMs) which was stable over 2 weeks and associated with a marked increase in the SERCA2a-catalyzed SR Ca 2+ sequestration.RNAi-Based Modulation of Cardiac Ca 2+ Homeostasis in Heart FailureIn order to select potential PLB-siRNA sequences for the generation of PLB-shR-NAs, we initially co-transfected Cos-7 cells with an GFP-rat PLB fusion construct plus different siRNAs directed against rat PLB.", [["cardiac myocytes", "ANATOMY", 112, 128], ["PNCMs", "ANATOMY", 130, 135], ["Cardiac", "ANATOMY", 278, 285], ["Cos-7 cells", "ANATOMY", 432, 443], ["Ca", "CHEMICAL", 233, 235], ["Ca", "CHEMICAL", 286, 288], ["Ca 2+", "CHEMICAL", 233, 238], ["Ca 2+", "CHEMICAL", 286, 291], ["PLB", "GENE_OR_GENE_PRODUCT", 69, 72], ["rat", "ORGANISM", 108, 111], ["cardiac myocytes", "CELL", 112, 128], ["PNCMs", "CELL", 130, 135], ["SERCA2a", "GENE_OR_GENE_PRODUCT", 212, 219], ["Ca 2+", "SIMPLE_CHEMICAL", 233, 238], ["PLB", "GENE_OR_GENE_PRODUCT", 349, 352], ["PLB", "GENE_OR_GENE_PRODUCT", 391, 394], ["Cos-7 cells", "CELL", 432, 443], ["GFP", "GENE_OR_GENE_PRODUCT", 452, 455], ["rat", "ORGANISM", 456, 459], ["PLB", "GENE_OR_GENE_PRODUCT", 460, 463], ["rat", "ORGANISM", 520, 523], ["PLB", "GENE_OR_GENE_PRODUCT", 524, 527], ["PLB gene", "DNA", 69, 77], ["primary neonatal rat cardiac myocytes", "CELL_TYPE", 91, 128], ["PNCMs", "CELL_TYPE", 130, 135], ["SERCA2a", "PROTEIN", 212, 219], ["PLB", "PROTEIN", 349, 352], ["PLB", "PROTEIN", 391, 394], ["shR", "PROTEIN", 395, 398], ["Cos-7 cells", "CELL_LINE", 432, 443], ["GFP-rat PLB fusion construct", "DNA", 452, 480], ["rat PLB", "PROTEIN", 520, 527], ["rat", "SPECIES", 108, 111], ["rat", "SPECIES", 456, 459], ["rat", "SPECIES", 520, 523], ["rat", "SPECIES", 108, 111], ["rat", "SPECIES", 520, 523], ["this vector", "TREATMENT", 15, 26], ["a marked increase", "PROBLEM", 187, 204], ["the SERCA2a", "TEST", 208, 219], ["RNAi", "TEST", 253, 257], ["Cardiac Ca", "TEST", 278, 288], ["potential PLB-siRNA sequences", "TEST", 339, 368], ["PLB", "TEST", 391, 394], ["an GFP", "TEST", 449, 455], ["rat PLB fusion construct", "TREATMENT", 456, 480], ["different siRNAs", "TREATMENT", 486, 502], ["cardiac myocytes", "ANATOMY", 112, 128], ["stable", "OBSERVATION_MODIFIER", 147, 153], ["marked", "OBSERVATION_MODIFIER", 189, 195], ["increase", "OBSERVATION_MODIFIER", 196, 204], ["SERCA2a", "ANATOMY", 212, 219], ["Cardiac", "ANATOMY", 278, 285], ["Ca", "OBSERVATION", 286, 288], ["Heart", "ANATOMY", 307, 312], ["PLB", "ANATOMY", 391, 394]]], ["Among five tested siRNAs, three were highly efficient in downregulating the fusion transcripts.", [["fusion transcripts", "RNA", 76, 94], ["downregulating the fusion transcripts", "TREATMENT", 57, 94], ["fusion transcripts", "OBSERVATION", 76, 94]]], ["The most efficient of these siRNAs was then cloned into a shRNA expression plasmid, as a DNA sequence encoding the PLB-shRNA.", [["plasmid", "ANATOMY", 75, 82], ["DNA", "CELLULAR_COMPONENT", 89, 92], ["PLB", "GENE_OR_GENE_PRODUCT", 115, 118], ["siRNAs", "DNA", 28, 34], ["shRNA expression plasmid", "DNA", 58, 82], ["DNA sequence", "DNA", 89, 101], ["PLB", "PROTEIN", 115, 118], ["shRNA", "DNA", 119, 124], ["these siRNAs", "TREATMENT", 22, 34], ["a shRNA expression plasmid", "TREATMENT", 56, 82], ["a DNA sequence", "TEST", 87, 101], ["siRNAs", "OBSERVATION", 28, 34], ["PLB", "ANATOMY", 115, 118], ["shRNA", "ANATOMY", 119, 124]]], ["The co-transfection experiments with the GFP-rat PLB fusion constructs showed the very high efficacy of PLB-shRNA17 (Fig. 9 ).", [["PLB-shRNA17", "CHEMICAL", 104, 115], ["PLB-shRNA17", "CHEMICAL", 104, 115], ["GFP", "GENE_OR_GENE_PRODUCT", 41, 44], ["rat", "ORGANISM", 45, 48], ["PLB", "GENE_OR_GENE_PRODUCT", 49, 52], ["PLB-shRNA17", "SIMPLE_CHEMICAL", 104, 115], ["GFP-rat PLB fusion constructs", "DNA", 41, 70], ["PLB-shRNA17", "PROTEIN", 104, 115], ["rat", "SPECIES", 45, 48], ["The co-transfection experiments", "TEST", 0, 31], ["the GFP", "TEST", 37, 44], ["very", "OBSERVATION_MODIFIER", 82, 86], ["high", "OBSERVATION_MODIFIER", 87, 91]]], ["Based on these results we constructed an AdV designated AdshPLBr which generates PLB-shRNA17 (Fig. 10) .", [["AdV", "ORGANISM", 41, 44], ["AdshPLBr", "GENE_OR_GENE_PRODUCT", 56, 64], ["PLB-shRNA17", "GENE_OR_GENE_PRODUCT", 81, 92], ["AdshPLBr", "PROTEIN", 56, 64], ["PLB", "PROTEIN", 81, 84], ["shRNA17", "PROTEIN", 85, 92], ["AdV", "SPECIES", 41, 44]]], ["To assess the efficacy of the vector AdshPLBr in downregulating endogenously expressed PLB in the actual target cells, we transduced primary neonatal rat cardiomyocytes (PNCMs) with AdshPLBr and investigated the dose-and time-dependency of its action.", [["cells", "ANATOMY", 112, 117], ["cardiomyocytes", "ANATOMY", 154, 168], ["PNCMs", "ANATOMY", 170, 175], ["AdshPLBr", "CHEMICAL", 37, 45], ["AdshPLBr", "GENE_OR_GENE_PRODUCT", 37, 45], ["PLB", "GENE_OR_GENE_PRODUCT", 87, 90], ["cells", "CELL", 112, 117], ["rat", "ORGANISM", 150, 153], ["cardiomyocytes", "CELL", 154, 168], ["PNCMs", "CELL", 170, 175], ["AdshPLBr", "GENE_OR_GENE_PRODUCT", 182, 190], ["vector AdshPLBr", "DNA", 30, 45], ["PLB", "PROTEIN", 87, 90], ["target cells", "CELL_TYPE", 105, 117], ["primary neonatal rat cardiomyocytes", "CELL_TYPE", 133, 168], ["PNCMs", "CELL_TYPE", 170, 175], ["rat", "SPECIES", 150, 153], ["rat", "SPECIES", 150, 153], ["AdshPLBr", "TREATMENT", 182, 190]]], ["A control AdV (AdshCAR4m) generating an shRNA irrelevant for PLB and cardiac Ca 2+ metabolism was employed to test for target specificity of AdshPLBr.", [["cardiac", "ANATOMY", 69, 76], ["Ca", "CHEMICAL", 77, 79], ["Ca 2+", "CHEMICAL", 77, 82], ["AdV", "ORGANISM", 10, 13], ["AdshCAR4m", "GENE_OR_GENE_PRODUCT", 15, 24], ["PLB", "GENE_OR_GENE_PRODUCT", 61, 64], ["Ca 2+", "SIMPLE_CHEMICAL", 77, 82], ["AdshPLBr", "GENE_OR_GENE_PRODUCT", 141, 149], ["AdshCAR4m", "PROTEIN", 15, 24], ["PLB", "PROTEIN", 61, 64], ["AdshPLBr", "PROTEIN", 141, 149], ["AdV", "SPECIES", 10, 13], ["A control AdV (AdshCAR4m)", "TREATMENT", 0, 25], ["an shRNA", "TREATMENT", 37, 45], ["cardiac Ca", "TEST", 69, 79], ["cardiac", "ANATOMY", 69, 76], ["Ca", "OBSERVATION", 77, 79]]], ["The treatment of PNCMs with AdshPLBr resulted in strong dose-dependent downregulation of PLB-mRNA expression, by 27% at an MOI of 10 and by 87% at an MOI of 100, 2 days after transduction (Fig. 11a) .", [["PNCMs", "ANATOMY", 17, 22], ["PNCMs", "DISEASE", 17, 22], ["AdshPLBr", "CHEMICAL", 28, 36], ["AdshPLBr", "CHEMICAL", 28, 36], ["PNCMs", "PATHOLOGICAL_FORMATION", 17, 22], ["AdshPLBr", "SIMPLE_CHEMICAL", 28, 36], ["PLB", "GENE_OR_GENE_PRODUCT", 89, 92], ["PLB", "PROTEIN", 89, 92], ["AdshPLBr", "TREATMENT", 28, 36], ["an MOI", "TEST", 120, 126], ["strong", "OBSERVATION_MODIFIER", 49, 55], ["PLB", "ANATOMY", 89, 92]]], ["Rapid, strong, and enduring PLB silencing was observed after treatment of PNCMs with AdshPLBr (MOI = 100) over a prolonged 13-day investigation period.", [["AdshPLBr", "CHEMICAL", 85, 93], ["PLB", "GENE_OR_GENE_PRODUCT", 28, 31], ["PNCMs", "PATHOLOGICAL_FORMATION", 74, 79], ["PLB", "PROTEIN", 28, 31], ["enduring PLB silencing", "PROBLEM", 19, 41], ["PNCMs", "TREATMENT", 74, 79], ["AdshPLBr (MOI", "TREATMENT", 85, 98], ["strong", "OBSERVATION_MODIFIER", 7, 13]]], ["PLB-mRNA abundance was extremely low <0.1% of baseline as quantitated by real-time-RT-PCR (not shown) as early as day 1 and remaining at this level until day 13 (end of experiment).", [["PLB", "GENE_OR_GENE_PRODUCT", 0, 3], ["PLB", "PROTEIN", 0, 3], ["PLB", "TEST", 0, 3], ["mRNA abundance", "TEST", 4, 18], ["extremely low", "PROBLEM", 23, 36], ["RT-PCR", "TEST", 83, 89]]], ["By contrast, PLB-mRNA expression stayed at baseline level both in non-transduced controls and AdshCAR4m-treated PNCMs (Fig. 11b) .", [["PNCMs", "ANATOMY", 112, 117], ["AdshCAR4m", "CHEMICAL", 94, 103], ["PLB", "GENE_OR_GENE_PRODUCT", 13, 16], ["AdshCAR4m", "SIMPLE_CHEMICAL", 94, 103], ["PNCMs", "PATHOLOGICAL_FORMATION", 112, 117], ["PLB", "PROTEIN", 13, 16], ["AdshCAR4m-treated PNCMs", "CELL_LINE", 94, 117], ["AdshCAR4m", "TEST", 94, 103]]], ["Similar but delayed changes occurred at the PLB protein level.", [["PLB", "GENE_OR_GENE_PRODUCT", 44, 47], ["PLB", "PROTEIN", 44, 47], ["delayed changes", "PROBLEM", 12, 27], ["delayed", "OBSERVATION_MODIFIER", 12, 19], ["changes", "OBSERVATION", 20, 27], ["PLB", "ANATOMY", 44, 47], ["protein level", "OBSERVATION", 48, 61]]], ["A decrease in PLB protein became first visible on day 3 (51 \u00b1 4% remaining) as compared to controls.", [["PLB", "GENE_OR_GENE_PRODUCT", 14, 17], ["PLB protein", "PROTEIN", 14, 25], ["A decrease in PLB protein", "PROBLEM", 0, 25], ["decrease", "OBSERVATION_MODIFIER", 2, 10], ["PLB protein", "OBSERVATION", 14, 25]]], ["PLB protein then further decreased continuously until day 7 (7 \u00b1 2% remaining).", [["PLB", "GENE_OR_GENE_PRODUCT", 0, 3], ["PLB protein", "PROTEIN", 0, 11], ["PLB protein", "TEST", 0, 11], ["protein", "OBSERVATION", 4, 11], ["decreased", "OBSERVATION_MODIFIER", 25, 34]]], ["By contrast, the protein levels of SERCA2, NCX1, TnI, and CSQ2 remained unchanged indicating the absence of unspecific side effects on these cardiac proteins of both the To confirm equal loading of the samples, membranes were stripped and reprobed with a monoclonal antibody against actin.", [["cardiac", "ANATOMY", 141, 148], ["samples", "ANATOMY", 202, 209], ["membranes", "ANATOMY", 211, 220], ["SERCA2", "GENE_OR_GENE_PRODUCT", 35, 41], ["NCX1", "GENE_OR_GENE_PRODUCT", 43, 47], ["TnI", "GENE_OR_GENE_PRODUCT", 49, 52], ["CSQ2", "GENE_OR_GENE_PRODUCT", 58, 62], ["cardiac", "ORGAN", 141, 148], ["membranes", "CELLULAR_COMPONENT", 211, 220], ["actin", "GENE_OR_GENE_PRODUCT", 283, 288], ["SERCA2", "PROTEIN", 35, 41], ["NCX1", "PROTEIN", 43, 47], ["TnI", "PROTEIN", 49, 52], ["CSQ2", "PROTEIN", 58, 62], ["cardiac proteins", "PROTEIN", 141, 157], ["monoclonal antibody", "PROTEIN", 255, 274], ["actin", "PROTEIN", 283, 288], ["the protein levels", "TEST", 13, 31], ["SERCA2", "TEST", 35, 41], ["NCX1", "TEST", 43, 47], ["TnI", "TEST", 49, 52], ["CSQ2", "TEST", 58, 62], ["unspecific side effects", "PROBLEM", 108, 131], ["these cardiac proteins", "TEST", 135, 157], ["a monoclonal antibody", "TREATMENT", 253, 274], ["SERCA2", "ANATOMY", 35, 41]]], ["Note: siTRPV1 is a synthetic siRNA directed against the vanilloid receptor 1 (TRPV1).", [["siTRPV1", "CHEMICAL", 6, 13], ["siTRPV1", "GENE_OR_GENE_PRODUCT", 6, 13], ["vanilloid receptor 1", "GENE_OR_GENE_PRODUCT", 56, 76], ["TRPV1", "GENE_OR_GENE_PRODUCT", 78, 83], ["siTRPV1", "PROTEIN", 6, 13], ["vanilloid receptor 1", "PROTEIN", 56, 76], ["TRPV1", "PROTEIN", 78, 83], ["siTRPV1", "TREATMENT", 6, 13], ["a synthetic siRNA", "TREATMENT", 17, 34], ["the vanilloid receptor", "TREATMENT", 52, 74]]], ["Lower Dose-dependency of pSL-shPLB17 action.", [["pSL-", "SIMPLE_CHEMICAL", 25, 29], ["shPLB17", "GENE_OR_GENE_PRODUCT", 29, 36], ["shPLB17", "PROTEIN", 29, 36], ["pSL-shPLB17 action", "TREATMENT", 25, 43]]], ["Cos-7 cells were co-transfected with the pSL-shPLB17 and pPLB-GFP as indicated.", [["Cos-7 cells", "ANATOMY", 0, 11], ["Cos-7 cells", "CELL", 0, 11], ["pSL-shPLB17", "GENE_OR_GENE_PRODUCT", 41, 52], ["pPLB-GFP", "GENE_OR_GENE_PRODUCT", 57, 65], ["Cos-7 cells", "CELL_LINE", 0, 11], ["pSL-shPLB17", "DNA", 41, 52], ["pPLB", "PROTEIN", 57, 61], ["GFP", "PROTEIN", 62, 65], ["the pSL-shPLB17", "TEST", 37, 52], ["pPLB", "TEST", 57, 61]]], ["Immunoblots were carried out 24 h after transfection as described above vector itself and of the shRNA that it generates ( Fig. 12a/b) .", [["Immunoblots", "TEST", 0, 11], ["transfection", "TREATMENT", 40, 52]]], ["To examine the functional consequences of the PLB-shRNA-induced decline in the PLB protein level, PNCMs were transduced with AdshPLBr or control vector AdshCAR4m (each at an MOI of 100).", [["PNCMs", "ANATOMY", 98, 103], ["PLB", "GENE_OR_GENE_PRODUCT", 46, 49], ["PLB", "GENE_OR_GENE_PRODUCT", 79, 82], ["PNCMs", "PATHOLOGICAL_FORMATION", 98, 103], ["AdshPLBr", "GENE_OR_GENE_PRODUCT", 125, 133], ["AdshCAR4m", "GENE_OR_GENE_PRODUCT", 152, 161], ["PLB", "PROTEIN", 46, 49], ["PLB", "PROTEIN", 79, 82], ["PNCMs", "CELL_TYPE", 98, 103], ["AdshPLBr", "PROTEIN", 125, 133], ["AdshCAR4m", "DNA", 152, 161], ["induced decline", "PROBLEM", 56, 71], ["the PLB protein level", "TEST", 75, 96], ["PNCMs", "TEST", 98, 103], ["AdshPLBr", "TREATMENT", 125, 133], ["control vector AdshCAR4m", "TREATMENT", 137, 161], ["PLB", "ANATOMY", 46, 49], ["PLB", "ANATOMY", 79, 82]]], ["Cell homogenate SR Ca 2+ uptake rates were determined at submicromolar (0.34 \u00b5M) and saturating (3.68 \u00b5M) free Ca 2+ concentrations.", [["Cell homogenate", "ANATOMY", 0, 15], ["Ca", "CHEMICAL", 19, 21], ["Ca", "CHEMICAL", 111, 113], ["Ca 2+", "CHEMICAL", 19, 24], ["Ca 2+", "CHEMICAL", 111, 116], ["Cell", "CELL", 0, 4], ["Ca 2+", "SIMPLE_CHEMICAL", 19, 24], ["Ca 2+", "SIMPLE_CHEMICAL", 111, 116], ["Cell homogenate SR Ca", "TEST", 0, 21], ["uptake rates", "TEST", 25, 37], ["submicromolar", "TEST", 57, 70], ["saturating", "TEST", 85, 95], ["free Ca", "TEST", 106, 113]]], ["At the latter, the SR Ca 2+ -ATPase is known to be insensitive to non-phosphorylated PLB, whereas at submicromolar Ca 2+ non-phosphorylated PLB has been shown to decrease the Ca 2+ affinity of this enzyme 17.", [["Ca", "CHEMICAL", 22, 24], ["Ca", "CHEMICAL", 115, 117], ["Ca", "CHEMICAL", 175, 177], ["Ca 2+", "CHEMICAL", 22, 27], ["Ca 2+", "CHEMICAL", 115, 120], ["Ca 2+", "CHEMICAL", 175, 180], ["Ca 2+ -ATPase", "GENE_OR_GENE_PRODUCT", 22, 35], ["PLB", "GENE_OR_GENE_PRODUCT", 85, 88], ["PLB", "GENE_OR_GENE_PRODUCT", 140, 143], ["SR Ca 2+ -ATPase", "PROTEIN", 19, 35], ["non-phosphorylated PLB", "PROTEIN", 66, 88], ["enzyme 17", "PROTEIN", 198, 207], ["the SR Ca", "TEST", 15, 24], ["non-phosphorylated PLB", "PROBLEM", 66, 88], ["submicromolar Ca", "TEST", 101, 117], ["the Ca", "TEST", 171, 177], ["this enzyme", "TEST", 193, 204]]], ["The rate of Ca 2+ uptake determined at 0.34 \u00b5M free Ca 2+ and normalized to the maximum uptake rate (Vmax) values at saturating Ca 2+ (relative Ca 2+ uptake rate) did not differ between non-transduced and AdshCAR4m-or AdshPLBr-treated PNCMs one day after transduction day 1 (approximately 45% of Vmax each).", [["PNCMs", "ANATOMY", 235, 240], ["Ca", "CHEMICAL", 12, 14], ["Ca", "CHEMICAL", 52, 54], ["Ca", "CHEMICAL", 128, 130], ["Ca", "CHEMICAL", 144, 146], ["AdshCAR4m", "CHEMICAL", 205, 214], ["AdshPLBr", "CHEMICAL", 218, 226], ["Ca 2+", "CHEMICAL", 12, 17], ["Ca 2+", "CHEMICAL", 52, 57], ["Ca 2+", "CHEMICAL", 128, 133], ["Ca 2+", "CHEMICAL", 144, 149], ["Ca 2+", "SIMPLE_CHEMICAL", 12, 17], ["Ca 2+", "SIMPLE_CHEMICAL", 128, 133], ["Ca 2+", "SIMPLE_CHEMICAL", 144, 149], ["AdshCAR4m", "GENE_OR_GENE_PRODUCT", 205, 214], ["AdshPLBr", "CELL", 218, 226], ["non-transduced and AdshCAR4m-or AdshPLBr-treated PNCMs", "CELL_LINE", 186, 240], ["The rate", "TEST", 0, 8], ["Ca", "TEST", 12, 14], ["free Ca", "TEST", 47, 54], ["the maximum uptake rate", "TEST", 76, 99], ["Vmax", "TEST", 101, 105], ["Ca", "TEST", 128, 130], ["relative Ca", "TEST", 135, 146], ["uptake rate", "TEST", 150, 161], ["AdshCAR4m", "TEST", 205, 214]]], ["The relative Ca 2+ uptake rate remained at this level both in non-transduced and AdshCAR4m-transduced PNCMs until day 7 after transduction.", [["PNCMs", "ANATOMY", 102, 107], ["Ca", "CHEMICAL", 13, 15], ["Ca 2+", "CHEMICAL", 13, 18], ["Ca 2+", "SIMPLE_CHEMICAL", 13, 18], ["AdshCAR4m", "GENE_OR_GENE_PRODUCT", 81, 90], ["PNCMs", "CELL", 102, 107], ["non-transduced and AdshCAR4m-transduced PNCMs", "CELL_LINE", 62, 107], ["The relative Ca", "TEST", 0, 15], ["uptake rate", "TEST", 19, 30], ["Ca", "OBSERVATION", 13, 15]]], ["In contrast, it increased steadily in AdshPLBr-transduced PNCMs reaching 100% of Vmax on day 5 after transduction and remaining at this high level until the end of the experiment on day 7 (Fig. 13a) .", [["PNCMs", "ANATOMY", 58, 63], ["AdshPLBr", "GENE_OR_GENE_PRODUCT", 38, 46], ["PNCMs", "CELL", 58, 63], ["AdshPLBr-transduced PNCMs", "CELL_LINE", 38, 63], ["transduced PNCMs", "TREATMENT", 47, 63], ["transduction", "TREATMENT", 101, 113], ["increased", "OBSERVATION_MODIFIER", 16, 25], ["steadily", "OBSERVATION_MODIFIER", 26, 34]]], ["This indicates an increase in the Ca 2+ affinity of the SR Ca 2+ -ATPase in the PLB-deficient PNCMs.", [["PNCMs", "ANATOMY", 94, 99], ["Ca", "CHEMICAL", 34, 36], ["Ca", "CHEMICAL", 59, 61], ["Ca 2+", "CHEMICAL", 34, 39], ["Ca 2+", "CHEMICAL", 59, 64], ["SR Ca 2+ -ATPase", "GENE_OR_GENE_PRODUCT", 56, 72], ["PLB", "GENE_OR_GENE_PRODUCT", 80, 83], ["PNCMs", "PATHOLOGICAL_FORMATION", 94, 99], ["SR Ca 2+ -ATPase", "PROTEIN", 56, 72], ["PLB", "PROTEIN", 80, 83], ["an increase", "PROBLEM", 15, 26], ["the Ca", "TEST", 30, 36], ["the SR Ca", "TEST", 52, 61], ["increase", "OBSERVATION_MODIFIER", 18, 26], ["PLB", "ANATOMY", 80, 83], ["deficient PNCMs", "OBSERVATION", 84, 99]]], ["As shown in Fig. 13b , a linear relationship between the relative rates of Ca 2+ uptake and the respective relative PLB protein levels was observed in AdshPLBrtransduced PNCMs.", [["PNCMs", "ANATOMY", 170, 175], ["Ca", "CHEMICAL", 75, 77], ["Ca 2+", "CHEMICAL", 75, 80], ["Ca 2+", "SIMPLE_CHEMICAL", 75, 80], ["PLB", "GENE_OR_GENE_PRODUCT", 116, 119], ["PNCMs", "PATHOLOGICAL_FORMATION", 170, 175], ["PLB", "PROTEIN", 116, 119], ["AdshPLBrtransduced PNCMs", "CELL_LINE", 151, 175], ["Ca", "TEST", 75, 77], ["the respective relative PLB protein levels", "TEST", 92, 134], ["PLB", "ANATOMY", 116, 119], ["protein levels", "OBSERVATION", 120, 134]]], ["In addition we investigated the degree of stimulation of Ca 2+ uptake by protein kinase A (PKA)-dependent in vitro phosphorylation following transduction of PNCMs with AdshPLBr at an MOI of 100.", [["Ca", "CHEMICAL", 57, 59], ["Ca 2+", "CHEMICAL", 57, 62], ["Ca 2+", "SIMPLE_CHEMICAL", 57, 62], ["protein kinase A", "GENE_OR_GENE_PRODUCT", 73, 89], ["PKA", "GENE_OR_GENE_PRODUCT", 91, 94], ["PNCMs", "PATHOLOGICAL_FORMATION", 157, 162], ["AdshPLBr", "SIMPLE_CHEMICAL", 168, 176], ["protein kinase A", "PROTEIN", 73, 89], ["PKA", "PROTEIN", 91, 94], ["PNCMs", "PROTEIN", 157, 162], ["AdshPLBr", "PROTEIN", 168, 176], ["Ca", "TEST", 57, 59], ["protein kinase", "TEST", 73, 87], ["PKA", "TEST", 91, 94], ["vitro phosphorylation", "TREATMENT", 109, 130], ["transduction of PNCMs", "TREATMENT", 141, 162], ["AdshPLBr", "TREATMENT", 168, 176]]], ["On day 1 after transduction the PKA-induced increase in the rate of Ca 2+ uptake was 82% both in Fig. 12 Time-dependency of AdshPLBr-mediated PLB protein downregulation. (a) Western blot analysis of PLB protein expression.", [["Ca", "CHEMICAL", 68, 70], ["Ca 2+", "CHEMICAL", 68, 73], ["PKA", "GENE_OR_GENE_PRODUCT", 32, 35], ["Ca 2+", "SIMPLE_CHEMICAL", 68, 73], ["AdshPLBr", "GENE_OR_GENE_PRODUCT", 124, 132], ["PLB", "GENE_OR_GENE_PRODUCT", 142, 145], ["PLB", "GENE_OR_GENE_PRODUCT", 199, 202], ["PKA", "PROTEIN", 32, 35], ["AdshPLBr", "PROTEIN", 124, 132], ["PLB", "PROTEIN", 142, 145], ["PLB", "PROTEIN", 199, 202], ["the PKA", "TEST", 28, 35], ["Ca", "TEST", 68, 70], ["uptake", "TEST", 74, 80], ["AdshPLBr-mediated PLB protein downregulation", "TREATMENT", 124, 168], ["blot analysis", "TEST", 182, 195], ["PLB protein expression", "PROBLEM", 199, 221], ["increase", "OBSERVATION_MODIFIER", 44, 52], ["PLB", "ANATOMY", 142, 145], ["protein downregulation", "OBSERVATION", 146, 168], ["PLB", "ANATOMY", 199, 202], ["protein expression", "OBSERVATION", 203, 221]]], ["PNCMs were transduced with AdshPLBr or a control vector at an MOI of 100.", [["PNCMs", "ANATOMY", 0, 5], ["PNCMs", "CELL", 0, 5], ["AdshPLBr", "GENE_OR_GENE_PRODUCT", 27, 35], ["PNCMs", "CELL_TYPE", 0, 5], ["AdshPLBr", "PROTEIN", 27, 35], ["AdshPLBr", "TREATMENT", 27, 35], ["a control vector", "TREATMENT", 39, 55]]], ["Cells were harvested at indicated time points after transduction and Westernblots carried out.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["transduction", "TREATMENT", 52, 64]]], ["Significant PLB downregulation became visible 3 days post-transduction while the expression levels of SERCA, NCX1, TnI, and CSQ2 were unaffected during the 7-day investigation period (b) Relative expression levels of PLB, SERCA, NCX1, TnI, and CSQ2 protein normalized to the respective Western blot signals at the corresponding time points in control vector-transduced PNCMs non-transduced and in AdshPLBr-transduced PNCMs.", [["PNCMs", "ANATOMY", 369, 374], ["PNCMs", "ANATOMY", 417, 422], ["PLB", "GENE_OR_GENE_PRODUCT", 12, 15], ["SERCA", "GENE_OR_GENE_PRODUCT", 102, 107], ["NCX1", "GENE_OR_GENE_PRODUCT", 109, 113], ["TnI", "GENE_OR_GENE_PRODUCT", 115, 118], ["CSQ2", "GENE_OR_GENE_PRODUCT", 124, 128], ["PLB", "GENE_OR_GENE_PRODUCT", 217, 220], ["SERCA", "GENE_OR_GENE_PRODUCT", 222, 227], ["NCX1", "GENE_OR_GENE_PRODUCT", 229, 233], ["TnI", "GENE_OR_GENE_PRODUCT", 235, 238], ["CSQ2", "GENE_OR_GENE_PRODUCT", 244, 248], ["PNCMs", "CELL", 369, 374], ["AdshPLBr", "GENE_OR_GENE_PRODUCT", 397, 405], ["PNCMs", "CELL", 417, 422], ["PLB", "PROTEIN", 12, 15], ["SERCA", "PROTEIN", 102, 107], ["NCX1", "PROTEIN", 109, 113], ["TnI", "PROTEIN", 115, 118], ["CSQ2", "PROTEIN", 124, 128], ["PLB", "PROTEIN", 217, 220], ["SERCA", "PROTEIN", 222, 227], ["NCX1", "PROTEIN", 229, 233], ["TnI", "PROTEIN", 235, 238], ["CSQ2", "PROTEIN", 244, 248], ["PNCMs", "CELL_LINE", 369, 374], ["AdshPLBr-transduced PNCMs", "CELL_LINE", 397, 422], ["Significant PLB downregulation", "PROBLEM", 0, 30], ["SERCA", "TEST", 102, 107], ["NCX1", "TEST", 109, 113], ["TnI", "TEST", 115, 118], ["CSQ2", "TEST", 124, 128], ["NCX1", "TEST", 229, 233], ["TnI", "TEST", 235, 238], ["CSQ2 protein", "TEST", 244, 256], ["PLB", "ANATOMY", 12, 15], ["downregulation", "OBSERVATION", 16, 30], ["SERCA", "ANATOMY", 102, 107], ["PLB", "ANATOMY", 217, 220], ["SERCA", "ANATOMY", 222, 227]]], ["In homogenates of AdshPLBrtransduced PNCMs this PKA stimulation became completely lost around day 4/5 after transduction, whereas approximately 1.5-fold stimulation of Ca 2+ uptake was observed on days 4-7 in non-transduced PNCMs (Fig. 14) .", [["homogenates", "ANATOMY", 3, 14], ["PNCMs", "ANATOMY", 224, 229], ["Ca", "CHEMICAL", 168, 170], ["Ca 2+", "CHEMICAL", 168, 173], ["PNCMs", "GENE_OR_GENE_PRODUCT", 37, 42], ["PKA", "GENE_OR_GENE_PRODUCT", 48, 51], ["Ca 2+", "SIMPLE_CHEMICAL", 168, 173], ["PNCMs", "PATHOLOGICAL_FORMATION", 224, 229], ["AdshPLBrtransduced PNCMs", "CELL_LINE", 18, 42], ["PKA", "PROTEIN", 48, 51], ["AdshPLBrtransduced PNCMs", "TREATMENT", 18, 42], ["this PKA stimulation", "TREATMENT", 43, 63], ["Ca", "TEST", 168, 170]]], ["(Fig. 12b)Discussion of an RNAi-Based Approach to Heart Failure TherapyWe demonstrated highly efficient and specific ablation of endogenous PLB expression in PNCMs by PLB-shRNA expressed from an AdV. shRNA transcription resulted in downregulation of endogenous PLB-mRNA below 0.1% of baseline, persisting for 13 days.", [["Heart", "ANATOMY", 50, 55], ["PNCMs", "ANATOMY", 158, 163], ["PLB", "GENE_OR_GENE_PRODUCT", 140, 143], ["PNCMs", "GENE_OR_GENE_PRODUCT", 158, 163], ["PLB", "GENE_OR_GENE_PRODUCT", 167, 170], ["PLB", "GENE_OR_GENE_PRODUCT", 261, 264], ["PLB", "PROTEIN", 140, 143], ["PNCMs", "CELL_TYPE", 158, 163], ["PLB", "PROTEIN", 167, 170], ["PLB", "PROTEIN", 261, 264], ["an RNAi", "TREATMENT", 24, 31], ["Heart Failure TherapyWe", "TREATMENT", 50, 73], ["endogenous PLB expression", "PROBLEM", 129, 154], ["shRNA transcription", "TREATMENT", 200, 219], ["downregulation of endogenous PLB", "PROBLEM", 232, 264], ["Heart", "ANATOMY", 50, 55], ["Failure", "OBSERVATION", 56, 63], ["endogenous PLB expression", "OBSERVATION", 129, 154], ["PLB", "ANATOMY", 167, 170], ["endogenous PLB", "OBSERVATION", 250, 264]]], ["No changes of the expression of other cardiac proteins including Ca 2+ handling proteins occurred, indicating high target specificity of the PLB-shRNA vector.", [["cardiac", "ANATOMY", 38, 45], ["Ca", "CHEMICAL", 65, 67], ["Ca 2+", "CHEMICAL", 65, 70], ["Ca 2+", "GENE_OR_GENE_PRODUCT", 65, 70], ["PLB", "GENE_OR_GENE_PRODUCT", 141, 144], ["cardiac proteins", "PROTEIN", 38, 54], ["Ca 2+ handling proteins", "PROTEIN", 65, 88], ["PLB", "PROTEIN", 141, 144], ["shRNA vector", "DNA", 145, 157], ["other cardiac proteins", "PROBLEM", 32, 54], ["Ca", "TEST", 65, 67], ["handling proteins", "PROBLEM", 71, 88], ["cardiac", "ANATOMY", 38, 45], ["proteins", "OBSERVATION", 46, 54], ["high", "OBSERVATION_MODIFIER", 110, 114], ["PLB", "ANATOMY", 141, 144], ["shRNA vector", "OBSERVATION", 145, 157]]], ["A control vector had no effect on PLB indicating absence of unspecific effects of shRNA per se on PNCMs.", [["PNCMs", "ANATOMY", 98, 103], ["PLB", "GENE_OR_GENE_PRODUCT", 34, 37], ["PNCMs", "PATHOLOGICAL_FORMATION", 98, 103], ["PLB", "PROTEIN", 34, 37], ["PNCMs", "CELL_TYPE", 98, 103], ["A control vector", "TREATMENT", 0, 16], ["effect on PLB", "PROBLEM", 24, 37], ["unspecific effects of shRNA", "PROBLEM", 60, 87], ["PNCMs", "TREATMENT", 98, 103]]], ["At the functional level, the SERCA2a Ca 2+ affinity was markedly increased after PLB silencing accompanied by a loss of responsiveness to PKA-dependent stimulation of Ca 2+ uptake.", [["Ca", "CHEMICAL", 37, 39], ["Ca", "CHEMICAL", 167, 169], ["Ca 2+", "CHEMICAL", 37, 42], ["Ca 2+", "CHEMICAL", 167, 172], ["SERCA2a Ca 2", "GENE_OR_GENE_PRODUCT", 29, 41], ["PLB", "GENE_OR_GENE_PRODUCT", 81, 84], ["PKA", "GENE_OR_GENE_PRODUCT", 138, 141], ["Ca 2+", "SIMPLE_CHEMICAL", 167, 172], ["SERCA2a", "PROTEIN", 29, 36], ["PLB", "PROTEIN", 81, 84], ["PKA", "PROTEIN", 138, 141], ["the SERCA2a Ca", "TEST", 25, 39], ["PLB silencing", "PROBLEM", 81, 94], ["a loss of responsiveness", "PROBLEM", 110, 134], ["PKA", "TEST", 138, 141], ["SERCA2a", "ANATOMY", 29, 36], ["markedly", "OBSERVATION_MODIFIER", 56, 64], ["increased", "OBSERVATION_MODIFIER", 65, 74]]], ["SERCA2a and PLB form a functional complex regulating Ca 2+ uptake.", [["Ca", "CHEMICAL", 53, 55], ["Ca 2+", "CHEMICAL", 53, 58], ["SERCA2a", "GENE_OR_GENE_PRODUCT", 0, 7], ["PLB", "GENE_OR_GENE_PRODUCT", 12, 15], ["Ca 2+", "SIMPLE_CHEMICAL", 53, 58], ["SERCA2a", "PROTEIN", 0, 7], ["PLB", "PROTEIN", 12, 15], ["PLB", "ANATOMY", 12, 15]]], ["Altered levels of either protein may therefore have profound effects by changing the PLB/ SERCA2a ratio and thereby altering intracardiac Ca 2+ homeostasis.", [["intracardiac", "ANATOMY", 125, 137], ["Ca", "CHEMICAL", 138, 140], ["Ca 2+", "CHEMICAL", 138, 143], ["PLB", "GENE_OR_GENE_PRODUCT", 85, 88], ["SERCA2a", "GENE_OR_GENE_PRODUCT", 90, 97], ["Ca 2+", "SIMPLE_CHEMICAL", 138, 143], ["PLB", "PROTEIN", 85, 88], ["SERCA2a", "PROTEIN", 90, 97], ["Altered levels of either protein", "PROBLEM", 0, 32], ["profound effects", "PROBLEM", 52, 68], ["the PLB/ SERCA2a ratio", "TREATMENT", 81, 103], ["altering intracardiac Ca", "PROBLEM", 116, 140], ["SERCA2a", "ANATOMY", 90, 97], ["intracardiac", "ANATOMY", 125, 137], ["Ca", "OBSERVATION", 138, 140]]], ["This was demonstrated in normal and diseased hearts by use of transgenic animal models or gene transfer approches targeting PLB or SERCA2a (Iwanaga et al. 2004; del-Monte et al. 2001; Vetter et al. 2002; Miyamoto et al. 2000) .", [["hearts", "ANATOMY", 45, 51], ["hearts", "ORGAN", 45, 51], ["PLB", "GENE_OR_GENE_PRODUCT", 124, 127], ["SERCA2a", "GENE_OR_GENE_PRODUCT", 131, 138], ["PLB", "PROTEIN", 124, 127], ["SERCA2a", "PROTEIN", 131, 138], ["transgenic animal models", "TREATMENT", 62, 86], ["normal", "OBSERVATION", 25, 31], ["diseased", "OBSERVATION", 36, 44], ["hearts", "ANATOMY", 45, 51], ["SERCA2a", "ANATOMY", 131, 138]]], ["Reduction of the PLB/SERCA2a ratio was achieved by classical overexpression of cDNAs encoding SERCA2a, a dominant negative PL mutant, or PLB-targeted antibodies.", [["PLB", "GENE_OR_GENE_PRODUCT", 17, 20], ["SERCA2a", "GENE_OR_GENE_PRODUCT", 21, 28], ["SERCA2a", "GENE_OR_GENE_PRODUCT", 94, 101], ["PL", "GENE_OR_GENE_PRODUCT", 123, 125], ["PLB", "GENE_OR_GENE_PRODUCT", 137, 140], ["PLB", "PROTEIN", 17, 20], ["SERCA2a", "PROTEIN", 21, 28], ["cDNAs", "DNA", 79, 84], ["SERCA2a", "PROTEIN", 94, 101], ["dominant negative PL mutant", "PROTEIN", 105, 132], ["PLB", "PROTEIN", 137, 140], ["targeted antibodies", "PROTEIN", 141, 160], ["the PLB/SERCA2a ratio", "TEST", 13, 34], ["a dominant negative PL mutant", "PROBLEM", 103, 132], ["PLB", "TEST", 137, 140], ["PLB", "ANATOMY", 17, 20], ["SERCA2a", "ANATOMY", 21, 28], ["SERCA2a", "ANATOMY", 94, 101], ["dominant", "OBSERVATION_MODIFIER", 105, 113], ["negative PL mutant", "OBSERVATION", 114, 132], ["PLB", "ANATOMY", 137, 140]]], ["We and others have employed antisense RNAs directed against PLB-mRNA (Eizema et al. 2000; He et al. 1999) .Discussion of an RNAi-Based Approach to Heart Failure TherapyIn contrast, RNAi-based therapeutic strategies are not yet widely employed in the cardiovascular field.", [["Heart", "ANATOMY", 147, 152], ["cardiovascular", "ANATOMY", 250, 264], ["PLB", "GENE_OR_GENE_PRODUCT", 60, 63], ["cardiovascular", "ANATOMICAL_SYSTEM", 250, 264], ["antisense RNAs", "RNA", 28, 42], ["PLB", "PROTEIN", 60, 63], ["mRNA", "RNA", 64, 68], ["antisense RNAs", "TREATMENT", 28, 42], ["an RNAi", "TREATMENT", 121, 128], ["Heart Failure TherapyIn contrast", "TREATMENT", 147, 179], ["RNAi-based therapeutic strategies", "TREATMENT", 181, 214], ["Heart", "ANATOMY", 147, 152], ["Failure", "OBSERVATION", 153, 160]]], ["Synthetic siRNAs were recently employed to downregulate Values in the presence of added PKA normalized to those measured in the presence of 2 \u00b5M synthetic PKA peptide inhibitor.", [["PKA", "GENE_OR_GENE_PRODUCT", 88, 91], ["PKA", "GENE_OR_GENE_PRODUCT", 155, 158], ["PKA", "PROTEIN", 88, 91], ["Synthetic siRNAs", "TREATMENT", 0, 16], ["added PKA", "PROBLEM", 82, 91], ["2 \u00b5M synthetic PKA peptide inhibitor", "TREATMENT", 140, 176]]], ["Control Non-transduced cells PLB in cardiomyocytes (Watanabe et al. 2004 ).", [["cells", "ANATOMY", 23, 28], ["cardiomyocytes", "ANATOMY", 36, 50], ["cells", "CELL", 23, 28], ["cardiomyocytes", "CELL", 36, 50], ["Non-transduced cells", "CELL_LINE", 8, 28], ["PLB", "PROTEIN", 29, 32], ["cardiomyocytes", "CELL_TYPE", 36, 50], ["cardiomyocytes", "ANATOMY", 36, 50]]], ["Since siRNAs enable only transient gene silencing, we have developed an AdV generating shRNAs mediating efficient, specific, and stable PLB silencing.", [["AdV", "ORGANISM", 72, 75], ["PLB", "GENE_OR_GENE_PRODUCT", 136, 139], ["shRNAs", "DNA", 87, 93], ["PLB", "PROTEIN", 136, 139], ["AdV", "SPECIES", 72, 75], ["siRNAs", "PROBLEM", 6, 12], ["transient gene silencing", "PROBLEM", 25, 49], ["an AdV generating shRNAs mediating", "PROBLEM", 69, 103], ["transient", "OBSERVATION_MODIFIER", 25, 34], ["gene silencing", "OBSERVATION", 35, 49], ["AdV", "OBSERVATION", 72, 75], ["shRNAs", "OBSERVATION", 87, 93], ["stable", "OBSERVATION_MODIFIER", 129, 135], ["PLB silencing", "OBSERVATION", 136, 149]]], ["With respect to the duration of silencing a striking difference between previous work using synthetic siRNAs (Watanabe et al. 2004 ) and the current AdV-based approach was observed. siRNAs resulted in downregulation of PLB-mRNA to 5% of baseline within 12 h, but this effect was almost completely lost after 4 days.", [["AdV", "ORGANISM", 149, 152], ["PLB", "GENE_OR_GENE_PRODUCT", 219, 222], ["PLB", "PROTEIN", 219, 222], ["a striking difference", "PROBLEM", 42, 63], ["synthetic siRNAs", "TREATMENT", 92, 108], ["the current AdV-based approach", "TREATMENT", 137, 167], ["siRNAs", "PROBLEM", 182, 188], ["downregulation of PLB", "PROBLEM", 201, 222], ["downregulation", "OBSERVATION_MODIFIER", 201, 215], ["PLB", "ANATOMY", 219, 222]]], ["In contrast, PLB-mRNA levels remained below 0.1% of baseline over a 2-week period after PLB-shRNA-AdV treatment.", [["PLB", "GENE_OR_GENE_PRODUCT", 13, 16], ["PLB", "GENE_OR_GENE_PRODUCT", 88, 91], ["AdV", "ORGANISM", 98, 101], ["PLB", "PROTEIN", 13, 16], ["PLB-mRNA levels", "TEST", 13, 28], ["PLB-shRNA", "TREATMENT", 88, 97], ["AdV treatment", "TREATMENT", 98, 111]]], ["Vector-based shRNA generation was clearly superior to synthetic siRNAs with respect to silencing stability.", [["Vector-based shRNA generation", "TREATMENT", 0, 29], ["synthetic siRNAs", "TREATMENT", 54, 70]]], ["With respect to the efficacy of silencing the PLB-shRNA-AdV resulted in >99.9% ablation of PLB-mRNA, whereas a former study using a PLB-antisense-RNA-AdV achieved maximal PLB-mRNA ablation \u224875% (Eizema et al. 2000) .", [["PLB", "GENE_OR_GENE_PRODUCT", 46, 49], ["AdV", "ORGANISM", 56, 59], ["PLB", "GENE_OR_GENE_PRODUCT", 91, 94], ["PLB", "GENE_OR_GENE_PRODUCT", 132, 135], ["AdV", "ORGANISM", 150, 153], ["PLB", "GENE_OR_GENE_PRODUCT", 171, 174], ["PLB", "PROTEIN", 46, 49], ["shRNA", "DNA", 50, 55], ["PLB-mRNA", "RNA", 91, 99], ["PLB", "PROTEIN", 132, 135], ["PLB", "PROTEIN", 171, 174], ["a former study", "TEST", 109, 123], ["a PLB-antisense", "TREATMENT", 130, 145], ["maximal PLB", "TREATMENT", 163, 174], ["mRNA ablation", "TREATMENT", 175, 188], ["PLB", "ANATOMY", 46, 49], ["PLB", "ANATOMY", 91, 94]]], ["In line with previous reports, we found PLB ablation to improve SERCA2a dependent intracellular Ca 2+ handling.", [["intracellular", "ANATOMY", 82, 95], ["Ca", "CHEMICAL", 96, 98], ["Ca 2+", "CHEMICAL", 96, 101], ["PLB", "GENE_OR_GENE_PRODUCT", 40, 43], ["SERCA2a", "GENE_OR_GENE_PRODUCT", 64, 71], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 82, 95], ["Ca 2+", "SIMPLE_CHEMICAL", 96, 101], ["PLB", "PROTEIN", 40, 43], ["SERCA2a", "PROTEIN", 64, 71], ["PLB ablation", "TREATMENT", 40, 52], ["SERCA2a dependent intracellular Ca", "TREATMENT", 64, 98], ["PLB", "ANATOMY", 40, 43], ["ablation", "OBSERVATION", 44, 52]]], ["Significant upregulation of SERCA2a Ca 2+ affinity was first observed when PLB protein was down to 50% of baseline.", [["Ca", "CHEMICAL", 36, 38], ["Ca 2+", "CHEMICAL", 36, 41], ["SERCA2a Ca 2", "GENE_OR_GENE_PRODUCT", 28, 40], ["PLB", "GENE_OR_GENE_PRODUCT", 75, 78], ["SERCA2a", "PROTEIN", 28, 35], ["PLB protein", "PROTEIN", 75, 86], ["Significant upregulation of SERCA2a Ca", "PROBLEM", 0, 38], ["affinity", "PROBLEM", 42, 50], ["PLB protein", "TEST", 75, 86], ["upregulation", "OBSERVATION", 12, 24], ["SERCA2a", "ANATOMY", 28, 35], ["Ca", "OBSERVATION", 36, 38]]], ["Interestingly, PLB downregulation to 20% was sufficient to mediate maximal increase in the Ca 2+ affinity of SERCA2a, further reduction had no additional effect.", [["Ca", "CHEMICAL", 91, 93], ["Ca 2+", "CHEMICAL", 91, 96], ["PLB", "GENE_OR_GENE_PRODUCT", 15, 18], ["SERCA2a", "GENE_OR_GENE_PRODUCT", 109, 116], ["PLB", "PROTEIN", 15, 18], ["SERCA2a", "PROTEIN", 109, 116], ["PLB downregulation", "TEST", 15, 33], ["maximal increase", "PROBLEM", 67, 83], ["the Ca", "TEST", 87, 93], ["SERCA2a", "TREATMENT", 109, 116], ["further reduction", "TREATMENT", 118, 135], ["increase", "OBSERVATION_MODIFIER", 75, 83], ["SERCA2a", "ANATOMY", 109, 116]]], ["There was a steady loss of responsiveness to PKA-dependent Ca 2+ uptake stimulation by PLB-shRNA, and complete loss of responsiveness was observed on day 4-7.", [["Ca", "CHEMICAL", 59, 61], ["Ca 2+", "CHEMICAL", 59, 64], ["PKA", "GENE_OR_GENE_PRODUCT", 45, 48], ["Ca 2+", "SIMPLE_CHEMICAL", 59, 64], ["PLB", "GENE_OR_GENE_PRODUCT", 87, 90], ["PKA", "PROTEIN", 45, 48], ["PLB", "PROTEIN", 87, 90], ["a steady loss of responsiveness", "PROBLEM", 10, 41], ["PKA", "TEST", 45, 48], ["uptake stimulation", "TEST", 65, 83], ["PLB-shRNA", "TEST", 87, 96], ["complete loss of responsiveness", "PROBLEM", 102, 133], ["steady", "OBSERVATION_MODIFIER", 12, 18], ["loss", "OBSERVATION_MODIFIER", 19, 23], ["PLB", "ANATOMY", 87, 90]]], ["There was no loss of responsiveness to PKA-dependent Ca 2+ uptake stimulation in the control groups.", [["Ca", "CHEMICAL", 53, 55], ["Ca 2+", "CHEMICAL", 53, 58], ["PKA", "SIMPLE_CHEMICAL", 39, 42], ["Ca 2+", "SIMPLE_CHEMICAL", 53, 58], ["PKA", "PROTEIN", 39, 42], ["loss of responsiveness", "PROBLEM", 13, 35], ["PKA", "TEST", 39, 42], ["no", "UNCERTAINTY", 10, 12], ["loss", "OBSERVATION_MODIFIER", 13, 17]]], ["This indicates that the RNAi-mediated PLB silencing was linked to the anticipated loss of responsiveness of the SR Ca 2+ transport system to PKA-dependent phosphorylation normally mediated through PLB.Discussion of an RNAi-Based Approach to Heart Failure TherapyAlthough RNAi is a powerful method for gene silencing, its implementation for therapeutic purposes in humans requires that two technical problems are solved.", [["Heart", "ANATOMY", 241, 246], ["Ca", "CHEMICAL", 115, 117], ["Ca 2+", "CHEMICAL", 115, 120], ["PLB", "GENE_OR_GENE_PRODUCT", 38, 41], ["PKA", "GENE_OR_GENE_PRODUCT", 141, 144], ["PLB", "GENE_OR_GENE_PRODUCT", 197, 200], ["humans", "ORGANISM", 364, 370], ["PLB", "PROTEIN", 38, 41], ["PKA", "PROTEIN", 141, 144], ["PLB", "PROTEIN", 197, 200], ["humans", "SPECIES", 364, 370], ["humans", "SPECIES", 364, 370], ["the RNAi", "TEST", 20, 28], ["the anticipated loss of responsiveness", "PROBLEM", 66, 104], ["PKA", "TEST", 141, 144], ["an RNAi", "TREATMENT", 215, 222], ["Heart Failure", "PROBLEM", 241, 254], ["gene silencing", "TREATMENT", 301, 315], ["therapeutic purposes", "TREATMENT", 340, 360], ["Heart", "ANATOMY", 241, 246], ["Failure", "OBSERVATION", 247, 254]]], ["First, instability of chemically synthesized siRNAs in plasma and cells requires their repetitive administration in vivo.", [["plasma", "ANATOMY", 55, 61], ["cells", "ANATOMY", 66, 71], ["plasma", "ORGANISM_SUBSTANCE", 55, 61], ["cells", "CELL", 66, 71], ["chemically synthesized siRNAs in plasma and cells", "PROBLEM", 22, 71], ["their repetitive administration", "TREATMENT", 81, 112], ["chemically synthesized siRNAs", "OBSERVATION", 22, 51]]], ["The loss of initially efficient target gene silencing in cardiomyocytes within 3 days allows an estimate of the required siRNA application frequency for this specific target tissue.", [["cardiomyocytes", "ANATOMY", 57, 71], ["tissue", "ANATOMY", 174, 180], ["cardiomyocytes", "CELL", 57, 71], ["tissue", "TISSUE", 174, 180], ["cardiomyocytes", "CELL_TYPE", 57, 71], ["siRNA application frequency", "TREATMENT", 121, 148], ["loss", "OBSERVATION_MODIFIER", 4, 8], ["cardiomyocytes", "ANATOMY", 57, 71]]], ["The problem may be overcome by viral vector systems producing shRNAs over long time periods in vivo.", [["shRNAs", "DNA", 62, 68], ["viral vector systems", "TREATMENT", 31, 51], ["may be", "UNCERTAINTY", 12, 18]]], ["For intermediate stability, AdV-shRNA systems as used here may suffice, and even provide advantages over long-term stable AAV vectors (Wang et al. 2005; Minamisawa et al. 1999a,b) if the RNAi effect is needed only temporarily in an acute and potentially reversible condition (e.g., heart failure due to viral or autoimmune myocarditis).", [["heart", "ANATOMY", 282, 287], ["heart failure", "DISEASE", 282, 295], ["viral or autoimmune myocarditis", "DISEASE", 303, 334], ["AdV", "ORGANISM", 28, 31], ["AAV", "ORGANISM", 122, 125], ["heart", "ORGAN", 282, 287], ["AdV-shRNA systems", "TREATMENT", 28, 45], ["the RNAi effect", "PROBLEM", 183, 198], ["an acute and potentially reversible condition", "PROBLEM", 229, 274], ["heart failure", "PROBLEM", 282, 295], ["viral or autoimmune myocarditis", "PROBLEM", 303, 334], ["stability", "OBSERVATION_MODIFIER", 17, 26], ["acute", "OBSERVATION_MODIFIER", 232, 237], ["heart", "ANATOMY", 282, 287], ["failure", "OBSERVATION", 288, 295]]], ["Second, cardiac targeting of synthetic siRNAs is currently only possible by experimental methods unsuitable for possible transfer to any clinical setting (Lewis et al. 2002) .", [["cardiac", "ANATOMY", 8, 15], ["cardiac", "ORGAN", 8, 15], ["synthetic siRNAs", "PROBLEM", 29, 45], ["cardiac", "ANATOMY", 8, 15], ["synthetic siRNAs", "OBSERVATION", 29, 45]]], ["In contrast, recent developments in vector technology (e.g., pseudotyped AAVs with cardiotropic properties) are likely to allow cardiac targeting of transgene and shRNA expression cassettes by simple intravenous injection (Inagaki et al. 2006; Pacak et al. 2006) .", [["cardiac", "ANATOMY", 128, 135], ["intravenous", "ANATOMY", 200, 211], ["pseudotyped", "ORGANISM", 61, 72], ["AAVs", "GENE_OR_GENE_PRODUCT", 73, 77], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 200, 211], ["transgene and shRNA expression cassettes", "DNA", 149, 189], ["cardiotropic properties", "TREATMENT", 83, 106], ["transgene and shRNA expression cassettes", "TREATMENT", 149, 189], ["simple intravenous injection", "TREATMENT", 193, 221]]], ["Importantly, the small expression cassette and specific PLB-shRNA sequence used in this study can easily be incorporated in different AAV and other vectors selected for purpose.", [["PLB", "GENE_OR_GENE_PRODUCT", 56, 59], ["AAV", "ORGANISM", 134, 137], ["small expression cassette", "DNA", 17, 42], ["PLB", "PROTEIN", 56, 59], ["shRNA sequence", "DNA", 60, 74], ["the small expression cassette", "TREATMENT", 13, 42], ["specific PLB-shRNA sequence", "TREATMENT", 47, 74], ["this study", "TEST", 83, 93], ["small", "OBSERVATION_MODIFIER", 17, 22]]], ["Within the framework of our proof-of-concept study which introduces a novel PL-shRNA tool we have not performed in vivo work, since the efficacy of PLB ablation for heart failure therapy in animal models has already been demonstrated (Iwanaga et al. 2004; delMonte et al. 2001; Vetter et al. 2002; Miyamoto et al. 2000) .", [["heart", "ANATOMY", 165, 170], ["heart failure", "DISEASE", 165, 178], ["PLB", "SIMPLE_CHEMICAL", 148, 151], ["heart", "ORGAN", 165, 170], ["PLB", "PROTEIN", 148, 151], ["concept study", "TEST", 37, 50], ["a novel PL-shRNA tool", "TREATMENT", 68, 89], ["PLB ablation", "TREATMENT", 148, 160], ["heart failure therapy", "TREATMENT", 165, 186], ["heart", "ANATOMY", 165, 170], ["failure", "OBSERVATION", 171, 178]]], ["In future cardiac gene therapy studies, we will use pseudotyped AAV8 and AAV9 vectors, since two recent studies (Inagaki et al. 2006; Pacak et al. 2006) have demonstrated important advantages of these pseudotypes over lentiviruses, adenoviruses, and previously used AAV vectors.", [["cardiac", "ANATOMY", 10, 17], ["cardiac", "ORGAN", 10, 17], ["pseudotyped", "ORGANISM", 52, 63], ["AAV8", "GENE_OR_GENE_PRODUCT", 64, 68], ["AAV9", "GENE_OR_GENE_PRODUCT", 73, 77], ["pseudotypes", "ORGANISM", 201, 212], ["lentiviruses", "ORGANISM", 218, 230], ["adenoviruses", "ORGANISM", 232, 244], ["AAV", "ORGANISM", 266, 269], ["AAV", "SPECIES", 266, 269], ["cardiac gene therapy studies", "TEST", 10, 38], ["pseudotyped AAV8 and AAV9 vectors", "TREATMENT", 52, 85], ["two recent studies", "TEST", 93, 111], ["these pseudotypes over lentiviruses", "TREATMENT", 195, 230], ["adenoviruses", "TREATMENT", 232, 244], ["AAV vectors", "TREATMENT", 266, 277]]], ["One remaining challenge is the modification of the cassette in such a way as to allow exogenously regulatable shRNA expression and adjustment of the degree of PLB modulation to changing physiological conditions.", [["PLB", "GENE_OR_GENE_PRODUCT", 159, 162], ["PLB", "PROTEIN", 159, 162], ["the cassette", "TREATMENT", 47, 59], ["exogenously regulatable shRNA expression", "TREATMENT", 86, 126], ["PLB modulation", "TREATMENT", 159, 173], ["PLB modulation", "OBSERVATION", 159, 173]]], ["This appears to be particularly important in humans since chronic PLB deficiency due to genomic mutations was associated with cardiomyopathies (Schmitt et al. 2003; Zhao et al. 2006; Haghighi et al. 2003 Haghighi et al. , 2006 .", [["PLB deficiency", "DISEASE", 66, 80], ["cardiomyopathies", "DISEASE", 126, 142], ["humans", "ORGANISM", 45, 51], ["PLB", "GENE_OR_GENE_PRODUCT", 66, 69], ["PLB", "PROTEIN", 66, 69], ["humans", "SPECIES", 45, 51], ["humans", "SPECIES", 45, 51], ["chronic PLB deficiency", "PROBLEM", 58, 80], ["genomic mutations", "PROBLEM", 88, 105], ["cardiomyopathies", "PROBLEM", 126, 142], ["appears to be", "UNCERTAINTY", 5, 18], ["chronic", "OBSERVATION_MODIFIER", 58, 65], ["PLB deficiency", "OBSERVATION", 66, 80]]], ["Whereas in mice complete knockout of PLB (as may also be achieved by RNAi) was able to rescue the severe cardiomyopathic phenotype of MLP knockout mice (Minamisawa 1999a,b) , suggesting that unregulated PLB silencing is appropriate in this species, application in humans most probably requires regulatable RNAi.", [["cardiomyopathic phenotype", "DISEASE", 105, 130], ["mice", "ORGANISM", 11, 15], ["PLB", "GENE_OR_GENE_PRODUCT", 37, 40], ["MLP knockout mice", "ORGANISM", 134, 151], ["PLB", "GENE_OR_GENE_PRODUCT", 203, 206], ["humans", "ORGANISM", 264, 270], ["PLB", "PROTEIN", 37, 40], ["MLP", "PROTEIN", 134, 137], ["PLB", "PROTEIN", 203, 206], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 147, 151], ["humans", "SPECIES", 264, 270], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 147, 151], ["humans", "SPECIES", 264, 270], ["the severe cardiomyopathic phenotype", "PROBLEM", 94, 130], ["Minamisawa", "TEST", 153, 163], ["unregulated PLB silencing", "PROBLEM", 191, 216], ["PLB", "ANATOMY", 37, 40], ["severe", "OBSERVATION_MODIFIER", 98, 104], ["cardiomyopathic", "OBSERVATION", 105, 120], ["unregulated", "OBSERVATION_MODIFIER", 191, 202], ["PLB silencing", "OBSERVATION", 203, 216], ["regulatable RNAi", "OBSERVATION", 294, 310]]], ["Recent studies by our group have extended the repertoire of RNAi vector for the suppression of PLB by a series of AAV9based vectors.", [["PLB", "GENE_OR_GENE_PRODUCT", 95, 98], ["PLB", "PROTEIN", 95, 98], ["Recent studies", "TEST", 0, 14], ["RNAi vector", "TREATMENT", 60, 71], ["a series of AAV9based vectors", "TREATMENT", 102, 131]]], ["A long-term in vivo study of both the original AdV described above and analogous AAV9 vectors have demonstrate that over periods of 1 month (for the AdV vector) and 3 months (for the AAV9 vector) these RNAi vector significantly improve systolic and diastolic cardiac function, reduce cardiac hypertrophy and dilation, and improve survival (in the case of the AAV vectors only) (unpublished data).", [["cardiac", "ANATOMY", 259, 266], ["cardiac", "ANATOMY", 284, 291], ["cardiac hypertrophy", "DISEASE", 284, 303], ["AdV", "ORGANISM", 47, 50], ["AAV9", "GENE_OR_GENE_PRODUCT", 81, 85], ["AdV", "ORGANISM", 149, 152], ["cardiac", "ORGAN", 259, 266], ["cardiac", "ORGAN", 284, 291], ["AAV", "ORGANISM", 359, 362], ["AAV9 vectors", "DNA", 81, 93], ["RNAi vector", "DNA", 202, 213], ["AdV", "SPECIES", 149, 152], ["vivo study", "TEST", 15, 25], ["analogous AAV9 vectors", "TREATMENT", 71, 93], ["the AdV vector", "TREATMENT", 145, 159], ["the AAV9 vector", "TREATMENT", 179, 194], ["systolic", "TEST", 236, 244], ["cardiac hypertrophy", "PROBLEM", 284, 303], ["dilation", "PROBLEM", 308, 316], ["the AAV vectors", "TREATMENT", 355, 370], ["long-term", "OBSERVATION_MODIFIER", 2, 11], ["cardiac", "ANATOMY", 259, 266], ["cardiac", "ANATOMY", 284, 291], ["hypertrophy", "OBSERVATION", 292, 303], ["dilation", "OBSERVATION", 308, 316]]], ["Furthermore, the catecholamine-induced deregulations of several functionally relevant miRNA in cardiomyocytes were restore to normal by RNAi vector treatment (unpublished data).Three Levels of Cardiac TargetingDuring the past decade, the molecular and structural foundations and the key problems associated with cardiac gene therapy -and thereby also many of those encountered in regulatory RNA-based approaches -have been defined in considerable detail.", [["cardiomyocytes", "ANATOMY", 95, 109], ["cardiac", "ANATOMY", 312, 319], ["catecholamine", "CHEMICAL", 17, 30], ["catecholamine", "CHEMICAL", 17, 30], ["catecholamine", "SIMPLE_CHEMICAL", 17, 30], ["cardiomyocytes", "CELL", 95, 109], ["cardiac", "ORGAN", 312, 319], ["cardiomyocytes", "CELL_TYPE", 95, 109], ["the catecholamine", "TREATMENT", 13, 30], ["RNAi vector treatment", "TREATMENT", 136, 157], ["the key problems", "PROBLEM", 279, 295], ["cardiac gene therapy", "TREATMENT", 312, 332], ["cardiomyocytes", "ANATOMY", 95, 109], ["Cardiac", "ANATOMY", 193, 200], ["TargetingDuring", "OBSERVATION", 201, 216], ["gene therapy", "OBSERVATION", 320, 332]]], ["It has become obvious that efficient and selective transport of any regulatory RNA or cDNA vector to the myocardium (Targeting) is a first key issue and major problem.", [["myocardium", "ANATOMY", 105, 115], ["myocardium", "MULTI-TISSUE_STRUCTURE", 105, 115], ["regulatory RNA", "RNA", 68, 82], ["cDNA vector", "DNA", 86, 97], ["any regulatory RNA", "TREATMENT", 64, 82], ["cDNA vector", "TREATMENT", 86, 97], ["myocardium", "ANATOMY", 105, 115]]], ["Future clinical cardiac RNA and gene therapy protocols will probably involve direct intracoronary vector infusion to achieve target selectivity (level I of targeting).", [["cardiac", "ANATOMY", 16, 23], ["Future clinical cardiac RNA", "TREATMENT", 0, 27], ["gene therapy protocols", "TREATMENT", 32, 54], ["direct intracoronary vector infusion", "TREATMENT", 77, 113]]], ["This may be enhanced by the use cardiac-specific promotors resulting in further confinement of regulatory RNA or cDNA expression (level II).", [["cardiac", "ANATOMY", 32, 39], ["regulatory RNA", "RNA", 95, 109], ["regulatory RNA", "PROBLEM", 95, 109], ["cDNA expression", "PROBLEM", 113, 128], ["may be", "UNCERTAINTY", 5, 11]]], ["Importantly, for regulatory RNA, e.g., shRNA transcription common tissue-specific type II polymerase promoters cannot be used since proper shRNA transcription has until recently only been achieved with type III promoters none of which was tissue-specific.", [["tissue", "ANATOMY", 66, 72], ["tissue", "ANATOMY", 239, 245], ["tissue", "TISSUE", 66, 72], ["type II polymerase", "GENE_OR_GENE_PRODUCT", 82, 100], ["tissue", "TISSUE", 239, 245], ["regulatory RNA", "RNA", 17, 31], ["type II polymerase promoters", "DNA", 82, 110], ["type III promoters", "DNA", 202, 220], ["regulatory RNA", "TREATMENT", 17, 31], ["shRNA transcription common tissue", "PROBLEM", 39, 72], ["specific type II polymerase promoters", "TREATMENT", 73, 110], ["proper shRNA transcription", "TREATMENT", 132, 158], ["type III promoters", "TREATMENT", 202, 220]]], ["This problem may be overcome, however, by the introduction of microRNA-based shRNA expression systems which also allow the use of cardiac-specific and drug-regulatable type II polymerase promotors.", [["cardiac", "ANATOMY", 130, 137], ["type II polymerase", "GENE_OR_GENE_PRODUCT", 168, 186], ["regulatable type II polymerase promotors", "PROTEIN", 156, 196], ["based shRNA expression systems", "PROBLEM", 71, 101], ["may be", "UNCERTAINTY", 13, 19], ["cardiac", "ANATOMY", 130, 137]]], ["This makes level II of targeting also available for regulatory RNA-based therapies.", [["regulatory RNA", "TREATMENT", 52, 66], ["based therapies", "TREATMENT", 67, 82]]], ["Another major breakthrough in the field of cardiac RNA and gene therapy was the discovery that certain pseudotyped AAV vectors (in particular AAV9 and derivates thereof) are cardiotropic even after simple intravenous injection (level III of targeting).", [["cardiac", "ANATOMY", 43, 50], ["intravenous", "ANATOMY", 205, 216], ["cardiac", "ORGAN", 43, 50], ["pseudotyped", "ORGANISM", 103, 114], ["AAV", "ORGANISM", 115, 118], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 205, 216], ["Another major breakthrough", "PROBLEM", 0, 26], ["cardiac RNA", "TREATMENT", 43, 54], ["gene therapy", "TREATMENT", 59, 71], ["pseudotyped AAV vectors", "TREATMENT", 103, 126], ["cardiotropic", "PROBLEM", 174, 186], ["simple intravenous injection", "TREATMENT", 198, 226], ["major", "OBSERVATION_MODIFIER", 8, 13], ["breakthrough", "OBSERVATION_MODIFIER", 14, 26], ["cardiac RNA", "ANATOMY", 43, 54]]], ["Although AAV9 is not yet absolutely cardiac-specific but also reaches the liver by the intravenous route, further modification of the AAV capsid may solve or alleviate this issue.", [["liver", "ANATOMY", 74, 79], ["intravenous", "ANATOMY", 87, 98], ["AAV9", "GENE_OR_GENE_PRODUCT", 9, 13], ["liver", "ORGAN", 74, 79], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 87, 98], ["AAV", "ORGANISM", 134, 137], ["AAV9", "PROTEIN", 9, 13], ["the intravenous route", "TREATMENT", 83, 104], ["the AAV capsid", "TREATMENT", 130, 144], ["liver", "ANATOMY", 74, 79]]], ["Currently, the use of AAV9 in combination with level I and II targeting already enables highly cardiac-specific RNA and gene therapy protocols one of which is evaluated in a first clinical trial.Stability and Control of Regulatory RNA and Gene TherapyDepending on the target disease, the therapeutic goal may be achieved by regulatory RNA or transgene expression for only few days or weeks or require long-term of even life-long stability.", [["cardiac", "ANATOMY", 95, 102], ["AAV9", "CHEMICAL", 22, 26], ["AAV9", "CHEMICAL", 22, 26], ["AAV9", "SIMPLE_CHEMICAL", 22, 26], ["AAV9", "PROTEIN", 22, 26], ["Regulatory RNA", "RNA", 220, 234], ["regulatory RNA", "RNA", 324, 338], ["AAV9", "TREATMENT", 22, 26], ["gene therapy protocols", "TREATMENT", 120, 142], ["Regulatory RNA", "TREATMENT", 220, 234], ["Gene TherapyDepending", "TREATMENT", 239, 260], ["the target disease", "PROBLEM", 264, 282], ["Regulatory RNA", "OBSERVATION", 220, 234], ["long stability", "OBSERVATION_MODIFIER", 424, 438]]], ["Currently available adenovectors are capable of achieving the short-term goal which may also suffice in bridge-to-recovery or bridge-to-transplant situations.", [["adenovectors", "TREATMENT", 20, 32]]], ["Nevertheless, even for short-term therapies the generally better safety profile of AAV vectors will lead to the use of this vector type in any clinical RNA or gene therapy protocol.", [["AAV", "ORGANISM", 83, 86], ["AAV", "SPECIES", 83, 86], ["short-term therapies", "TREATMENT", 23, 43], ["AAV vectors", "TREATMENT", 83, 94], ["this vector type", "TREATMENT", 119, 135], ["any clinical RNA", "TREATMENT", 139, 155], ["gene therapy protocol", "TREATMENT", 159, 180]]], ["For all long-term therapies AAV vectors are a priori the system of choice due to their impressive long-term cardiac stability and function in several experimental studies.", [["cardiac", "ANATOMY", 108, 115], ["AAV", "ORGANISM", 28, 31], ["cardiac", "ORGAN", 108, 115], ["AAV", "SPECIES", 28, 31], ["all long-term therapies", "TREATMENT", 4, 27], ["AAV vectors", "TREATMENT", 28, 39], ["several experimental studies", "TEST", 142, 170], ["cardiac", "ANATOMY", 108, 115], ["stability", "OBSERVATION", 116, 125]]], ["Whereas control of transgene expression is available for some years via drug-regulatable system, this goal has only recently been achieved for regulatory RNA therapies.", [["drug-regulatable system", "TREATMENT", 72, 95], ["regulatory RNA therapies", "TREATMENT", 143, 167]]], ["As for conventional gene therapy, optimized clinical RNA therapy protocols are also likely to involve drug-regulatable systems since under certain conditions shRNAs (and likely also other regulatory RNA, e.g., miRNAs) have shown serious adverse effects.", [["shRNAs", "GENE_OR_GENE_PRODUCT", 158, 164], ["regulatory RNA", "RNA", 188, 202], ["conventional gene therapy", "TREATMENT", 7, 32], ["clinical RNA therapy protocols", "TREATMENT", 44, 74], ["drug-regulatable systems", "TREATMENT", 102, 126], ["certain conditions shRNAs", "PROBLEM", 139, 164], ["serious adverse effects", "PROBLEM", 229, 252]]], ["The option to shut off their expression will therefore significantly add to therapeutic safety in the clinical setting.Practical Issues of Clinical TranslationEven when the above basic issues are solved satisfactorily, the intensity of efforts to establish a regulatory RNA or gene therapeutic regime in the clinic will be critically influenced by four determinants.", [["a regulatory RNA", "TREATMENT", 257, 273], ["gene therapeutic regime", "TREATMENT", 277, 300]]], ["First, that the specific therapeutic target is not accessible by other means, e.g., conventional pharmacotherapy.", [["conventional pharmacotherapy", "TREATMENT", 84, 112]]], ["Second, that the target disease is sufficiently severe to justify the efforts and risks of any experimental therapeutic approach.", [["the target disease", "PROBLEM", 13, 31], ["any experimental therapeutic approach", "TREATMENT", 91, 128], ["target", "OBSERVATION_MODIFIER", 17, 23], ["disease", "OBSERVATION", 24, 31]]], ["Third, that the number of patients which may possibly benefit from the experimental therapy to be established is relatively high since this will greatly facilitate fundraising and incorporation of industrial partners.", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["the experimental therapy", "TREATMENT", 67, 91], ["may possibly", "UNCERTAINTY", 41, 53]]], ["Fourth, any therapeutic protocol which addresses a pathomechanism (e.g., disturbed cardiac Ca 2+ homeostasis) common to cardiac diseases of diverse etiologies will have a broader range of application than strategies which target specific pathogenic steps, and need to be tailor-made for every different type of pathogenesis.", [["cardiac", "ANATOMY", 83, 90], ["cardiac", "ANATOMY", 120, 127], ["Ca", "CHEMICAL", 91, 93], ["cardiac diseases", "DISEASE", 120, 136], ["Ca 2+", "CHEMICAL", 91, 96], ["cardiac", "ORGAN", 120, 127], ["any therapeutic protocol", "TREATMENT", 8, 32], ["a pathomechanism", "PROBLEM", 49, 65], ["disturbed cardiac Ca", "PROBLEM", 73, 93], ["cardiac diseases of diverse etiologies", "PROBLEM", 120, 158], ["application than strategies", "TREATMENT", 188, 215], ["pathogenesis", "PROBLEM", 311, 323], ["cardiac", "ANATOMY", 120, 127], ["diseases", "OBSERVATION", 128, 136]]], ["Without doubt, in cardiovascular medicine in general and specifically in the fields of cardio-myopathies and heart failure, a large number of patients are in urgent need of improved treatment, and the first regulatory RNA and gene therapeutic protocols adequately fulfill the above criteria.", [["cardiovascular", "ANATOMY", 18, 32], ["heart", "ANATOMY", 109, 114], ["cardio-myopathies", "DISEASE", 87, 104], ["heart failure", "DISEASE", 109, 122], ["heart", "ORGAN", 109, 114], ["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150], ["cardio-myopathies", "PROBLEM", 87, 104], ["heart failure", "PROBLEM", 109, 122], ["improved treatment", "TREATMENT", 173, 191], ["gene therapeutic protocols", "TREATMENT", 226, 252], ["cardio", "ANATOMY", 87, 93], ["myopathies", "OBSERVATION", 94, 104], ["heart", "ANATOMY", 109, 114], ["failure", "OBSERVATION", 115, 122], ["large", "OBSERVATION_MODIFIER", 126, 131], ["number", "OBSERVATION_MODIFIER", 132, 138]]]], "PMC7378303": [["Intensivmedizin im FokusDie durch die \u201ecoronavirus disease 2019\u201c (COVID-19) ausgel\u00f6ste Pandemie hat die Intensivmedizin in den Fokus der \u00d6ffentlichkeit ger\u00fcckt.", [["\u201ecoronavirus disease", "DISEASE", 38, 58], ["Intensivmedizin im FokusDie durch die \u201ecoronavirus disease 2019\u201c (COVID-19", "SPECIES", 0, 74], ["Intensivmedizin", "TREATMENT", 0, 15], ["\u201ecoronavirus disease", "PROBLEM", 38, 58]]], ["Nachdem ab Ende Februar 2020 t\u00e4glich \u00dcberlebens- und Sterbezahlen im internationalen Vergleich ver\u00f6ffentlicht werden, wurde auch schnell deutlich, dass die Sterblichkeit v. a. in dem Moment eskaliert, in dem die intensivmedizinischen Versorgungsm\u00f6glichkeiten enden [1]. \u201eFlatten the curve\u201c wurde zum Leitsatz des Konzepts, die Fallzahlen niedrig zu halten, um die Behandlungsm\u00f6glichkeiten nicht zu \u00fcberfordern, und derzeit \u00fcberleben die meisten der schwer Erkrankten allein durch eine supportive und standardisierte intensivmedizinische Behandlung.", [["Fallzahlen niedrig zu halten, um die Behandlungsm\u00f6glichkeiten nicht zu \u00fcberfordern, und derzeit \u00fcberleben die meisten der schwer Erkrankten allein durch eine supportive und standardisierte intensivmedizinische", "SPECIES", 327, 536], ["Nachdem", "TEST", 0, 7], ["\u00dcberlebens", "TEST", 37, 47], ["zum Leitsatz des", "TREATMENT", 296, 312]]], ["Intensivteams lassen sich zwar in einem gewissen Umfang erweitern, aber die Personalkapazit\u00e4t von IntensivpflegerInnen und Intensiv\u00e4rzten/Intensiv\u00e4rztinnen ist nicht beliebig und rasch expandierbar.", [["Personalkapazit\u00e4t von IntensivpflegerInnen und Intensiv\u00e4rzten/Intensiv\u00e4rztinnen ist nicht beliebig und rasch expandierbar", "SPECIES", 76, 197]]], ["Hinzu kommt, dass die potenzielle Virusexposition im Intensivsetting (Intubation, Bronchoskopie, endotracheale Absaugman\u00f6ver etc.) f\u00fcr das gesamte Team eine reale Bedrohung darstellt und durch Personalausf\u00e4lle eine regelrechte Abw\u00e4rtsspirale entstehen kann.Intensivmedizin im FokusIm Folgenden werden die Besonderheiten der COVID-19-Behandlung in der Intensivmedizin aufgezeigt, wie sie in der t\u00e4glichen Praxis zu erleben sind sowie in den vergangenen Monaten erarbeitet und publiziert wurden.", [["Intubation", "TREATMENT", 70, 80], ["Intensivmedizin", "TREATMENT", 257, 272]]], ["Besondere therapeutische Herausforderungen bestehen beim Lungenversagen durch COVID-19, beim Multiorganversagen und beim schweren Inflammationssyndrom; \u00fcberall hier ist bisher noch wenig Evidenz dar\u00fcber vorhanden, welche Interventionen am effektivsten sind.", [["COVID", "TEST", 78, 83], ["Inflammationssyndrom", "PROBLEM", 130, 150]]], ["Neben der raschen Durchf\u00fchrung klinischer Studien st\u00fctzt sich die Behandlung deshalb auch auf Analogien zu anderen Syndromen wie der Sepsis und dem Makrophagenaktivierungssyndrom.Merke ::: Falldefinition \u2013 COVID-19-Verdacht und -Diagnostik?Jeder Patient mit akuter Atemwegsinfektion, der eine station\u00e4re Behandlung ben\u00f6tigt, kann eine SARS-CoV-2-Infektion haben und muss entsprechend isoliert und getestet werden.Klinischer Verlauf und IntensivpflichtigkeitPatienten mit einer SARS-CoV-2-Infektion pr\u00e4sentieren sich h\u00e4ufig mit allgemeinem Krankheitsgef\u00fchl, Husten, Fieber, Geruchs- und Geschmacksst\u00f6rungen sowie auch Diarrh\u00f6en.Klinischer Verlauf und IntensivpflichtigkeitDas Vorliegen bestimmter laborchemischer Konstellationen l\u00e4sst einen schweren COVID-19-Verlauf vermutenKlinischer Verlauf und IntensivpflichtigkeitNeben einer bilateralen Pneumonie gibt es auch laborchemische Konstellationen, die nach der Erfahrung der Autoren einen schweren Verlauf wahrscheinlicher werden lassen (Tab.", [["Sepsis", "DISEASE", 133, 139], ["Patient", "SPECIES", 246, 253], ["Neben der raschen Durchf\u00fchrung klinischer Studien st\u00fctzt sich die Behandlung deshalb auch auf Analogien zu anderen Syndromen wie der Sepsis und dem Makrophagenaktivierungssyndrom", "SPECIES", 0, 178], ["Klinischer Verlauf und IntensivpflichtigkeitPatienten mit einer SARS-CoV-2-Infektion pr\u00e4sentieren sich h\u00e4ufig mit allgemeinem Krankheitsgef\u00fchl, Husten, Fieber, Geruchs- und Geschmacksst\u00f6rungen sowie auch Diarrh\u00f6en", "SPECIES", 413, 626], ["Klinischer Verlauf und IntensivpflichtigkeitDas Vorliegen bestimmter laborchemischer Konstellationen l\u00e4sst einen schweren COVID-19-Verlauf vermutenKlinischer Verlauf und IntensivpflichtigkeitNeben einer bilateralen Pneumonie gibt es auch laborchemische Konstellationen, die nach der Erfahrung der Autoren einen schweren Verlauf wahrscheinlicher werden lassen", "SPECIES", 627, 985], ["Neben der raschen Durchf\u00fchrung klinischer", "TREATMENT", 0, 41], ["Falldefinition", "TEST", 189, 203], ["COVID", "TEST", 206, 211], ["CoV", "TEST", 340, 343], ["Klinischer", "TEST", 413, 423], ["CoV", "TEST", 482, 485], ["Infektion", "TREATMENT", 488, 497], ["Klinischer", "TEST", 627, 637], ["Verlauf", "TEST", 638, 645], ["IntensivpflichtigkeitDas", "TEST", 650, 674], ["Vorliegen", "TEST", 675, 684], ["bestimmter", "TEST", 685, 695], ["laborchemischer", "TEST", 696, 711], ["Konstellationen", "TEST", 712, 727], ["l\u00e4sst", "TEST", 728, 733], ["schweren", "TEST", 740, 748], ["COVID", "TEST", 749, 754], ["Verlauf vermutenKlinischer Verlauf", "TREATMENT", 758, 792]]], ["F\u00fcr viele der Parameter ist bisher kein sinnvoller \u201eCut-off\u201c-Wert zwischen unkomplizierten und komplizierten Verl\u00e4ufen vorhanden, z.", [["F\u00fcr viele der Parameter ist bisher kein sinnvoller \u201eCut-off\u201c-Wert zwischen unkomplizierten und komplizierten Verl\u00e4ufen vorhanden", "SPECIES", 0, 128]]], ["T. zeigen sich allerdings dramatische Erh\u00f6hungen dieser Werte.Pathophysiologie ::: LungenversagenSchwere Verlaufsformen von COVID-19 gehen nahezu immer mit einer pulmonalen Beteiligung einher, die sich etwa ab dem 7. bis 10.", [["T. zeigen", "SPECIES", 0, 9], ["bis", "TEST", 217, 220]]], ["Tag nach Symptombeginn mit einer deutlichen Hypox\u00e4mie bemerkbar macht [2].", [["Tag", "GENE_OR_GENE_PRODUCT", 0, 3]]], ["Bei der dann oftmals einsetzenden raschen Dynamik der weiteren respiratorischen Verschlechterung steht klinisch eine kompensatorische Steigerung der Atemfrequenz im Vordergrund, wobei erstaunlicherweise h\u00e4ufig keine subjektive Dyspnoe des Patienten besteht.", [["Bei der dann oftmals einsetzenden raschen Dynamik der weiteren respiratorischen Verschlechterung steht klinisch eine kompensatorische Steigerung der Atemfrequenz im Vordergrund, wobei erstaunlicherweise h\u00e4ufig keine subjektive Dyspnoe des Patienten besteht", "SPECIES", 0, 256]]], ["Dieses Ph\u00e4nomen ist inzwischen auch als \u201esilent hypoxia\u201c bekannt und hat nicht selten dazu gef\u00fchrt, dass Patienten in Verkennung der Schwere ihrer Erkrankung, erst in einem sehr kritischen Zustand die Klinik aufgesucht haben.Pathophysiologie ::: Lungenversagen\u201eSilent hypoxia\u201c beschreibt die fehlende subjektive Dyspnoe bei rascher respiratorischer AggravationPathophysiologie ::: LungenversagenAus klinischer Sicht finden sich bei den schweren Verl\u00e4ufen 3 folgende wesentliche Phasen der Erkrankung:Pathophysiologie ::: LungenversagenIn der Fr\u00fchphase, die \u00fcberwiegend mild mit typischen Infektionszeichen einhergeht, dominiert die unspezifische Immunantwort des Organismus auf SARS-CoV\u20112, die in der Mehrzahl der F\u00e4lle in Folge ausheilt.", [["hypoxia", "DISEASE", 268, 275], ["als \u201esilent hypoxia", "PROBLEM", 36, 55], ["Silent hypoxia", "PROBLEM", 261, 275], ["beschreibt", "PROBLEM", 277, 287]]], ["Bei etwa 14 % aller infizierten Patienten findet sich ab der 2.", [["Bei etwa", "TREATMENT", 0, 8]]], ["Woche eine pneumonische Phase, die typischerweise mit einer lymphozyt\u00e4ren Pneumonitis beginnt und sich dann auch CT-morphologisch in Form von Milchglastr\u00fcbungen in den peripheren und basal gelegenen Lungenabschnitten darstellen l\u00e4sst (Abb.", [["Woche eine pneumonische Phase, die typischerweise mit einer lymphozyt\u00e4ren Pneumonitis beginnt und sich dann auch CT-morphologisch in Form von Milchglastr\u00fcbungen in den peripheren und basal gelegenen Lungenabschnitten darstellen l\u00e4sst", "SPECIES", 0, 233], ["Pneumonitis", "PROBLEM", 74, 85], ["CT", "TEST", 113, 115], ["Pneumonitis", "OBSERVATION", 74, 85]]], ["In etwa zur gleichen Zeit nimmt die \u201ehost inflammatory response\u201c des befallenen Organismus stetig zu: Es finden sich nun zunehmend konsolidierte Lungenareale, die histologisch am ehesten dem Bild eines f\u00fcr das \u201eacute respiratory distress syndrome\u201c (ARDS) typischen diffusen Alveolarschadens (\u201ediffuse alveolar damage\u201c, DAD) entsprechen.", [["respiratory distress syndrome\u201c", "DISEASE", 217, 247], ["ARDS", "DISEASE", 249, 253], ["Organismus stetig zu: Es finden sich nun zunehmend konsolidierte Lungenareale, die histologisch am ehesten dem Bild eines f\u00fcr das \u201eacute respiratory distress syndrome\u201c (ARDS) typischen diffusen Alveolarschadens (\u201ediffuse alveolar damage\u201c, DAD) entsprechen", "SPECIES", 80, 335], ["inflammatory response", "PROBLEM", 42, 63], ["respiratory distress syndrome", "PROBLEM", 217, 246], ["ARDS)", "PROBLEM", 249, 254], ["typischen diffusen Alveolarschadens", "PROBLEM", 255, 290], ["\u201ediffuse alveolar damage", "PROBLEM", 292, 316], ["respiratory distress", "OBSERVATION", 217, 237], ["alveolar", "ANATOMY", 301, 309]]], ["Der \u00dcbergang in die Hyperinflammationsphase ist flie\u00dfend und manifestiert sich bei einem Teil der Patienten meistens ab der 3.", [["Hyperinflammationsphase ist flie\u00dfend", "TREATMENT", 20, 56]]], ["Woche mit einem sepsis\u00e4hnlichen Krankheitsbild [3].Pathophysiologie ::: LungenversagenAls Risikofaktoren f\u00fcr einen schweren Verlauf gelten derzeit h\u00f6heres Patientenalter (>60 Jahre), m\u00e4nnliches Geschlecht und das Vorliegen von Begleiterkrankungen wie Diabetes, Malignomen oder Immunsuppression.", [["Diabetes", "DISEASE", 251, 259], ["LungenversagenAls", "TEST", 72, 89], ["Risikofaktoren", "TEST", 90, 104], ["Patientenalter", "TEST", 155, 169], ["Diabetes", "PROBLEM", 251, 259]]], ["Etwa 5 % der infizierten Patienten werden beatmungspflichtig.Pathophysiologie ::: LungenversagenErwachsene Patienten mit schwerem Verlauf sollten sp\u00e4testens bei einer pulsoxymetrisch gemessenen Sauerstoffs\u00e4ttigung (SpO2) unter 90 % einer Sauerstofftherapie unterzogen werden, wobei ein SpO2-Zielwert um die 94 % ausreichend ist.", [["LungenversagenErwachsene Patienten mit schwerem Verlauf sollten sp\u00e4testens bei einer pulsoxymetrisch gemessenen Sauerstoffs\u00e4ttigung (SpO2) unter 90 % einer Sauerstofftherapie unterzogen werden, wobei ein SpO2-Zielwert um die 94 % ausreichend", "SPECIES", 82, 323], ["Etwa", "TREATMENT", 0, 4], ["Sauerstoffs\u00e4ttigung", "TEST", 194, 213], ["SpO2", "TEST", 215, 219], ["Sauerstofftherapie", "TEST", 238, 256], ["wobei ein SpO2", "TEST", 276, 290]]], ["Inwieweit eine intensivmedizinische Behandlung notwendig wird, kann gem\u00e4\u00df der aktuellen S1-Leitlinie erwogen werden, wenn eines der nachfolgenden Kriterien erf\u00fcllt ist [4]:Hypox\u00e4mie (SpO2 <94 % unter 4 l O2/min) und Dyspnoe,Atemfrequenz >25\u201330/min,Wert des systolischen Blutdrucks <100 mm Hg,erh\u00f6hte Lactatwerte.Pathophysiologie ::: LungenversagenDie intensivmedizinische Betreuung von COVID-19-Patienten stellt f\u00fcr das gesamte Behandlungsteam eine gro\u00dfe Herausforderung dar.", [["O2", "CHEMICAL", 204, 206], ["Hg", "CHEMICAL", 289, 291], ["LungenversagenDie intensivmedizinische Betreuung von COVID-19-Patienten stellt f\u00fcr das gesamte Behandlungsteam eine gro\u00dfe Herausforderung dar", "SPECIES", 333, 474], ["Hypox\u00e4mie", "TEST", 172, 181], ["SpO2", "TEST", 183, 187], ["Atemfrequenz", "TEST", 224, 236], ["Blutdrucks", "TEST", 270, 280]]], ["Gerade in der Fr\u00fchphase ist das Abw\u00e4gen einer nichtinvasiven vs. einer invasiven Beatmung von mehreren Faktoren abh\u00e4ngig: Neben dem \u00fcblichen Nutzen/Risiko f\u00fcr den Patienten und dem Vorhandensein von Ressourcen sollte auch das Expositionsrisiko f\u00fcr Pflegekr\u00e4fte und \u00c4rzte ber\u00fccksichtigt werden.", [["Beatmung von mehreren Faktoren abh\u00e4ngig: Neben dem \u00fcblichen Nutzen/Risiko f\u00fcr den Patienten und dem Vorhandensein von Ressourcen sollte auch das Expositionsrisiko f\u00fcr Pflegekr\u00e4fte und \u00c4rzte ber\u00fccksichtigt werden", "SPECIES", 81, 292]]], ["Nicht wenige Patienten, die zwar hypox\u00e4misch, aber spontan atmend auf eine Intensivstation verlegt werden, sind aufgrund deliranter Zust\u00e4nde und der damit fehlenden Compliance nicht suffizient mithilfe nichtinvasiver Ma\u00dfnahmen zu stabilisieren.Bauchlagerung ::: LungenversagenNeben der klassischen Sauerstoffinsufflation werden inzwischen immer mehr Fallserien publiziert, die sich mit der Bauchlagerung bei wachen und spontan atmenden Patienten befassen.", [["LungenversagenNeben der klassischen Sauerstoffinsufflation werden inzwischen immer mehr Fallserien publiziert, die sich mit der Bauchlagerung bei wachen und spontan atmenden Patienten befassen", "SPECIES", 262, 454], ["LungenversagenNeben der klassischen Sauerstoffinsufflation", "TREATMENT", 262, 320]]], ["Wenngleich es auch weiterhin unklar bleibt, ob diese Ma\u00dfnahme dauerhaft die Oxygenierung verbessert und eine ansonsten anstehende Intubation verhindern kann, kann im Einzelfall bei kooperativen und klinisch stabilen Patienten eine Bauchlagerung mit nasalem \u201ehigh flow\u201c (\u201ehigh flow nasal cannulae\u201c, HFNC) oder einfacher Sauerstoffapplikation versucht werden.Merke ::: Nasale High-flow-Sauerstofftherapie und nichtinvasive Beatmung ::: LungenversagenBei fortbestehender Hypox\u00e4mie, erkennbarer Ersch\u00f6pfung des Patienten und problematischer Therapieadh\u00e4renz des Patienten sollte fr\u00fchzeitig eine ITN eingeleitet werden.Merke ::: Nasale High-flow-Sauerstofftherapie und nichtinvasive Beatmung ::: LungenversagenIn den aktuellen S1-Leitlinien wird empfohlen, dass ein erfahrener Arzt diese Intervention m\u00f6glichst mithilfe eines Videolaryngoskops und unter ausreichendem Abstand zum Patienten durchf\u00fchrt.", [["Lungenversagen", "CHEMICAL", 691, 705], ["Wenngleich es auch weiterhin unklar bleibt, ob diese Ma\u00dfnahme dauerhaft die Oxygenierung verbessert und eine ansonsten anstehende Intubation verhindern kann, kann im Einzelfall bei kooperativen und klinisch stabilen Patienten eine Bauchlagerung mit nasalem \u201ehigh flow\u201c (\u201ehigh flow nasal cannulae", "SPECIES", 0, 295], ["erkennbarer Ersch\u00f6pfung des Patienten und problematischer Therapieadh\u00e4renz des Patienten sollte fr\u00fchzeitig eine ITN eingeleitet werden", "SPECIES", 479, 613], ["den aktuellen S1-Leitlinien wird empfohlen", "SPECIES", 708, 750], ["Intubation", "TREATMENT", 130, 140], ["kann", "TREATMENT", 152, 156], ["\u201ehigh flow nasal cannulae", "TREATMENT", 270, 295], ["HFNC", "TREATMENT", 298, 302], ["LungenversagenBei", "TEST", 434, 451], ["Hypox\u00e4mie", "PROBLEM", 468, 477], ["S1", "ANATOMY", 722, 724]]], ["Idealerweise wird nach kurzer Pr\u00e4oxygenierung die Narkose mithilfe einer \u201erapid sequence induction\u201c eingeleitet [4].Invasive Beatmung ::: LungenversagenSchon fr\u00fchzeitig nach Beginn der Pandemie berichteten Intensivmediziner von auff\u00e4lligen Unterschieden zum klassischen ARDS.", [["ARDS", "DISEASE", 270, 274], ["Idealerweise wird nach kurzer", "TREATMENT", 0, 29], ["Narkose mithilfe einer \u201erapid sequence induction", "TREATMENT", 50, 98], ["ARDS", "PROBLEM", 270, 274], ["ARDS", "OBSERVATION", 270, 274]]], ["Eine italienische Arbeitsgruppe hat hierzu ein pathophysiologisches Konzept entwickelt.", [["Eine italienische", "TEST", 0, 17]]], ["Dieses unterscheidet in der Fr\u00fchphase der Erkrankung einen \u201eL-Typ\u201c, der sich durch eine noch normale Lungen-Compliance mit reduzierter Rekrutierbarkeit sowie eine hohe Shunt-Fraktion auszeichnet, von einem sp\u00e4ter auftretenden \u201eH-Typ\u201c, der nun die klassischen Merkmale des ARDS beinhaltet [5].", [["ARDS", "DISEASE", 272, 276], ["Fr\u00fchphase der Erkrankung einen \u201eL-Typ\u201c, der sich durch eine noch normale Lungen-Compliance mit reduzierter Rekrutierbarkeit sowie eine hohe Shunt-Fraktion auszeichnet, von einem sp\u00e4ter auftretenden \u201eH-Typ\u201c, der nun die klassischen Merkmale des ARDS beinhaltet", "SPECIES", 28, 287], ["mit reduzierter", "TREATMENT", 119, 134], ["Shunt", "TREATMENT", 168, 173]]], ["M\u00f6glicherweise f\u00fchrt ein Verlust der pulmonalen Autoregulation der Durchblutung in Kombination mit einer gest\u00f6rten Mikrozirkulation bereits fr\u00fchzeitig bei dem L\u2011Typ zur signifikanten Verschlechterung der Oxygenierung.Invasive Beatmung ::: LungenversagenDen hieraus gezogenen R\u00fcckschluss, solche Patienten (L-Typ) mit eher niedrigem \u201epositive end-expiratory pressure\u201c (PEEP) und h\u00f6heren Tidalvolumina zu beatmen, erscheint aus Sicht der Autoren des vorliegenden Beitrags allerdings nicht sinnvoll [6].", [["M\u00f6glicherweise f\u00fchrt ein Verlust der pulmonalen Autoregulation der Durchblutung in Kombination mit einer gest\u00f6rten Mikrozirkulation bereits fr\u00fchzeitig bei dem L\u2011Typ zur signifikanten Verschlechterung der Oxygenierung", "SPECIES", 0, 216], ["LungenversagenDen hieraus gezogenen R\u00fcckschluss, solche Patienten (L-Typ) mit eher niedrigem \u201epositive end-expiratory pressure\u201c (PEEP) und h\u00f6heren Tidalvolumina zu beatmen, erscheint aus Sicht der Autoren des vorliegenden Beitrags allerdings nicht sinnvoll", "SPECIES", 239, 495], ["M\u00f6glicherweise f\u00fchrt ein Verlust der pulmonalen Autoregulation", "TREATMENT", 0, 62], ["Kombination mit einer gest\u00f6rten", "TREATMENT", 83, 114], ["Mikrozirkulation bereits", "TREATMENT", 115, 139], ["PEEP", "TREATMENT", 368, 372], ["Tidalvolumina zu beatmen", "TREATMENT", 386, 410]]], ["Obwohl auch bei einem Teil der Patienten eine zum Gasaustausch verh\u00e4ltnism\u00e4\u00dfige gute Compliance beobachtet werden konnte, wurde sich weiterhin an den geltenden ARDS-Empfehlungen orientiert:Invasive Beatmung ::: LungenversagenAtemzugvolumen \u22646 ml/kg ideales K\u00f6rpergewicht, Plateaudruck <30 cm H2O, angepasster PEEP nach ARDS-Network-Tabelle und ein \u201edriving pressure\u201c unter 15 cm H2O [7].Invasive Beatmung ::: LungenversagenM\u00f6glicherweise bietet die Bauchlagerung die Chance auf verh\u00e4ltnism\u00e4\u00dfig \u201ePEEP-schonende\u201c VentilationInvasive Beatmung ::: LungenversagenWenngleich die Empfehlungen zur Bauchlage laut der PROSEVA(\u201eProning in severe ARDS\u201c)-Studie nur f\u00fcr Patienten mit schwer- bis mittelgradigem ARDS (arterieller Sauerstoffpartialdruck [paO2]/inspiratorische Sauerstofffraktion [FIO2] <150 mm Hg) gilt, wurden alle beatmeten Patienten an unserer Klinik fr\u00fchzeitig f\u00fcr bis zu 48 h in die Bauchlage \u00fcberf\u00fchrt [8].", [["ARDS", "DISEASE", 160, 164], ["H2O", "CHEMICAL", 292, 295], ["ARDS", "DISEASE", 319, 323], ["H2O", "CHEMICAL", 379, 382], ["ARDS", "DISEASE", 636, 640], ["schwer- bis", "CHEMICAL", 672, 683], ["ARDS", "DISEASE", 699, 703], ["H2O", "CHEMICAL", 292, 295], ["H2O", "CHEMICAL", 379, 382], ["Hg", "CHEMICAL", 797, 799], ["LungenversagenM\u00f6glicherweise bietet die Bauchlagerung die Chance auf verh\u00e4ltnism\u00e4\u00dfig \u201ePEEP-schonende\u201c VentilationInvasive Beatmung", "SPECIES", 409, 539], ["nur f\u00fcr Patienten mit schwer- bis mittelgradigem ARDS (arterieller Sauerstoffpartialdruck [paO2]/inspiratorische Sauerstofffraktion", "SPECIES", 650, 781], ["Obwohl auch bei einem Teil der Patienten eine zum", "TREATMENT", 0, 49], ["ARDS", "PROBLEM", 160, 164], ["LungenversagenAtemzugvolumen", "TREATMENT", 211, 239], ["K\u00f6rpergewicht", "TEST", 257, 270], ["Plateaudruck", "TEST", 272, 284], ["PEEP nach ARDS", "TREATMENT", 309, 323], ["Tabelle und ein \u201edriving pressure\u201c", "TREATMENT", 332, 366], ["PEEP", "TREATMENT", 495, 499], ["severe ARDS", "PROBLEM", 629, 640], ["ARDS", "PROBLEM", 699, 703], ["Sauerstoffpartialdruck", "TEST", 717, 739], ["paO2", "TEST", 741, 745], ["inspiratorische Sauerstofffraktion", "TREATMENT", 747, 781], ["FIO2", "TEST", 783, 787], ["severe", "OBSERVATION_MODIFIER", 629, 635], ["ARDS", "OBSERVATION", 636, 640]]], ["M\u00f6glicherweise hat die dadurch bedingte Redistribution der pulmonalen Durchblutung dazu beigetragen, dass sich die Oxygenierung bei den meisten Patienten deutlich verbessert hat und verh\u00e4ltnism\u00e4\u00dfig \u201ePEEP-schonend\u201c ventiliert werden konnte.Invasive Beatmung ::: LungenversagenSollte in Einzelf\u00e4llen eine refrakt\u00e4re Hypox\u00e4mie persistieren, kann \u00fcber den Einsatz von inhalativem Stickstoffmonoxid (NO) oder in geeigneten Zentren \u00fcber die Implantation einer venoven\u00f6sen extrakorporalen Membranoxygenierung (ECMO) nachgedacht werden.Invasive Beatmung ::: LungenversagenDa es zum aktuellen Zeitpunkt keine gr\u00f6\u00dferen randomisierten Studien zur speziellen Atemtherapie bei COVID-19 gibt, leiten sich alle Empfehlungen von den Leitlinien zur invasiven Beatmung bei akuter respiratorischer Insuffizienz ab [6].Hyperinflammation. ::: COVID-19 als SystemerkrankungDa sich ein solches systemisches Inflammationsreaktionssyndrom (SIRS) erst im Verlauf und nicht bei allen Patienten entwickelt [11] ist ein standardisiertes Monitoring empfehlenswert.", [["NO", "CHEMICAL", 395, 397], ["Hyperinflammation", "DISEASE", 799, 816], ["SIRS", "DISEASE", 915, 919], ["NO", "CHEMICAL", 395, 397], ["M\u00f6glicherweise hat die dadurch bedingte Redistribution der pulmonalen Durchblutung dazu beigetragen, dass sich die Oxygenierung bei den meisten Patienten deutlich verbessert hat und verh\u00e4ltnism\u00e4\u00dfig \u201ePEEP-schonend\u201c ventiliert werden konnte", "SPECIES", 0, 238], ["LungenversagenDa es zum aktuellen Zeitpunkt keine gr\u00f6\u00dferen randomisierten Studien zur speziellen Atemtherapie bei COVID-19 gibt, leiten sich alle Empfehlungen von den Leitlinien zur invasiven Beatmung bei akuter respiratorischer Insuffizienz ab", "SPECIES", 550, 794], ["PEEP", "TREATMENT", 199, 203], ["LungenversagenSollte", "TREATMENT", 261, 281], ["Zentren", "TREATMENT", 418, 425], ["Implantation einer venoven\u00f6sen extrakorporalen Membranoxygenierung", "TREATMENT", 435, 501], ["LungenversagenDa", "TEST", 550, 566], ["Zeitpunkt", "TEST", 584, 593], ["COVID", "TEST", 664, 669], ["Hyperinflammation", "PROBLEM", 799, 816], ["COVID", "TEST", 822, 827], ["sich ein solches", "TEST", 854, 870], ["Inflammationsreaktionssyndrom (SIRS)", "PROBLEM", 884, 920]]], ["Es empfiehlt sich hierzu, bei schweren Verl\u00e4ufen von COVID-19 neben den \u00fcblichen Parametern mindestens 3\u2011malw\u00f6chentlich die Konzentrationen von IL\u20116 und Ferritin zu messen.", [["IL", "PROTEIN", 144, 146], ["Ferritin", "PROTEIN", 153, 161], ["Es empfiehlt sich hierzu, bei schweren Verl\u00e4ufen von COVID-19 neben den \u00fcblichen Parametern mindestens 3\u2011malw\u00f6chentlich die Konzentrationen von IL\u20116 und Ferritin zu messen", "SPECIES", 0, 171]]], ["Ergebnisse einer aktuellen PrePrint-MC-RCT-Studie aus dem Vereinigten K\u00f6nigreich (www.recoverytrial.net) deuten nun daraufhin, dass v. a. die beatmeten Patienten mit schwerer COVID-19-Infektion von einer Dexamethasonbehandlung (einmal 6 mg/Tag) profitieren.", [["Dexamethasonbehandlung", "CHEMICAL", 204, 226], ["Ergebnisse einer aktuellen PrePrint-MC-RCT-Studie aus dem Vereinigten K\u00f6nigreich (www.recoverytrial.net) deuten nun daraufhin, dass v. a. die beatmeten Patienten mit schwerer COVID-19-Infektion von einer Dexamethasonbehandlung (einmal 6 mg/Tag) profitieren", "SPECIES", 0, 256], ["COVID", "TEST", 175, 180], ["Dexamethasonbehandlung (einmal", "TREATMENT", 204, 234]]], ["Dexamethasonbehandelte Patienten hatten eine 35 % niedrigere Mortalit\u00e4t.", [["Dexamethasonbehandelte", "TREATMENT", 0, 22]]], ["Etwa 25 % der von den Autoren des vorliegenden Beitrags behandelten Patienten hatten zudem bei Aufnahme einen schweren Mangel an IgG, sodass empfohlen wird, einmal w\u00f6chentlich die Immunglobuline zu kontrollieren.Hyperinflammation. ::: COVID-19 als SystemerkrankungBei einem Konzentrationsanstieg des IL\u20116 >1000 ng/l und dem klinischen Bild eines SIRS wird im Einzelfall sowohl eine pharmakologische Therapie mit IL-6-Blockade als auch eine extrakorporale Zytokinelimination erwogen.", [["Hyperinflammation", "DISEASE", 212, 229], ["COVID-19 als SystemerkrankungBei einem Konzentrationsanstieg des IL\u20116 >1000 ng/l und dem klinischen Bild eines SIRS wird im Einzelfall sowohl eine pharmakologische Therapie mit IL-6-Blockade als auch eine extrakorporale", "SPECIES", 235, 454], ["Etwa", "TREATMENT", 0, 4], ["an IgG, sodass empfohlen wird", "TREATMENT", 126, 155], ["Hyperinflammation", "PROBLEM", 212, 229], ["COVID", "TEST", 235, 240], ["SystemerkrankungBei", "TEST", 248, 267], ["einem", "TEST", 268, 273], ["des IL", "TEST", 296, 302], ["Bild eines SIRS wird", "TREATMENT", 335, 355], ["im Einzelfall sowohl eine pharmakologische", "TREATMENT", 356, 398], ["mit IL", "TREATMENT", 408, 414], ["Blockade", "TREATMENT", 417, 425]]], ["Zur IL-6-Blockade und auch zu anderen immunmodulatorischen Interventionen werden weltweit mehrere gro\u00dfe randomisierte Studien durchgef\u00fchrt.", [["Zur IL", "TREATMENT", 0, 6], ["Blockade", "TREATMENT", 9, 17]]], ["Besteht eine gesicherte sekund\u00e4re HLH (mindestens 5 von 8 HLH-Kriterien positiv, [12]) muss eine noch aggressivere immunsuppressive Therapie erwogen werden.", [["HLH", "DISEASE", 34, 37], ["Besteht eine gesicherte sekund\u00e4re HLH (mindestens 5 von 8 HLH-Kriterien positiv", "SPECIES", 0, 79], ["Besteht eine gesicherte sekund\u00e4re HLH (mindestens", "TREATMENT", 0, 49], ["Kriterien positiv", "TREATMENT", 62, 79], ["muss", "TREATMENT", 87, 91]]], ["Hierzu wird bei intensivpflichtigen Patienten \u00fcblicherweise einem modifizierten Regime aus Dexamethason und IL-1-Blockade (auf das \u00fcblicherweise angewandte Etoposid verzichten die Autoren) nach einem Wiener Modell [13] gefolgt.", [["Hierzu wird bei intensivpflichtigen Patienten \u00fcblicherweise einem modifizierten Regime aus Dexamethason und IL-1-Blockade (auf das \u00fcblicherweise angewandte Etoposid verzichten die Autoren) nach einem Wiener Modell [13] gefolgt", "SPECIES", 0, 226], ["Hierzu wird bei intensivpflichtigen", "TREATMENT", 0, 35], ["\u00fcblicherweise einem modifizierten Regime", "TREATMENT", 46, 86], ["aus Dexamethason und IL", "TREATMENT", 87, 110], ["Blockade (auf das \u00fcblicherweise angewandte", "TREATMENT", 113, 155]]], ["Je nach klinischer Auspr\u00e4gung des SIRS erfolgt eine Kombination mit extrakorporaler Zytokinelimination (Adsorption oder Plasmaaustausch).Endothelsch\u00e4digung. ::: COVID-19 als SystemerkrankungObwohl es sich hier wahrscheinlich um die pathophysiologisch interessanteste Zielstruktur handelt, gibt es weder eine Routinemethodik zum Monitoring noch zur Therapie.", [["Je nach klinischer Auspr\u00e4gung des SIRS erfolgt eine Kombination mit extrakorporaler Zytokinelimination", "SPECIES", 0, 102], ["Je nach klinischer Auspr\u00e4gung des SIRS", "TREATMENT", 0, 38], ["mit extrakorporaler Zytokinelimination (Adsorption oder Plasmaaustausch", "TREATMENT", 64, 135], ["COVID", "TEST", 161, 166]]], ["Im Kontext wissenschaftlicher Untersuchungen gelang es jedoch auch, zirkulierende Sch\u00e4digungsmarker wie Von-Willebrand-Faktor (vWF), sTie2 (l\u00f6slicher Tie2-Rezeptor), und Glykokalyxspaltprodukte im Blut nachzuweisen.", [["vWF", "GENE_OR_GENE_PRODUCT", 127, 130], ["vWF", "PROTEIN", 127, 130], ["Tie2", "PROTEIN", 150, 154], ["Im Kontext wissenschaftlicher Untersuchungen gelang es jedoch auch, zirkulierende Sch\u00e4digungsmarker wie Von-Willebrand-Faktor (vWF), sTie2 (l\u00f6slicher Tie2-Rezeptor), und Glykokalyxspaltprodukte im Blut nachzuweisen", "SPECIES", 0, 214]]], ["Die h\u00e4ufig schweren Verl\u00e4ufe bei Patienten mit vorbekannter kardiovaskul\u00e4rer Begleitmorbidit\u00e4t k\u00f6nnten durch eine besondere Anf\u00e4lligkeit dieses vorgesch\u00e4digten Endothels gut erkl\u00e4rbar sein.", [["Die h\u00e4ufig schweren Verl\u00e4ufe bei Patienten mit vorbekannter kardiovaskul\u00e4rer Begleitmorbidit\u00e4t k\u00f6nnten durch eine besondere Anf\u00e4lligkeit dieses vorgesch\u00e4digten Endothels gut erkl\u00e4rbar sein", "SPECIES", 0, 188]]], ["Spezifische Therapien lassen sich hierbei allerdings (noch) nicht ableiten.Endothelsch\u00e4digung. ::: COVID-19 als SystemerkrankungIm Kontext der Ebola-Virus-Erkrankung \u2013 die ebenfalls durch eine schwere Endotheldysfunktion charakterisiert ist \u2013 wurden \u00fcber die Jahre immer wieder pleiotrope Effekte der Statine postuliert.", [["Virus", "ORGANISM", 149, 154], ["Ebola-Virus-Erkrankung \u2013 die ebenfalls durch eine schwere Endotheldysfunktion charakterisiert ist \u2013 wurden \u00fcber die Jahre immer wieder pleiotrope Effekte der Statine postuliert", "SPECIES", 143, 319], ["COVID", "TEST", 99, 104], ["SystemerkrankungIm", "TEST", 112, 130], ["Virus", "PROBLEM", 149, 154], ["Erkrankung", "PROBLEM", 155, 165]]], ["Theoretisch k\u00f6nnten diese Substanzen auch bei COVID-19 protektive Effekte vermitteln.", [["Theoretisch k\u00f6nnten diese Substanzen auch bei COVID-19 protektive Effekte vermitteln", "SPECIES", 0, 84], ["Theoretisch", "TEST", 0, 11], ["COVID", "TEST", 46, 51]]], ["Hierzu finden aktuell bereits In-vitro-Untersuchungen statt.(Hyper\u2011)Koagulopathie. ::: COVID-19 als SystemerkrankungBereits relativ fr\u00fch im Verlauf der Pandemie haben sich Berichte vermehrter Thrombosen mit teilweise fatalen Lungenarterienembolien (LAE) geh\u00e4uft [15].", [["COVID", "TEST", 87, 92], ["Verlauf der Pandemie", "TREATMENT", 140, 160], ["sich", "PROBLEM", 167, 171], ["Thrombosen mit teilweise fatalen Lungenarterienembolien (LAE)", "TREATMENT", 192, 253]]], ["Hinzu kommt die klinische Beobachtung von reduzierten Filterlaufzeiten bei kontinuierlichen Dialyseverfahren und bei ECMO-Oxygenatoren.", [["Hinzu kommt die klinische Beobachtung von reduzierten Filterlaufzeiten bei kontinuierlichen Dialyseverfahren und bei ECMO-Oxygenatoren", "SPECIES", 0, 134], ["Oxygenatoren", "TREATMENT", 122, 134]]], ["Eine Konzentrationserh\u00f6hung der Dimere ist wahrscheinlich Ausdruck einer kontinuierlichen Aktivierung des Gerinnungssystems mit entsprechender Fibrinolyse im Rahmen der Endothelsch\u00e4digung.(Hyper\u2011)Koagulopathie. ::: COVID-19 als SystemerkrankungPatienten ohne absolute KI sollten eine Antikoagulation \u00fcber das prophylaktische Ma\u00df hinaus erhalten(Hyper\u2011)Koagulopathie. ::: COVID-19 als SystemerkrankungZudem wird eine \u00dcberwachung der Thrombozyten, International Normalized Ratio [INR], des Fibrinogens und des Antithrombin III (ATIII) empfohlen.", [["Antithrombin III", "GENE_OR_GENE_PRODUCT", 508, 524], ["ATIII", "GENE_OR_GENE_PRODUCT", 526, 531], ["Antithrombin III", "PROTEIN", 508, 524], ["ATIII", "PROTEIN", 526, 531], ["Eine Konzentrationserh\u00f6hung der Dimere ist wahrscheinlich", "TREATMENT", 0, 57], ["Aktivierung des", "TREATMENT", 90, 105], ["COVID", "TEST", 215, 220], ["Patienten", "TEST", 244, 253], ["COVID", "TEST", 371, 376], ["International Normalized Ratio", "TEST", 446, 476], ["INR", "TEST", 478, 481], ["des Fibrinogens und des Antithrombin III (ATIII) empfohlen", "TREATMENT", 484, 542]]], ["Empfohlen wird von der Gesellschaft f\u00fcr Thrombose- und H\u00e4mostaseforschung eine halbtherapeutische Dosis (z.", [["Empfohlen wird von der Gesellschaft f\u00fcr Thrombose- und H\u00e4mostaseforschung eine halbtherapeutische Dosis (z.", "SPECIES", 0, 107], ["Thrombose", "TEST", 40, 49]]], ["B. mit niedermolekularem Heparin [NMH] in 2\u2011mal prophylaktischer Dosis).", [["Heparin", "CHEMICAL", 25, 32], ["NMH", "CHEMICAL", 34, 37], ["B. mit niedermolekularem", "SPECIES", 0, 24], ["B. mit niedermolekularem Heparin", "TREATMENT", 0, 32], ["NMH", "TREATMENT", 34, 37], ["2\u2011mal prophylaktischer Dosis", "TREATMENT", 42, 70]]], ["Bei akuter respiratorischer und/oder h\u00e4modynamischer Verschlechterung sollte differenzialdiagnostisch immer an eine akute LAE gedacht werden und entsprechend rasch eine Echokardiographie erfolgen.Merke ::: Nieren ::: Extrapulmonale OrganbeteiligungenKlinisch weisen laut Literatur bis zu 50 % der Patienten eine Nierenfunktionsverschlechterung im Sinne einer AKI auf, und die renale Beteiligung bei COVID-19 erh\u00f6ht die Mortalit\u00e4t um den Faktor 10 [17].Merke ::: Nieren ::: Extrapulmonale OrganbeteiligungenAls Ausdruck der Endothell\u00e4sion findet sich bei den meisten Patienten interessanterweise bereits fr\u00fch eine Mikroalbuminurie, deren pr\u00e4diktive Bedeutung als Biomarker f\u00fcr den klinischen Verlauf und das Outcome gerade multizentrisch federf\u00fchrend von der Universit\u00e4tsklinik G\u00f6ttingen untersucht wird.", [["Bei akuter respiratorischer und/oder h\u00e4modynamischer Verschlechterung sollte differenzialdiagnostisch immer an eine akute LAE gedacht werden und entsprechend rasch eine Echokardiographie erfolgen", "SPECIES", 0, 195], ["OrganbeteiligungenKlinisch weisen laut Literatur bis zu 50 % der Patienten eine Nierenfunktionsverschlechterung im Sinne einer AKI auf, und die renale Beteiligung bei COVID-19 erh\u00f6ht die Mortalit\u00e4t um den Faktor 10", "SPECIES", 232, 446], ["Extrapulmonale OrganbeteiligungenAls Ausdruck der Endothell\u00e4sion findet sich bei den meisten Patienten interessanterweise bereits fr\u00fch eine Mikroalbuminurie, deren pr\u00e4diktive Bedeutung als Biomarker f\u00fcr den klinischen Verlauf und das Outcome gerade multizentrisch federf\u00fchrend von der Universit\u00e4tsklinik G\u00f6ttingen untersucht wird", "SPECIES", 473, 802], ["Extrapulmonale OrganbeteiligungenKlinisch", "TREATMENT", 217, 258], ["AKI", "PROBLEM", 359, 362], ["Extrapulmonale OrganbeteiligungenAls", "PROBLEM", 473, 509]]], ["Studien zu Initiierung, Intensit\u00e4t und Dauer einer Nierenersatztherapie sind in Planung.Merke ::: Herz ::: Extrapulmonale OrganbeteiligungenNeu auftretende ventrikul\u00e4re Tachykardien (VT) sollten bei erh\u00f6hten Konzentrationen der kardialen Biomarker an eine Myokarditis denken lassen.Merke ::: Herz ::: Extrapulmonale OrganbeteiligungenEs ist hier auch wichtig, auf die Nebenwirkungen der medikament\u00f6sen Therapie von COVID-19 zu achten, da sowohl Hydroxychloroquin als auch Azithromycin und Lopinavir/Ritonavir, die alle zu Beginn der Pandemie h\u00e4ufig eingesetzt wurden, eine QT-Zeit-Verl\u00e4ngerung hervorrufen k\u00f6nnen.Merke ::: Nervensystem ::: Extrapulmonale OrganbeteiligungenDer Einsatz eines 2\u2011Kanal-EEG kann sowohl zum Monitoring der Sedierungstiefe als auch zur Detektion von Krampfaktivit\u00e4t empfohlen werden.Merke ::: Nervensystem ::: Extrapulmonale OrganbeteiligungenMao et al. aus Wuhan verzeichneten in ihrer Studie bei 5 % der hospitalisierten COVID-19-Patienten Schlaganf\u00e4lle; viele dieser Patienten geh\u00f6rten jedoch zur Gruppe der \u00fcber 70-J\u00e4hrigen und wiesen mehrere kardiovaskul\u00e4re Risikofaktoren auf, aber auch wieder erh\u00f6hte Konzentrationen der D\u2011Dimere als Hinweis auf eine Hyperkoagulabilit\u00e4t.", [["Extrapulmonale OrganbeteiligungenEs ist hier auch wichtig, auf die Nebenwirkungen der medikament\u00f6sen Therapie von COVID-19 zu achten, da sowohl Hydroxychloroquin als auch Azithromycin und Lopinavir/Ritonavir, die alle zu Beginn der Pandemie h\u00e4ufig eingesetzt wurden, eine QT-Zeit-Verl\u00e4ngerung hervorrufen k\u00f6nnen", "SPECIES", 301, 612], ["Extrapulmonale OrganbeteiligungenDer Einsatz eines 2\u2011Kanal-EEG kann sowohl zum Monitoring der Sedierungstiefe als auch zur Detektion von Krampfaktivit\u00e4t empfohlen werden", "SPECIES", 640, 809], ["der hospitalisierten COVID-19-Patienten Schlaganf\u00e4lle; viele dieser Patienten geh\u00f6rten jedoch zur Gruppe der \u00fcber 70-J\u00e4hrigen und wiesen mehrere kardiovaskul\u00e4re Risikofaktoren auf, aber auch wieder erh\u00f6hte Konzentrationen der D\u2011Dimere als Hinweis auf eine Hyperkoagulabilit\u00e4t", "SPECIES", 929, 1204], ["Extrapulmonale OrganbeteiligungenNeu auftretende", "TREATMENT", 107, 155], ["Tachykardien (VT", "TREATMENT", 169, 185], ["sollten bei erh\u00f6hten Konzentrationen", "TREATMENT", 187, 223], ["da sowohl Hydroxychloroquin als", "TREATMENT", 435, 466], ["Azithromycin", "TREATMENT", 472, 484], ["Lopinavir", "TREATMENT", 489, 498], ["Ritonavir", "TREATMENT", 499, 508], ["Extrapulmonale OrganbeteiligungenDer Einsatz eines", "TREATMENT", 640, 690], ["Kanal", "TEST", 693, 698], ["EEG", "TEST", 699, 702], ["COVID", "TEST", 950, 955]]], ["Eine neuere Studie aus New York dokumentierte allerdings auch bei j\u00fcngeren Patienten (<50 Jahre) Schlaganf\u00e4lle, sodass wohl alle Altersgruppen vulnerabel zu sein scheinen [28].Merke ::: Darm ::: Extrapulmonale OrganbeteiligungenDas lebensbedrohliche Krankheitsbild der nichtokklusiven mesenterialen Isch\u00e4mie (NOMI) scheint bei COVID-19 vermehrt aufzutreten.Merke ::: Darm ::: Extrapulmonale OrganbeteiligungenTats\u00e4chlich wiesen 10 % der von den Autoren behandelten Patienten einen NOMI-\u00e4hnlichen Zustand auf; in einem Kolonresektat lie\u00df sich elektronenmikroskopisch auch noch Wochen nach der Initialerkrankung SARS-CoV\u20112 im Endothel des Darms nachweisen (unver\u00f6ffentlichte eigene Daten).Antivirale und immunmodulatorische TherapieZusammenfassend gibt es bisher wenig Evidenz f\u00fcr den Einsatz spezifischer oder adjuvanter Therapien.", [["OrganbeteiligungenDas lebensbedrohliche Krankheitsbild der nichtokklusiven mesenterialen Isch\u00e4mie (NOMI) scheint bei COVID-19 vermehrt aufzutreten", "SPECIES", 210, 356], ["von den Autoren behandelten Patienten einen NOMI-\u00e4hnlichen Zustand auf; in einem Kolonresektat lie\u00df sich elektronenmikroskopisch auch noch Wochen nach der Initialerkrankung SARS-CoV\u20112 im Endothel des Darms nachweisen (unver\u00f6ffentlichte eigene Daten", "SPECIES", 437, 685], ["Extrapulmonale", "TEST", 195, 209], ["scheint bei COVID", "TREATMENT", 315, 332], ["Extrapulmonale OrganbeteiligungenTats\u00e4chlich wiesen", "TREATMENT", 376, 427], ["Antivirale", "TREATMENT", 687, 697]]], ["Prinzipiell gilt jedoch bei aller therapeutischer Not auch w\u00e4hrend einer Pandemie der Leitsatz \u201efirst do no harm\u201c.", [["Prinzipiell gilt jedoch bei aller therapeutischer Not auch w\u00e4hrend einer Pandemie der Leitsatz \u201efirst", "SPECIES", 0, 101], ["Prinzipiell gilt jedoch", "TREATMENT", 0, 23]]], ["In Tab.", [["Tab", "PROTEIN", 3, 6]]], ["2 sind einige Therapieoptionen mit aktueller Bewertung, Empfehlung und einem kurzen Kommentar der Autoren aufgelistet.Antivirale und immunmodulatorische TherapiePrinzipiell gilt trotz aller therapeutischer Not der Leitsatz \u201eprimum non nocere\u201cAntivirale und immunmodulatorische TherapieBesonders erw\u00e4hnenswert sind die oben bereits angesprochene Therapie mit Dexamethason bei der s(schweren)COVID-19-Erkrankung und die virostatische Therapie mit Remdesivir, f\u00fcr deren Einsatz die Evidenz derzeit am besten ist.", [["TherapiePrinzipiell gilt trotz aller therapeutischer Not der Leitsatz \u201eprimum non nocere\u201c", "SPECIES", 153, 242], ["TherapieBesonders erw\u00e4hnenswert sind die oben bereits angesprochene Therapie mit Dexamethason bei der s(schweren)COVID-19-Erkrankung und die virostatische Therapie mit Remdesivir, f\u00fcr deren Einsatz die Evidenz derzeit am besten", "SPECIES", 277, 504], ["Antivirale und immunmodulatorische TherapiePrinzipiell gilt", "TREATMENT", 118, 177], ["Antivirale und immunmodulatorische TherapieBesonders", "TREATMENT", 242, 294], ["COVID", "TEST", 390, 395]]], ["Remdesivir, das urspr\u00fcnglich zur Behandlung der Ebola-Virus-Infektion entwickelt wurde, hat in einer gro\u00dfen randomisierten Studie zwar kein verbessertes \u00dcberleben, aber eine Verk\u00fcrzung der Beatmungsdauer von 15 auf 11 Tage zeigen k\u00f6nnen.Fazit f\u00fcr die Praxis", [["Ebola-Virus-Infektion entwickelt wurde, hat in einer gro\u00dfen randomisierten Studie zwar kein verbessertes \u00dcberleben, aber eine Verk\u00fcrzung der Beatmungsdauer von 15 auf 11 Tage zeigen k\u00f6nnen", "SPECIES", 48, 236], ["Remdesivir", "TREATMENT", 0, 10], ["Infektion", "PROBLEM", 60, 69]]]], "42d591ee60f6c593530251494f9cb93a23221082": [["Severe acute respiratory syndrome (SARS) was the first major novel infectious disease to hit the international community in the 21st century.", [["acute respiratory syndrome", "DISEASE", 7, 33], ["SARS", "DISEASE", 35, 39], ["Severe acute respiratory syndrome", "PROBLEM", 0, 33], ["SARS", "PROBLEM", 35, 39], ["novel infectious disease", "PROBLEM", 61, 85], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome", "OBSERVATION", 13, 33], ["infectious", "OBSERVATION", 67, 77]]], ["1 It alarmed the world with its high infectivity and significant mortality; the lack of a rapid, reliable diagnostic test; and the lack of effective specific treatment and vaccination.", [["its high infectivity", "PROBLEM", 28, 48], ["diagnostic test", "TEST", 106, 121], ["effective specific treatment", "TREATMENT", 139, 167], ["vaccination", "TREATMENT", 172, 183]]], ["1 A prominent feature of SARS was nosocomial clustering with transmission to health care workers, patients, and visitors.", [["SARS", "DISEASE", 25, 29], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["SARS", "PROBLEM", 25, 29], ["prominent", "OBSERVATION_MODIFIER", 4, 13], ["SARS", "OBSERVATION", 25, 29]]], ["Until the outbreak struck Hong Kong's and Taiwan's hospitals, it had not yet been identified as a dangerous disease.", [["a dangerous disease", "PROBLEM", 96, 115], ["dangerous", "OBSERVATION_MODIFIER", 98, 107], ["disease", "OBSERVATION", 108, 115]]], ["[2] [3] [4] [5] [6] Hospital outbreaks of SARS typically occurred within the first week after admission of the very first SARS cases.", [["SARS", "DISEASE", 42, 46], ["SARS", "DISEASE", 122, 126], ["[2] [3] [4] [5] [6", "SIMPLE_CHEMICAL", 0, 18], ["SARS", "PROBLEM", 42, 46]]]], "PMC7295850": [["IntroductionDuring the SARS-CoV2 pandemic many doctors and nurses have been reluctant to provide care to COVID-19 patients.", [["SARS-CoV2 pandemic", "DISEASE", 23, 41], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122]]], ["The UK\u2019s doctors\u2019 leaders have warned repeatedly that the lack of appropriate PPE puts doctors\u2019 lives at risk.1 PPE levels in Australia\u2019s state of Queensland were very low, noted the state\u2019s Clinical Senate Chair Alex Markwell.2 Bulgaria has seen a wave of doctors and nurses resigning at two hospitals in the country\u2019s capital3 over the lack of access to PPE, Zimbabwean doctors and nurses have reportedly gone on strike over the lack of protective equipment,4 and nurses across the USA have protested about the lack of PPE.5 These healthcare workers had every reason to be concerned for their own well-being.", [["UK", "GENE_OR_GENE_PRODUCT", 4, 6], ["1 PPE levels", "TEST", 110, 122]]], ["At the time of writing 100 doctors who provided care to Italian COVID-19 patients have died as a result of contracting SARS-CoV2 on the job.6 Many more have fallen very seriously sick.", [["SARS", "DISEASE", 119, 123], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["contracting SARS", "PROBLEM", 107, 123]]], ["A list of \u2018Fallen Coronavirus Heroes\u2019 maintained by Michael C Gibson, a medical doctor, lists (on 5 April 2020) 136 healthcare professionals who lost their lives as a result of COVID-19 infections they acquired while caring for infected patients.7 The number is now almost certainly significantly higher, and it is bound to increase daily for some time to come.", [["infections", "DISEASE", 186, 196], ["patients", "ORGANISM", 237, 245], ["patients", "SPECIES", 237, 245], ["COVID-19 infections", "PROBLEM", 177, 196], ["number", "OBSERVATION_MODIFIER", 252, 258], ["significantly", "OBSERVATION_MODIFIER", 283, 296], ["higher", "OBSERVATION_MODIFIER", 297, 303]]], ["Despite some effort I have failed to track down a list looking at COVID-19 care-related deaths of other healthcare workers, such as nurses.", [["deaths", "DISEASE", 88, 94]]], ["However, there can be no doubt that the death toll among healthcare professionals caring for COVID-19 patients all over the world will be significant.IntroductionIn response to concerns about the availability of healthcare professionals during expected COVID-19 case surges, a state government in one of Germany\u2019s most populous states, North-Rhine Westphalia, seriously considered introducing a compulsory service obligation for healthcare professionals.8 Little did doctors know, when they joined the profession, that at some point further down the road, government would be planning to draft them into compulsory service, much like soldiers.", [["death", "DISEASE", 40, 45], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["COVID", "TREATMENT", 93, 98], ["no doubt", "UNCERTAINTY", 22, 30]]], ["Desperate governments around the globe have come up with their own policies and ethics documents looking at the question of whether healthcare workers have a professional duty of care under the circumstances.", [["globe", "ANATOMY", 33, 38]]], ["In all earnestness the Canadian province of British Columbia issued an ethics document that, while arguably producing conflicting guidance, could be interpreted as the view that healthcare workers do have an obligation to provide care if and only if they do not face \u2018certain and significant harm\u2019.9 The guidance is based on a pandemic influenza ethical guidance document10 that shows a flaw that is replicated in many other documents of this kind.11 It proffers a collection of disparate ethical values to consider, a vegetable garden equivalent of values, for you to pick and choose the ones that sound nicest.", [["influenza", "DISEASE", 336, 345], ["a pandemic influenza ethical guidance", "TREATMENT", 325, 362], ["collection", "OBSERVATION_MODIFIER", 465, 475]]], ["As patients we depend on doctors and nurses to provide professional care to us, because they have the specialist training, and they have a monopoly on the provision of these kinds of services.", [["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11]]], ["Until the 1994 version of that influential document, doctors promised to provide emergency care, without any ifs, ands or buts.", [["emergency care", "TREATMENT", 81, 95]]], ["However, that promise has not been repeated in subsequent iterations of that document,13 so that approach does not address the question at hand.", [["hand", "ORGANISM_SUBDIVISION", 139, 143]]], ["As Ariel R Schwartz notes, \u2018the history of medical ethics reveals that the medical community has never come to a consensus on the nature and scope of its responsibilities during an epidemic\u2019.14 His description of the behaviour of doctors during infectious disease outbreaks from the black plague in the 14th and 15th centuries to the bubonic plague in the 17th century suggests a deeply individualistic response.", [["infectious disease outbreaks", "DISEASE", 245, 273], ["bubonic", "DISEASE", 334, 341], ["infectious disease outbreaks", "PROBLEM", 245, 273], ["bubonic", "OBSERVATION_MODIFIER", 334, 341], ["plague", "OBSERVATION", 342, 348]]], ["Many ran away to protect themselves; others stayed behind to care for their patients.", [["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84]]], ["The same pattern of behaviour held true during the 2014-16 Ebola virus disease outbreaks in West African countries.What healthcare professionals owe usNeither the history of how healthcare professionals responded in the past to pandemic outbreaks, nor their professed values, provide us with much guidance on what the professionals themselves take to be their professional obligations.", [["Ebola virus disease", "DISEASE", 59, 78], ["Ebola virus", "ORGANISM", 59, 70], ["Ebola virus", "SPECIES", 59, 70], ["Ebola virus", "SPECIES", 59, 70], ["16 Ebola virus disease outbreaks", "PROBLEM", 56, 88]]], ["Medical associations, unlike statutory regulatory bodies, despite protestations to the contrary, are essentially glorified trade unions representing their members\u2019 interests.", [["regulatory bodies", "OBSERVATION", 39, 56]]]], "e283c964691d950836fd62790ff4c032b8b1a56a": [["IntroductionPorcine reproductive and respiratory syndrome (PRRS) is the most economically important infectious disease for the swine industry worldwide.", [["IntroductionPorcine reproductive and respiratory syndrome", "DISEASE", 0, 57], ["PRRS", "DISEASE", 59, 63], ["PRRS", "SPECIES", 59, 63], ["swine", "SPECIES", 127, 132], ["PRRS", "SPECIES", 59, 63], ["swine", "SPECIES", 127, 132], ["IntroductionPorcine reproductive", "PROBLEM", 0, 32], ["respiratory syndrome", "PROBLEM", 37, 57], ["respiratory syndrome", "OBSERVATION", 37, 57], ["infectious", "OBSERVATION", 100, 110]]], ["PRRS is characterized by reproductive failure in sows and respiratory disease in pigs of all ages [1, 2] .", [["respiratory", "ANATOMY", 58, 69], ["PRRS", "DISEASE", 0, 4], ["reproductive failure", "DISEASE", 25, 45], ["respiratory disease", "DISEASE", 58, 77], ["sows", "ORGANISM_SUBDIVISION", 49, 53], ["pigs", "ORGANISM", 81, 85], ["pigs", "SPECIES", 81, 85], ["PRRS", "SPECIES", 0, 4], ["pigs", "SPECIES", 81, 85], ["reproductive failure", "PROBLEM", 25, 45], ["respiratory disease", "PROBLEM", 58, 77], ["reproductive", "OBSERVATION_MODIFIER", 25, 37], ["failure", "OBSERVATION", 38, 45], ["respiratory disease", "OBSERVATION", 58, 77]]], ["The annual loss associated with PRRS is approximately 664 million USD, as estimated by swine producers in the United States [3] .", [["PRRS", "DISEASE", 32, 36], ["PRRS", "SPECIES", 32, 36], ["swine", "SPECIES", 87, 92], ["The annual loss", "PROBLEM", 0, 15], ["annual loss", "OBSERVATION", 4, 15]]], ["PRRS virus (PRRSV) is a member of the Arteriviridae virus family in the order Nidovirales, along with equine arteritis virus (EAV), murine lactate dehydrogenase-elevating virus (LDV), and simian hemorrhagic fever virus (SHFV) [4, 5] .", [["PRRS virus", "DISEASE", 0, 10], ["equine arteritis", "DISEASE", 102, 118], ["lactate", "CHEMICAL", 139, 146], ["simian hemorrhagic fever", "DISEASE", 188, 212], ["lactate", "CHEMICAL", 139, 146], ["PRRS virus", "ORGANISM", 0, 10], ["PRRSV", "ORGANISM", 12, 17], ["Arteriviridae virus", "ORGANISM", 38, 57], ["Nidovirales", "GENE_OR_GENE_PRODUCT", 78, 89], ["equine arteritis virus", "ORGANISM", 102, 124], ["EAV", "ORGANISM", 126, 129], ["murine", "ORGANISM", 132, 138], ["lactate dehydrogenase-elevating virus", "ORGANISM", 139, 176], ["LDV", "ORGANISM", 178, 181], ["simian hemorrhagic fever virus", "ORGANISM", 188, 218], ["murine lactate dehydrogenase", "PROTEIN", 132, 160], ["PRRS virus", "SPECIES", 0, 10], ["PRRSV", "SPECIES", 12, 17], ["Arteriviridae virus", "SPECIES", 38, 57], ["equine arteritis virus", "SPECIES", 102, 124], ["murine", "SPECIES", 132, 138], ["simian hemorrhagic fever virus", "SPECIES", 188, 218], ["PRRS virus", "SPECIES", 0, 10], ["PRRSV", "SPECIES", 12, 17], ["equine arteritis virus", "SPECIES", 102, 124], ["EAV", "SPECIES", 126, 129], ["LDV", "SPECIES", 178, 181], ["simian hemorrhagic fever virus", "SPECIES", 188, 218], ["SHFV", "SPECIES", 220, 224], ["PRRS virus", "PROBLEM", 0, 10], ["Nidovirales", "TREATMENT", 78, 89], ["equine arteritis virus", "PROBLEM", 102, 124], ["murine lactate dehydrogenase", "TEST", 132, 160], ["elevating virus", "PROBLEM", 161, 176], ["simian hemorrhagic fever virus", "PROBLEM", 188, 218], ["hemorrhagic", "OBSERVATION_MODIFIER", 195, 206]]], ["PRRSV is a small, enveloped virus with a single-stranded, nonsegmented, positive-sense RNA genome that is approximately 15 kb in length [5, 6] .", [["PRRSV", "ORGANISM", 0, 5], ["nonsegmented, positive-sense RNA genome", "DNA", 58, 97], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "PROBLEM", 0, 5], ["a small, enveloped virus", "PROBLEM", 9, 33], ["a single-stranded, nonsegmented, positive-sense RNA genome", "PROBLEM", 39, 97], ["small", "OBSERVATION_MODIFIER", 11, 16], ["enveloped", "OBSERVATION_MODIFIER", 18, 27], ["virus", "OBSERVATION", 28, 33], ["RNA genome", "OBSERVATION", 87, 97], ["approximately", "OBSERVATION_MODIFIER", 106, 119], ["15 kb", "OBSERVATION_MODIFIER", 120, 125]]], ["The genome of PRRSV encodes at least ten open reading frames (ORFs) called ORF1a, ORF1b, ORF2a, ORF2b, ORF3, ORF4, ORF5a, ORF5, ORF6, and ORF7 [7, 8] .", [["PRRSV", "ORGANISM", 14, 19], ["ORF1a", "GENE_OR_GENE_PRODUCT", 75, 80], ["ORF1b", "GENE_OR_GENE_PRODUCT", 82, 87], ["ORF2a", "GENE_OR_GENE_PRODUCT", 89, 94], ["ORF2b", "GENE_OR_GENE_PRODUCT", 96, 101], ["ORF3", "GENE_OR_GENE_PRODUCT", 103, 107], ["ORF4", "GENE_OR_GENE_PRODUCT", 109, 113], ["ORF5a", "GENE_OR_GENE_PRODUCT", 115, 120], ["ORF5", "GENE_OR_GENE_PRODUCT", 122, 126], ["ORF6", "GENE_OR_GENE_PRODUCT", 128, 132], ["ORF7", "GENE_OR_GENE_PRODUCT", 138, 142], ["open reading frames", "DNA", 41, 60], ["ORFs", "DNA", 62, 66], ["ORF1a", "DNA", 75, 80], ["ORF1b", "DNA", 82, 87], ["ORF2a", "DNA", 89, 94], ["ORF2b", "DNA", 96, 101], ["ORF3", "DNA", 103, 107], ["ORF4", "DNA", 109, 113], ["ORF5a", "DNA", 115, 120], ["ORF5", "DNA", 122, 126], ["ORF6", "DNA", 128, 132], ["ORF7", "DNA", 138, 142], ["PRRSV", "SPECIES", 14, 19], ["PRRSV", "SPECIES", 14, 19], ["ORF5", "TEST", 122, 126], ["ORF6", "TEST", 128, 132], ["ORF7", "TEST", 138, 142]]], ["PRRSVs used to be grouped into European (type 1) and North American (type 2) genotypes, but currently classified as two species, betaarterivirus suid 1 and betaarterivirus suid 2, respectively.", [["PRRSVs", "PROTEIN", 0, 6], ["PRRSVs", "TREATMENT", 0, 6], ["genotypes", "PROBLEM", 77, 86], ["betaarterivirus suid", "TREATMENT", 129, 149]]], ["There is substantial genetic and antigenic variation among PRRSV strains, even within the same virus species [9, 10] .", [["PRRSV", "ORGANISM", 59, 64], ["PRRSV", "SPECIES", 59, 64], ["substantial genetic and antigenic variation", "PROBLEM", 9, 52], ["PRRSV strains", "PROBLEM", 59, 72], ["substantial", "OBSERVATION_MODIFIER", 9, 20], ["genetic", "OBSERVATION_MODIFIER", 21, 28], ["antigenic variation", "OBSERVATION", 33, 52], ["PRRSV strains", "OBSERVATION", 59, 72]]], ["Since the first emergence of PRRS more than two decades ago, numerous efforts have been made to develop an effective control measure for this challenging disease.", [["PRRS", "DISEASE", 29, 33], ["PRRS", "SPECIES", 29, 33], ["this challenging disease", "PROBLEM", 137, 161]]], ["Currently, vaccination is the primary control method, and is widely used to control PRRS in pigs.", [["PRRS", "DISEASE", 84, 88], ["PRRS", "ORGANISM", 84, 88], ["pigs", "ORGANISM", 92, 96], ["pigs", "SPECIES", 92, 96], ["PRRS", "SPECIES", 84, 88], ["pigs", "SPECIES", 92, 96], ["vaccination", "TREATMENT", 11, 22]]], ["However, the use of commercial vaccines with either modified live virus (MLV) or killed virus is inadequate to control PRRSV infection [11] because of the highly divergent PRRSV strains in the field.", [["PRRSV infection", "DISEASE", 119, 134], ["modified live virus", "ORGANISM", 52, 71], ["MLV", "ORGANISM", 73, 76], ["PRRSV", "ORGANISM", 119, 124], ["PRRSV", "ORGANISM", 172, 177], ["PRRSV", "SPECIES", 119, 124], ["MLV", "SPECIES", 73, 76], ["PRRSV", "SPECIES", 119, 124], ["PRRSV", "SPECIES", 172, 177], ["commercial vaccines", "TREATMENT", 20, 39], ["modified live virus (MLV", "TREATMENT", 52, 76], ["killed virus", "PROBLEM", 81, 93], ["PRRSV infection", "PROBLEM", 119, 134], ["the highly divergent PRRSV strains", "PROBLEM", 151, 185], ["PRRSV strains", "OBSERVATION", 172, 185]]], ["Antiviral therapeutics could be an alternative or additional control measure to combat these viral infections when a successful vaccine that matches the circulating virus is not available.", [["viral infections", "DISEASE", 93, 109], ["Antiviral therapeutics", "TREATMENT", 0, 22], ["an alternative", "TREATMENT", 32, 46], ["additional control measure", "TREATMENT", 50, 76], ["these viral infections", "PROBLEM", 87, 109], ["a successful vaccine", "TREATMENT", 115, 135], ["the circulating virus", "PROBLEM", 149, 170]]], ["Therefore, pharmacological intervention might be a suitable and useful control strategy for PRRS.", [["PRRS", "DISEASE", 92, 96], ["PRRS", "ORGANISM", 92, 96], ["PRRS", "SPECIES", 92, 96], ["pharmacological intervention", "TREATMENT", 11, 39], ["PRRS", "PROBLEM", 92, 96]]], ["Many previous studies reported that a variety of natural compounds had been proven to exert antiviral activity against a number of viruses, such as equine herpesvirus 1 (EHV-1) [12] , hepatitis B virus [13] , human cytomegalovirus (HCMV) [14] , and respiratory infections including the common cold [15] and PRRSV [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] .", [["respiratory", "ANATOMY", 249, 260], ["hepatitis B", "DISEASE", 184, 195], ["human cytomegalovirus (HCMV)", "DISEASE", 209, 237], ["respiratory infections", "DISEASE", 249, 271], ["equine herpesvirus 1", "ORGANISM", 148, 168], ["EHV-1) [12] ,", "ORGANISM", 170, 183], ["hepatitis B virus [13]", "ORGANISM", 184, 206], ["human cytomegalovirus", "ORGANISM", 209, 230], ["HCMV", "ORGANISM", 232, 236], ["PRRSV", "ORGANISM", 307, 312], ["[16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29]", "SIMPLE_CHEMICAL", 313, 382], ["equine herpesvirus 1", "SPECIES", 148, 168], ["EHV-1", "SPECIES", 170, 175], ["hepatitis B virus", "SPECIES", 184, 201], ["human", "SPECIES", 209, 214], ["cytomegalovirus", "SPECIES", 215, 230], ["equine herpesvirus 1", "SPECIES", 148, 168], ["EHV-1", "SPECIES", 170, 175], ["hepatitis B virus", "SPECIES", 184, 201], ["human cytomegalovirus", "SPECIES", 209, 230], ["HCMV", "SPECIES", 232, 236], ["Many previous studies", "TEST", 0, 21], ["natural compounds", "TREATMENT", 49, 66], ["a number of viruses", "PROBLEM", 119, 138], ["equine herpesvirus", "TEST", 148, 166], ["EHV", "TEST", 170, 173], ["hepatitis B virus", "PROBLEM", 184, 201], ["human cytomegalovirus (HCMV)", "PROBLEM", 209, 237], ["respiratory infections", "PROBLEM", 249, 271], ["PRRSV", "TEST", 307, 312], ["antiviral activity", "OBSERVATION", 92, 110], ["viruses", "OBSERVATION", 131, 138], ["respiratory", "ANATOMY", 249, 260], ["infections", "OBSERVATION", 261, 271]]], ["However, no such effective drugs are commercially available to prevent PRRSV infection.", [["PRRSV infection", "DISEASE", 71, 86], ["PRRSV", "ORGANISM", 71, 76], ["PRRSV", "SPECIES", 71, 76], ["such effective drugs", "TREATMENT", 12, 32], ["PRRSV infection", "PROBLEM", 71, 86], ["no", "UNCERTAINTY", 9, 11], ["infection", "OBSERVATION", 77, 86]]], ["Chalcones (1,3-diaryl-2-propen-1-ones), which constitute a key class of natural products belonging to the Flavonoid family [30] [31] [32] [33] , were previously reported to have a wide range of biological activities, such as antiviral, antibacterial, antifungal, immunomodulatory, anti-inflammatory, antitumor, insect antifeedant, and antimutagenic activities [31] [32] [33] [34] [35] [36] [37] [38] .", [["antitumor", "ANATOMY", 300, 309], ["Chalcones", "CHEMICAL", 0, 9], ["1,3-diaryl-2-propen-1-ones", "CHEMICAL", 11, 37], ["[30] [31] [32] [33]", "CHEMICAL", 123, 142], ["Chalcones", "CHEMICAL", 0, 9], ["1,3-diaryl-2-propen-1-ones", "CHEMICAL", 11, 37], ["Flavonoid", "CHEMICAL", 106, 115], ["Chalcones", "SIMPLE_CHEMICAL", 0, 9], ["1,3-diaryl-2-propen-1-ones", "SIMPLE_CHEMICAL", 11, 37], ["[30] [31] [32] [33]", "SIMPLE_CHEMICAL", 123, 142], ["antitumor", "CANCER", 300, 309], ["[31] [32] [33] [34] [35] [36] [37] [38]", "SIMPLE_CHEMICAL", 360, 399], ["Chalcones", "TREATMENT", 0, 9], ["diaryl", "TREATMENT", 15, 21], ["antiviral, antibacterial", "TREATMENT", 225, 249], ["antifungal", "TREATMENT", 251, 261], ["immunomodulatory", "TREATMENT", 263, 279], ["anti-inflammatory", "TREATMENT", 281, 298], ["antimutagenic activities", "TEST", 335, 359]]], ["Thus, the present study aimed to evaluate the antiviral effects of DiNap [(E)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(naphthalen-1-yl)prop-2-en-1-one], a synthetic analog of the chalcone flavokawain, on PRRSV replication in cell culture systems.", [["cell culture", "ANATOMY", 221, 233], ["DiNap [(E)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(naphthalen-1-yl)prop-2-en-1-one", "CHEMICAL", 67, 146], ["flavokawain", "CHEMICAL", 184, 195], ["DiNap", "CHEMICAL", 67, 72], ["(E)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(naphthalen-1-yl)prop-2-en-1-one", "CHEMICAL", 74, 146], ["chalcone", "CHEMICAL", 175, 183], ["flavokawain", "CHEMICAL", 184, 195], ["DiNap [(E)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(naphthalen-1-yl)prop-2-en-1-one", "SIMPLE_CHEMICAL", 67, 146], ["chalcone flavokawain", "SIMPLE_CHEMICAL", 175, 195], ["PRRSV", "ORGANISM", 200, 205], ["cell", "CELL", 221, 225], ["PRRSV", "SPECIES", 200, 205], ["the present study", "TEST", 6, 23], ["DiNap [(E)", "TREATMENT", 67, 77], ["-dimethoxyphenyl", "TREATMENT", 94, 110], ["a synthetic analog of the chalcone flavokawain", "TREATMENT", 149, 195], ["PRRSV replication", "TREATMENT", 200, 217]]], ["A study was then carried out in a pig model to demonstrate the inhibitory effects of DiNap on PRRSV infection.ChemistryThe synthesis of the flavokawain analog DiNap is presented in Scheme 1, which began with the preparation 2-hydroxy-4,6-dimethoxyacetophenone (2).", [["DiNap", "CHEMICAL", 85, 90], ["PRRSV infection", "DISEASE", 94, 109], ["flavokawain", "CHEMICAL", 140, 151], ["DiNap", "CHEMICAL", 159, 164], ["2-hydroxy-4,6-dimethoxyacetophenone", "CHEMICAL", 224, 259], ["flavokawain", "CHEMICAL", 140, 151], ["DiNap", "CHEMICAL", 159, 164], ["2-hydroxy-4,6-dimethoxyacetophenone", "CHEMICAL", 224, 259], ["pig", "ORGANISM", 34, 37], ["DiNap", "SIMPLE_CHEMICAL", 85, 90], ["PRRSV", "ORGANISM", 94, 99], ["flavokawain", "SIMPLE_CHEMICAL", 140, 151], ["DiNap", "SIMPLE_CHEMICAL", 159, 164], ["2-hydroxy-4,6-dimethoxyacetophenone (2)", "SIMPLE_CHEMICAL", 224, 263], ["PRRSV", "SPECIES", 94, 99], ["pig", "SPECIES", 34, 37], ["PRRSV", "SPECIES", 94, 99], ["A study", "TEST", 0, 7], ["a pig model", "TREATMENT", 32, 43], ["DiNap", "PROBLEM", 85, 90], ["PRRSV infection", "PROBLEM", 94, 109], ["hydroxy", "TEST", 226, 233], ["dimethoxyacetophenone", "TREATMENT", 238, 259], ["PRRSV infection", "OBSERVATION", 94, 109]]], ["Compound 2 was quantitatively obtained from the reaction of 2,4,6-trihydroacetophenone (1) with dimethyl sulfate in the presence of potassium carbonate in acetone.", [["2,4,6-trihydroacetophenone", "CHEMICAL", 60, 86], ["dimethyl sulfate", "CHEMICAL", 96, 112], ["potassium carbonate", "CHEMICAL", 132, 151], ["acetone", "CHEMICAL", 155, 162], ["2,4,6-trihydroacetophenone", "CHEMICAL", 60, 86], ["dimethyl sulfate", "CHEMICAL", 96, 112], ["potassium carbonate", "CHEMICAL", 132, 151], ["acetone", "CHEMICAL", 155, 162], ["2,4,6-trihydroacetophenone (1)", "SIMPLE_CHEMICAL", 60, 90], ["dimethyl sulfate", "SIMPLE_CHEMICAL", 96, 112], ["potassium carbonate", "SIMPLE_CHEMICAL", 132, 151], ["acetone", "SIMPLE_CHEMICAL", 155, 162], ["the reaction", "TEST", 44, 56], ["trihydroacetophenone", "TREATMENT", 66, 86], ["dimethyl sulfate", "TREATMENT", 96, 112], ["potassium carbonate in acetone", "TREATMENT", 132, 162]]], ["The corresponding acetophenone 2 was then subjected to the Claisen-Schmidt condensation reaction with 1-naphthaldehyde (3) in the presence of potassium hydroxide in methanol to provide flavokawain analogs (DiNap) with a yield of 32%.", [["acetophenone", "CHEMICAL", 18, 30], ["1-naphthaldehyde", "CHEMICAL", 102, 118], ["potassium hydroxide", "CHEMICAL", 142, 161], ["flavokawain", "CHEMICAL", 185, 196], ["DiNap", "CHEMICAL", 206, 211], ["acetophenone", "CHEMICAL", 18, 30], ["1-naphthaldehyde", "CHEMICAL", 102, 118], ["potassium hydroxide", "CHEMICAL", 142, 161], ["methanol", "CHEMICAL", 165, 173], ["flavokawain", "CHEMICAL", 185, 196], ["acetophenone 2", "SIMPLE_CHEMICAL", 18, 32], ["1-naphthaldehyde (3)", "SIMPLE_CHEMICAL", 102, 122], ["potassium hydroxide", "SIMPLE_CHEMICAL", 142, 161], ["methanol", "SIMPLE_CHEMICAL", 165, 173], ["flavokawain analogs", "SIMPLE_CHEMICAL", 185, 204], ["DiNap", "SIMPLE_CHEMICAL", 206, 211], ["The corresponding acetophenone", "TREATMENT", 0, 30], ["Schmidt condensation reaction", "PROBLEM", 67, 96], ["potassium hydroxide in methanol", "TREATMENT", 142, 173], ["flavokawain analogs", "TREATMENT", 185, 204]]], ["Synthesis of (E)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(naphthalen-1-yl)prop-2-en-1-one (DiNap).In Vitro Evaluation of the Effects of DiNap on PRRSV ReplicationThe antiviral effect of DiNap on PRRSV replication was evaluated in MARC-145 cells and porcine alveolar macrophages (PAMs).", [["MARC-145 cells", "ANATOMY", 226, 240], ["alveolar macrophages", "ANATOMY", 253, 273], ["PAMs", "ANATOMY", 275, 279], ["E)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(naphthalen-1-yl)prop-2-en-1-one", "CHEMICAL", 14, 85], ["DiNap", "CHEMICAL", 87, 92], ["DiNap", "CHEMICAL", 132, 137], ["DiNap", "CHEMICAL", 182, 187], ["(E)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(naphthalen-1-yl)prop-2-en-1-one", "CHEMICAL", 13, 85], ["DiNap", "CHEMICAL", 87, 92], ["DiNap", "CHEMICAL", 132, 137], ["DiNap", "CHEMICAL", 182, 187], ["(E)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(naphthalen-1-yl)prop-2-en-1-one", "SIMPLE_CHEMICAL", 13, 85], ["DiNap", "SIMPLE_CHEMICAL", 87, 92], ["DiNap", "SIMPLE_CHEMICAL", 132, 137], ["PRRSV", "ORGANISM", 141, 146], ["DiNap", "SIMPLE_CHEMICAL", 182, 187], ["PRRSV", "ORGANISM", 191, 196], ["MARC-145 cells", "CELL", 226, 240], ["porcine", "ORGANISM", 245, 252], ["alveolar macrophages", "CELL", 253, 273], ["PAMs", "CELL", 275, 279], ["DiNap", "PROTEIN", 182, 187], ["MARC-145 cells", "CELL_LINE", 226, 240], ["porcine alveolar macrophages", "CELL_TYPE", 245, 273], ["PAMs", "CELL_TYPE", 275, 279], ["PRRSV", "SPECIES", 191, 196], ["porcine", "SPECIES", 245, 252], ["PRRSV", "SPECIES", 141, 146], ["PRRSV", "SPECIES", 191, 196], ["MARC-145", "SPECIES", 226, 234], ["Synthesis", "TEST", 0, 9], ["E)", "TEST", 14, 16], ["hydroxy", "TEST", 22, 29], ["dimethoxyphenyl", "TREATMENT", 34, 49], ["Vitro Evaluation", "TEST", 97, 113], ["DiNap", "TREATMENT", 132, 137], ["PRRSV Replication", "TREATMENT", 141, 158], ["The antiviral effect", "TREATMENT", 158, 178], ["DiNap", "TREATMENT", 182, 187], ["PRRSV replication", "TREATMENT", 191, 208], ["porcine alveolar macrophages", "TREATMENT", 245, 273], ["alveolar macrophages", "OBSERVATION", 253, 273]]], ["DiNap reduced VR2332 replication in both cell lines in a dose-dependent manner ( Figure 1 ).", [["cell lines", "ANATOMY", 41, 51], ["DiNap", "CHEMICAL", 0, 5], ["VR2332", "CHEMICAL", 14, 20], ["DiNap", "SIMPLE_CHEMICAL", 0, 5], ["VR2332", "SIMPLE_CHEMICAL", 14, 20], ["cell lines", "CELL", 41, 51], ["VR2332", "DNA", 14, 20], ["cell lines", "CELL_LINE", 41, 51], ["DiNap", "TREATMENT", 0, 5], ["both cell lines", "TREATMENT", 36, 51], ["both cell lines", "OBSERVATION", 36, 51]]], ["In MARC-145 cells, VR2332 replication was decreased by approximately 10-or 1000-fold in the presence of DiNap at concentrations of 0.02 or 0.04 mM, respectively.", [["MARC-145 cells", "ANATOMY", 3, 17], ["VR2332", "CHEMICAL", 19, 25], ["DiNap", "CHEMICAL", 104, 109], ["VR2332", "CHEMICAL", 19, 25], ["DiNap", "CHEMICAL", 104, 109], ["MARC-145 cells", "CELL", 3, 17], ["VR2332", "CELL", 19, 25], ["DiNap", "SIMPLE_CHEMICAL", 104, 109], ["MARC-145 cells", "CELL_LINE", 3, 17], ["MARC-145", "SPECIES", 3, 11], ["145 cells", "OBSERVATION_MODIFIER", 8, 17]]], ["Viral growth was completely suppressed at a 0.06 mM concentration of DiNap, while the lowest concentration (0.01 mM) did not exert a significant effect on viral replication ( Figure 1A ).", [["DiNap", "CHEMICAL", 69, 74], ["DiNap", "CHEMICAL", 69, 74], ["Viral", "ORGANISM", 0, 5], ["DiNap", "SIMPLE_CHEMICAL", 69, 74], ["Viral growth", "PROBLEM", 0, 12], ["a 0.06 mM concentration of DiNap", "TREATMENT", 42, 74], ["viral replication", "TREATMENT", 155, 172], ["growth", "OBSERVATION_MODIFIER", 6, 12], ["significant", "OBSERVATION_MODIFIER", 133, 144], ["viral replication", "OBSERVATION", 155, 172]]], ["In addition, DiNap did not show significant toxicity in MARC-145 cells, even at a concentration of 0.06 mM at up to 48 h post treatment (hpt) ( Figure 1C ).", [["MARC-145 cells", "ANATOMY", 56, 70], ["DiNap", "CHEMICAL", 13, 18], ["toxicity", "DISEASE", 44, 52], ["MARC-145", "CHEMICAL", 56, 64], ["DiNap", "CHEMICAL", 13, 18], ["DiNap", "SIMPLE_CHEMICAL", 13, 18], ["MARC-145 cells", "CELL", 56, 70], ["MARC-145 cells", "CELL_LINE", 56, 70], ["MARC-145", "SPECIES", 56, 64], ["significant toxicity in MARC", "PROBLEM", 32, 60], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["toxicity", "OBSERVATION", 44, 52], ["145 cells", "OBSERVATION_MODIFIER", 61, 70]]], ["Consistent with the results obtained in MARC-145 cells, in PAMs, DiNap also reduced VR2332 replication by approximately 10-or 100-fold in the presence of the 0.02 or 0.04 mM concentrations; the highest concentration (0.06 mM) caused the complete suppression of VR2332 replication, while 0.01 mM DiNap was not effective ( Figure 1B) .", [["MARC-145 cells", "ANATOMY", 40, 54], ["DiNap", "CHEMICAL", 65, 70], ["VR2332", "CHEMICAL", 84, 90], ["VR2332", "CHEMICAL", 261, 267], ["DiNap", "CHEMICAL", 295, 300], ["DiNap", "CHEMICAL", 65, 70], ["VR2332", "CHEMICAL", 261, 267], ["DiNap", "CHEMICAL", 295, 300], ["MARC-145 cells", "CELL", 40, 54], ["PAMs", "CELL", 59, 63], ["DiNap", "GENE_OR_GENE_PRODUCT", 65, 70], ["VR2332", "GENE_OR_GENE_PRODUCT", 84, 90], ["VR2332", "SIMPLE_CHEMICAL", 261, 267], ["DiNap", "SIMPLE_CHEMICAL", 295, 300], ["MARC-145 cells", "CELL_LINE", 40, 54], ["PAMs", "CELL_TYPE", 59, 63], ["MARC-145", "SPECIES", 40, 48], ["0.04 mM concentrations", "TREATMENT", 166, 188], ["VR2332 replication", "TREATMENT", 261, 279]]], ["Similarly, DiNap did not cause significant toxicity in PAMs, even at concentrations of 0.06 mM at up to 48 hpt ( Figure 1D ). a prototype PRRSV, was evaluated at five different concentrations (0, 0.01, 0.02, 0.04, and 0.06 mM) in MARC-145 cells (A) and porcine alveolar macrophages (PAMs) (B) by measuring progeny virus production over time.", [["MARC-145 cells", "ANATOMY", 230, 244], ["alveolar macrophages", "ANATOMY", 261, 281], ["PAMs", "ANATOMY", 283, 287], ["DiNap", "CHEMICAL", 11, 16], ["toxicity", "DISEASE", 43, 51], ["DiNap", "CHEMICAL", 11, 16], ["DiNap", "SIMPLE_CHEMICAL", 11, 16], ["PRRSV", "ORGANISM", 138, 143], ["MARC-145 cells", "CELL", 230, 244], ["A", "CELL", 246, 247], ["porcine", "ORGANISM", 253, 260], ["alveolar macrophages", "CELL", 261, 281], ["PAMs", "CELL", 283, 287], ["B", "CELL", 290, 291], ["MARC-145 cells", "CELL_LINE", 230, 244], ["porcine alveolar macrophages", "CELL_TYPE", 253, 281], ["PAMs", "CELL_TYPE", 283, 287], ["porcine", "SPECIES", 253, 260], ["PRRSV", "SPECIES", 138, 143], ["MARC-145", "SPECIES", 230, 238], ["significant toxicity in PAMs", "PROBLEM", 31, 59], ["a prototype PRRSV", "PROBLEM", 126, 143], ["porcine alveolar macrophages", "PROBLEM", 253, 281], ["not cause", "UNCERTAINTY", 21, 30], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["toxicity", "OBSERVATION", 43, 51], ["alveolar macrophages", "OBSERVATION", 261, 281]]], ["Both types of cells were prepared in 6-well cell culture plates, and the cell monolayers were pretreated for 2 h before infection with growth medium containing DiNap.", [["cells", "ANATOMY", 14, 19], ["cell", "ANATOMY", 44, 48], ["cell monolayers", "ANATOMY", 73, 88], ["infection", "DISEASE", 120, 129], ["DiNap", "CHEMICAL", 160, 165], ["cells", "CELL", 14, 19], ["cell", "CELL", 44, 48], ["cell monolayers", "CELL", 73, 88], ["DiNap", "SIMPLE_CHEMICAL", 160, 165], ["well cell culture plates", "TEST", 39, 63], ["the cell monolayers", "TEST", 69, 88], ["infection", "PROBLEM", 120, 129], ["cell monolayers", "OBSERVATION", 73, 88]]], ["Then, the cells were inoculated with VR2332 at an MOI of 0.01 and incubated for 1 additional hour.", [["cells", "ANATOMY", 10, 15], ["VR2332", "CHEMICAL", 37, 43], ["VR2332", "CHEMICAL", 37, 43], ["cells", "CELL", 10, 15], ["VR2332", "SIMPLE_CHEMICAL", 37, 43], ["an MOI", "TEST", 47, 53]]], ["The cell monolayers were replenished with growth medium containing the same concentrations of DiNap and incubated for 4 additional days under the same culture conditions.", [["cell monolayers", "ANATOMY", 4, 19], ["DiNap", "CHEMICAL", 94, 99], ["DiNap", "CHEMICAL", 94, 99], ["cell monolayers", "CELL", 4, 19], ["DiNap", "SIMPLE_CHEMICAL", 94, 99], ["The cell monolayers", "TEST", 0, 19], ["growth medium", "TREATMENT", 42, 55], ["DiNap", "TREATMENT", 94, 99], ["the same culture conditions", "TEST", 142, 169], ["cell monolayers", "OBSERVATION", 4, 19]]], ["An MTT [3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay was also conducted on both cell lines to assess the cytotoxicity of DiNap in MARC-145 cells (C) and PAMs (D) at the same concentrations described above.", [["cell lines", "ANATOMY", 102, 112], ["MARC-145 cells", "ANATOMY", 152, 166], ["MTT", "CHEMICAL", 3, 6], ["3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide", "CHEMICAL", 8, 67], ["DiNap", "CHEMICAL", 143, 148], ["MARC-145", "CHEMICAL", 152, 160], ["MTT", "CHEMICAL", 3, 6], ["3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide", "CHEMICAL", 8, 67], ["MTT [3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide", "SIMPLE_CHEMICAL", 3, 67], ["cell lines", "CELL", 102, 112], ["DiNap", "SIMPLE_CHEMICAL", 143, 148], ["MARC-145 cells", "CELL", 152, 166], ["C", "CELL", 168, 169], ["PAMs", "CELL", 175, 179], ["D", "SIMPLE_CHEMICAL", 181, 182], ["cell lines", "CELL_LINE", 102, 112], ["DiNap", "PROTEIN", 143, 148], ["MARC-145 cells", "CELL_LINE", 152, 166], ["An MTT", "TEST", 0, 6], ["dimethylthiazol", "TREATMENT", 14, 29], ["diphenyltetrazolium bromide", "TREATMENT", 40, 67], ["the cytotoxicity", "TEST", 123, 139], ["PAMs (D)", "TREATMENT", 175, 183]]], ["The cytotoxicity data are expressed as the relative cell viability.", [["cell", "ANATOMY", 52, 56], ["cell", "CELL", 52, 56], ["The cytotoxicity data", "TEST", 0, 21], ["relative cell viability", "OBSERVATION", 43, 66]]], ["Asterisks indicate significant differences (* p < 0.05, ** p < 0.001) in viral replication between groups.Serum ViremiaThe viral loads in the serum samples were quantified by real-time reverse transcription-polymerase chain reaction (qRT-PCR) (TaqMan \u00ae ), and the results are summarized in Figure 2 .", [["Serum", "ANATOMY", 106, 111], ["serum samples", "ANATOMY", 142, 155], ["Serum", "ORGANISM_SUBSTANCE", 106, 111], ["serum samples", "ORGANISM_SUBSTANCE", 142, 155], ["significant differences", "PROBLEM", 19, 42], ["viral replication between groups", "TREATMENT", 73, 105], ["Serum Viremia", "PROBLEM", 106, 119], ["The viral loads", "TEST", 119, 134], ["the serum samples", "TEST", 138, 155], ["polymerase chain reaction", "PROBLEM", 207, 232], ["qRT", "TEST", 234, 237], ["significant", "OBSERVATION_MODIFIER", 19, 30], ["viral replication", "OBSERVATION", 73, 90], ["Viremia", "OBSERVATION", 112, 119], ["viral loads", "OBSERVATION", 123, 134]]], ["One pig (1, 4 or 7) in each group was challenged with VR2332 and maintained in the group with the other two unchallenged pigs to observe the effects of DiNap on virus transmission between challenged and unchallenged pigs.Serum ViremiaIn group 1 (NC), the pig (1) challenged with VR2332 had the highest viral load, with virus titers of 10 5.55 TCID 50 /mL at 7 days post challenge (dpc), which gradually decreased to 10 1.39 TCID 50 /mL at 28 dpc.", [["Serum", "ANATOMY", 221, 226], ["VR2332", "CHEMICAL", 54, 60], ["DiNap", "CHEMICAL", 152, 157], ["VR2332", "CHEMICAL", 279, 285], ["VR2332", "CHEMICAL", 54, 60], ["pig", "ORGANISM", 4, 7], ["VR2332", "SIMPLE_CHEMICAL", 54, 60], ["pigs", "ORGANISM", 121, 125], ["DiNap", "SIMPLE_CHEMICAL", 152, 157], ["pigs", "ORGANISM", 216, 220], ["Serum", "ORGANISM_SUBSTANCE", 221, 226], ["pig", "ORGANISM", 255, 258], ["VR2332", "ORGANISM", 279, 285], ["pig", "SPECIES", 4, 7], ["pigs", "SPECIES", 121, 125], ["pigs", "SPECIES", 216, 220], ["pig", "SPECIES", 255, 258], ["pig", "SPECIES", 4, 7], ["pigs", "SPECIES", 121, 125], ["pigs", "SPECIES", 216, 220], ["pig", "SPECIES", 255, 258], ["DiNap", "TREATMENT", 152, 157], ["virus transmission", "TREATMENT", 161, 179], ["Serum ViremiaIn", "TEST", 221, 236], ["the highest viral load", "PROBLEM", 290, 312], ["virus titers", "TEST", 319, 331], ["viral load", "OBSERVATION", 302, 312]]], ["Similarly, the two unchallenged pigs (2 and 3) in the same group also showed peak viral titers of 10 3.83 and 10 4.64 TCID 50 /mL at 7 dpc, which also gradually decreased to 10 1.23 and 10 2.01 TCID 50 /mL, respectively, at 28 dpc ( Figure 2A ).Serum ViremiaIn group 2 (DiNap at 0.04 mM/kg body weight), the pig (4) challenged with VR2332 had a peak viral titer of 10 4.18 TCID 50 /mL at 7 dpc, which was more than 10-fold lower than the titers found in the pig (1) challenged with the virus in group 1; the viral titer gradually decreased to 10 0.93 TCID 50 /mL at 28 dpc.", [["Serum", "ANATOMY", 245, 250], ["body", "ANATOMY", 290, 294], ["DiNap", "CHEMICAL", 270, 275], ["VR2332", "CHEMICAL", 332, 338], ["pigs", "ORGANISM", 32, 36], ["Serum", "ORGANISM_SUBSTANCE", 245, 250], ["body", "ORGANISM_SUBDIVISION", 290, 294], ["pig", "ORGANISM", 308, 311], ["VR2332", "SIMPLE_CHEMICAL", 332, 338], ["pig", "ORGANISM", 458, 461], ["pigs", "SPECIES", 32, 36], ["pig", "SPECIES", 308, 311], ["pig", "SPECIES", 458, 461], ["pig", "SPECIES", 308, 311], ["pig", "SPECIES", 458, 461], ["peak viral titers", "TEST", 77, 94], ["TCID", "TEST", 118, 122], ["TCID", "TEST", 194, 198], ["Serum ViremiaIn", "TEST", 245, 260], ["DiNap", "TEST", 270, 275], ["weight", "TEST", 295, 301], ["a peak viral titer", "TEST", 343, 361], ["the virus", "TREATMENT", 482, 491], ["the viral titer", "TEST", 504, 519], ["two", "OBSERVATION_MODIFIER", 15, 18], ["unchallenged", "OBSERVATION_MODIFIER", 19, 31], ["pigs", "OBSERVATION", 32, 36], ["peak", "OBSERVATION_MODIFIER", 77, 81], ["viral titers", "OBSERVATION", 82, 94]]], ["Among the two unchallenged pigs in the same group, one pig (5) showed a peak virus titer of 10 3.25 TCID 50 /mL at 7 dpc, which was also lower than the titers in both unchallenged pigs (2 and 3) in group 1, and the titer gradually declined to 10 1.39 TCID 50 /mL at 28 dpc.", [["pigs", "ORGANISM", 27, 31], ["pig", "ORGANISM", 55, 58], ["pigs", "ORGANISM", 180, 184], ["pigs", "SPECIES", 27, 31], ["pig", "SPECIES", 55, 58], ["pigs", "SPECIES", 180, 184], ["pigs", "SPECIES", 27, 31], ["pig", "SPECIES", 55, 58], ["pigs", "SPECIES", 180, 184], ["a peak virus titer", "TEST", 70, 88], ["two", "OBSERVATION_MODIFIER", 10, 13], ["unchallenged", "OBSERVATION_MODIFIER", 14, 26], ["pigs", "OBSERVATION", 27, 31], ["lower", "OBSERVATION_MODIFIER", 137, 142], ["unchallenged pigs", "OBSERVATION", 167, 184]]], ["The other unchallenged pig (6) did not show viremia at up to 7 dpc, although the virus was detected at 14 dpc, with a titer of 10 3.14 TCID 50 /mL, which slowly decreased to 10 2.19 TCID 50 /mL at 28 dpc ( Figure 2A ).Serum ViremiaConsistent with these results, in group 3 (DiNap at 0.2 mM/kg body weight), the pig (7) challenged with VR2332 had peak viremia with a virus titer of 10 4.08 TCID 50 /mL at 7 dpc, which was more than 10-fold lower than the titer found in the pig (1) challenged with virus in group 1, and the virus titer gradually decreased to 10 1.02 TCID 50 /mL at 28 dpc.", [["Serum", "ANATOMY", 218, 223], ["body", "ANATOMY", 293, 297], ["viremia", "DISEASE", 44, 51], ["DiNap", "CHEMICAL", 274, 279], ["VR2332", "CHEMICAL", 335, 341], ["viremia", "DISEASE", 351, 358], ["pig", "ORGANISM", 23, 26], ["Serum", "ORGANISM_SUBSTANCE", 218, 223], ["body", "ORGANISM_SUBDIVISION", 293, 297], ["pig", "ORGANISM", 311, 314], ["VR2332", "SIMPLE_CHEMICAL", 335, 341], ["pig", "ORGANISM", 473, 476], ["pig", "SPECIES", 23, 26], ["pig", "SPECIES", 473, 476], ["pig", "SPECIES", 23, 26], ["pig", "SPECIES", 311, 314], ["pig", "SPECIES", 473, 476], ["viremia", "PROBLEM", 44, 51], ["the virus", "PROBLEM", 77, 86], ["a titer", "TEST", 116, 123], ["Serum ViremiaConsistent", "TEST", 218, 241], ["DiNap", "TEST", 274, 279], ["weight", "TEST", 298, 304], ["peak viremia", "PROBLEM", 346, 358], ["a virus titer", "TEST", 364, 377], ["virus", "PROBLEM", 497, 502], ["the virus titer", "TEST", 519, 534], ["viremia", "OBSERVATION", 44, 51], ["peak viremia", "OBSERVATION", 346, 358]]], ["Neither unchallenged pig (8 and 9) in the same group displayed viremia at up to 7 dpc, although the virus was detected in both of the pigs at 14 dpc, with titers of 10 2.17 and 10 2.92 TCID 50 /mL, which slowly declined to 10 1.24 and 10 1.51 TCID 50 /mL, respectively, at 28 dpc ( Figure 2A ).Serum ViremiaIn addition, the average virus titers were measured in the pigs in each group.", [["Serum", "ANATOMY", 294, 299], ["viremia", "DISEASE", 63, 70], ["pig", "ORGANISM", 21, 24], ["pigs", "ORGANISM", 134, 138], ["Serum", "ORGANISM_SUBSTANCE", 294, 299], ["pigs", "ORGANISM", 366, 370], ["pig", "SPECIES", 21, 24], ["pigs", "SPECIES", 134, 138], ["pigs", "SPECIES", 366, 370], ["pig", "SPECIES", 21, 24], ["pigs", "SPECIES", 134, 138], ["pigs", "SPECIES", 366, 370], ["viremia", "PROBLEM", 63, 70], ["the virus", "PROBLEM", 96, 105], ["titers", "TEST", 155, 161], ["TCID", "TEST", 243, 247], ["Serum ViremiaIn", "TEST", 294, 309], ["the average virus titers", "TEST", 320, 344], ["viremia", "OBSERVATION", 63, 70], ["virus", "OBSERVATION", 100, 105]]], ["The pigs in group 1 (NC) exhibited an average peak viremia titer of 10 4.67 TCID 50 /mL at 7 dpc, which gradually decreased to 10 1.54 TCID 50 /mL at 28 dpc.", [["viremia", "DISEASE", 51, 58], ["pigs", "ORGANISM", 4, 8], ["pigs", "SPECIES", 4, 8], ["an average peak viremia titer", "TEST", 35, 64]]], ["In contrast, the pigs in group 2 (DiNap at 0.04 mM) and 3 (DiNap at 0.2 mM) had average titers of 10 2.47 TCID 50 /mL and 10 1.36 TCID 50 /mL, respectively, at 7 dpc, which were approximately 100-fold (p < 0.05) and 1000-fold (p < 0.001) lower than the average titer observed in the pigs in group 1 (NC) ( Figure 2B ).", [["pigs", "ORGANISM", 17, 21], ["pigs", "ORGANISM", 283, 287], ["pigs", "SPECIES", 17, 21], ["pigs", "SPECIES", 283, 287], ["pigs", "SPECIES", 283, 287], ["DiNap", "TEST", 34, 39], ["DiNap", "TEST", 59, 64], ["average titers", "TEST", 80, 94]]], ["These results suggest that DiNap has significant antiviral effects against PRRSV, decreasing viral transmission and replication in pigs.Figure 2.Serum viremia was measured in pig serum from each group at 0 (before challenge), 7, 14, and 28 dpc by real-time reverse transcription-polymerase chain reaction (qRT-PCR) (TaqMan \u00ae ).", [["Serum", "ANATOMY", 145, 150], ["serum", "ANATOMY", 179, 184], ["DiNap", "CHEMICAL", 27, 32], ["DiNap", "CHEMICAL", 27, 32], ["DiNap", "SIMPLE_CHEMICAL", 27, 32], ["PRRSV", "ORGANISM", 75, 80], ["pigs", "ORGANISM", 131, 135], ["Serum", "ORGANISM_SUBSTANCE", 145, 150], ["pig", "ORGANISM", 175, 178], ["serum", "ORGANISM_SUBSTANCE", 179, 184], ["PRRSV", "SPECIES", 75, 80], ["pigs", "SPECIES", 131, 135], ["pig", "SPECIES", 175, 178], ["PRRSV", "SPECIES", 75, 80], ["pigs", "SPECIES", 131, 135], ["pig", "SPECIES", 175, 178], ["significant antiviral effects", "PROBLEM", 37, 66], ["PRRSV", "PROBLEM", 75, 80], ["decreasing viral transmission", "TREATMENT", 82, 111], ["replication in pigs", "TREATMENT", 116, 135], ["Serum viremia", "TEST", 145, 158], ["pig serum", "TEST", 175, 184], ["polymerase chain reaction", "PROBLEM", 279, 304], ["qRT", "TEST", 306, 309], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["antiviral effects", "OBSERVATION", 49, 66], ["viremia", "OBSERVATION", 151, 158]]], ["Viral RNA was extracted from serum samples, and the viral loads were quantified by qRT-PCR.", [["serum samples", "ANATOMY", 29, 42], ["Viral", "ORGANISM", 0, 5], ["serum samples", "ORGANISM_SUBSTANCE", 29, 42], ["Viral RNA", "RNA", 0, 9], ["Viral RNA", "PROBLEM", 0, 9], ["serum samples", "TEST", 29, 42], ["the viral loads", "TEST", 48, 63], ["qRT", "TEST", 83, 86], ["RNA", "OBSERVATION", 6, 9]]], ["The level of viremia was calculated and expressed as a TCID 50 /mL equivalent based on the standard curve of the cycle threshold (Ct) number plotted against the known virus titer of VR2332.", [["viremia", "DISEASE", 13, 20], ["VR2332", "SIMPLE_CHEMICAL", 182, 188], ["viremia", "PROBLEM", 13, 20], ["a TCID", "TREATMENT", 53, 59], ["the standard curve", "TEST", 87, 105], ["Ct", "TEST", 130, 132], ["viremia", "OBSERVATION", 13, 20]]], ["The measured virus titers in the serum samples are presented for individual animals (A) and as an average for each group (B).", [["serum samples", "ANATOMY", 33, 46], ["serum samples", "ORGANISM_SUBSTANCE", 33, 46], ["The measured virus titers", "TEST", 0, 25], ["the serum samples", "TEST", 29, 46], ["virus", "OBSERVATION", 13, 18]]], ["Asterisks indicate significant differences (* p < 0.05) in virus titers between groups.", [["significant differences", "PROBLEM", 19, 42], ["significant", "OBSERVATION_MODIFIER", 19, 30]]], ["Note: v indicates the pig challenged with virus in each group.Anti-PRRSV IgG ResponseThe PRRSV-specific antibody (IgG) response was measured in serum samples by enzyme-linked immunosorbent assay (ELISA) based on the nucleocapsid (N) protein.", [["serum samples", "ANATOMY", 144, 157], ["pig", "ORGANISM", 22, 25], ["PRRSV", "ORGANISM", 67, 72], ["PRRSV-specific antibody", "GENE_OR_GENE_PRODUCT", 89, 112], ["IgG", "GENE_OR_GENE_PRODUCT", 114, 117], ["serum samples", "ORGANISM_SUBSTANCE", 144, 157], ["PRRSV IgG", "PROTEIN", 67, 76], ["PRRSV-specific antibody", "PROTEIN", 89, 112], ["IgG", "PROTEIN", 114, 117], ["nucleocapsid (N) protein", "PROTEIN", 216, 240], ["PRRSV", "SPECIES", 67, 72], ["pig", "SPECIES", 22, 25], ["PRRSV", "SPECIES", 67, 72], ["PRRSV", "SPECIES", 89, 94], ["virus", "PROBLEM", 42, 47], ["Anti-PRRSV IgG", "TEST", 62, 76], ["The PRRSV", "TEST", 85, 94], ["specific antibody", "TEST", 95, 112], ["serum samples", "TEST", 144, 157], ["enzyme", "TEST", 161, 167], ["immunosorbent assay", "TEST", 175, 194], ["ELISA", "TEST", 196, 201]]], ["As summarized in Figure 3 , all pigs in each group were seronegative at up to 7 dpc.", [["pigs", "ORGANISM", 32, 36], ["pigs", "SPECIES", 32, 36]]], ["Following infection, all 3 pigs (1 to 3) in group 1 (NC) became seropositive at 14 dpc, and the S/P (sample-to-positive) ratio gradually increased up to 28 dpc.", [["infection", "DISEASE", 10, 19], ["pigs", "ORGANISM", 27, 31], ["pigs", "SPECIES", 27, 31], ["pigs", "SPECIES", 27, 31], ["infection", "PROBLEM", 10, 19], ["seropositive", "PROBLEM", 64, 76], ["the S/P (sample", "TEST", 92, 107], ["ratio", "TEST", 121, 126], ["infection", "OBSERVATION", 10, 19]]], ["Similarly, in group 2, two pigs [virus challenged (4) and unchallenged (5) ] became seropositive at 14 dpc.", [["pigs", "ORGANISM", 27, 31], ["pigs", "SPECIES", 27, 31], ["seropositive", "PROBLEM", 84, 96]]], ["The other unchallenged pig (6) in the same group was seronegative at up to 14 dpc and became seropositive at 21 dpc.", [["pig", "ORGANISM", 23, 26], ["pig", "SPECIES", 23, 26], ["pig", "SPECIES", 23, 26], ["seronegative", "PROBLEM", 53, 65], ["seropositive", "PROBLEM", 93, 105]]], ["In group 3, the challenged pig (7) became seropositive at 14 dpc, similar to the challenged pig (1) in group 1.", [["pig", "ORGANISM", 27, 30], ["pig", "ORGANISM", 92, 95], ["pig", "SPECIES", 27, 30], ["pig", "SPECIES", 92, 95], ["pig", "SPECIES", 27, 30], ["pig", "SPECIES", 92, 95], ["seropositive", "PROBLEM", 42, 54]]], ["However, the two other unchallenged pigs (8 and 9) in the same group were seronegative at up to 14 dpc and became seropositive at 21 dpc.", [["pigs", "ORGANISM", 36, 40], ["pigs", "SPECIES", 36, 40], ["seropositive", "PROBLEM", 114, 126], ["unchallenged", "OBSERVATION_MODIFIER", 23, 35], ["pigs", "OBSERVATION", 36, 40]]], ["There were no differences in the antibody (IgG) titers found among the groups (Figure 3 ).", [["IgG", "GENE_OR_GENE_PRODUCT", 43, 46], ["IgG", "PROTEIN", 43, 46], ["the antibody (IgG) titers", "TEST", 29, 54], ["no", "UNCERTAINTY", 11, 13], ["differences", "OBSERVATION_MODIFIER", 14, 25]]], ["These results suggested that DiNap delayed viral transmission among pigs infected with PRRSV.", [["DiNap", "CHEMICAL", 29, 34], ["DiNap", "GENE_OR_GENE_PRODUCT", 29, 34], ["pigs", "ORGANISM", 68, 72], ["PRRSV", "ORGANISM", 87, 92], ["pigs", "SPECIES", 68, 72], ["PRRSV", "SPECIES", 87, 92], ["pigs", "SPECIES", 68, 72], ["PRRSV", "SPECIES", 87, 92], ["DiNap delayed viral transmission", "PROBLEM", 29, 61], ["PRRSV", "PROBLEM", 87, 92]]], ["Anti-PRRSV antibody (IgG) responses measured by enzyme-linked immunosorbent assay (ELISA) in the pigs in each group.", [["Anti-PRRSV antibody", "GENE_OR_GENE_PRODUCT", 0, 19], ["IgG", "GENE_OR_GENE_PRODUCT", 21, 24], ["pigs", "ORGANISM", 97, 101], ["Anti-PRRSV antibody", "PROTEIN", 0, 19], ["IgG", "PROTEIN", 21, 24], ["pigs", "SPECIES", 97, 101], ["Anti-PRRSV", "SPECIES", 0, 10], ["pigs", "SPECIES", 97, 101], ["Anti-PRRSV antibody", "TEST", 0, 19], ["enzyme", "TEST", 48, 54], ["immunosorbent assay", "TEST", 62, 81]]], ["PRRSV-specific antibodies (IgG) were detected in the serum samples by using a commercially available ELISA kit (IDEXX PRRS X3 Ab Test).", [["serum samples", "ANATOMY", 53, 66], ["PRRSV", "ORGANISM", 0, 5], ["IgG", "GENE_OR_GENE_PRODUCT", 27, 30], ["serum samples", "ORGANISM_SUBSTANCE", 53, 66], ["PRRSV-specific antibodies", "PROTEIN", 0, 25], ["IgG", "PROTEIN", 27, 30], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "TEST", 0, 5], ["specific antibodies", "TEST", 6, 25], ["IgG", "TEST", 27, 30], ["the serum samples", "TEST", 49, 66]]], ["An S/P ratio (ratio between the net optical density of the test samples and the net optical density of the positive control) \u22650.4 was considered positive for the PRRSV antibody.", [["samples", "ANATOMY", 64, 71], ["PRRSV", "ORGANISM", 162, 167], ["PRRSV antibody", "PROTEIN", 162, 176], ["PRRSV", "SPECIES", 162, 167], ["An S/P ratio", "TEST", 0, 12], ["the test samples", "TEST", 55, 71], ["the PRRSV antibody", "PROBLEM", 158, 176], ["PRRSV antibody", "OBSERVATION", 162, 176]]], ["The results are expressed as the S/P ratio of the samples, with S/P \u22650.4 considered positive for the PRRSV antibody (IgG).", [["samples", "ANATOMY", 50, 57], ["PRRSV", "ORGANISM", 101, 106], ["IgG", "GENE_OR_GENE_PRODUCT", 117, 120], ["PRRSV antibody", "PROTEIN", 101, 115], ["IgG", "PROTEIN", 117, 120], ["PRRSV", "SPECIES", 101, 106], ["the samples", "TEST", 46, 57], ["S/P \u2265", "TEST", 64, 69], ["the PRRSV antibody", "TEST", 97, 115]]], ["Note: v indicates the pig challenged with virus in each group.Average Daily Weight GainThe effect of DiNap on the growth rate of the pigs was evaluated over the course of PRRSV infection.", [["DiNap", "CHEMICAL", 101, 106], ["PRRSV infection", "DISEASE", 171, 186], ["DiNap", "CHEMICAL", 101, 106], ["pig", "ORGANISM", 22, 25], ["DiNap", "SIMPLE_CHEMICAL", 101, 106], ["pigs", "ORGANISM", 133, 137], ["PRRSV", "ORGANISM", 171, 176], ["DiNap", "PROTEIN", 101, 106], ["pigs", "SPECIES", 133, 137], ["pig", "SPECIES", 22, 25], ["pigs", "SPECIES", 133, 137], ["PRRSV", "SPECIES", 171, 176], ["virus", "PROBLEM", 42, 47], ["DiNap", "TREATMENT", 101, 106], ["the pigs", "TREATMENT", 129, 137], ["PRRSV infection", "PROBLEM", 171, 186], ["infection", "OBSERVATION", 177, 186]]], ["The average daily weight gain (ADWG) was measured for all pigs in each group up to 28 dpc.", [["pigs", "ORGANISM", 58, 62], ["pigs", "SPECIES", 58, 62], ["ADWG", "TEST", 31, 35]]], ["DiNap significantly enhanced the ADWG for both treatment groups (groups 2 and 3) compared with that of the pigs in group 1 (NC) (Figure 4 ). .", [["DiNap", "CHEMICAL", 0, 5], ["ADWG", "CHEMICAL", 33, 37], ["DiNap", "SIMPLE_CHEMICAL", 0, 5], ["ADWG", "SIMPLE_CHEMICAL", 33, 37], ["pigs", "ORGANISM", 107, 111], ["pigs", "SPECIES", 107, 111], ["both treatment groups (groups", "TREATMENT", 42, 71]]], ["ADWG was calculated for the pigs in each group at 28 days and is expressed in kg/day.", [["ADWG", "SIMPLE_CHEMICAL", 0, 4], ["pigs", "ORGANISM", 28, 32], ["pigs", "SPECIES", 28, 32], ["pigs", "SPECIES", 28, 32], ["ADWG", "TEST", 0, 4], ["the pigs in each group", "TREATMENT", 24, 46]]], ["Asterisks indicate significant differences (* p < 0.05) in the ADWG of the pigs between groups.Lung Pathology and Residual Viral Loads in Lung TissuesAll pigs in the untreated control group (group 1) exhibited higher lung lesion scores (gross and microscopic) than those in group 2 and group 3 ( Figure 5 ).", [["Lung", "ANATOMY", 95, 99], ["Lung Tissues", "ANATOMY", 138, 150], ["lung lesion", "ANATOMY", 217, 228], ["pigs", "ORGANISM", 75, 79], ["Lung", "ORGAN", 95, 99], ["Lung Tissues", "CANCER", 138, 150], ["pigs", "ORGANISM", 154, 158], ["lung lesion", "MULTI-TISSUE_STRUCTURE", 217, 228], ["pigs", "SPECIES", 75, 79], ["pigs", "SPECIES", 154, 158], ["significant differences", "PROBLEM", 19, 42], ["Lung Pathology", "TEST", 95, 109], ["Residual Viral Loads in Lung Tissues", "PROBLEM", 114, 150], ["All pigs", "TREATMENT", 150, 158], ["higher lung lesion scores", "PROBLEM", 210, 235], ["significant", "OBSERVATION_MODIFIER", 19, 30], ["differences", "OBSERVATION_MODIFIER", 31, 42], ["Pathology", "OBSERVATION", 100, 109], ["Residual", "OBSERVATION_MODIFIER", 114, 122], ["Viral Loads", "OBSERVATION", 123, 134], ["Lung Tissues", "ANATOMY", 138, 150], ["higher", "OBSERVATION_MODIFIER", 210, 216], ["lung", "ANATOMY", 217, 221], ["lesion", "OBSERVATION", 222, 228], ["gross", "OBSERVATION_MODIFIER", 237, 242]]], ["The residual viral loads were also measured in the lung tissues collected from the pigs in each group.", [["lung tissues", "ANATOMY", 51, 63], ["lung tissues", "TISSUE", 51, 63], ["pigs", "ORGANISM", 83, 87], ["pigs", "SPECIES", 83, 87], ["The residual viral loads", "PROBLEM", 0, 24], ["residual", "OBSERVATION_MODIFIER", 4, 12], ["viral loads", "OBSERVATION", 13, 24], ["lung tissues", "ANATOMY", 51, 63], ["pigs", "OBSERVATION_MODIFIER", 83, 87]]], ["DiNap appeared to reduce the viral loads observed in the lung tissues of the pigs in each treatment group (groups 2 and 3) compared to those in group 1 (NC).", [["lung tissues", "ANATOMY", 57, 69], ["DiNap", "CHEMICAL", 0, 5], ["DiNap", "GENE_OR_GENE_PRODUCT", 0, 5], ["lung tissues", "TISSUE", 57, 69], ["pigs", "ORGANISM", 77, 81], ["DiNap", "PROTEIN", 0, 5], ["pigs", "SPECIES", 77, 81], ["pigs", "SPECIES", 77, 81], ["the viral loads", "PROBLEM", 25, 40], ["viral loads", "OBSERVATION", 29, 40], ["lung", "ANATOMY", 57, 61], ["tissues", "ANATOMY_MODIFIER", 62, 69], ["pigs", "OBSERVATION_MODIFIER", 77, 81]]], ["The pigs in groups 2 and 3 exhibited average virus titers of 10 3.28 TCID 50 /mL and 10 2.68 TCID 50 /mL, respectively, which were approximately 10-and 100-fold lower than the titer of 10 4.65 TCID 50 /mL observed in group 1.", [["pigs", "ORGANISM", 4, 8], ["pigs", "SPECIES", 4, 8], ["The pigs in groups", "TEST", 0, 18], ["average virus titers", "TEST", 37, 57]]], ["In group 1, the pig (1) challenged with VR2332 had a virus titer of 10 4.84 TCID 50 /mL in its lung tissue, and the unchallenged pigs (2 and 3) in the same group exhibited virus titers of 10 4.94 and 10 4.17 TCID 50 /mL, respectively.", [["lung tissue", "ANATOMY", 95, 106], ["VR2332", "CHEMICAL", 40, 46], ["pig", "ORGANISM", 16, 19], ["VR2332", "SIMPLE_CHEMICAL", 40, 46], ["lung tissue", "TISSUE", 95, 106], ["pigs", "ORGANISM", 129, 133], ["pig", "SPECIES", 16, 19], ["pigs", "SPECIES", 129, 133], ["pig", "SPECIES", 16, 19], ["a virus titer", "TEST", 51, 64], ["virus titers", "TEST", 172, 184], ["lung tissue", "ANATOMY", 95, 106]]], ["However, in group 2, the pig (4) challenged with the virus had a virus titer of 10 2.10 TCID 50 /mL, which was approximately 100-fold lower than the titer found in the challenged pig (1) in group 1.", [["pig", "ORGANISM", 25, 28], ["pig", "ORGANISM", 179, 182], ["pig", "SPECIES", 25, 28], ["pig", "SPECIES", 179, 182], ["pig", "SPECIES", 25, 28], ["pig", "SPECIES", 179, 182], ["the pig (4)", "TREATMENT", 21, 32], ["the virus", "PROBLEM", 49, 58], ["a virus titer", "TREATMENT", 63, 76]]], ["The two unchallenged pigs (5 and 6) in the same group had titers of 10 3.51 and 10 4.24 TCID 50 /mL, respectively, which were also lower than or similar to the titers found in both unchallenged pigs (2 and 3) in group 1.", [["pigs", "ORGANISM", 21, 25], ["pigs", "ORGANISM", 194, 198], ["pigs", "SPECIES", 21, 25], ["pigs", "SPECIES", 194, 198], ["pigs", "SPECIES", 194, 198], ["titers", "TEST", 58, 64], ["the titers", "TEST", 156, 166], ["two", "OBSERVATION_MODIFIER", 4, 7], ["unchallenged", "OBSERVATION_MODIFIER", 8, 20], ["pigs", "OBSERVATION_MODIFIER", 21, 25], ["lower", "OBSERVATION_MODIFIER", 131, 136], ["both", "ANATOMY_MODIFIER", 176, 180], ["unchallenged pigs", "OBSERVATION", 181, 198]]], ["In group 3, the pig (7) that was challenged with the virus exhibited a virus titer of 10 1.98 TCID 50 /mL in its lung tissues, which was also more than 100-fold lower than the titer found in the pig (1) that was challenged by the virus in group 1.", [["lung tissues", "ANATOMY", 113, 125], ["pig", "ORGANISM", 16, 19], ["lung tissues", "TISSUE", 113, 125], ["pig", "ORGANISM", 195, 198], ["pig", "SPECIES", 16, 19], ["pig", "SPECIES", 195, 198], ["pig", "SPECIES", 16, 19], ["pig", "SPECIES", 195, 198], ["the virus", "PROBLEM", 49, 58], ["a virus titer", "TEST", 69, 82], ["lung tissues", "ANATOMY", 113, 125]]], ["Moreover, both unchallenged pigs (8 and 9) in the same group also had lower virus titers of 10 2.98 and 10 3.11 TCID 50 /mL, respectively, in their lung tissues than the titers found in both unchallenged pigs (2 and 3) in group 1 ( Figure 6 ).", [["lung tissues", "ANATOMY", 148, 160], ["pigs", "ORGANISM", 28, 32], ["lung tissues", "TISSUE", 148, 160], ["pigs", "ORGANISM", 204, 208], ["pigs", "SPECIES", 28, 32], ["pigs", "SPECIES", 204, 208], ["pigs", "SPECIES", 28, 32], ["pigs", "SPECIES", 204, 208], ["lower virus titers", "PROBLEM", 70, 88], ["the titers", "TEST", 166, 176], ["both", "OBSERVATION_MODIFIER", 10, 14], ["unchallenged", "OBSERVATION", 15, 27], ["lower virus", "ANATOMY", 70, 81], ["lung tissues", "ANATOMY", 148, 160], ["both", "ANATOMY_MODIFIER", 186, 190], ["unchallenged pigs", "OBSERVATION", 191, 208]]], ["Quantification of residual viral loads in lung tissues collected from pigs in each group at 28 dpc.", [["lung tissues", "ANATOMY", 42, 54], ["lung tissues", "TISSUE", 42, 54], ["pigs", "ORGANISM", 70, 74], ["pigs", "SPECIES", 70, 74], ["residual viral loads in lung tissues", "PROBLEM", 18, 54], ["residual", "OBSERVATION_MODIFIER", 18, 26], ["viral loads", "OBSERVATION", 27, 38], ["lung", "ANATOMY", 42, 46], ["tissues", "OBSERVATION", 47, 54]]], ["Viral RNA was extracted from the lung, and viral loads in the lung tissues were quantified by qRT-PCR.", [["lung", "ANATOMY", 33, 37], ["lung tissues", "ANATOMY", 62, 74], ["Viral", "ORGANISM", 0, 5], ["lung", "ORGAN", 33, 37], ["lung tissues", "TISSUE", 62, 74], ["Viral RNA", "RNA", 0, 9], ["Viral RNA", "PROBLEM", 0, 9], ["viral loads in the lung tissues", "PROBLEM", 43, 74], ["RNA", "OBSERVATION", 6, 9], ["lung", "ANATOMY", 33, 37], ["viral loads", "OBSERVATION", 43, 54], ["lung tissues", "ANATOMY", 62, 74]]], ["The viral loads in lung tissues were measured and expressed as TCID 50 /mL equivalents based on the standard curve of the Ct number plotted against the known virus titer of VR2332.", [["lung tissues", "ANATOMY", 19, 31], ["lung tissues", "TISSUE", 19, 31], ["VR2332", "SIMPLE_CHEMICAL", 173, 179], ["The viral loads in lung tissues", "PROBLEM", 0, 31], ["the Ct", "TEST", 118, 124], ["viral loads", "OBSERVATION", 4, 15], ["lung tissues", "ANATOMY", 19, 31]]], ["Asterisks indicate significant differences (* p < 0.05) in virus titers between groups.DiscussionThe chalcone flavokawain was found to exhibit promising anticancer and anti-inflammatory properties in previous studies [39, 40] .", [["anticancer", "ANATOMY", 153, 163], ["chalcone", "CHEMICAL", 101, 109], ["flavokawain", "CHEMICAL", 110, 121], ["chalcone", "CHEMICAL", 101, 109], ["flavokawain", "CHEMICAL", 110, 121], ["chalcone flavokawain", "SIMPLE_CHEMICAL", 101, 121], ["anticancer", "CANCER", 153, 163], ["significant differences", "PROBLEM", 19, 42], ["previous studies", "TEST", 200, 216], ["significant", "OBSERVATION_MODIFIER", 19, 30]]], ["DiNap, a synthetic analog of the chalcone flavokawain, was evaluated in this study for its potential antiviral activity against PRRSV infection in cell culture systems and in a pig model.", [["cell culture", "ANATOMY", 147, 159], ["DiNap", "CHEMICAL", 0, 5], ["flavokawain", "CHEMICAL", 42, 53], ["PRRSV infection", "DISEASE", 128, 143], ["chalcone", "CHEMICAL", 33, 41], ["flavokawain", "CHEMICAL", 42, 53], ["DiNap", "SIMPLE_CHEMICAL", 0, 5], ["chalcone flavokawain", "SIMPLE_CHEMICAL", 33, 53], ["PRRSV", "ORGANISM", 128, 133], ["cell", "CELL", 147, 151], ["pig", "ORGANISM", 177, 180], ["PRRSV", "SPECIES", 128, 133], ["pig", "SPECIES", 177, 180], ["PRRSV", "SPECIES", 128, 133], ["pig", "SPECIES", 177, 180], ["this study", "TEST", 72, 82], ["PRRSV infection in cell culture systems", "PROBLEM", 128, 167], ["a pig model", "TREATMENT", 175, 186], ["chalcone flavokawain", "OBSERVATION", 33, 53], ["infection", "OBSERVATION", 134, 143]]], ["Chemically, DiNap is a synthetic analog of flavokawain, containing a chalcone scaffold of 1,3-diaryl-2-propen-1-one.", [["DiNap", "CHEMICAL", 12, 17], ["flavokawain", "CHEMICAL", 43, 54], ["chalcone", "CHEMICAL", 69, 77], ["1,3-diaryl-2-propen-1-one", "CHEMICAL", 90, 115], ["DiNap", "CHEMICAL", 12, 17], ["flavokawain", "CHEMICAL", 43, 54], ["chalcone", "CHEMICAL", 69, 77], ["1,3-diaryl-2-propen-1-one", "CHEMICAL", 90, 115], ["DiNap", "SIMPLE_CHEMICAL", 12, 17], ["flavokawain", "SIMPLE_CHEMICAL", 43, 54], ["chalcone", "SIMPLE_CHEMICAL", 69, 77], ["1,3-diaryl-2-propen-1-one", "SIMPLE_CHEMICAL", 90, 115], ["a chalcone scaffold", "TREATMENT", 67, 86], ["diaryl", "TREATMENT", 94, 100], ["propen", "TREATMENT", 103, 109]]], ["DiNap has a 2-hydroxy-4,6-dimethoxybenzene moiety at the C1 position of 2-propene-1-one, which is a common structural feature of the naturally occurring compounds flavokawain A, B, and C. DiNap also contains a naphthalenyl moiety at the C3 position of 2-propene-1-one, which has been found in several antiviral agents [41, 42] .", [["DiNap", "CHEMICAL", 0, 5], ["2-hydroxy-4,6-dimethoxybenzene", "CHEMICAL", 12, 42], ["2-propene-1-one", "CHEMICAL", 72, 87], ["flavokawain", "CHEMICAL", 163, 174], ["DiNap", "CHEMICAL", 188, 193], ["naphthalenyl", "CHEMICAL", 210, 222], ["2-propene-1-one", "CHEMICAL", 252, 267], ["DiNap", "CHEMICAL", 0, 5], ["2-hydroxy-4,6-dimethoxybenzene", "CHEMICAL", 12, 42], ["2-propene-1-one", "CHEMICAL", 72, 87], ["flavokawain A, B, and C. DiNap", "CHEMICAL", 163, 193], ["naphthalenyl", "CHEMICAL", 210, 222], ["2-propene-1-one", "CHEMICAL", 252, 267], ["DiNap", "SIMPLE_CHEMICAL", 0, 5], ["2-hydroxy-4,6-dimethoxybenzene moiety", "SIMPLE_CHEMICAL", 12, 49], ["2-propene-1-one", "SIMPLE_CHEMICAL", 72, 87], ["flavokawain A", "SIMPLE_CHEMICAL", 163, 176], ["B", "SIMPLE_CHEMICAL", 178, 179], ["C. DiNap", "SIMPLE_CHEMICAL", 185, 193], ["naphthalenyl moiety", "SIMPLE_CHEMICAL", 210, 229], ["2-propene-1-one", "SIMPLE_CHEMICAL", 252, 267], ["hydroxy", "TEST", 14, 21], ["dimethoxybenzene moiety", "TREATMENT", 26, 49], ["propene", "TREATMENT", 74, 81], ["a naphthalenyl moiety", "TREATMENT", 208, 229], ["propene", "TREATMENT", 254, 261]]], ["In addition, chalcones, the main pharmacophore of DiNap, have been reported to show a wide spectrum of biological activities, including antiviral [43] , antioxidative [44] , and anti-inflammatory activities [45] .", [["chalcones", "CHEMICAL", 13, 22], ["DiNap", "CHEMICAL", 50, 55], ["chalcones", "CHEMICAL", 13, 22], ["DiNap", "CHEMICAL", 50, 55], ["chalcones", "SIMPLE_CHEMICAL", 13, 22], ["DiNap", "GENE_OR_GENE_PRODUCT", 50, 55], ["antioxidative [44]", "SIMPLE_CHEMICAL", 153, 171], ["DiNap", "PROTEIN", 50, 55], ["antiviral", "TREATMENT", 136, 145]]], ["These previous studies are further supported by the results presented in the current study.", [["These previous studies", "TEST", 0, 22], ["the current study", "TEST", 73, 90]]], ["DiNap effectively suppressed VR2332 replication in MARC-145 cells and PAMs at concentrations ranging from 0.02 to 0.06 mM, without showing significant cytotoxicity, even at up to 48 hpt.", [["MARC-145 cells", "ANATOMY", 51, 65], ["DiNap", "CHEMICAL", 0, 5], ["VR2332", "CHEMICAL", 29, 35], ["MARC-145", "CHEMICAL", 51, 59], ["DiNap", "SIMPLE_CHEMICAL", 0, 5], ["VR2332", "SIMPLE_CHEMICAL", 29, 35], ["MARC-145 cells", "CELL", 51, 65], ["PAMs", "CELL", 70, 74], ["VR2332", "PROTEIN", 29, 35], ["MARC-145 cells", "CELL_LINE", 51, 65], ["MARC-145", "SPECIES", 51, 59], ["PAMs", "TEST", 70, 74], ["concentrations", "TEST", 78, 92], ["significant cytotoxicity", "PROBLEM", 139, 163], ["145 cells", "OBSERVATION_MODIFIER", 56, 65], ["significant", "OBSERVATION_MODIFIER", 139, 150], ["cytotoxicity", "OBSERVATION", 151, 163]]], ["It is worth noting that the highest concentration of DiNap (0.06 mM) used in this study completely suppressed VR2332 replication in both cell lines (Figure 1) .", [["cell lines", "ANATOMY", 137, 147], ["DiNap", "CHEMICAL", 53, 58], ["VR2332", "CHEMICAL", 110, 116], ["DiNap", "CHEMICAL", 53, 58], ["VR2332", "CHEMICAL", 110, 116], ["DiNap", "SIMPLE_CHEMICAL", 53, 58], ["VR2332", "SIMPLE_CHEMICAL", 110, 116], ["cell lines", "CELL", 137, 147], ["cell lines", "CELL_LINE", 137, 147], ["this study", "TEST", 77, 87], ["highest", "OBSERVATION_MODIFIER", 28, 35], ["concentration", "OBSERVATION_MODIFIER", 36, 49], ["both cell lines", "OBSERVATION", 132, 147]]], ["Although approximately 20% cell death was observed when DiNap was added at 0.06 mM, no significant side effects or toxicity were observed after treatment in pigs.DiscussionIn the pig experiment, we demonstrated that DiNap exerted its potential inhibitory effects against PRRSV infectivity in a dose-dependent manner.", [["cell", "ANATOMY", 27, 31], ["death", "DISEASE", 32, 37], ["DiNap", "CHEMICAL", 56, 61], ["toxicity", "DISEASE", 115, 123], ["DiNap", "CHEMICAL", 216, 221], ["DiNap", "CHEMICAL", 56, 61], ["DiNap", "CHEMICAL", 216, 221], ["cell", "CELL", 27, 31], ["DiNap", "SIMPLE_CHEMICAL", 56, 61], ["pigs", "ORGANISM", 157, 161], ["pig", "ORGANISM", 179, 182], ["DiNap", "SIMPLE_CHEMICAL", 216, 221], ["PRRSV", "ORGANISM", 271, 276], ["DiNap", "PROTEIN", 56, 61], ["pigs", "SPECIES", 157, 161], ["pigs", "SPECIES", 157, 161], ["pig", "SPECIES", 179, 182], ["PRRSV", "SPECIES", 271, 276], ["20% cell death", "PROBLEM", 23, 37], ["DiNap", "TEST", 56, 61], ["significant side effects", "PROBLEM", 87, 111], ["toxicity", "PROBLEM", 115, 123], ["treatment", "TREATMENT", 144, 153], ["PRRSV infectivity", "PROBLEM", 271, 288], ["20%", "OBSERVATION_MODIFIER", 23, 26], ["cell death", "OBSERVATION", 27, 37]]], ["Compared to the pigs in the untreated control group (group 1), the pigs treated with DiNap in group 2 and group 3 had reduced viral loads in the serum and lungs and increased weight gain (Figures 2, 4 and 6 ).", [["serum", "ANATOMY", 145, 150], ["lungs", "ANATOMY", 155, 160], ["DiNap", "CHEMICAL", 85, 90], ["weight gain", "DISEASE", 175, 186], ["DiNap", "CHEMICAL", 85, 90], ["pigs", "ORGANISM", 16, 20], ["pigs", "ORGANISM", 67, 71], ["DiNap", "SIMPLE_CHEMICAL", 85, 90], ["serum", "ORGANISM_SUBSTANCE", 145, 150], ["lungs", "ORGAN", 155, 160], ["pigs", "SPECIES", 16, 20], ["pigs", "SPECIES", 67, 71], ["pigs", "SPECIES", 16, 20], ["pigs", "SPECIES", 67, 71], ["the pigs", "TREATMENT", 63, 71], ["DiNap in group", "TREATMENT", 85, 99], ["reduced viral loads in the serum and lungs", "PROBLEM", 118, 160], ["increased weight gain", "PROBLEM", 165, 186], ["Figures", "TEST", 188, 195], ["viral loads", "OBSERVATION", 126, 137], ["serum", "ANATOMY", 145, 150], ["lungs", "ANATOMY", 155, 160], ["increased", "OBSERVATION_MODIFIER", 165, 174], ["weight gain", "OBSERVATION", 175, 186]]], ["Consistent with these findings, the pigs treated with DiNap also had fewer lesions (gross and microscopic) in their lungs than the control pigs ( Figure 5 ), suggesting that DiNap exerted significant effects on PRRSV infection.", [["lesions", "ANATOMY", 75, 82], ["lungs", "ANATOMY", 116, 121], ["DiNap", "CHEMICAL", 54, 59], ["DiNap", "CHEMICAL", 174, 179], ["PRRSV infection", "DISEASE", 211, 226], ["DiNap", "CHEMICAL", 54, 59], ["pigs", "ORGANISM", 36, 40], ["DiNap", "GENE_OR_GENE_PRODUCT", 54, 59], ["lesions", "PATHOLOGICAL_FORMATION", 75, 82], ["lungs", "ORGAN", 116, 121], ["pigs", "ORGANISM", 139, 143], ["DiNap", "GENE_OR_GENE_PRODUCT", 174, 179], ["PRRSV", "ORGANISM", 211, 216], ["pigs", "SPECIES", 36, 40], ["pigs", "SPECIES", 139, 143], ["pigs", "SPECIES", 36, 40], ["pigs", "SPECIES", 139, 143], ["PRRSV", "SPECIES", 211, 216], ["fewer lesions", "PROBLEM", 69, 82], ["gross and microscopic) in their lungs", "PROBLEM", 84, 121], ["DiNap", "PROBLEM", 174, 179], ["PRRSV infection", "PROBLEM", 211, 226], ["fewer", "OBSERVATION_MODIFIER", 69, 74], ["lesions", "OBSERVATION", 75, 82], ["gross", "OBSERVATION_MODIFIER", 84, 89], ["lungs", "ANATOMY", 116, 121], ["significant", "OBSERVATION_MODIFIER", 188, 199], ["PRRSV infection", "OBSERVATION", 211, 226]]], ["More importantly, two injections of DiNap were able to delay virus transmission by approximately 1 week with direct contact between the infected (virus challenged) and uninfected (not virus challenged) pigs in both treatment groups (groups 2 and 3).", [["DiNap", "CHEMICAL", 36, 41], ["DiNap", "CHEMICAL", 36, 41], ["DiNap", "GENE_OR_GENE_PRODUCT", 36, 41], ["pigs", "ORGANISM", 202, 206], ["pigs", "SPECIES", 202, 206], ["pigs", "SPECIES", 202, 206], ["DiNap", "TREATMENT", 36, 41], ["the infected (virus challenged", "PROBLEM", 132, 162], ["infected", "OBSERVATION", 136, 144]]], ["However, the virus was easily transmitted between the infected and uninfected pigs in the untreated control group (group 1), indicating that DiNap could be useful as a prophylactic or postexposure treatment agent in cases of PRRSV infection.", [["DiNap", "CHEMICAL", 141, 146], ["PRRSV infection", "DISEASE", 225, 240], ["pigs", "ORGANISM", 78, 82], ["DiNap", "SIMPLE_CHEMICAL", 141, 146], ["PRRSV", "ORGANISM", 225, 230], ["pigs", "SPECIES", 78, 82], ["PRRSV", "SPECIES", 225, 230], ["PRRSV", "SPECIES", 225, 230], ["the virus", "PROBLEM", 9, 18], ["a prophylactic", "TREATMENT", 166, 180], ["postexposure treatment agent", "TREATMENT", 184, 212], ["PRRSV infection", "PROBLEM", 225, 240], ["virus", "OBSERVATION", 13, 18], ["infected", "OBSERVATION", 54, 62], ["uninfected", "OBSERVATION_MODIFIER", 67, 77], ["pigs", "OBSERVATION_MODIFIER", 78, 82], ["PRRSV infection", "OBSERVATION", 225, 240]]], ["Because DiNap was produced in limited quantities on a laboratory scale, the antiviral effect of DiNap was only preliminarily evaluated with a small number of pigs in the current study.", [["DiNap", "CHEMICAL", 8, 13], ["DiNap", "CHEMICAL", 96, 101], ["DiNap", "GENE_OR_GENE_PRODUCT", 8, 13], ["DiNap", "SIMPLE_CHEMICAL", 96, 101], ["pigs", "ORGANISM", 158, 162], ["DiNap", "PROTEIN", 8, 13], ["pigs", "SPECIES", 158, 162], ["the antiviral effect of DiNap", "TREATMENT", 72, 101], ["the current study", "TEST", 166, 183], ["small", "OBSERVATION_MODIFIER", 142, 147], ["number", "OBSERVATION_MODIFIER", 148, 154]]], ["Therefore, more detailed animal experiments are needed to determine how long the antiviral effect of DiNap lasts in the future.DiscussionTaken together, these results demonstrated that DiNap might be useful as a potential prophylactic and postexposure anti-PRRSV drug for the treatment of PRRSV-infected pigs, although the efficacy and safety of long-term use of higher concentrations of DiNap remains to be confirmed in future experiments.General MethodsAll reagents and solvents were purchased from Sigma-Aldrich (Milwaukee, WI, USA) and Alfa Aesar (Ward Hill, MA, USA).", [["DiNap", "CHEMICAL", 101, 106], ["DiNap", "CHEMICAL", 185, 190], ["PRRSV-infected", "DISEASE", 289, 303], ["DiNap", "CHEMICAL", 388, 393], ["DiNap", "SIMPLE_CHEMICAL", 101, 106], ["DiNap", "SIMPLE_CHEMICAL", 185, 190], ["PRRSV", "ORGANISM", 289, 294], ["pigs", "ORGANISM", 304, 308], ["DiNap", "SIMPLE_CHEMICAL", 388, 393], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 501, 514], ["PRRSV", "SPECIES", 289, 294], ["pigs", "SPECIES", 304, 308], ["PRRSV", "SPECIES", 289, 294], ["pigs", "SPECIES", 304, 308], ["DiNap", "TREATMENT", 101, 106], ["a potential prophylactic and postexposure anti-PRRSV drug", "TREATMENT", 210, 267], ["the treatment", "TREATMENT", 272, 285], ["PRRSV", "PROBLEM", 289, 294], ["infected pigs", "TREATMENT", 295, 308], ["higher concentrations of DiNap", "TREATMENT", 363, 393], ["infected", "OBSERVATION", 295, 303]]], ["All experiments involving moisture-sensitive compounds were carried out in an argon atmosphere.", [["an argon atmosphere", "TREATMENT", 75, 94]]], ["Analytical thin-layer chromatography was performed on precoated silica gel F 254 thin layer chromatography (TLC) plates (E, Merck, Kenilworth, NJ, USA) with visualization under UV light.", [["silica", "CHEMICAL", 64, 70], ["Analytical thin-layer chromatography", "TEST", 0, 36], ["precoated silica gel F", "TREATMENT", 54, 76], ["thin layer chromatography", "TEST", 81, 106], ["UV light", "OBSERVATION", 177, 185]]], ["The final products were purified by preparative medium-pressure liquid chromatography (MPLC) (Biotage Isolera One instrument) on a silica column (Biotage SNAP HP-Sil) spectrometer (Biotage, Uppsala, Sweden).", [["SNAP", "CHEMICAL", 154, 158], ["silica", "CHEMICAL", 131, 137], ["preparative medium-pressure liquid chromatography", "TREATMENT", 36, 85], ["a silica column (Biotage SNAP HP-Sil) spectrometer", "TREATMENT", 129, 179], ["silica column", "ANATOMY", 131, 144]]], ["Nuclear magnetic resonance (NMR) analyses were performed using a Bruker 400 (400 MHz for 1 H; 100 MHz for 13 C) spectrometer (Bruker, Rheinstetten, Germany).", [["Nuclear magnetic resonance", "TEST", 0, 26], ["a Bruker", "TEST", 63, 71]]], ["The chemical shifts are reported in parts per million (\u03b4).", [["chemical shifts", "OBSERVATION", 4, 19]]], ["The deuterium lock signal of the sample solvent was used as a reference, and the coupling constants (J) are given in hertz (Hz).", [["deuterium", "CHEMICAL", 4, 13], ["the sample solvent", "TREATMENT", 29, 47]]], ["The splitting pattern abbreviations are as follows: s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; and m, multiplet.", [["The splitting pattern abbreviations", "PROBLEM", 0, 35]]], ["The purity of all tested compounds was confirmed to be higher than 95% by analytical high-performance liquid chromatography (HPLC) analysis performed with a dual-pump Shimadzu LC-6AD system equipped with a VP-ODS C18 column (4.6 mm \u00d7 250 mm, 5 \u00b5m, Shimadzu).1-(2-Hydroxy-4,6-dimethoxyphenyl)ethanone (2)A mixture of 2 ,4 ,6 -trihydroacetophenone hydrate (2.0 g, 11.89 mmol), potassium carbonate (3.62 g, 26.17 mmol) and dimethylsulfate (2.32 mL, 24.38 mmol) in acetone (30 mL) was stirred under argon at 66 \u2022 C for 2 h.", [["1-(2-Hydroxy-4,6-dimethoxyphenyl)ethanone", "CHEMICAL", 258, 299], ["2 ,4 ,6 -trihydroacetophenone hydrate", "CHEMICAL", 316, 353], ["potassium carbonate", "CHEMICAL", 375, 394], ["dimethylsulfate", "CHEMICAL", 420, 435], ["acetone", "CHEMICAL", 461, 468], ["1-(2-Hydroxy-4,6-dimethoxyphenyl)ethanone", "CHEMICAL", 258, 299], ["2 ,4 ,6 -trihydroacetophenone hydrate", "CHEMICAL", 316, 353], ["potassium carbonate", "CHEMICAL", 375, 394], ["dimethylsulfate", "CHEMICAL", 420, 435], ["acetone", "CHEMICAL", 461, 468], ["1-(2-Hydroxy-4,6-dimethoxyphenyl)ethanone (2)A", "SIMPLE_CHEMICAL", 258, 304], ["2 ,4 ,6 -trihydroacetophenone hydrate", "SIMPLE_CHEMICAL", 316, 353], ["potassium carbonate", "SIMPLE_CHEMICAL", 375, 394], ["dimethylsulfate", "SIMPLE_CHEMICAL", 420, 435], ["acetone", "SIMPLE_CHEMICAL", 461, 468], ["HPLC) analysis", "TEST", 125, 139], ["a VP-ODS C18 column", "TREATMENT", 204, 223], ["2-Hydroxy", "TEST", 261, 270], ["dimethoxyphenyl)ethanone", "TREATMENT", 275, 299], ["trihydroacetophenone hydrate", "TREATMENT", 325, 353], ["potassium carbonate", "TREATMENT", 375, 394], ["dimethylsulfate", "TREATMENT", 420, 435], ["argon", "TREATMENT", 495, 500]]], ["The resulting mixture was cooled to room temperature, filtered, and washed with acetone.", [["acetone", "CHEMICAL", 80, 87], ["acetone", "CHEMICAL", 80, 87], ["acetone", "SIMPLE_CHEMICAL", 80, 87], ["acetone", "TREATMENT", 80, 87]]], ["The filtrate was extracted with ethyl acetate.", [["ethyl acetate", "CHEMICAL", 32, 45], ["ethyl acetate", "CHEMICAL", 32, 45], ["ethyl acetate", "SIMPLE_CHEMICAL", 32, 45], ["The filtrate", "TREATMENT", 0, 12], ["ethyl acetate", "TREATMENT", 32, 45], ["filtrate", "OBSERVATION", 4, 12]]], ["The organic layer was washed three times with saturated NaHCO 3 solution, dried over Na 2 SO 4 , and concentrated under reduced pressure to produce compound 2 with 100% yield (R f = 0.34 (1:9 ethyl acetate: hexane); 1 DiNap was synthesized following the procedure reported in the literature with slight modifications [46] .", [["NaHCO", "CHEMICAL", 56, 61], ["Na 2 SO 4", "CHEMICAL", 85, 94], ["1:9 ethyl acetate: hexane", "CHEMICAL", 188, 213], ["DiNap", "CHEMICAL", 218, 223], ["NaHCO 3", "CHEMICAL", 56, 63], ["Na 2 SO 4", "CHEMICAL", 85, 94], ["ethyl acetate", "CHEMICAL", 192, 205], ["hexane", "CHEMICAL", 207, 213], ["Na 2 SO 4", "SIMPLE_CHEMICAL", 85, 94], ["1:9 ethyl acetate: hexane", "SIMPLE_CHEMICAL", 188, 213], ["DiNap", "SIMPLE_CHEMICAL", 218, 223], ["The organic layer", "TREATMENT", 0, 17], ["saturated NaHCO 3 solution", "TREATMENT", 46, 72], ["1:9 ethyl acetate: hexane", "TREATMENT", 188, 213], ["the procedure", "TREATMENT", 250, 263], ["organic", "OBSERVATION_MODIFIER", 4, 11], ["layer", "OBSERVATION_MODIFIER", 12, 17]]], ["Briefly, a mixture of compound 2 (0.2 g, 1.02 mmol), 1-naphthaldehyde (0.14 mL, 1.02 mmol) and potassium hydroxide (1 g) in methanol (20 mL) was stirred at 50 \u2022 C for 3 days.", [["compound 2", "CHEMICAL", 22, 32], ["1-naphthaldehyde", "CHEMICAL", 53, 69], ["potassium hydroxide", "CHEMICAL", 95, 114], ["methanol", "CHEMICAL", 124, 132], ["1-naphthaldehyde", "CHEMICAL", 53, 69], ["potassium hydroxide", "CHEMICAL", 95, 114], ["methanol", "CHEMICAL", 124, 132], ["1-naphthaldehyde", "SIMPLE_CHEMICAL", 53, 69], ["potassium hydroxide", "SIMPLE_CHEMICAL", 95, 114], ["methanol", "SIMPLE_CHEMICAL", 124, 132], ["naphthaldehyde", "TREATMENT", 55, 69], ["potassium hydroxide", "TREATMENT", 95, 114], ["methanol", "TREATMENT", 124, 132]]], ["The mixture was extracted with ethyl acetate.", [["ethyl acetate", "CHEMICAL", 31, 44], ["ethyl acetate", "CHEMICAL", 31, 44], ["ethyl acetate", "SIMPLE_CHEMICAL", 31, 44], ["ethyl acetate", "TREATMENT", 31, 44]]], ["The organic layer was washed three times with water, dried over Na 2 SO 4 , concentrated under reduced pressure, and purified by MPLC to produce DiNap with 32% yield (R f = 0.27 (1:9 ethyl acetate: hexane); 1Viruses and CellsVR2332, a prototype strain of type 2 PRRSV, was used in the present study.", [["Na 2 SO 4", "CHEMICAL", 64, 73], ["DiNap", "CHEMICAL", 145, 150], ["1:9 ethyl acetate: hexane", "CHEMICAL", 179, 204], ["CellsVR2332", "CHEMICAL", 220, 231], ["Na 2 SO 4", "CHEMICAL", 64, 73], ["DiNap", "CHEMICAL", 145, 150], ["ethyl acetate", "CHEMICAL", 183, 196], ["hexane", "CHEMICAL", 198, 204], ["CellsVR2332", "CHEMICAL", 220, 231], ["Na 2 SO 4", "SIMPLE_CHEMICAL", 64, 73], ["MPLC", "SIMPLE_CHEMICAL", 129, 133], ["DiNap", "SIMPLE_CHEMICAL", 145, 150], ["1:9 ethyl acetate: hexane", "SIMPLE_CHEMICAL", 179, 204], ["1Viruses", "SIMPLE_CHEMICAL", 207, 215], ["CellsVR2332", "SIMPLE_CHEMICAL", 220, 231], ["PRRSV", "ORGANISM", 262, 267], ["PRRSV", "SPECIES", 262, 267], ["The organic layer", "TREATMENT", 0, 17], ["DiNap", "TEST", 145, 150], ["1:9 ethyl acetate: hexane", "TREATMENT", 179, 204], ["1Viruses", "TREATMENT", 207, 215], ["CellsVR2332", "TREATMENT", 220, 231], ["a prototype strain of type 2 PRRSV", "TREATMENT", 233, 267], ["the present study", "TEST", 281, 298], ["organic", "OBSERVATION_MODIFIER", 4, 11], ["layer", "OBSERVATION_MODIFIER", 12, 17]]], ["MARC-145, an African Green Monkey Kidney cell line (highly permissive to PRRSV) [47] , and PAMs (the primary target cell for PRRSV replication in pigs) [48, 49] were used for the in vitro experiments.", [["Kidney cell line", "ANATOMY", 34, 50], ["cell", "ANATOMY", 116, 120], ["MARC-145", "CHEMICAL", 0, 8], ["Green Monkey Kidney cell line", "CELL", 21, 50], ["PRRSV", "ORGANISM", 73, 78], ["PAMs", "CELL", 91, 95], ["cell", "CELL", 116, 120], ["PRRSV", "ORGANISM", 125, 130], ["pigs", "ORGANISM", 146, 150], ["African Green Monkey Kidney cell line", "CELL_LINE", 13, 50], ["pigs", "SPECIES", 146, 150], ["PRRSV", "SPECIES", 73, 78], ["PRRSV", "SPECIES", 125, 130], ["MARC", "TEST", 0, 4], ["an African Green Monkey Kidney cell line", "TREATMENT", 10, 50], ["PAMs", "PROBLEM", 91, 95], ["PRRSV replication", "TREATMENT", 125, 142], ["Kidney", "ANATOMY", 34, 40], ["cell line", "OBSERVATION", 41, 50]]], ["PAMs were collected from 6-week-old, PRRSV-free pigs by bronchoalveolar lavage, as described previously [50, 51] .", [["bronchoalveolar lavage", "ANATOMY", 56, 78], ["PAMs", "CELL", 0, 4], ["PRRSV", "ORGANISM", 37, 42], ["pigs", "ORGANISM", 48, 52], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 56, 78], ["pigs", "SPECIES", 48, 52], ["PRRSV", "SPECIES", 37, 42], ["pigs", "SPECIES", 48, 52], ["PAMs", "TEST", 0, 4], ["PRRSV", "PROBLEM", 37, 42], ["bronchoalveolar lavage", "TEST", 56, 78], ["bronchoalveolar lavage", "OBSERVATION", 56, 78]]], ["MARC-145 cells were used for virus propagation, while the antiviral assays were performed in both cell lines (MARC-145 and PAMs).", [["MARC-145 cells", "ANATOMY", 0, 14], ["cell lines", "ANATOMY", 98, 108], ["MARC-145", "ANATOMY", 110, 118], ["PAMs", "ANATOMY", 123, 127], ["MARC-145", "CHEMICAL", 0, 8], ["MARC-145 cells", "CELL", 0, 14], ["cell lines", "CELL", 98, 108], ["MARC-145", "CELL", 110, 118], ["PAMs", "CELL", 123, 127], ["MARC-145 cells", "CELL_LINE", 0, 14], ["cell lines", "CELL_LINE", 98, 108], ["MARC-145", "CELL_LINE", 110, 118], ["PAMs", "CELL_LINE", 123, 127], ["virus propagation", "TREATMENT", 29, 46], ["the antiviral assays", "TEST", 54, 74], ["145 cells", "OBSERVATION_MODIFIER", 5, 14], ["cell lines", "OBSERVATION", 98, 108]]], ["Both cell lines were maintained in RPMI-1640 medium (Gibco, Invitrogen, Carlsbad, CA, USA) supplemented with heat-inactivated 10% fetal bovine serum (FBS, Gibco, Invitrogen), 2 mM L-glutamine, and 100x antibiotic-antimycotic solution (Anti-anti, Invitrogen; 1x solution contains 100 IU/mL penicillin, 100 \u00b5g/mL streptomycin, and 0.25 \u00b5g/mL Fungizone \u00ae (amphotericin B)) (named \"growth medium\") at 37 \u2022 C in a humidified 5% CO 2 atmosphere.Antiviral Effect of DiNap Against PRRSV Replication in CellsMARC-145 cells and PAMs were prepared in 6-well cell culture plates (BD, Falcon) 24 to 48 h before the start of the experiment.", [["cell lines", "ANATOMY", 5, 15], ["fetal bovine serum", "ANATOMY", 130, 148], ["FBS", "ANATOMY", 150, 153], ["CellsMARC-145 cells", "ANATOMY", 494, 513], ["cell", "ANATOMY", 547, 551], ["RPMI-1640", "CHEMICAL", 35, 44], ["L-glutamine", "CHEMICAL", 180, 191], ["penicillin", "CHEMICAL", 289, 299], ["streptomycin", "CHEMICAL", 311, 323], ["Fungizone \u00ae", "CHEMICAL", 340, 351], ["amphotericin B", "CHEMICAL", 353, 367], ["DiNap", "CHEMICAL", 459, 464], ["L-glutamine", "CHEMICAL", 180, 191], ["penicillin", "CHEMICAL", 289, 299], ["streptomycin", "CHEMICAL", 311, 323], ["Fungizone", "CHEMICAL", 340, 349], ["amphotericin B", "CHEMICAL", 353, 367], ["CO", "CHEMICAL", 423, 425], ["cell lines", "CELL", 5, 15], ["bovine", "ORGANISM", 136, 142], ["serum", "ORGANISM_SUBSTANCE", 143, 148], ["FBS", "ORGANISM_SUBSTANCE", 150, 153], ["L-glutamine", "SIMPLE_CHEMICAL", 180, 191], ["100x", "SIMPLE_CHEMICAL", 197, 201], ["penicillin", "SIMPLE_CHEMICAL", 289, 299], ["streptomycin", "SIMPLE_CHEMICAL", 311, 323], ["Fungizone \u00ae", "SIMPLE_CHEMICAL", 340, 351], ["amphotericin B", "SIMPLE_CHEMICAL", 353, 367], ["DiNap", "SIMPLE_CHEMICAL", 459, 464], ["PRRSV", "ORGANISM", 473, 478], ["CellsMARC-145 cells", "CELL", 494, 513], ["PAMs", "CELL", 518, 522], ["cell", "CELL", 547, 551], ["cell lines", "CELL_LINE", 5, 15], ["CellsMARC-145 cells", "CELL_LINE", 494, 513], ["PAMs", "CELL_TYPE", 518, 522], ["bovine", "SPECIES", 136, 142], ["PRRSV", "SPECIES", 473, 478], ["bovine", "SPECIES", 136, 142], ["PRRSV", "SPECIES", 473, 478], ["CellsMARC-145", "SPECIES", 494, 507], ["RPMI", "TEST", 35, 39], ["Gibco", "TEST", 53, 58], ["Invitrogen", "TEST", 60, 70], ["heat", "TREATMENT", 109, 113], ["fetal bovine serum", "TEST", 130, 148], ["FBS", "TEST", 150, 153], ["Gibco", "TEST", 155, 160], ["Invitrogen", "TEST", 162, 172], ["2 mM L-glutamine", "TREATMENT", 175, 191], ["100x antibiotic", "TREATMENT", 197, 212], ["antimycotic solution", "TREATMENT", 213, 233], ["Anti-anti, Invitrogen", "TREATMENT", 235, 256], ["penicillin", "TREATMENT", 289, 299], ["streptomycin", "TREATMENT", 311, 323], ["Fungizone", "TREATMENT", 340, 349], ["amphotericin B)", "TREATMENT", 353, 368], ["a humidified", "TREATMENT", 407, 419], ["Antiviral Effect", "TREATMENT", 439, 455], ["DiNap", "TREATMENT", 459, 464], ["PRRSV Replication", "TREATMENT", 473, 490], ["CellsMARC", "TEST", 494, 503], ["PAMs", "TEST", 518, 522], ["BD, Falcon)", "TREATMENT", 568, 579], ["cell lines", "OBSERVATION", 5, 15], ["145 cells", "OBSERVATION_MODIFIER", 504, 513]]], ["Following this, the cell monolayers were pretreated for 2 h before infection with growth medium containing DiNap at five different concentrations (0, 0.01, 0.02, 0.04, and 0.06 mM).", [["cell monolayers", "ANATOMY", 20, 35], ["infection", "DISEASE", 67, 76], ["DiNap", "CHEMICAL", 107, 112], ["cell monolayers", "CELL", 20, 35], ["DiNap", "SIMPLE_CHEMICAL", 107, 112], ["the cell monolayers", "TEST", 16, 35], ["infection", "PROBLEM", 67, 76]]], ["After the pretreatment incubation, the cell monolayers were washed with growth medium, inoculated with VR2332 at a multiplicity of infection (MOI) of 0.01 and incubated for 1 h.", [["cell monolayers", "ANATOMY", 39, 54], ["VR2332", "CHEMICAL", 103, 109], ["infection", "DISEASE", 131, 140], ["cell monolayers", "CELL", 39, 54], ["VR2332", "SIMPLE_CHEMICAL", 103, 109], ["the pretreatment incubation", "TREATMENT", 6, 33], ["the cell monolayers", "TEST", 35, 54], ["infection", "PROBLEM", 131, 140], ["cell monolayers", "OBSERVATION", 39, 54], ["infection", "OBSERVATION", 131, 140]]], ["After the final 1-h incubation, the viral inoculum was discarded, and the cell monolayers were replenished with growth medium containing the same concentrations of DiNap as a treatment and incubated for 4 more days under the same culture conditions.", [["cell monolayers", "ANATOMY", 74, 89], ["DiNap", "CHEMICAL", 164, 169], ["DiNap", "CHEMICAL", 164, 169], ["cell monolayers", "CELL", 74, 89], ["DiNap", "SIMPLE_CHEMICAL", 164, 169], ["the viral inoculum", "TREATMENT", 32, 50], ["the cell monolayers", "TEST", 70, 89], ["growth medium", "TREATMENT", 112, 125], ["DiNap", "TREATMENT", 164, 169], ["a treatment", "TREATMENT", 173, 184], ["the same culture conditions", "TEST", 221, 248], ["viral inoculum", "OBSERVATION", 36, 50], ["cell monolayers", "OBSERVATION", 74, 89]]], ["The cell culture supernatants were collected every 24 h, centrifuged, and stored at \u221280 \u2022 C until analysis.", [["cell", "ANATOMY", 4, 8], ["supernatants", "ANATOMY", 17, 29], ["cell", "CELL", 4, 8], ["The cell culture supernatants", "TEST", 0, 29]]], ["The progeny virus titers were measured using a microtitration infectivity assay [52] ; the virus titration assay was described briefly in a previous study [53] .", [["The progeny virus titers", "TEST", 0, 24], ["a microtitration infectivity assay", "TEST", 45, 79], ["the virus titration assay", "TEST", 87, 112], ["a previous study", "TEST", 138, 154]]], ["The virus titers were calculated based on the cytopathic effect (CPE) and are expressed as TCID 50 /mL [54] .MTT AssayThe cytotoxic effect of DiNap was assessed in MARC-145 cells and PAMs using an MTT [3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT, Sigma-Aldrich, St. Louis, MO, USA) assay, as described previously [55, 56] .", [["MARC-145 cells", "ANATOMY", 164, 178], ["DiNap", "CHEMICAL", 142, 147], ["3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide", "CHEMICAL", 202, 261], ["MTT", "CHEMICAL", 109, 112], ["DiNap", "CHEMICAL", 142, 147], ["MTT", "CHEMICAL", 197, 200], ["3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide", "CHEMICAL", 202, 261], ["MTT", "CHEMICAL", 264, 267], ["DiNap", "SIMPLE_CHEMICAL", 142, 147], ["MARC-145 cells", "CELL", 164, 178], ["PAMs", "CELL", 183, 187], ["3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide", "SIMPLE_CHEMICAL", 202, 261], ["MARC-145 cells", "CELL_LINE", 164, 178], ["PAMs", "CELL_TYPE", 183, 187], ["MARC-145", "SPECIES", 164, 172], ["The virus titers", "TEST", 0, 16], ["MTT Assay", "TEST", 109, 118], ["DiNap", "TEST", 142, 147], ["PAMs", "TEST", 183, 187], ["an MTT", "TEST", 194, 200], ["dimethylthiazol", "TREATMENT", 208, 223], ["diphenyltetrazolium bromide", "TREATMENT", 234, 261], ["virus", "OBSERVATION", 4, 9], ["cytopathic", "OBSERVATION_MODIFIER", 46, 56]]], ["In brief, MARC-145 cells and PAMs were prepared in 96-well cell culture plates (BD, Falcon) and treated with growth medium containing DiNap (0, 0.01, 0.02, 0.04, and 0.06 mM) for 24 and 48 h.", [["MARC-145 cells", "ANATOMY", 10, 24], ["cell", "ANATOMY", 59, 63], ["DiNap", "CHEMICAL", 134, 139], ["DiNap", "CHEMICAL", 134, 139], ["MARC-145 cells", "CELL", 10, 24], ["PAMs", "CELL", 29, 33], ["cell", "CELL", 59, 63], ["DiNap", "SIMPLE_CHEMICAL", 134, 139], ["MARC-145 cells", "CELL_LINE", 10, 24], ["PAMs", "CELL_TYPE", 29, 33], ["PAMs", "TEST", 29, 33], ["growth medium containing DiNap", "TREATMENT", 109, 139], ["145 cells", "OBSERVATION_MODIFIER", 15, 24]]], ["After incubation, the cell supernatants were discarded, and 20 \u00b5L of freshly made MTT (5 mg/mL) solution was added along with growth medium to each well.", [["cell supernatants", "ANATOMY", 22, 39], ["MTT", "CHEMICAL", 82, 85], ["MTT", "CHEMICAL", 82, 85], ["cell", "CELL", 22, 26], ["MTT", "SIMPLE_CHEMICAL", 82, 85], ["the cell supernatants", "TREATMENT", 18, 39], ["MTT", "TREATMENT", 82, 85]]], ["Then, the cells were incubated for another 3 h under the same conditions.", [["cells", "ANATOMY", 10, 15], ["cells", "CELL", 10, 15]]], ["After incubation, the MTT solutions were removed, and the plates were dried at 65 \u2022 C overnight.", [["MTT", "CHEMICAL", 22, 25], ["MTT", "SIMPLE_CHEMICAL", 22, 25], ["the MTT solutions", "TREATMENT", 18, 35], ["the plates", "TREATMENT", 54, 64]]], ["Then, 200 \u00b5L of dimethyl sulfoxide (DMSO; Hybri-Max \u00ae , Sigma-Aldrich) was added to each well to dissolve the formazan crystals.", [["dimethyl sulfoxide", "CHEMICAL", 16, 34], ["DMSO", "CHEMICAL", 36, 40], ["formazan", "CHEMICAL", 110, 118], ["dimethyl sulfoxide", "CHEMICAL", 16, 34], ["DMSO", "CHEMICAL", 36, 40], ["formazan", "CHEMICAL", 110, 118], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 16, 34], ["DMSO", "SIMPLE_CHEMICAL", 36, 40], ["Hybri-Max \u00ae", "SIMPLE_CHEMICAL", 42, 53], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 56, 69], ["formazan crystals", "SIMPLE_CHEMICAL", 110, 127], ["dimethyl sulfoxide (DMSO", "TREATMENT", 16, 40], ["Hybri-Max \u00ae", "TREATMENT", 42, 53], ["Sigma-Aldrich)", "TREATMENT", 56, 70], ["the formazan crystals", "TREATMENT", 106, 127]]], ["The plates were further incubated at 37 \u2022 C for 5 to 10 min to dissolve any air bubbles before the MTT signal was measured using an ELISA microplate reader at an absorbance of 540 nm.Animal Experiment and SamplesIn total, 9 three-week-old PRRSV-negative pigs were purchased.", [["MTT", "CHEMICAL", 99, 102], ["PRRSV", "ORGANISM", 239, 244], ["pigs", "ORGANISM", 254, 258], ["pigs", "SPECIES", 254, 258], ["PRRSV", "SPECIES", 239, 244], ["pigs", "SPECIES", 254, 258], ["The plates", "TREATMENT", 0, 10], ["any air bubbles", "PROBLEM", 72, 87], ["the MTT signal", "TEST", 95, 109], ["an ELISA microplate", "TEST", 129, 148], ["Samples", "TEST", 205, 212], ["plates", "OBSERVATION_MODIFIER", 4, 10], ["air bubbles", "OBSERVATION", 76, 87]]], ["On their arrival at the facility, the pigs were randomly housed in three groups (3 pigs per group), designated group 1 (pigs 1 to 3), group 2 (pigs 4 to 6), and group 3 (pigs 7 to 9) and allowed to acclimatize for 3 days.", [["pigs", "ORGANISM", 38, 42], ["pigs", "ORGANISM", 83, 87], ["pigs", "ORGANISM", 143, 147], ["pigs", "ORGANISM", 170, 174], ["pigs", "SPECIES", 38, 42], ["pigs", "SPECIES", 83, 87], ["pigs", "SPECIES", 120, 124], ["pigs", "SPECIES", 143, 147], ["pigs", "SPECIES", 170, 174], ["pigs", "SPECIES", 38, 42]]], ["Then, qRT-PCR (TaqMan) and ELISA were used to confirm that the pigs were negative for PRRSV.", [["pigs", "ORGANISM", 63, 67], ["PRRSV", "ORGANISM", 86, 91], ["pigs", "SPECIES", 63, 67], ["pigs", "SPECIES", 63, 67], ["PRRSV", "SPECIES", 86, 91], ["qRT", "TEST", 6, 9], ["PCR", "TEST", 10, 13], ["ELISA", "TEST", 27, 32], ["the pigs", "TEST", 59, 67], ["PRRSV", "PROBLEM", 86, 91]]], ["On day 0, one pig (1, 4, and 7 in groups 1, 2,and 3, respectively) in each group was challenged with VR2332 at a titer of 10 3 /mL TCID 50 (2 mL/pig) through the intranasal (IN) route, and the challenged pigs were then maintained in their groups to observe the transmission of the virus to the unchallenged contact pigs.", [["VR2332", "CHEMICAL", 101, 107], ["VR2332", "CHEMICAL", 101, 107], ["pig", "ORGANISM", 14, 17], ["VR2332", "SIMPLE_CHEMICAL", 101, 107], ["pig", "ORGANISM", 145, 148], ["pigs", "ORGANISM", 204, 208], ["pigs", "ORGANISM", 315, 319], ["pig", "SPECIES", 14, 17], ["pigs", "SPECIES", 204, 208], ["pigs", "SPECIES", 315, 319], ["pig", "SPECIES", 14, 17], ["pig", "SPECIES", 145, 148], ["pigs", "SPECIES", 204, 208], ["the challenged pigs", "TREATMENT", 189, 208], ["the virus", "PROBLEM", 277, 286], ["contact pigs", "OBSERVATION", 307, 319]]], ["On the same day, all 3 pigs in group 2 and group 3 were injected with 0.32 mM (0.04 mM/kg body weight) and 1.6 mM (0.2 mM/kg body weight) DiNap prepared in 2 mL of DMSO behind the base of each ear intramuscularly (IM), respectively.", [["body", "ANATOMY", 90, 94], ["body", "ANATOMY", 125, 129], ["ear", "ANATOMY", 193, 196], ["DiNap", "CHEMICAL", 138, 143], ["DMSO", "CHEMICAL", 164, 168], ["DMSO", "CHEMICAL", 164, 168], ["pigs", "ORGANISM", 23, 27], ["body", "ORGANISM_SUBDIVISION", 90, 94], ["body", "ORGANISM_SUBDIVISION", 125, 129], ["DiNap", "SIMPLE_CHEMICAL", 138, 143], ["DMSO", "SIMPLE_CHEMICAL", 164, 168], ["ear", "ORGAN", 193, 196], ["pigs", "SPECIES", 23, 27], ["all 3 pigs in group 2 and group 3", "TREATMENT", 17, 50], ["mM/kg body weight)", "TREATMENT", 119, 137], ["DiNap", "TREATMENT", 138, 143], ["DMSO", "TREATMENT", 164, 168], ["base", "ANATOMY_MODIFIER", 180, 184], ["ear intramuscularly", "ANATOMY", 193, 212]]], ["All 3 pigs in group 1 constituted the nontreated challenged control (NC) group.", [["pigs", "ORGANISM", 6, 10], ["pigs", "SPECIES", 6, 10], ["the nontreated challenged control (NC) group", "TREATMENT", 34, 78]]], ["The treatment with DiNap was repeated with the same concentrations at 3 dpc.", [["DiNap", "CHEMICAL", 19, 24], ["DiNap", "SIMPLE_CHEMICAL", 19, 24], ["The treatment", "TREATMENT", 0, 13], ["DiNap", "TREATMENT", 19, 24]]], ["After this, the pigs were observed daily for clinical signs up to 28 dpc.", [["pigs", "ORGANISM", 16, 20], ["pigs", "SPECIES", 16, 20], ["pigs", "SPECIES", 16, 20], ["the pigs", "TREATMENT", 12, 20], ["clinical signs", "TEST", 45, 59]]], ["The pigs were weighed at 0 (before challenge) and 28 dpc.", [["pigs", "ORGANISM", 4, 8], ["pigs", "SPECIES", 4, 8], ["pigs", "SPECIES", 4, 8], ["The pigs", "TREATMENT", 0, 8]]], ["Serum samples were collected at 0 (before challenge), 7, 14, 21, and 28 dpc for virological and serological assays.", [["Serum samples", "ANATOMY", 0, 13], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["Serum samples", "TEST", 0, 13], ["virological and serological assays", "TEST", 80, 114]]], ["At the end of 28 dpc, all pigs were euthanized, and the results of pathological examinations, including the presence of gross lung lesions, were recorded by an expert pathologist based on the standard scoring system, as described previously [57] .", [["gross lung lesions", "ANATOMY", 120, 138], ["lung lesions", "DISEASE", 126, 138], ["pigs", "ORGANISM", 26, 30], ["lung lesions", "CANCER", 126, 138], ["pigs", "SPECIES", 26, 30], ["pigs", "SPECIES", 26, 30], ["all pigs", "TREATMENT", 22, 30], ["pathological examinations", "TEST", 67, 92], ["gross lung lesions", "PROBLEM", 120, 138], ["gross", "OBSERVATION_MODIFIER", 120, 125], ["lung", "ANATOMY", 126, 130], ["lesions", "OBSERVATION", 131, 138]]], ["In addition, lung tissue samples were collected in 10% neutral buffered formalin for the examination of microscopic changes.", [["lung tissue samples", "ANATOMY", 13, 32], ["formalin", "CHEMICAL", 72, 80], ["lung tissue samples", "CANCER", 13, 32], ["formalin", "SIMPLE_CHEMICAL", 72, 80], ["lung tissue samples", "TEST", 13, 32], ["the examination", "TEST", 85, 100], ["microscopic changes", "PROBLEM", 104, 123], ["lung tissue", "ANATOMY", 13, 24], ["microscopic", "OBSERVATION", 104, 115]]], ["Furthermore, additional lung tissue samples were collected and stored at \u221280 \u2022 C until analysis.", [["lung tissue samples", "ANATOMY", 24, 43], ["lung tissue samples", "CANCER", 24, 43], ["additional lung tissue samples", "TEST", 13, 43], ["analysis", "TEST", 87, 95], ["lung", "ANATOMY", 24, 28], ["tissue", "OBSERVATION", 29, 35]]], ["Viral loads were quantified in the serum and lung tissue samples.", [["serum", "ANATOMY", 35, 40], ["lung tissue samples", "ANATOMY", 45, 64], ["Viral", "ORGANISM", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 35, 40], ["lung tissue samples", "TISSUE", 45, 64], ["Viral loads", "TEST", 0, 11], ["the serum", "TEST", 31, 40], ["lung tissue", "ANATOMY", 45, 56]]], ["The animal experiment protocols were approved by the Chonbuk National University Institutional Animal Care and Use Committee (approval number: 2012-0025).Serum ELISAPRRSV-specific antibodies (IgG) were detected in the serum samples from each group by using a commercially available ELISA kit (IDEXX PRRS X3 Ab Test, IDEXX Laboratories, AG, Berne, Switzerland) following the instructions supplied by the manufacturer.", [["Serum", "ANATOMY", 154, 159], ["serum samples", "ANATOMY", 218, 231], ["Serum", "ORGANISM_SUBSTANCE", 154, 159], ["ELISAPRRSV-specific antibodies", "GENE_OR_GENE_PRODUCT", 160, 190], ["IgG", "GENE_OR_GENE_PRODUCT", 192, 195], ["serum samples", "ORGANISM_SUBSTANCE", 218, 231], ["Serum ELISAPRRSV-specific antibodies", "PROTEIN", 154, 190], ["IgG", "PROTEIN", 192, 195], ["Serum ELISAPRRSV", "TEST", 154, 170], ["specific antibodies", "TEST", 171, 190], ["IgG", "TEST", 192, 195], ["the serum samples", "TEST", 214, 231], ["Ab Test", "TEST", 307, 314]]], ["An S/P ratio (ratio between the net optical density of the test samples and the net optical density of the positive control) \u2265 0.4 was considered positive for the PRRSV antibody.Lung Tissue Scoring and PathologyAt the end of 28 dpc, the lungs of the euthanized pigs were scored for gross lesions immediately after necropsy [57] .", [["samples", "ANATOMY", 64, 71], ["Lung Tissue", "ANATOMY", 178, 189], ["lungs", "ANATOMY", 237, 242], ["gross lesions", "ANATOMY", 282, 295], ["PRRSV", "ORGANISM", 163, 168], ["Lung Tissue", "TISSUE", 178, 189], ["lungs", "ORGAN", 237, 242], ["pigs", "ORGANISM", 261, 265], ["gross lesions", "CANCER", 282, 295], ["PRRSV antibody", "PROTEIN", 163, 177], ["pigs", "SPECIES", 261, 265], ["PRRSV", "SPECIES", 163, 168], ["pigs", "SPECIES", 261, 265], ["An S/P ratio", "TEST", 0, 12], ["the test samples", "TEST", 55, 71], ["the PRRSV antibody", "PROBLEM", 159, 177], ["Pathology", "TEST", 202, 211], ["gross lesions", "PROBLEM", 282, 295], ["PRRSV antibody", "OBSERVATION", 163, 177], ["Tissue", "OBSERVATION", 183, 189], ["Pathology", "OBSERVATION", 202, 211], ["lungs", "ANATOMY", 237, 242], ["lesions", "OBSERVATION", 288, 295]]], ["The microscopic lesions were also scored in lung tissue sections by staining with hematoxylin and eosin (H & E).", [["lesions", "ANATOMY", 16, 23], ["lung tissue sections", "ANATOMY", 44, 64], ["hematoxylin", "CHEMICAL", 82, 93], ["eosin", "CHEMICAL", 98, 103], ["microscopic lesions", "CANCER", 4, 23], ["lung tissue sections", "MULTI-TISSUE_STRUCTURE", 44, 64], ["hematoxylin", "SIMPLE_CHEMICAL", 82, 93], ["H & E", "SIMPLE_CHEMICAL", 105, 110], ["The microscopic lesions", "PROBLEM", 0, 23], ["hematoxylin", "TEST", 82, 93], ["microscopic", "OBSERVATION_MODIFIER", 4, 15], ["lesions", "OBSERVATION", 16, 23], ["lung tissue", "ANATOMY", 44, 55]]], ["The scoring of the microscopic lesions was performed according to a scale from 0 to 3 depending on the degree of inflammation (especially the presence of interstitial pneumonia), where 0 indicated no lesions, 1 indicated mild interstitial pneumonia, 2 indicated moderate/multifocal interstitial pneumonia, and 3 indicated severe intense/diffuse interstitial pneumonia.Quantification of Viral Loads in Serum and Lung TissueViral RNA was extracted from the serum and lung tissue samples using the MagMAX\u2122 Viral RNA Isolation Kit (Ambion, Applied Biosystems, Life Technologies, Inc., Carlsbad, CA, USA) and a total RNA extraction kit (Hybrid-RTM, GeneAll, Seoul, Korea), respectively, according to the manufacturer's instructions.", [["lesions", "ANATOMY", 31, 38], ["interstitial", "ANATOMY", 154, 166], ["lesions", "ANATOMY", 200, 207], ["interstitial", "ANATOMY", 226, 238], ["interstitial", "ANATOMY", 282, 294], ["interstitial", "ANATOMY", 345, 357], ["Serum", "ANATOMY", 401, 406], ["Lung", "ANATOMY", 411, 415], ["serum", "ANATOMY", 455, 460], ["lung tissue samples", "ANATOMY", 465, 484], ["inflammation", "DISEASE", 113, 125], ["interstitial pneumonia", "DISEASE", 154, 176], ["interstitial pneumonia", "DISEASE", 226, 248], ["interstitial pneumonia", "DISEASE", 282, 304], ["interstitial pneumonia", "DISEASE", 345, 367], ["lesions", "CANCER", 31, 38], ["lesions", "PATHOLOGICAL_FORMATION", 200, 207], ["Viral", "ORGANISM", 386, 391], ["Serum", "ORGANISM_SUBSTANCE", 401, 406], ["Lung", "ORGAN", 411, 415], ["serum", "ORGANISM_SUBSTANCE", 455, 460], ["lung tissue samples", "TISSUE", 465, 484], ["Serum and Lung TissueViral RNA", "RNA", 401, 431], ["the microscopic lesions", "PROBLEM", 15, 38], ["inflammation", "PROBLEM", 113, 125], ["interstitial pneumonia", "PROBLEM", 154, 176], ["lesions", "PROBLEM", 200, 207], ["mild interstitial pneumonia", "PROBLEM", 221, 248], ["moderate/multifocal interstitial pneumonia", "PROBLEM", 262, 304], ["severe intense/diffuse interstitial pneumonia", "PROBLEM", 322, 367], ["Viral Loads in Serum and Lung TissueViral RNA", "PROBLEM", 386, 431], ["the serum", "TEST", 451, 460], ["the MagMAX", "TREATMENT", 491, 501], ["Viral RNA Isolation Kit (Ambion", "TREATMENT", 503, 534], ["Life Technologies", "TREATMENT", 556, 573], ["a total RNA extraction", "TREATMENT", 604, 626], ["microscopic", "OBSERVATION_MODIFIER", 19, 30], ["lesions", "OBSERVATION", 31, 38], ["inflammation", "OBSERVATION", 113, 125], ["interstitial", "ANATOMY_MODIFIER", 154, 166], ["pneumonia", "OBSERVATION", 167, 176], ["no", "UNCERTAINTY", 197, 199], ["lesions", "OBSERVATION", 200, 207], ["mild", "OBSERVATION_MODIFIER", 221, 225], ["interstitial", "ANATOMY_MODIFIER", 226, 238], ["pneumonia", "OBSERVATION", 239, 248], ["moderate", "OBSERVATION_MODIFIER", 262, 270], ["multifocal", "OBSERVATION_MODIFIER", 271, 281], ["interstitial", "ANATOMY_MODIFIER", 282, 294], ["pneumonia", "OBSERVATION", 295, 304], ["severe", "OBSERVATION_MODIFIER", 322, 328], ["intense", "OBSERVATION_MODIFIER", 329, 336], ["diffuse", "OBSERVATION_MODIFIER", 337, 344], ["interstitial", "ANATOMY_MODIFIER", 345, 357], ["pneumonia", "OBSERVATION", 358, 367], ["Viral Loads", "OBSERVATION", 386, 397], ["Lung", "ANATOMY", 411, 415], ["TissueViral RNA", "OBSERVATION", 416, 431], ["lung", "ANATOMY", 465, 469], ["RNA Isolation Kit", "OBSERVATION", 509, 526]]], ["The viral loads in the serum and tissues were quantified by real-time reverse transcription-polymerase chain reaction (qRT-PCR) using a TaqMan \u00ae assay based on a previous study [58] .", [["serum", "ANATOMY", 23, 28], ["tissues", "ANATOMY", 33, 40], ["serum", "ORGANISM_SUBSTANCE", 23, 28], ["tissues", "TISSUE", 33, 40], ["The viral loads in the serum and tissues", "TEST", 0, 40], ["polymerase chain reaction", "PROBLEM", 92, 117], ["a TaqMan \u00ae assay", "TEST", 134, 150], ["a previous study", "TEST", 160, 176], ["viral loads", "OBSERVATION", 4, 15], ["tissues", "ANATOMY", 33, 40]]], ["The primer and probe sequences were as follows: forward primer TGTCAGATTCAGGGAGRATAAGTTAC; probe 6-FAM TGTGGAGTTYAGTYTGCC; and reverse primer ATCARGCGCACAGTRTGATGC.", [["primer and probe sequences", "DNA", 4, 30], ["probe 6", "DNA", 91, 98], ["FAM TGTGGAGTTYAGTYTGCC", "DNA", 99, 121], ["reverse primer ATCARGCGCACAGTRTGATGC", "DNA", 127, 163], ["The primer and probe sequences", "TEST", 0, 30], ["forward primer TGTCAGATTCAGGGAGRATAAGTTAC", "TREATMENT", 48, 89], ["FAM TGTGGAGTTYAGTYTGCC", "TREATMENT", 99, 121], ["reverse primer ATCARGCGCACAGTRTGATGC", "TREATMENT", 127, 163]]], ["A one-step quantitative real-time RT-PCR (qRT-PCR) kit (AgPath-ID\u2122 One-Step RT-PCR, Ambion, Applied Biosystems, Life Technologies, Inc., Carlsbad, CA, USA) was used to measure the viral loads in the serum and lung tissues.", [["serum", "ANATOMY", 199, 204], ["lung tissues", "ANATOMY", 209, 221], ["serum", "ORGANISM_SUBSTANCE", 199, 204], ["lung tissues", "TISSUE", 209, 221], ["PCR", "TEST", 37, 40], ["qRT", "TEST", 42, 45], ["PCR", "TEST", 46, 49], ["kit", "TEST", 51, 54], ["AgPath", "TEST", 56, 62], ["PCR", "TEST", 79, 82], ["Ambion", "TREATMENT", 84, 90], ["Life Technologies", "TREATMENT", 112, 129], ["the viral loads in the serum and lung tissues", "PROBLEM", 176, 221], ["viral loads", "OBSERVATION", 180, 191], ["serum", "ANATOMY", 199, 204], ["lung tissues", "ANATOMY", 209, 221]]], ["Polymerase chain reaction (PCR) amplification was performed with a 7500 Fast Real-time PCR system (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's guidelines.", [["Polymerase chain reaction", "PROBLEM", 0, 25]]], ["One-step qRT-PCR was performed in a total of 25 \u00b5L containing 5 \u00b5L of template RNA, 12.5 \u00b5L of 2\u00d7 RT-PCR buffer, 0.5 \u00b5L of each forward and reverse primer (20 pmol, at a final concentration of 0.8 pmol), 0.2 \u00b5L of the TaqMan \u00ae probes (25 pmol, at a final concentration of 1 pmol), 0.5 \u00b5L of RNAse inhibitor (40 U/\u00b5L; RiboLock TM , Thermo Fisher Scientific Inc., Germany), 1 \u00b5L of 25X RT-PCR enzyme mix, and 4.8 \u00b5L of nuclease-free water.", [["RNAse", "GENE_OR_GENE_PRODUCT", 291, 296], ["template RNA", "RNA", 70, 82], ["nuclease", "PROTEIN", 417, 425], ["PCR", "TEST", 13, 16], ["template RNA", "TREATMENT", 70, 82], ["RT-PCR buffer", "TREATMENT", 98, 111], ["the TaqMan \u00ae probes", "TREATMENT", 214, 233], ["RNAse inhibitor", "TREATMENT", 291, 306], ["PCR enzyme mix", "TEST", 387, 401], ["nuclease", "TEST", 417, 425]]], ["The cycling conditions were as follows: (a) Reverse transcription for 10 min at 45 \u2022 C; (b) a 10-min activation step at 95 \u2022 C; and (c) 40 cycles of 15 s at 95 \u2022 C and 45 s at 60 \u2022 C. Samples with a threshold cycle (C t ) of 35 cycles or fewer were considered positive.", [["a threshold cycle", "TEST", 197, 214], ["positive", "OBSERVATION", 260, 268]]], ["A standard curve was generated from known virus titers and used to calculate the amount of PRRSV in each sample by converting the C t value to the TCID 50 /mL equivalent.Data AnalysisRepeated measures analysis of variance (ANOVA) was used to analyze the significance of differences among the treatment groups for the in vitro evaluation of the effect of DiNap on PRRSV replication in cells and for the serum viremia and serum ELISA (anti-PRRSV IgG) results.", [["sample", "ANATOMY", 105, 111], ["cells", "ANATOMY", 384, 389], ["serum", "ANATOMY", 402, 407], ["serum", "ANATOMY", 420, 425], ["DiNap", "CHEMICAL", 354, 359], ["PRRSV", "ORGANISM", 91, 96], ["DiNap", "SIMPLE_CHEMICAL", 354, 359], ["PRRSV", "ORGANISM", 363, 368], ["cells", "CELL", 384, 389], ["serum", "ORGANISM_SUBSTANCE", 402, 407], ["serum", "ORGANISM_SUBSTANCE", 420, 425], ["anti-PRRSV IgG", "GENE_OR_GENE_PRODUCT", 433, 447], ["PRRSV IgG", "PROTEIN", 438, 447], ["PRRSV", "SPECIES", 91, 96], ["PRRSV", "SPECIES", 363, 368], ["PRRSV", "SPECIES", 438, 443], ["A standard curve", "TREATMENT", 0, 16], ["known virus titers", "PROBLEM", 36, 54], ["the treatment groups", "TREATMENT", 288, 308], ["the in vitro evaluation", "TEST", 313, 336], ["DiNap", "TREATMENT", 354, 359], ["PRRSV replication in cells", "TREATMENT", 363, 389], ["the serum viremia", "TEST", 398, 415], ["serum ELISA", "TEST", 420, 431], ["anti-PRRSV IgG", "TEST", 433, 447]]], ["The Mann-Whitney U test (a nonparametric t test) was used to analyze the significance of differences among groups for ADWG, lung lesions (gross and microscopic) and viral loads in lung tissues. p < 0.05 indicated a statistically significant difference.", [["lung lesions", "ANATOMY", 124, 136], ["lung tissues", "ANATOMY", 180, 192], ["lung lesions", "DISEASE", 124, 136], ["lung lesions", "CANCER", 124, 136], ["lung tissues", "TISSUE", 180, 192], ["The Mann-Whitney U test", "TEST", 0, 23], ["a nonparametric t test)", "TEST", 25, 48], ["ADWG", "PROBLEM", 118, 122], ["lung lesions", "PROBLEM", 124, 136], ["viral loads in lung tissues", "PROBLEM", 165, 192], ["a statistically significant difference", "PROBLEM", 213, 251], ["lung", "ANATOMY", 124, 128], ["lesions", "OBSERVATION", 129, 136], ["viral loads", "OBSERVATION", 165, 176], ["lung tissues", "ANATOMY", 180, 192]]], ["Graph Pad Prism 5.0.2 (GraphPad Software, Inc., CA, USA) was used to produce the graphs, while statistical analysis was performed using SPSS Advanced Statistics 17.0 software (SPSS, Inc., Chicago, IL, USA).", [["Graph Pad Prism", "TEST", 0, 15], ["GraphPad Software", "TEST", 23, 40], ["the graphs", "TEST", 77, 87], ["statistical analysis", "TEST", 95, 115], ["Statistics", "TEST", 150, 160], ["software", "TEST", 166, 174], ["SPSS", "TEST", 176, 180]]], ["Acknowledgments: The authors are happy to acknowledge the undergraduate students and laboratory technicians from the College of Veterinary Medicine and Veterinary Diagnostic Center (VDC), respectively, Chonbuk National University for their assistance during the animal experiment.Conflicts of Interest:The authors declared that there are no conflicts of interest.", [["no", "UNCERTAINTY", 338, 340]]]], "8c2a95a18eb0bcd59b7288d6081ac3fa028328dd": [["IntroductionThe coronavirus disease 2019 (COVID-19) pandemic witnessed several clusters of children with fever and multisystem inflammation resembling Kawasaki disease (KD).", [["coronavirus disease", "DISEASE", 16, 35], ["fever", "DISEASE", 105, 110], ["multisystem inflammation", "DISEASE", 115, 139], ["Kawasaki disease", "DISEASE", 151, 167], ["KD", "DISEASE", 169, 171], ["coronavirus", "ORGANISM", 16, 27], ["children", "ORGANISM", 91, 99], ["children", "SPECIES", 91, 99], ["coronavirus disease 2019 (COVID-19", "SPECIES", 16, 50], ["The coronavirus disease", "PROBLEM", 12, 35], ["fever", "PROBLEM", 105, 110], ["multisystem inflammation", "PROBLEM", 115, 139], ["Kawasaki disease", "PROBLEM", 151, 167], ["coronavirus disease", "OBSERVATION", 16, 35], ["multisystem", "OBSERVATION_MODIFIER", 115, 126], ["inflammation", "OBSERVATION", 127, 139], ["Kawasaki disease", "OBSERVATION", 151, 167]]], ["Due to the evidence of a preceding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in most of these patients, post-viral immunological reactions were thought to play an important role in the pathogenesis.", [["acute respiratory syndrome coronavirus", "DISEASE", 42, 80], ["infection", "DISEASE", 96, 105], ["SARS-CoV-2", "ORGANISM", 84, 94], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["severe acute respiratory syndrome coronavirus", "SPECIES", 35, 80], ["SARS-CoV-2", "SPECIES", 84, 94], ["a preceding severe acute respiratory syndrome coronavirus", "PROBLEM", 23, 80], ["SARS", "PROBLEM", 84, 88], ["infection", "PROBLEM", 96, 105], ["post-viral immunological reactions", "PROBLEM", 133, 167], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["acute", "OBSERVATION_MODIFIER", 42, 47], ["respiratory syndrome coronavirus", "OBSERVATION", 48, 80], ["infection", "OBSERVATION", 96, 105]]], ["1, 2 The condition, called \"pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 infection (PIMS-TS)\", has thus far been reported mainly from Europe and the United States, 1,2 and no cases have been diagnosed in Asia.", [["multisystem syndrome", "DISEASE", 51, 71], ["SARS-CoV-2 infection", "DISEASE", 99, 119], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 99, 109], ["pediatric inflammatory multisystem syndrome", "PROBLEM", 28, 71], ["SARS", "PROBLEM", 99, 103], ["CoV-2 infection", "PROBLEM", 104, 119], ["inflammatory", "OBSERVATION_MODIFIER", 38, 50], ["multisystem syndrome", "OBSERVATION", 51, 71]]], ["We herein analyzed the clinical data on patients in whom KD was diagnosed during a local COVID-19 epidemic to investigate the relationship between KD and SARS-CoV-2 infections in Japan, which has the highest KD incidence in the world.MethodsThe present retrospective observational study was conducted at Tokyo Metropolitan Children's Medical Center (Tokyo, Japan), one of the largest pediatric referral centers in the nation.", [["SARS-CoV-2 infections", "DISEASE", 154, 175], ["patients", "ORGANISM", 40, 48], ["SARS-CoV-2", "ORGANISM", 154, 164], ["patients", "SPECIES", 40, 48], ["SARS-CoV-2", "SPECIES", 154, 164], ["a local COVID", "TEST", 81, 94], ["SARS", "PROBLEM", 154, 158], ["CoV", "PROBLEM", 159, 162], ["2 infections", "PROBLEM", 163, 175]]], ["Children who received a KD diagnosis and were treated at our hospital between December 1, 2019 and May 31, 2020 were included.", [["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8]]], ["Patients who were treated for KD elsewhere before being transferred to our hospital were excluded.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["To compare the clinical presentations before and during the local COVID-19 epidemic, the patients were divided into two groups, period 1 and period 2, based on whether the diagnosis was made before or after March 1, 2020.", [["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["the local COVID", "TEST", 56, 71]]], ["The patients' data were extracted from their medical records.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["Levels of anti-SARS-CoV-2 IgM and IgG in the sera were measured by chemiluminescent microparticle immunoassay using the iFlash 3000 chemiluminescent immune analyzer (YHLO Biotechnology Co., Ltd., Shenzhen, China) with a cutoff value of 10 AU/mL for IgM and IgG.", [["sera", "ANATOMY", 45, 49], ["anti-SARS-CoV-2 IgM", "GENE_OR_GENE_PRODUCT", 10, 29], ["IgG", "GENE_OR_GENE_PRODUCT", 34, 37], ["sera", "ORGANISM_SUBSTANCE", 45, 49], ["IgM", "GENE_OR_GENE_PRODUCT", 249, 252], ["IgG", "GENE_OR_GENE_PRODUCT", 257, 260], ["anti-SARS", "PROTEIN", 10, 19], ["CoV", "PROTEIN", 20, 23], ["IgM", "PROTEIN", 26, 29], ["IgG", "PROTEIN", 34, 37], ["IgM", "PROTEIN", 249, 252], ["IgG", "PROTEIN", 257, 260], ["Levels", "TEST", 0, 6], ["anti-SARS", "TEST", 10, 19], ["CoV", "TEST", 20, 23], ["IgM", "TEST", 26, 29], ["IgG in the sera", "TEST", 34, 49], ["chemiluminescent microparticle immunoassay", "TEST", 67, 109], ["the iFlash", "TEST", 116, 126], ["a cutoff value", "TEST", 218, 232], ["IgM", "TEST", 249, 252], ["IgG", "TEST", 257, 260]]], ["Cryopreserved sera obtained before and one week after the initial intravenous immunoglobulin (IVIG) treatmentAccepted ArticleThis article is protected by copyright.", [["sera", "ANATOMY", 14, 18], ["intravenous", "ANATOMY", 66, 77], ["sera", "ORGANISM_SUBSTANCE", 14, 18], ["intravenous immunoglobulin", "SIMPLE_CHEMICAL", 66, 92], ["Cryopreserved sera", "TEST", 0, 18], ["the initial intravenous immunoglobulin (IVIG) treatment", "TREATMENT", 54, 109]]], ["To evaluate the possible effect of IVIG on post-treatment serum anti-SARS-CoV-2 antibody levels, the anti-SARS-CoV-2 antibody levels in the IVIG preparations used for treatment were measured.", [["serum", "ANATOMY", 58, 63], ["IVIG", "SIMPLE_CHEMICAL", 35, 39], ["serum", "ORGANISM_SUBSTANCE", 58, 63], ["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 64, 79], ["anti-SARS-CoV-2 antibody", "GENE_OR_GENE_PRODUCT", 101, 125], ["IVIG", "ORGANISM", 140, 144], ["anti-SARS", "PROTEIN", 64, 73], ["CoV", "PROTEIN", 74, 77], ["anti-SARS", "PROTEIN", 101, 110], ["IVIG", "TREATMENT", 35, 39], ["post-treatment serum anti-SARS", "TEST", 43, 73], ["CoV", "TEST", 74, 77], ["antibody levels", "TEST", 80, 95], ["the anti-SARS", "TEST", 97, 110], ["CoV", "TEST", 111, 114], ["antibody levels", "TEST", 117, 132], ["the IVIG preparations", "TREATMENT", 136, 157], ["treatment", "TREATMENT", 167, 176], ["possible", "UNCERTAINTY", 16, 24]]], ["The study was approved by our institutional review board (2020b-26).ResultsIn total, 44 patients with KD were analyzed; 30 were from period 1, and 14 were from period 2 ( Table 1 ).", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["The study", "TEST", 0, 9], ["KD", "TEST", 102, 104]]], ["No patients presented signs of shock.", [["shock", "DISEASE", 31, 36], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["shock", "PROBLEM", 31, 36], ["shock", "OBSERVATION", 31, 36]]], ["There was no significant difference in the clinical or laboratory characteristics of the two groups except for platelet count.", [["platelet", "ANATOMY", 111, 119], ["platelet", "CELL", 111, 119], ["significant difference", "PROBLEM", 13, 35], ["platelet count", "TEST", 111, 125], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35], ["platelet count", "OBSERVATION", 111, 125]]], ["Coronary artery aneurysms were observed in two (5 %) patients at one month after the primary treatment.ResultsTwo patients were positive for the anti-SARS-CoV-2 antibody (Table S1 ).", [["Coronary artery aneurysms", "ANATOMY", 0, 25], ["Coronary artery aneurysms", "DISEASE", 0, 25], ["Coronary artery", "MULTI-TISSUE_STRUCTURE", 0, 15], ["patients", "ORGANISM", 53, 61], ["patients", "ORGANISM", 114, 122], ["anti-SARS-CoV-2 antibody", "GENE_OR_GENE_PRODUCT", 145, 169], ["anti-SARS-CoV-2 antibody", "PROTEIN", 145, 169], ["S1", "PROTEIN", 177, 179], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 114, 122], ["Coronary artery aneurysms", "PROBLEM", 0, 25], ["the primary treatment", "TREATMENT", 81, 102], ["the anti-SARS", "TEST", 141, 154], ["CoV", "TEST", 155, 158], ["artery", "ANATOMY", 9, 15], ["aneurysms", "OBSERVATION", 16, 25]]], ["Patient 1 was also positive for the anti-Mycoplasma pneumoniae antibody on particle agglutination test.", [["anti-Mycoplasma pneumoniae", "ORGANISM", 36, 62], ["anti-Mycoplasma pneumoniae antibody", "PROTEIN", 36, 71], ["Patient", "SPECIES", 0, 7], ["anti-Mycoplasma pneumoniae", "SPECIES", 36, 62], ["anti-Mycoplasma pneumoniae", "SPECIES", 36, 62], ["the anti-Mycoplasma pneumoniae antibody", "PROBLEM", 32, 71], ["particle agglutination test", "TEST", 75, 102]]], ["Patient 2 was hospitalized for SARS-CoV-2 infection at our hospital one month before KD diagnosis; KD onset occurred 56 days after COVID-19 onset.ResultsAlthough the anti-SARS-CoV-2 IgG level in all the IVIG preparations was below the cutoff, it was higher than that in the patients' serum.DiscussionOur study revealed that most patients with KD at our hospital had clinical characteristics more compatible with classical KD than with PIMS-TS.", [["serum", "ANATOMY", 284, 289], ["SARS-CoV-2 infection", "DISEASE", 31, 51], ["KD", "DISEASE", 343, 345], ["anti-SARS-CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 166, 185], ["patients", "ORGANISM", 274, 282], ["serum", "ORGANISM_SUBSTANCE", 284, 289], ["patients", "ORGANISM", 329, 337], ["anti-SARS-CoV", "PROTEIN", 166, 179], ["IgG", "PROTEIN", 182, 185], ["Patient", "SPECIES", 0, 7], ["patients", "SPECIES", 274, 282], ["patients", "SPECIES", 329, 337], ["SARS-CoV-2", "SPECIES", 31, 41], ["SARS", "PROBLEM", 31, 35], ["CoV", "PROBLEM", 36, 39], ["2 infection", "PROBLEM", 40, 51], ["KD onset", "PROBLEM", 99, 107], ["COVID", "TEST", 131, 136], ["the anti-SARS-CoV", "TEST", 162, 179], ["IgG level", "TEST", 182, 191], ["the IVIG preparations", "TREATMENT", 199, 220], ["DiscussionOur study", "TEST", 290, 309], ["classical KD", "PROBLEM", 412, 424], ["infection", "OBSERVATION", 42, 51]]], ["Their demographic, clinical, and laboratory features differed from those of patients with PIMS-TS, who are typically older and have a higher incidence of hemodynamic instability and gastrointestinal symptoms and a lower platelet count.", [["gastrointestinal", "ANATOMY", 182, 198], ["platelet", "ANATOMY", 220, 228], ["hemodynamic instability", "DISEASE", 154, 177], ["patients", "ORGANISM", 76, 84], ["gastrointestinal", "ORGAN", 182, 198], ["platelet", "CELL", 220, 228], ["patients", "SPECIES", 76, 84], ["hemodynamic instability", "PROBLEM", 154, 177], ["gastrointestinal symptoms", "PROBLEM", 182, 207], ["a lower platelet count", "TEST", 212, 234], ["hemodynamic instability", "OBSERVATION", 154, 177], ["gastrointestinal", "ANATOMY", 182, 198], ["platelet count", "OBSERVATION", 220, 234]]], ["1 No dramatic increase in KD incidence or changes in its clinical features were observed during the local COVID-19 epidemic, unlike in other countries where PIMS-TS is endemic.", [["PIMS", "CHEMICAL", 157, 161], ["dramatic increase", "PROBLEM", 5, 22], ["KD incidence", "PROBLEM", 26, 38], ["changes in its clinical features", "PROBLEM", 42, 74], ["the local COVID", "TEST", 96, 111], ["endemic", "PROBLEM", 168, 175], ["dramatic", "OBSERVATION_MODIFIER", 5, 13], ["increase", "OBSERVATION_MODIFIER", 14, 22], ["KD", "OBSERVATION_MODIFIER", 26, 28], ["incidence", "OBSERVATION_MODIFIER", 29, 38], ["endemic", "OBSERVATION_MODIFIER", 168, 175]]], ["Only one (2 %) patient was positive for anti-SARS-CoV-2 IgG in contrast to around 80 % of patients with PIMS-TS in Europe.", [["PIMS-TS", "DISEASE", 104, 111], ["patient", "ORGANISM", 15, 22], ["anti-SARS-CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 40, 59], ["patients", "ORGANISM", 90, 98], ["anti-SARS", "PROTEIN", 40, 49], ["CoV", "PROTEIN", 50, 53], ["IgG", "PROTEIN", 56, 59], ["patient", "SPECIES", 15, 22], ["patients", "SPECIES", 90, 98], ["anti-SARS", "TEST", 40, 49], ["CoV", "TEST", 50, 53], ["PIMS", "PROBLEM", 104, 108]]], ["All rights reserved There was an apparent drop in KD cases from period 1 to period 2.", [["an apparent drop in KD cases", "PROBLEM", 30, 58], ["drop", "OBSERVATION_MODIFIER", 42, 46]]], ["However, the number of patients with KD treated at our hospital in the previous year during the period corresponding to periods 1 and 2 was 32 and 19, respectively, showing a similar trend with the present subjects.Accepted ArticleConsidering that the incidence of KD is lower in spring than in winter, 3 this drop was assumed merely to reflect the normal seasonality of KD rather than any effect of COVID-19.Accepted ArticleSeveral reasons may explain the lack of PIMS-TS reports in Asia.", [["KD", "DISEASE", 37, 39], ["COVID-19", "CHEMICAL", 400, 408], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["ArticleConsidering", "TREATMENT", 224, 242], ["COVID", "TEST", 400, 405], ["KD", "OBSERVATION", 265, 267], ["lower", "OBSERVATION_MODIFIER", 271, 276], ["normal", "OBSERVATION", 349, 355]]], ["First, patients with COVID-19 have thus far been much fewer in Asia than in Europe, leading to fewer children having the disease.", [["patients", "ORGANISM", 7, 15], ["children", "ORGANISM", 101, 109], ["patients", "SPECIES", 7, 15], ["children", "SPECIES", 101, 109], ["COVID", "TEST", 21, 26], ["the disease", "PROBLEM", 117, 128], ["disease", "OBSERVATION", 121, 128]]], ["Second, PIMS-TS apparently shows a predilection for individuals of black or Hispanic descent, 1,2 suggesting that genetic factors may contribute to its uneven distribution.", [["PIMS", "TEST", 8, 12], ["black or Hispanic descent", "PROBLEM", 67, 92], ["genetic factors", "PROBLEM", 114, 129]]], ["The same trend was observed in Kawasaki shock syndrome, a severe form of KD characterized by clinical presentations very similar to those of PIMS-TS.", [["Kawasaki shock syndrome", "DISEASE", 31, 54], ["KD", "DISEASE", 73, 75], ["Kawasaki shock syndrome", "PROBLEM", 31, 54], ["KD", "PROBLEM", 73, 75], ["Kawasaki shock syndrome", "OBSERVATION", 31, 54]]], ["4 These ethnic groups may have some genetic factors that make them more susceptible to hyperinflammatory states.", [["hyperinflammatory states", "PROBLEM", 87, 111]]], ["Our study incidentally revealed a higher anti-SARS-CoV-2 IgG level in IVIG preparations than in the patients' serum, indicating potential cross-reactivity between SARS-CoV-2 and common human coronaviruses, as previously demonstrated in a study analyzing human sera collected prior to the COVID-19 pandemic.", [["serum", "ANATOMY", 110, 115], ["sera", "ANATOMY", 260, 264], ["anti-SARS-CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 41, 60], ["IVIG", "SIMPLE_CHEMICAL", 70, 74], ["patients", "ORGANISM", 100, 108], ["serum", "ORGANISM_SUBSTANCE", 110, 115], ["SARS-CoV-2", "ORGANISM", 163, 173], ["human", "ORGANISM", 185, 190], ["coronaviruses", "ORGANISM", 191, 204], ["human", "ORGANISM", 254, 259], ["sera", "ORGANISM_SUBSTANCE", 260, 264], ["anti-SARS", "PROTEIN", 41, 50], ["IgG", "PROTEIN", 57, 60], ["patients", "SPECIES", 100, 108], ["human", "SPECIES", 185, 190], ["human", "SPECIES", 254, 259], ["SARS-CoV", "SPECIES", 163, 171], ["human coronaviruses", "SPECIES", 185, 204], ["human", "SPECIES", 254, 259], ["Our study", "TEST", 0, 9], ["a higher anti-SARS", "TEST", 32, 50], ["CoV", "TEST", 51, 54], ["IVIG preparations", "TREATMENT", 70, 87], ["the patients' serum", "TEST", 96, 115], ["potential cross-reactivity", "PROBLEM", 128, 154], ["SARS", "TEST", 163, 167], ["CoV", "TEST", 168, 171], ["common human coronaviruses", "PROBLEM", 178, 204], ["a study", "TEST", 236, 243], ["human sera", "TEST", 254, 264], ["the COVID", "TEST", 284, 293], ["pandemic", "PROBLEM", 297, 305], ["common human coronaviruses", "ANATOMY", 178, 204]]], ["5 According to recent reports from Europe and the United States, more than half of patients with PIMS-TS are known to present without Kawasaki-like symptoms.", [["PIMS-TS", "DISEASE", 97, 104], ["Kawasaki-like symptoms", "DISEASE", 134, 156], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["Kawasaki-like symptoms", "PROBLEM", 134, 156]]], ["1,2 Because the current study focused only on patients with KD, the exact epidemiology of PIMS-TS was not analyzed.", [["PIMS", "DISEASE", 90, 94], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["the current study", "TEST", 12, 29]]], ["Furthermore, the present report was based on a small, retrospective study at a single institution; nationwide studies are needed to clarify the actual state of PIMS-TS in Japan.Accepted ArticleIn summary, our study revealed that most patients who received a diagnosis of KD during the COVID-19 epidemic in our catchment area had classical KD rather than PIMS-TS with This article is protected by copyright.", [["KD", "DISEASE", 271, 273], ["patients", "ORGANISM", 234, 242], ["patients", "SPECIES", 234, 242], ["retrospective study", "TEST", 54, 73], ["nationwide studies", "TEST", 99, 117], ["our study", "TEST", 205, 214], ["KD", "PROBLEM", 271, 273], ["the COVID", "TEST", 281, 290], ["small", "OBSERVATION_MODIFIER", 47, 52]]], ["All rights reserved Neurological symptoms 0 (0) 0 (0) 0 (0) -Accepted ArticleThis article is protected by copyright.", [["Neurological symptoms", "TEST", 20, 41]]], ["All rights reserved Peripheral hypoperfusion 0 (0) 0 (0) 0 (0) -", [["Peripheral", "ANATOMY", 20, 30], ["Peripheral hypoperfusion", "DISEASE", 20, 44], ["Peripheral hypoperfusion", "TEST", 20, 44], ["hypoperfusion", "OBSERVATION", 31, 44]]]], "PMC7126624": [["IntroductionDNA diagnostic has become an important area of molecular biology and biotechnology studies.", [["biotechnology studies", "TEST", 81, 102]]], ["The detection of specific base sequences in human, viral and bacterial nucleic acid is becoming increasingly important in several areas, with applications ranging from the detection of disease-causing and food-contaminating organisms to forensic and environmental research.IntroductionConventional methods for the analysis of specific gene sequences are based on either direct sequencing or DNA hybridization methods.", [["nucleic acid", "CHEMICAL", 71, 83], ["human", "ORGANISM", 44, 49], ["DNA", "CELLULAR_COMPONENT", 391, 394], ["specific gene sequences", "DNA", 326, 349], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49], ["specific base sequences in human", "TEST", 17, 49], ["viral and bacterial nucleic acid", "PROBLEM", 51, 83], ["disease", "PROBLEM", 185, 192], ["contaminating organisms", "PROBLEM", 210, 233], ["the analysis", "TEST", 310, 322], ["specific gene sequences", "TEST", 326, 349], ["direct sequencing", "TEST", 370, 387], ["DNA hybridization methods", "TREATMENT", 391, 416], ["bacterial nucleic acid", "OBSERVATION", 61, 83]]], ["Although the DNA sequencing has undergone very big progress in the last decade (Kling, 2003, Kartalov and Quake, 2004, Aborn et al., 2005), these traditional methods, based on the coupling of electrophoretic separations and radioisotopic (32P) detection, are generally labour intensive and time consuming.", [["DNA", "CELLULAR_COMPONENT", 13, 16], ["electrophoretic separations", "TREATMENT", 192, 219], ["radioisotopic (32P) detection", "TEST", 224, 253]]], ["Therefore, the second option is more commonly used in diagnostic laboratories.IntroductionGenosensors (or DNA hybridization biosensors) offer a promising alternative to carry out the specific gene sequence identification (De los Santos-\u00c1lvarez et al., 2004, Wang, 2002, Pale\u010dek et al., 1998).", [["DNA", "CELLULAR_COMPONENT", 106, 109], ["IntroductionGenosensors (or DNA hybridization biosensors", "TREATMENT", 78, 134]]], ["These biosensors commonly rely on the immobilization of a single-stranded (ss) oligonucleotide probe onto a transducer surface to recognize \u2013 by hybridization \u2013 its complementary target sequence.IntroductionAmong the different kind of transducers found in the literature \u2013 chemiluminescent (Nguyen and Heffelfinger, 1995), quartz crystal microbalance (Hashimoto et al., 1994, Steel et al., 1998), fiber optical (Piunno et al., 1995), evanescent wave (Watts et al., 1995) or an-acoustic wave (Su et al., 1996) \u2013 those based on electrochemical transduction, due to their high sensitivity, small dimensions, low cost and compatibility with micro-fabrication technology provide a very interesting alternative.IntroductionThese electrochemical biosensing devices can monitor sequence-specific hybridization processes: (i) directly, based on the intrinsic DNA electroactivity (Kerman et al., 2005, Erdem et al., 2004, Ozkan et al., 2002, Lucarelli et al., 2002) or (ii) indirectly by measuring changes in the electrical properties of the electrode\u2013solution interface \u2013 electrochemical properties of conducting polymers (Thompson et al., 2003, Cha et al., 2003, Wang et al., 1999), capacitance (Berney et al., 2000) or impedance (Souteyrand et al., 1997, Alfonta et al., 2001) \u2013 or using different covalently and non-covalently bound markers.IntroductionNon-covalent markers (hybridization indicators) are electroactive compounds \u2013 metal complexes (Wang et al., 1997, Zhao and Ju, 2004, Nojima et al., 2003, Kara et al., 2002, Aoki and Umezawa, 2003) or organic compounds (Zhu et al., 2005, Teh et al., 2005, Marrazza et al., 1999, Hashimoto et al., 1998) \u2013 that interact in a different way with single strands (ss-) and double strands (ds-) of DNA.IntroductionCovalently bound markers can be subdivided in two groups, electroactive and non-electroactive.", [["surface", "ANATOMY", 119, 126], ["quartz", "CHEMICAL", 323, 329], ["DNA", "CELLULAR_COMPONENT", 850, 853], ["DNA", "CELLULAR_COMPONENT", 1738, 1741], ["complementary target sequence", "DNA", 165, 194], ["non-covalently bound markers", "PROTEIN", 1306, 1334], ["Covalently bound markers", "PROTEIN", 1754, 1778], ["These biosensors", "TEST", 0, 16], ["the immobilization", "TREATMENT", 34, 52], ["a single-stranded (ss) oligonucleotide probe", "TREATMENT", 56, 100], ["a transducer surface", "TREATMENT", 106, 126], ["electrochemical transduction", "TREATMENT", 526, 554], ["their high sensitivity", "PROBLEM", 563, 585], ["small dimensions, low cost", "PROBLEM", 587, 613], ["micro-fabrication technology", "TREATMENT", 637, 665], ["These electrochemical biosensing devices", "TREATMENT", 717, 757], ["DNA", "PROBLEM", 1738, 1741], ["IntroductionCovalently bound markers", "TREATMENT", 1742, 1778], ["small", "OBSERVATION_MODIFIER", 587, 592], ["dimensions", "OBSERVATION_MODIFIER", 593, 603], ["low cost", "OBSERVATION_MODIFIER", 605, 613], ["bound markers", "OBSERVATION", 1321, 1334]]], ["Ferrocene and its derivatives (Nakayama et al., 2002, Xu et al., 2000, Xu et al., 2001), Pt(II) complex (Hern\u00e1ndez-Santos et al., 2005), colloidal gold (Ozsoz et al., 2003, Cai et al., 2002), or tris(2,2\u2032-bipyridyl)cobalt(III)-doped silica nanoparticles (Zhu et al., 2003) are used as electroactive markers, while as non-electroactive marker, the use of enzymes, linked directly to the DNA strand (Zhang et al., 2003, Zhang et al., 2004) or indirectly through biotin\u2013avidin (Abad-Valle et al., 2005, Azek et al., 2000) or fluorescein\u2013antifluorescein bridges (Hern\u00e1ndez-Santos et al., 2004), has been extensively reported.IntroductionAs can be seen, metal complexes and metal nanoparticles have an important role in the development of electrochemical genosensors.", [["Ferrocene", "CHEMICAL", 0, 9], ["Pt", "CHEMICAL", 89, 91], ["tris(2,2\u2032-bipyridyl", "CHEMICAL", 195, 214], ["cobalt", "CHEMICAL", 215, 221], ["biotin\u2013avidin", "CHEMICAL", 460, 473], ["fluorescein\u2013antifluorescein", "CHEMICAL", 522, 549], ["Ferrocene", "CHEMICAL", 0, 9], ["Pt(II)", "CHEMICAL", 89, 95], ["tris(2,2\u2032-bipyridyl)cobalt(III)", "CHEMICAL", 195, 226], ["silica", "CHEMICAL", 233, 239], ["fluorescein\u2013antifluorescein", "CHEMICAL", 522, 549], ["Ferrocene", "SIMPLE_CHEMICAL", 0, 9], ["Pt(II)", "SIMPLE_CHEMICAL", 89, 95], ["colloidal gold", "SIMPLE_CHEMICAL", 137, 151], ["tris(2,2\u2032-bipyridyl)cobalt(III)-doped silica nanoparticles", "SIMPLE_CHEMICAL", 195, 253], ["DNA", "CELLULAR_COMPONENT", 386, 389], ["fluorescein\u2013antifluorescein bridges", "SIMPLE_CHEMICAL", 522, 557], ["metal complexes", "SIMPLE_CHEMICAL", 649, 664], ["metal nanoparticles", "SIMPLE_CHEMICAL", 669, 688], ["enzymes", "PROTEIN", 354, 361], ["Ferrocene", "TREATMENT", 0, 9], ["its derivatives", "TREATMENT", 14, 29], ["colloidal gold", "TEST", 137, 151], ["Cai et al.", "TEST", 173, 183], ["tris", "TEST", 195, 199], ["doped silica nanoparticles", "TREATMENT", 227, 253], ["electroactive markers", "TEST", 285, 306], ["enzymes", "TEST", 354, 361], ["fluorescein\u2013antifluorescein bridges", "PROBLEM", 522, 557], ["IntroductionAs", "TREATMENT", 621, 635], ["metal complexes and metal nanoparticles", "TREATMENT", 649, 688], ["electrochemical genosensors", "PROBLEM", 734, 761], ["electrochemical genosensors", "OBSERVATION", 734, 761]]], ["In addition to the works cited above, where metal complexes are used as hybridization indicators or electroactive labels, examples of transition metal complexes, e.g. Ru(bpy)32+, Os(bpy)32+, mediating the electro-oxidation of nucleobases, have also been found in literature (Yang et al., 2002, Gore et al., 2003).IntroductionIn this work, it was used for first time sodium aurothiomalate as electroactive label in a DNA hybridization biosensor.", [["Ru", "CHEMICAL", 167, 169], ["Os", "CHEMICAL", 179, 181], ["sodium aurothiomalate", "CHEMICAL", 366, 387], ["transition metal", "CHEMICAL", 134, 150], ["Ru(bpy)32+", "CHEMICAL", 167, 177], ["Os(bpy)32+", "CHEMICAL", 179, 189], ["nucleobases", "CHEMICAL", 226, 237], ["sodium aurothiomalate", "CHEMICAL", 366, 387], ["Ru(bpy)32+", "SIMPLE_CHEMICAL", 167, 177], ["Os(bpy)32+", "SIMPLE_CHEMICAL", 179, 189], ["sodium aurothiomalate", "SIMPLE_CHEMICAL", 366, 387], ["DNA", "CELLULAR_COMPONENT", 416, 419], ["transition metal complexes", "PROBLEM", 134, 160], ["Ru(bpy)", "TEST", 167, 174], ["Os(bpy)", "TEST", 179, 186], ["first time sodium aurothiomalate", "TREATMENT", 355, 387], ["a DNA hybridization biosensor", "TREATMENT", 414, 443]]], ["This gold(I) complex has been previously used in our laboratory with success as electroactive label for immunosensor devices using glassy carbon electrodes (GCEs) as electrochemical transducers (de la Escosura-Mu\u00f1iz et al., 2004a).", [["glassy carbon", "CHEMICAL", 131, 144], ["glassy carbon", "CHEMICAL", 131, 144], ["glassy carbon electrodes", "SIMPLE_CHEMICAL", 131, 155], ["gold(I) complex", "PROTEIN", 5, 20], ["immunosensor devices", "TREATMENT", 104, 124], ["glassy carbon electrodes", "TREATMENT", 131, 155]]], ["The electrochemical detection in these immunosensors is based on the catalytic effect of ionic gold on silver electrodeposition (de la Escosura-Mu\u00f1iz et al., 2004b).IntroductionGCEs have been widely used in the construction of electrochemical DNA hybridization biosensors in combination with different oligonucleotides immobilization methods, such as (i) film entrapment using polymers (Wang et al., 1999, Xu et al., 2001, Cai et al., 2002, Zhu et al., 2003), (ii) covalent attachment on functionalized glassy carbon electrodes\u2014polymers, carbon nanotubes, etc. (Zhao and Ju, 2004, Kara et al., 2002, Zhu et al., 2005, Teh et al., 2005, Piro et al., 2005, Cai et al., 2003) or (iii) by electrostatic adsorption on gold colloid modified surfaces (Lin et al., 2002).IntroductionDirect adsorption of oligonucleotides onto pre-oxidized glassy carbon electrodes is used in this work, in combination with the electroactive label sodium aurothiomalate for the electrochemical detection of a SARS virus sequence, using a silver catalytic electrodeposition method.Apparatus and electrodes ::: ExperimentalCyclic voltammetric experiments were performed with an ECO CHEMIE Autolab PGSTAT 10 potentiostat interfaced to a Pentium 120 computer system and controlled by an Autolab GPES Version 4.6 for Windows 98.Apparatus and electrodes ::: ExperimentalAll measurements were carried out at room temperature in a 20 mL cell (protected from light) with a three-electrode configuration.", [["cell", "ANATOMY", 1403, 1407], ["silver", "CHEMICAL", 103, 109], ["carbon nanotubes", "CHEMICAL", 538, 554], ["glassy carbon", "CHEMICAL", 831, 844], ["sodium aurothiomalate", "CHEMICAL", 922, 943], ["SARS", "DISEASE", 983, 987], ["silver", "CHEMICAL", 1012, 1018], ["silver", "CHEMICAL", 103, 109], ["glassy carbon", "CHEMICAL", 503, 516], ["carbon", "CHEMICAL", 538, 544], ["glassy carbon", "CHEMICAL", 831, 844], ["sodium aurothiomalate", "CHEMICAL", 922, 943], ["silver", "CHEMICAL", 1012, 1018], ["ionic gold", "SIMPLE_CHEMICAL", 89, 99], ["silver", "SIMPLE_CHEMICAL", 103, 109], ["DNA", "CELLULAR_COMPONENT", 243, 246], ["glassy carbon electrodes", "SIMPLE_CHEMICAL", 503, 527], ["carbon nanotubes", "SIMPLE_CHEMICAL", 538, 554], ["sodium aurothiomalate", "SIMPLE_CHEMICAL", 922, 943], ["silver", "SIMPLE_CHEMICAL", 1012, 1018], ["cell", "CELL", 1403, 1407], ["SARS virus", "SPECIES", 983, 993], ["The electrochemical detection", "TEST", 0, 29], ["these immunosensors", "TEST", 33, 52], ["silver electrodeposition", "TREATMENT", 103, 127], ["IntroductionGCEs", "TREATMENT", 165, 181], ["electrochemical DNA hybridization biosensors", "TREATMENT", 227, 271], ["different oligonucleotides immobilization methods", "TREATMENT", 292, 341], ["covalent attachment", "PROBLEM", 465, 484], ["functionalized glassy carbon electrodes\u2014polymers", "TREATMENT", 488, 536], ["carbon nanotubes", "TREATMENT", 538, 554], ["Cai et al.", "TEST", 655, 665], ["electrostatic adsorption", "PROBLEM", 685, 709], ["gold colloid modified surfaces", "TREATMENT", 713, 743], ["IntroductionDirect adsorption of oligonucleotides onto pre-oxidized glassy carbon electrodes", "TREATMENT", 763, 855], ["the electroactive label sodium aurothiomalate", "TREATMENT", 898, 943], ["the electrochemical detection", "TEST", 948, 977], ["a SARS virus sequence", "PROBLEM", 981, 1002], ["a silver catalytic electrodeposition method", "TREATMENT", 1010, 1053], ["ExperimentalCyclic voltammetric experiments", "TEST", 1083, 1126], ["an ECO", "TEST", 1147, 1153], ["an Autolab GPES Version", "TREATMENT", 1254, 1277], ["All measurements", "TEST", 1338, 1354], ["a three-electrode configuration", "TREATMENT", 1436, 1467], ["carbon nanotubes", "OBSERVATION", 538, 554]]], ["Working glassy carbon electrodes (GCEs) were home made, using 3 mm diameter glassy carbon rods (Goodfellow, Spain), sealed into Teflon holders with a spurr resin for electron microscopy purchased from Sigma (Spain).", [["glassy carbon", "CHEMICAL", 8, 21], ["glassy carbon", "CHEMICAL", 8, 21], ["glassy carbon", "CHEMICAL", 76, 89], ["Working glassy carbon electrodes", "TREATMENT", 0, 32], ["3 mm diameter glassy carbon rods", "TREATMENT", 62, 94], ["a spurr resin", "TREATMENT", 148, 161], ["electron microscopy", "TEST", 166, 185]]], ["Electrical contact was a brass rod welded to glassy carbon with a silver loaded conductive epoxy resin purchased from Circuit Works (USA).", [["glassy carbon", "CHEMICAL", 45, 58], ["silver", "CHEMICAL", 66, 72], ["glassy carbon", "CHEMICAL", 45, 58], ["silver", "CHEMICAL", 66, 72], ["epoxy", "CHEMICAL", 91, 96], ["glassy carbon", "SIMPLE_CHEMICAL", 45, 58], ["silver", "SIMPLE_CHEMICAL", 66, 72], ["a brass rod welded to glassy carbon", "TREATMENT", 23, 58], ["a silver loaded conductive epoxy resin", "TREATMENT", 64, 102]]], ["The renewal of the glassy carbon surface was achieved by polishing with 1.0 and 0.3 \u03bcm alpha-alumina on a microcloth polishing sheet of 8 in, followed by washing in an ultrasonic Selecta bath for 5 min.Apparatus and electrodes ::: ExperimentalA platinum wire as counter electrode and an Ag/AgCl reference electrode were used.Apparatus and electrodes ::: ExperimentalA Metrohm AG Herisau magnetic stirrer was used for the electrochemical pre-treatment of the electrode surface and the gold electrodeposition and oxidation.Reagents and solutions ::: ExperimentalSynthetic 30-mer oligonucleotides were obtained from Eurogentec (Spain).", [["alpha-alumina", "CHEMICAL", 87, 100], ["platinum", "CHEMICAL", 245, 253], ["Ag", "CHEMICAL", 287, 289], ["glassy carbon", "CHEMICAL", 19, 32], ["platinum", "CHEMICAL", 245, 253], ["Ag", "CHEMICAL", 287, 289], ["AgCl", "CHEMICAL", 290, 294], ["gold", "SIMPLE_CHEMICAL", 484, 488], ["Ag", "PROTEIN", 287, 289], ["the glassy carbon surface", "TREATMENT", 15, 40], ["a microcloth polishing sheet", "TREATMENT", 104, 132], ["an ultrasonic Selecta bath", "TREATMENT", 165, 191], ["ExperimentalA platinum wire as counter electrode", "TREATMENT", 231, 279], ["an Ag/AgCl reference electrode", "TREATMENT", 284, 314], ["ExperimentalA Metrohm AG Herisau magnetic stirrer", "TREATMENT", 354, 403], ["the electrochemical pre-treatment of the electrode surface", "TREATMENT", 417, 475], ["the gold electrodeposition and oxidation", "TREATMENT", 480, 520], ["ExperimentalSynthetic", "TEST", 548, 569], ["platinum wire", "OBSERVATION", 245, 258], ["gold electrodeposition", "OBSERVATION", 484, 506]]], ["The target sequence employed corresponds to a portion of the severe acute respiratory syndrome (SARS) virus, precisely the bases comprised between 29218 and 29247, both included.", [["acute respiratory syndrome", "DISEASE", 68, 94], ["SARS", "DISEASE", 96, 100], ["severe acute respiratory syndrome (SARS) virus", "SPECIES", 61, 107], ["the severe acute respiratory syndrome", "PROBLEM", 57, 94], ["SARS) virus", "PROBLEM", 96, 107], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["respiratory syndrome", "OBSERVATION", 74, 94], ["bases", "ANATOMY_MODIFIER", 123, 128]]], ["For selectivity studies, single-base and three-base-mismatch strands were also purchased.", [["selectivity studies", "TEST", 4, 23], ["three-base-mismatch strands", "TREATMENT", 41, 68], ["base", "ANATOMY_MODIFIER", 32, 36], ["base", "ANATOMY_MODIFIER", 47, 51], ["mismatch strands", "OBSERVATION", 52, 68]]], ["Mismatches are located in bases number 12 and 5, 15 and 26, respectively.Target (50 nmol): 5\u2032-ACA-GAG-CCT-AAA-AAG-GAC-AAA-AAG-AAA-AAG-3\u2032;Thiolated target (50 nmol): 5\u2032-ACA-GAG-CCT-AAA-AAG-GAC-AAA-AAG-AAA-AAG-SH-3\u2032;Single-base-mismatch target (49 nmol): 5\u2032-ACA-GAG-CCT-AAC-AAG-GAC-AAA-AAG-AAA-AAG-3\u2032;Three-base-mismatch target (184 nmol): 5\u2032-ACA-GCG-CCT-AAA-AAC-GAC-AAA-AAG-AGA-AAG-3\u2032;The probe is a complementary strand of the target that was also obtained from Eurogentec.", [["5\u2032-ACA-GAG-CCT-AAA-AAG-GAC-AAA-AAG-AAA-AAG-3\u2032", "CHEMICAL", 91, 136], ["5\u2032-ACA-GAG-CCT-AAA-AAG-GAC-AAA-AAG-AAA-AAG-SH-3\u2032", "CHEMICAL", 165, 213], ["5\u2032-ACA-GAG-CCT-AAC-AAG-GAC-AAA-AAG-AAA-AAG-3\u2032", "CHEMICAL", 253, 298], ["\u2032-ACA-GAG-CCT-AAA-AAG-GAC-AAA-AAG-AAA-AAG-3\u2032", "SIMPLE_CHEMICAL", 92, 136], ["Thiolated", "SIMPLE_CHEMICAL", 137, 146], ["5\u2032-ACA-GAG-CCT-AAA-AAG-GAC-AAA-AAG-AAA-AAG-SH-3\u2032", "SIMPLE_CHEMICAL", 165, 213], ["5\u2032-ACA-GAG-CCT-AAC-AAG-GAC-AAA-AAG-AAA-AAG-3\u2032", "SIMPLE_CHEMICAL", 253, 298], ["5\u2032-ACA-GCG-CCT-AAA-AAC-GAC-AAA-AAG-AGA-AAG-3\u2032", "SIMPLE_CHEMICAL", 338, 383], ["CCT-AAA-AAG-GAC-AAA-AAG-AAA-AAG-3\u2032;Thiolated target", "DNA", 102, 153], ["CCT-AAA-AAG-GAC-AAA-AAG-AAA-AAG-SH-3\u2032;Single-base-mismatch target", "DNA", 176, 241], ["AAG-GAC-AAA-AAG-AAA-AAG-3\u2032;Three-base-mismatch target", "DNA", 272, 325], ["184 nmol): 5\u2032-ACA-GCG-CCT-AAA-AAC-GAC-AAA-AAG-AGA-AAG-3\u2032", "DNA", 327, 383], ["Target", "TEST", 73, 79], ["ACA-", "TEST", 94, 98], ["GAG", "TEST", 98, 101], ["CCT", "TEST", 102, 105], ["AAA", "TEST", 106, 109], ["AAG", "TEST", 110, 113], ["GAC", "TEST", 114, 117], ["AAA", "TEST", 118, 121], ["AAG", "TEST", 122, 125], ["AAA", "TEST", 126, 129], ["AAG", "TEST", 130, 133], ["ACA-", "TEST", 168, 172], ["GAG", "TEST", 172, 175], ["CCT", "TEST", 176, 179], ["AAA", "TEST", 180, 183], ["AAG", "TEST", 184, 187], ["GAC", "TEST", 188, 191], ["AAA", "TEST", 192, 195], ["AAG", "TEST", 196, 199], ["AAA", "TEST", 200, 203], ["AAG", "TEST", 204, 207], ["SH", "TEST", 208, 210], ["ACA-GAG-CCT-AAC", "TEST", 256, 271], ["AAG", "TEST", 272, 275], ["GAC", "TEST", 276, 279], ["AAA", "TEST", 280, 283], ["AAG", "TEST", 284, 287], ["AAA", "TEST", 288, 291], ["AAG", "TEST", 292, 295], ["mismatch target", "TEST", 310, 325], ["5\u2032-ACA-GCG-CCT-AAA-AAC-GAC-AAA-AAG", "TEST", 338, 372], ["AGA", "TEST", 373, 376], ["AAG", "TEST", 377, 380], ["bases", "ANATOMY_MODIFIER", 26, 31], ["AAA", "ANATOMY", 106, 109], ["AAG", "ANATOMY", 110, 113], ["AAA", "ANATOMY", 118, 121], ["AAG", "ANATOMY", 122, 125], ["AAA", "ANATOMY", 126, 129], ["AAG", "ANATOMY", 130, 133], ["AAA", "ANATOMY", 180, 183], ["AAG", "ANATOMY", 184, 187], ["AAA", "ANATOMY", 192, 195], ["AAG", "ANATOMY", 196, 199], ["AAA", "ANATOMY", 200, 203], ["AAG", "ANATOMY", 204, 207], ["base", "ANATOMY_MODIFIER", 221, 225], ["AAG", "ANATOMY", 272, 275], ["AAA", "ANATOMY", 280, 283], ["AAA", "ANATOMY", 288, 291]]], ["Probe (50 nmol): 5\u2032-CTT-TTT-CTT-TTT-GTC-CTT-TTT-AGG-CTC-TGT-3\u2032.", [["5\u2032-CTT-TTT-CTT-TTT-GTC-CTT-TTT-AGG-CTC-TGT-3", "CHEMICAL", 17, 61], ["5\u2032-CTT-TTT-", "SIMPLE_CHEMICAL", 17, 28], ["TTT-CTT-TTT-GTC-CTT-TTT-AGG-CTC-TGT-3\u2032", "DNA", 24, 62], ["CTT", "TEST", 20, 23], ["CTT", "TEST", 28, 31], ["TTT", "TEST", 32, 35], ["GTC", "TEST", 36, 39], ["CTT", "TEST", 40, 43], ["TTT", "TEST", 44, 47], ["AGG", "TEST", 48, 51], ["CTC", "TEST", 52, 55], ["TGT", "TEST", 56, 59]]]]}